ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 7
CONTRI BUTORS
Bach. M
. K. . . . . . . .
Benet. L
. ....... Z
. R...
20 downloads
2692 Views
21MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 7
CONTRI BUTORS
Bach. M
. K. . . . . . . .
Benet. L
. ....... Z
. R. . . . . . . Bundy. G . L . . . . . . . Burgus. R . . . . . . . . Blohm. T
238
Lienhard. G
259
Morrow. D
169
157 194 99
........ Cheng. . . . . . . . . 129 Colten. H . R . . . . . . . 228 Cronin. T . . . . . . . . 119 Czuba. L . J . . . . . . . 78 Davies. J . . . . . . . . 217 . . . . . . . . 109 Drube. Engelhardt. E . L . . . . . 6 Friis. W. . . . . . . . . 39 G a l l o . D . . . . . . . . . 182 Gandour. R . D . . . . . . 279 . A . . . . . . 47 Harbert. Hitchings. . H. . . . . 1 Hoffer. . . . . . . . . 145 Hudyma. T . W . . . . . . . 208 Juby. P . F . . . . . . . . 208 Kaiser. . . . . . . . . 6. 18 Butler. K C
C
H
C
G
C
G
M
C
. E. . . . . . . .
. F. . . . . . . . . Nagasawa. H . T . . . . . . . . Pachter. 1 . J . . . . . . . . Rachlin. A . I . . . . . . . . Robinson. F . M . . . . . . . . Roe. A . M . . . . . . . . . . Rudzik. A . D . . . . . . . . . Sciavolino. F . C . . . . . . . Schowen. R . L . . . . . . . . Schwender. C . F . . . . . . . Stewart. J . M. . . . . . . . Thomas. R . C . . . . . . . . . Thompson. J . A . . . . . . . . Topliss. J . G. . . . . . . . Tozzi. S. . . . . . . . . . . Waitz. J . A . . . . . . . . . Wechter. W . J . . . . . . . . Weissman. A . . . . . . . . . Wiley. R . A . . . . . . . . . Z i r k l e . C . L. . . . . . . . .
249 182 269
157 145 31
59 39 99 279
69 289 296 269
59
89 109 217
47 259
6. 18
ANNUAL REPORTS IN MEDICINAL CHEMISTRY Volume 7 Sponsored by the Division of Medicinal Chemistry of the American Chemical Society Editor-in- Chief: RICHARD V. HEINZELMAN THE UPJOHN COMPANY KAUMAZOO, MICHIGAN
SECTION EDITORS EDWARD ENGELHARDT IRWIN PACHTER
@ACADEMIC
0
0
JOHN TOPLISS
WILLIAM WECHTER
PRESS
0
0
KENNETH BUTLER
ROBERT WILEY
New York and London 1972
COPYRIGHT 0 1972, BY ACADEMIC PRESS, INC. ALL RIGHTS RESERVED NO PART OF THIS BOOK MAY BE REPRODUCED IN ANY FORM, BY PHOTOSTAT, MICROFILM, RETRIEVAL SYSTEM, OR A N Y OTHER MEANS, WITHOUT WRITTEN PERMISSION FROM THE PUBLISHERS.
ACADEMIC P R E S S , INC.
111 Fifth Avenue, New York. New York 10003
Uniied Kingdom Edition published by
ACADEMIC P R E S S , INC. ( L O N D O N ) 24/28 Oval Road, London NW1
LTD.
LIBRARYOF CONGRESS CATALOG CARDNUMBER: 66-26843
PRINTED IN THE UNITED STATeS OF AMERICA
CONTENTS
............................ ..............................
Contributors
ii
Preface
ix
AWARD ADDRESS T h i r d Award Address
-
Medicinal Chemistry
. .- . . .
I n h i b i t o r s o f F o l a t e B i o s y n t h e s i s and U t i l i z a t i o n E v o l u t i o n a r y Changes as a Basis f o r Chemotherapy , George H. H i t c h i n g s , Wellcome Research L a b o r a t o r i e s , Research T r i a n g l e Park, N. C.
1. Section Editor:
1
CNS AGENTS
Edward L . Engelhardt, Merck Sharp and Dohme Research Laboratories, West P o i n t , Pennsylvania 19486
.............
6
................
18
1.
A n t i p s y c h o t i c and A n t i - a n x i e t y Agents Charles L. Z i r k l e and C a r l Kaiser, Smith K l i n e & French L a b o r a t o r i e s , Ph i 1ade 1 ph ia, Pa.
2.
Antidepressives and S t i m u l a n t s Carl K a i s e r and Charles L. Z i r k l e , Smith K l i n e & French L a b o r a t o r i e s , Ph i 1 adel ph i a , Pa.
3.
Analgesics and N a r c o t i c Antagonists Frank1 i n M. Robinson, Merck Sharp & Dohme L a b o r a t o r i e s , West P o i n t , Pa.
4.
Sedatives, Hypnotics, A n t i c o n v u l s a n t s and General Anesthetics A. D . Rudzik and W. F r i i s , The Upjohn Company, Kal amazoo, M ich igan
5.
,
..............
..........................
......
Recent Developments R e l a t i n g S e r o t o n i n and Behavior A l b e r t Weissman and Charles A. H a r b e r t , P f i z e r Inc., Groton, Conn.
V
31
39
47
vi
CONTENTS
II. Section Editor:
John G.
PHARMACODYNAMIC AGENTS
Topliss,
S c h e r i n g Corp.,
B l o o m f i e l d , N.
...................
6.
A n t i h y p e r t e n s i v e Agents Anthony M. Roe, Smi th K l i n e & French Research I n s t i t u t e , Welwyn Garden C i t y , H e r t f o r d s h i r e , England
7.
A n t i a n g i n a l Agents C h a r l e s F. Schwender, Warner-Lambert Research I n s t i t u t e , M o r r i s P l a i n s , N. J.
8.
A n t i t h r o m b o t i c Agents Leonard J. Czuba, P f i z e r ,
9.
69
.....................
78
Inc.,
Groton,
Connecticut
...............
Pulmonary and A n t i a l l e r g y Agents S . T o z z i , S c h e r i n g C o r p o r a t i o n , B l o o m f i e l d , New J e r s e y
Section Editor:
89
CHEMOTHERAPEUTIC AGENTS
Kenneth B u t l e r , P f i z e r I n c . ,
Groton C o n n e c t i c u t
..........................
99
.......................
109
.......................
119
Antibiotics F r ank C. S c i a v o l i n o ,
P f i z e r Inc.,
Groton, C o n n e c t i c u t
11.
A n t i f u n g a l Agents J. A l l a n Wa i tz , C. G. Drube, S c h e r i n g C o r p o r a t i o n , B l o o m f i e l d , New J e r s e y
12.
A n t i v i r a l Agents T im ot h y H. C r o n i n , P f i z e r In c.,
13.
59
......................
Ill.
10.
J.
Groton, C o n n e c t i c u t
.....................
A n t i n e o p l a s t i c Agents C. C. Cheng, Midwest Research I n s t i t u t e , Kansas C i t y , Missouri
129
vii CONTENTS
14.
A n t i p a r a s i t i c Agents M. H o f f e r and A. 1 . N u t l e y , New J e r s e y
IV. Section Editor:
.....................
R a c h l i n , Hoffmann-La
METABOLIC D I S E A S E S AND ENDOCRINE FUNCTION
I. J. P a c h t e r , B r i s t o l L a b o r a t o r i e s , New York
Syracuse,
. . . . . . . . . . . . . 157
15.
P r o s t a g l a n d i n s and R e l a t e d Compounds Gordon L. Bundy, The Upjohn Company, Kalamazoo, M i c h i g a n
16.
Atherosclerosis Thomas R. Blohm, M e r r e l l - N a t i o n a l L a b o r a t o r i e s , o f R i c h a r d s o n - M e r r e l l , Inc., C i n c i n n a t i , Ohio
........................
169
Division
. . . . . . . . . . 182
17.
S t e r o i d s and B i o l o g i c a l l y R e l a t e d Compounds Duane F. Morrow and Duane G a l l o , Mead Johnson Research Center, E v a n s v i l l e , I n d i a n a
18.
P e p t i d e Hormones o f t h e Hypothalamus and P i t u i t a r y Roger Burgus, The S a l k I n s t i t u t e , La J o l l a , C a l i f .
19.
N o n - s t e r o i d a l A n t i i n f l a m m a t o r y Agents P e t e r F. Juby and Thomas W. Hudyma, B r i s t o l L a b o r a t o r i e s , Syracuse, New York
. . . . . . 194
. . . . . . . . . . . . . 208
V.
Section E d i t o r :
20.
145
Roche I n c . ,
T O P I C S I N BIOLOGY
W i l l i a m J. Wechter, The Upjohn Company, Kalamazoo, Michigan
. . . . . . . . . . . . 217
Mechanisms o f R e s i s t a n c e t o A n t i b i o t i c s J u l i a n Davies, Department o f B i o c h e m i s t r y , U n i v e r s i t y o f Wisconsin, Madison, W i s c o n s i n
viii CONTENTS
.................
21.
The Serum Complement System Harvey R. Colten, Harvard Medical School, Boston, Mass.
22.
Immediate H y p e r s e n s i t i v i t y : L a b o r a t o r y Models and Exper imen t a 1 F ind ings Michael K. Bach, The Upjohn Company, Kalamazoo, M i c h i g a n
23.
....................
238
........
Trans i t on S t a t e Analogs as Enzyme I n h i b i t o r s G. E. Lienhard, Dept. o f B i o c h e m i s t r y , Dartmouth Medical Schoo , Hanover, N. H.
VI. Section Editor:
228
249
TOPICS I N CHEMISTRY
Robert A. Wiley, U n i v e r s i t y o f Kansas, Lawrence, Kansas
......... . .
24.
Biopharmaceutics and Pharmacokinetics L e s l i e Z. Benet, School o f Pharmacy, U n i v e r s i t y o f C a l i f o r n i a , San F r a n c i s c o , C a l i f .
25.
269 Reactions o f I n t e r e s t i n M e d i c i n a l Chemistry H e r b e r t T. Nagasawa and John A. Thompson, C o l l e g e o f Pharmacy, U n i v e r s i t y o f Minnesota and Veterans Admin s t r a t on H o s p i t a l , M i n n e a p o l i s , Minnesota
26.
I n t r a m o l e c u l a r C a t a l y s i s i n M e d i n i c a l Chemistry R i c h a r d D. Gandour and R i c h a r d L. Schowen, Department o f Chemistry, U n i v e r s i t y o f Kansas, Lawrence, Kansas
27
Peptide Synthesis John Morrow Stewart, U n i v e r s i t y o f Colorado, Medicine, Denver, Colorado
28.
P r e p a r a t i o n o f Radioisotope-Labeled Drugs Richard C. Thomas, The Upjohn Company, Kalamazoo, M i c h i g a n
259
.........
. . . . . ..
. . . . . . . . . . . . . . . . School . . . . o.f
279
.
289
..........
296
PREFACE When a new e d i t o r takes over t h e r e i n s t h e r e i s a n a t u r a l tendency t o make v i s i b l e changes i n t h e new volume o f a s e r i e s . A f t e r consul t a t i o n w i t h many o f our "customers," t h e new e d i t o r concluded t h a t t h e volume i n i t s present form i s admirably s e r v i n g i t s purpose. Consequently the reader w i l l f i n d o n l y minor changes i n format. There i s a growing tendency t o cover c e r t a i n v e r y a c t i v e areas y e a r l y , w h i l e a t t h e same time t r e a t i n g more mature f i e l d s on an everytwo- o r -three-year b a s i s . T h i s leaves room f o r t h e i n t r o d u c t i o n o f new t o p i c s on perhaps a one-time basis. I n f a c t , j u s t h a l f o f t h e present twenty-eight chapters deal w i t h t o p i c s n o t included i n t h e p r e v i o u s v o l urne. The sections, Topics i n Chemistry and Topics i n B i o l o g y c o n t a i n chapters which a r e o f t e n more p r o v o c a t i v e and l e s s drug o r i e n t e d than the rest. I n t h e l a t t e r s e c t i o n t h e emphasis on t h e r a p i d l y maturing f i e l d o f immunology i s d e l i b e r a t e ; some o f these chapter t o p i c s w i l l be developed i n a planned way over t h e n e x t two o r t h r e e years. The many dedicated hours devoted t o t h e volume by authors and s e c t i o n e d i t o r s a r e g r a t e f u l l y acknowledged by t h e e d i t o r and w i l l become apparent t o t h e reader as soon as he begins t o read. Suggestions f o r improvement and f o r new f i e l d s t o cover a r e always welcome.
Richard V. Heinzelman
Ka 1 amazoo, M i c h igan June, 1972
ix
This Page Intentionally Left Blank
AWARD ADDRESS
I n h i b i t o r s of F o l a t e B i o s y n t h e s i s and U t i l i z a t i o n E v o l u t i o n a r y Changes As a Basis f o r Chemotherapy
--
George H. H i t c h i n g s Wellcome Research L a b o r a t o r i e s , Research T r i a n g l e P a r k , N. C. Fourth Award i n Medicinal Chemistry, T h i r t e e n t h N a t i o n a l Medicinal Chemistry Symposium of t h e American Chemical S o c i e t y , Iowa C i t y , Iowa, June 18-22, 1972
The e x p l o r a t i o n of enzymes and m e t a b o l i c pathways by means of a n t i m e t a b o l i t e s h a s been p r o d u c t i v e of b o t h new m e d i c i n a l a g e n t s and advances i n fundamental knowledge'. One of t h e i m p l i c a t i o n s of such an approach t o chemotherapy i s t h a t i t i s n e c e s s a r i l y uncommitted w i t h r e s p e c t t o s p e c i f i c t a r g e t s . It feeds on t h e knowledge t h a t i t i t s e l f g e n e r a t e s , and t a k e s f u l l advantage of t h e new d i s c o v e r i e s a r i s i n g from b a s i c work e l s e w h e r e . I t s g o a l i s t h e unv e i l i n g of b i o c h e m i c a l d i f f e r e n c e s t h a t can be e x p l o i t e d f o r t h e development of new m e d i c i n a l a g e n t s . The program w i t h which your M e d a l i s t h a s been a s s o c i a t e d h a s been i n v o l v e d w i t h d i v e r s e c a t e g o r i e s : leukemia, p r o t o z o a l and b a c t e r i a l i n f e c t i o n s , gout and organ t r a n s p l a n t a t i o n . A l l of t h e s e comprise a s i n g l e package of a p p l i c a t i o n s from s t u d i e s of n u c l e i c a c i d metabolism. This e s s a y w i l l a t t e m p t t o d e s c r i b e t h e method of working p r i m a r i l y through one example, s e l e c t i v e i n h i b i t o r s of t h e b i o g e n e s i s and u t i l i z a t i o n Speof f o l a t e s and t h e i r a p p l i c a t i o n t o a n t i - m i c r o b i a l chemotherapy'. c i f i c a l l y , t h e combination of t r i m e t h o p r i m and s u l f a m e t h o x a z o l e i s now a v a i l a b l e i n some 60 c o u n t r i e s of t h e world ( w i t h t h e n o t a b l e e x c e p t i o n of t h e United S t a t e s ) and h a s been used i n some 25 x 10" c o u r s e s of t h e r a p y with highly s a t i s f a c t o r y r e s ~ l t s ~ ' ~ .
'0'
'OCH~ Trimethoprim
Sulfomethoxazole
I t s o r i g i n s can be t r a c e d t o e a r l y f i n d i n g s of t h e p r e s e n t program, t o t h e d e t e c t i o n of a n t i m e t a b o l i t e s t h a t p o s s e s s s e l e c t i v e e f f e c t s ' . Substances were found t h a t e x h i b i t e d a c o n s i s t e n t p a t t e r n of a n t i m e t a b o l i c
-2
AWARD ADDRESS
e f f e c t s i n m i c r o b i a l s y s tens. Some were unusable as chemotherapeutic a g e n t s because of m e t a b o l i c d e s t r u c t i o n o r pharmacodynamic a c t i o n s when they were t e s t e d i n chemotherapeutic t r i a l s . Among them, however, w a s a s i z a b l e group t h a t have " s i m i l a r b u t d i s t i n c t e f f e c t s i n d i f f e r e n t organisms" and i t w a s f e l t t h a t s u b s t a n c e s w i t h such s e l e c t i v e a c t i o n could b e regarded as l e a d s t o chemotherapeutic a g e n t s . S e v e r a l p o s s i b l e modes of selective a c t i o n were recognized: "(1) The compound may p o s s e s s s e v e r a l a c t i v e c e n t e r s which a l l o w i t t o b l o c k , more o r less i n d e p e n d e n t l y , d i f f e r e n t biochemical r e a c t i o n s i n d i f f e r e n t t i s s u e s ; (2) a s i n g l e r e a c t i o n may b e blocked i n a l l organisms b u t t h i s r e a c t i o n may b e of r e l a t i v e l y g r e a t e r i m p o r t a n c e t o one organism t h a n a n o t h e r ; (3) t h e d i s s o c i a t i o n of t h e i n h i b i t o r - c e l l r e c e p t o r complex may v a r y widely from organism t o organism; o r ( 4 ) t h e r e a c t i o n blocked may b e one which o c c u r s only s p o r a d i c a l l y i n n a t u r e as an o b l i g a t e b i o c h e m i c a l me chanism"
'.
Trimethoprim is a n o u t s t a n d i n g example of t h e t h i r d mechanism s t a t e d above. I t i n h i b i t s t h e d&hyd;ofolate r e d u c t a s e of E s c h e r i c h i a c o l i a t a c o n c e n t r a t i o n of ca. 10 9M. w h i l e a c o n c e n t r a t i o n of n e a r l y 10-4M i s r e q u i r e d f o r a comparable i n h i b i t i o n of human l i v e r d i h y d r o f o l a t e reductase'. The r a t i o n a l e f o r i t s use i n combination w i t h a sulfonamide is q u i t e s i m p l y s t a t e d . The t a r g e t is t h e m i c r o b i a l p o o l of t e t r a h y d r o f o l a t e c o f a c t o r s t h a t are e s s e n t i a l t o t h e metabolism and m u l t i p l i c a t i o n of t h e m i c r o b i a l c e l l . Such c o f a c t o r s occur u b i q u i t o u s l y and perform e s s e n t i a l f u n c t i o n s i n a l l cells: i n t h e b i o s y n t h e s i s of p u r i n e s and thymine, t h e s y n t h e s i s of s e r i n e and t h e m e t h y l a t i o n of homocysteine t o form methione. Microorganisms employ similar r e a c t i o n s i n t h e b i o s y n t h e s i s of r i b o f l a v i n , p a n t o t h e n a t e , t h i a m i n and d i h y d r o f o l a t e i t s e l f . A l l of t h e s e l a t t e r m e t a b o l i t e s have become "vitamins," i . e . , t h e mechanisms f o r t h e i r b i o g e n e s i s have been l o s t d u r i n g t h e c o u r s e of e v o l u t i o n , and h i g h e r organisms m u s t have them preformed from food. Perhaps t h i s i n i t s e l f makes t h e microorganism t h e more s e n s i t i v e t o i n t e r f e r e n c e w i t h t h e c a p a b i l i t i e s of t h e t e t r a h y d r o f o l a t e p o o l , A t some p o i n t , f o r example, r e d u c t i o n of t h e t e t r a h y d r o f o l a t e p o o l r e s u l t s i n i n h i b i t i o n of f o l a t e biosynthesis, a vicious cycle effect'
.
COFACTOR ACTIVITY
Cof a c t o r
Precursor
H,,FA
Product
-3
AWARD ADDRESS
The s e l e c t i v e e f f e c t s of sulfonamides rest on a similar b a s e . S u l f a n i l a m i d e , and i t s r e l a t i v e s , act as a n t a g o n i s t s of p-aminobenzoic a c i d , a b u i l d i n g b l o c k of t h e f o l a t e molecule, and t h u s i n h i b i t t h e t h e primary product of t h e b i o s y n t h e t i c b i o g e n e s i s of d i h y d r o f o l a t e r e a c t i o n e . S i n c e man r e q u i r e s preformed f o l a t e , t h i s a n t i m e t a b o l i c e f f e c t is d i r e c t e d a t a r e a c t i o n t h a t is p r e s e n t i n t h e p a r a s i t e and a b s e n t from t h e h o s t . T h i s , however, is only h a l f t h e e x p l a n a t i o n of t h e chemot h e r a p e u t i c a c t i v i t y of s u l f o n a m i d e s . T h e i r a c t i o n i s c o n t i n g e n t a l s o on t h e i n a b i l i t y of p a t h o g e n i c microorganisms t o i n c o r p o r a t e preformed f o l a t e s from t h e environment and s o t o by-pass t h e sulfonamide b l o c k . The a b i l i t y t o use preformed f o l a t e s i n e v o l u t i o n must have preceded t h e d e l e t i o n of t h e b i o s y n t h e t i c r o u t e . Pathogens c o n t i n u e t o s y n t h e s i z e f o l a t e s de novo because they have f a i l e d t o develop t h e a b i l i t y t o take advantage of t h e ample s u p p l i e s of f o l a t e s i n body f l u i d s ' .
--
Biogenesis
Hq FA The e f f e c t produced by a sulfonamide on t h e microorganism's t e t r a h y d r o f o l a t e p o o l s is a d e p l e t i o n c o n t i n g e n t on slow a t t r i t i o n and d i l u t i o n through c e l l u l a r d i v i s i o n . Eventually, the pool f a l l s t o a l e v e l t h a t w i l l no l o n g e r p e r m i t m u l t i p l i c a t i o n , and t h e organism p a s s e s i n t o a r e s t i n g phase, The sulfonamide is t h u s b a c t e r i o s t a t i c i n i t s a c t i o n . Trimethoprim, by b l o c k i n g t h e r e d u c t i o n of d i h y d r o f o l a t e , reduces t h e t e t r a h y d r o f o l a t e pool more r a p i d l y . I n p a r t , t h e a t t r i t i o n of t h e t e t r a h y d r o f o l a t e pool is a s s i s t e d by t h e a c t i v i t y of t h y m i d y l a t e s y n t h e t a s e , s i n c e i n t h i s r e a c t i o n t h e c o f a c t o r n o t only t r a n s f e r s a onecarbon fragment (methylene) b u t c o n t r i b u t e s t o t h e r e d u c t i o n of t h e The methylene group t o methyl, and is i t s e l f o x i d i z e d t o d i h y d r o f o l a t e . e f f e c t of t r i m e t h o p r i m i s t h u s t o t r a p f o l a t e s i n t h e dihydro- s t a t e , and t h e f u n c t i o n a l t e t r a h y d r o f o l a t e pool i s d e p l e t e d .
Dihy d r o f o l a t e Reductase
Thymidylate S y n t h e t ase
-4
AWARD ADDRESS
Trimethoprim, however, i s a c o m p e t i t i v e i n h i b i t o r of d i h y d r o f o l a t e reductase". The accumulation of d i h y d r o f o l a t e , through c o n t i n u i n g b i o s y n t h e s i s and r e o x i d a t i o n of t e t r a h y d r o f o l a t e , t e n d s t o i n c r e a s e t h e m e t a b o l i t e : a n t i m e t a b o l i t e r a t i o and diminishes t h e e f f e c t i v e n e s s of t h e blockade. Conjoint a p p l i c a t i o n of a sulfonamide, however, removes t h e s o u r c e of new d i h y d r o f o l a t e and improves t h e e f f e c t i v e n e s s of t h e i n hibition. I n p r a c t i c e t h e simultaneous u s e of t h e 2 i n h i b i t o r s r e s u l t s i n a 5-10-fold p o t e n t i a t i o n , broadening of t h e spectrum of a c t i o n , a decreased l i a b i l i t y t o t h e development of r e s i s t a n c e , and a c o n v e r s i o n of bacteriostatic to bactericidal effectsg. Trirnethoprim emerged from a group of diaminopyrimidine d e r i v a t i v e s which were viewed "as s t r u c t u r a l analogues of f o l i n i c a c i d of a remote s o r t " t h a t were s e l e c t i v e because they could have a " d i f f e r e n t i a l a f f i n i t y . . . f o r t h e r e c e p t o r s of t h e p a r a s i t e . , . I l l 1 . I n t h e b e g i n n i n g they were c h a r a c t e r i z e d as s u b s t a n c e s t h a t i n t e r f e r e d w i t h t h e u t i l i z a t i o n of f o l i c a c i d by l a c t i c a c i d b a c t e r i a . With t h e i s o l a t i o n and c h a r a c t e r i z a t i o n of d i h y d r o f o l a t e r e d u c t a s e , t h e i r t a r g e t w a s i d e n t i f i e d , The a p p l i c a t i o n of a spectrum of i n h i b i t o r s t o a s e l e c t i o n of p a r t i a l l y p u r i f i e d r e d u c t a s e s 6 documented t h e i r mechanism of a c t i o n , and r e v e a l e d w i t h c l a r i t y t h e magnitude of t h e i r d i f f e r e n t i a l a f f i n i t i e s f o r t h e r e d u c t a s e s of d i f f e r e n t species, Trimethoprim r e p r e s e n t s t h e c u l m i n a t i o n of an e f f o r t t o t a i l o r a molecule f o r maximum b i n d i n g t o b a c t e r i a l r e d u c t a s e s with minimum b i n d i n g t o mammalian r e d u c t a s e s g ' l a .
..
H
Pvr i me t ha mine
Di h y d r o f o l i c
Acid
Trim e t h o p r i m
-5
AWARD ADDRESS
Its s e l e c t i v i t y h a s i m p o r t a n t i m p l i c a t i o n s f o r b o t h chemotherapy and f o r e v o l u t i o n . The most probable i n t e r p r e t a t i o n of i t s a c t i o n is t h a t i t is bound p a r t l y w i t h i n and p a r t l y o u t s i d e t h e a c t i v e c e n t e r of t h e enzyme. It t h u s d i f f e r s i n l o c u s o f b i n d i n g from a s t r u c t u r a l analogue of f o l i c a c i d , such as m e t h o t r e x a t e , which h a s a l l t h e b i n d i n g groups of t h e subs t r a t e and would t h u s b e expected t o b i n d i n p r o p o r t i o n t o t h e s u b s t r a t e binding. The i m p l i c a t i o n of s e l e c t i v e b i n d i n g i n r e g i o n s of t h e enzyme n e a r t o , b u t n o t i n , t h e a c t i v e c e n t e r , i s t h a t e v o l u t i o n a r y changes have been much more a c t i v e i n t h e s e s u p p o r t i n g s t r u c t u r e s t h a n i n t h e a c t i v e c e n t e r i t s e l f . D i h y d r o f o l a t e r e d u c t a s e t h u s f a l l s i n l i n e w i t h hemoglobins and o t h e r p r o t e i n s , now known t o e x i s t i n manifold v a r i a n t s t h a t r e t a i n , i n t h e main, t h e f u n c t i o n of t h e p r i m i t i v e p r o t e i n . It is b e i n g recognized t h a t m u t a t i o n a l changes are o c c u r r i n g a t rates t h a t would have been regarded a s improbably enormous only 5 y e a r s ago, b u t t h a t t h e b u l k o f such mutations are n e u t r a l ' = . An e x c i t i n g c h a p t e r i n t h e h i s t o r y of d i h y d r o f o l a t e r e d u c t a s e s t i l l l i e s ahead when s t u d i e s on t h e sequence and conformation of t h e enzyme from d i f f e r e n t s o u r c e s w i l l permit comparative studies.
For chemotherapy, t r i m e t h o p r i m and i t s r e l a t i v e s c a r r y t h e i m p l i c a t i o n t h a t s e l e c t i v e i n h i b i t i o n of any f u n c t i o n may b e p o s s i b l e , and t h a t t h e most p r o b a b l e access t o s e l e c t i v e e f f e c t s may l i e i n t h e s u p p o r t i v e s t r u c t u r e s of t h e c e l l u l a r r e c e p t o r s .
References G. H. H i t c h i n g s , Cancer Res., 29, 1895 (1969). 417 (1965). G. H. H i t c h i n g s and J. J. B u r c h a l l , Adv. i n Enzymol., L. P. Garrod, Drugs, 1, 3 (1971). E d i t o r i a l , Drugs, 1, 7 (1971). 5. G. H. H i t c h i n g s , G T B . E l i o n , E. A. Falco, P. B . R u s s e l l , M. B. Sherwood and H. VanderWerff, J . B i o l . Chem., 1 (1950). 6 . J. J. B u r c h a l l and G. H. H i t c h i n g s , Mol. Pharmacol., 1, 126 (1965). 444 ( 1 9 7 i ) . 7. G. H. H i t c h i n g s , Ann. N . Y. Acad. sci., 8. G. M. Brown, J. B i o l . Chem., 237, 536 (1962). 9. G. H. H i t c h i n g s , Postgrad. Med. J. s u p p l . , 2, 7 (1969). 10. J. J. B u r c h a l l , Postgrad. Med. J. s u p p l . , 45, 29 (1969) 11. G. H. H i t c h i n g s , E. A. Falco, H. VanderWerff, P. B. R u s s e l l , and G. B. E l i o n , J. B i o l . Chem., 4 3 (1952). 143 (1971). 12. J. J. B u r c h a l l , Ann. N . Y . Acad. S c i . , 13. T. Ohta and M. Kimira, Nature, 233, 118 (1971).
1. 2. 3. 4.
27,
183, 186,
.
199,
186,
Section I Editor:
- CNS Agents
Edward L. Engelhardt
Merck Sharp and Dohme Research Laboratories, West Point, Pennsylvania 19486
Chapter 1.
Antipsychotic and Anti-anxiety Agents
Charles L. Z i r k l e and C a r l Kaiser Smith Kline & French Laboratories, Philadelphia, Pa. 19101
- Despite
continuation of the extensive research e f f o r t s i n agents emerged i n 1971. However, t h e e v e r expanding i n v e s t i g a t i o n s of t h e monoaminergic, p a r t i c u l a r l y catecholaminergic, pathways i n t h e b r a i n and of the effects of drugs upon them suggest t h a t this approach, which was so successful i n s e t t i n g t h e stage f o r the discovery o f L-dopa f o r t h e treatment of parkinsonism, w i l l eventually lead t o a b e t t e r understanding of the presently a v a i l a b l e drugs and t o more e f f e c t i v e o r s e l e c t i v e psythe chotropic agents. An important c l i n i c a l development was announced resolution of t h e controversy over the use of L i 2 C 0 3 a s prophylactic treatment of manic-depression.’ Results of an extensive 4 year study t o be reported by NIMH have confirmed the belief long held by s o m e clinicians t h a t d a i l y use of t h e drug i s effective i n preventing broad swings i n mood i n p a t i e n t s w i t h this disorder. A number of books and reviews c l i n i c a l ’ ” and t r e a t i n g t h e biochemical ,2 structure-activity9 ” aspects of t h e antipsychotics and anti-anxiety agents have been pub li shed. Introduction
t h i s f i e l d , no fundamentally new antipsychotics and anti-anxiety
-
-
Tricvclic compounds with a six-membered c e n t r a l r i n q Newer phenothiazine d e r i v a t i v e s with clinical antipsychotic e f f i c a c y included oxaf luma2 p i p o t i a z i n e (2, ,11 a potent cataleptogenic i n animals, zine (la> RP 19,336),‘J which h a s a pharmacological p r o f i l e s i m i l a r t o t h a t of Extensive s t u d i e s fluphenazine, and a r e l a t e d p i p e r i d i n o l SA 124 (g).” indicated c l o s p i r a z i n e ( I d , APY-606) ” had c l i n i c a l antipsychotic a c t i v i t y equivalent t o that of chlorpromazine.’
’
,’*
Several f a t t y a c i d esters of a l c o h o l i c phenothiazine d e r i v a t i v e s , undecyclenate and palmitate, fluphenazine e.g., pipotiazine (2) enanthate’ and decanoate,’ and perphenazine enanthate, as w e l l as t h e r e l a t e d thioxanthene, f lupenthixol decanoate, found c l i n i c a l u t i l i t y i n antipsychotic maintenance therapy.20 These esters can a f f o r d advantages i n absorption t o enable attainment of high drug-levels i n t h e CNS” and to provide clinical e f f i c a c y of 2 to 4 weeks duration following a s i n g l e injection.?O
Chap. 1
Antipsychotics, A n t i - A n x i e t y Agents
Z i r k l e , Kaiser
L
The most e f f e c t i v e of a series of phenothiazines having diazabicyclo[4.4.0Jdecane and -[4.3.03 nonane systems i n t h e s i d e chain w a s 2. I n r a t s l e was s i m i l a r t o perphenazine; i t blocked conditioned avoidance response7CAR) a t 0.5 mg/kg, sc." M c l o p a z i n e (If),5014 (Iq)and 5023 (3) were t h e most potent compounds i n a series of imidazolone and oxazolidone d e r i v a t i v e s of phenothiazine and 1-azaphenothiazine; they w e r e more potent than perphenazine i n tests f o r sedation and antiaggression i n mice and a s antiemetics i n dogs.23
asn NI
d) X=C1; R=
X
mo U
h) X=CF3; R=same a s i n g The most e f f e c t i v e member (&) i n a series of amine-altered congeners of unsaturated thioxanthene antipsychotics was nearly equipotent with chlorpromazine i n blocking CAR i n r a t s and i n depressing spontaneous motor a c t i v i t y (SMA) i n mice.'' Another thioxanthene (2,prothixene) decreased SMA i n mice only a t high doses; however, i t caused marked hypocholest e r e m i a i n rats.25 A dihydroanthracene, SK&F 28175 (2) produced phamacological responses c h a r a c t e r i s t i c of both neuroleptic and antidepressant , only chlorprodrugs whereas a demethyl analog, SK&F 25971 (21caused mazine-like effect ' . s
,
'
H
a
R
X
-2
2
a ) X=CF3; R = @ ( q b) X--ql-+;
a ) R=CH3
OH
R=N(CH3)2
b ) R=H
-
T r i c y c l i c communds with a seven-membered c e n t r a l r i n q A dibenzodiazepine, clozapine (5, W-1854), was e f f e c t i v e i n psychotic patients;'? however, i t produced n e i t h e r neuroleptic-like (e.g., catalepsy, antiemetid) a c t i o n s i n animal$' nor parkinsonism-like symptoms i n man. A d e r i v a t i v e was more potent than chlorpromazine i n of dibenzthiepin, GP 45795 various animal tests f o r neuroleptic a c t i v i t and i t antagonized amphetC l i n i c a l l y , 2 improved amine- and tetrabenazine-induced responses.2
(s),
8
Sect. 1
chronic schizophrenics.’’
-
CNS Agents
Engelhardt, Ed.
Among a series of related s t r u c t u r e s , noroctoand oxyprothepin had neurolepticclothepin (El, oxornetothepin l i k e a c t i v i t y equal t o , o r g r e a t e r than, t h a t of octoclothepin i n mice.” C l i n i c a l antipsychotic p r o p e r t i e s were reported’ for Dehydroclothepin (41, one of a series of dibenzthiepins and dibenzoselenopines, was more potent than perphenazine i n r o t a t i n g rod and c a t a l e p s y tests i n mice; however, t o x i c i t y and i n s t a b i l i t y i n aqueous a c i d are possible d e t e r r e n t s t o i t s c l i n i c a l investigation.” W o unsaturated congeners of peradithepin,” & and 7b, were s u b s t a n t i a l l y more potent than t h e parent i n a rat catalepsy t e s 3 ‘
(x) x.
(z)
H
X=C1; Y-0; R=CH, X=C1; Y = y ; R=H X t o c H s ; Y=%; R=(CH,)SOH x = m , ; y = h ; R=(%),oH
a > R-CH’,
b) R = ( q ) ’ O H
A dibenzazepine, 1f3-chlorocarpipramine1f (8, Y-4153). was e f f e c t i v e i n assays of neuroleptic a c t i v i t y (0.2-1X chlorpromazine) and i t i s claimed t o lack catoleptogenic properties.’*
-
Butyrophenones and r e l a t e d compounds The butyrophenone %was e f f e c t i v e i n t h e therapy of schizophrenics and caused only mild side effects;J6 i t s e l e c t i v e l y blocked CAR (0.U t r i f l u p e r i d o l ) i n mice. AHR-2277 was more potent than chlorpromazine, b u t less potent than haloperidol, i n suppressing CAR i n mice and cats i n doses below those producing obvious A r e l a t e d compound AHR-1900 (&) elicited neurolepticmotor defects.” I n a series l i k e behavioral effects i n mice, r a t s and s q u i r r e l monkeys.ie of butyrophenones bearing unsaturated amino s u b s t i t u e n t s , most potent CNS ~bbott-30360 (2) depressant a c t i v i t y i n mice was noted w i t h 2 . 5 ’ combined neuroleptic p r o p e r t i e s with a n a l g e t i c potency approximately equal The most potent compound (10)i n a series of to t h a t of morphine.‘0 methyl-branched aminobutyrophenones was only weakly depressant i n mice .‘I
(a)
A
Chap. 1
Antipsychotics, Anti-Anxiety Agents
H
10 -
11 -
O t h e r structures with antiDsychotic a c t i v i t y
Z i r k l e , Kaiser
-9
12 -
-
A molindone analog, AL 1612 antiemetic and neuroleptic properties i n animal^;'^ however, clinical antipsychotic a c t i v i t y w a s accompanied by a high i n c i dence of extrapyramidal s i d e effects.' Combined c l i n i c a l antipsychotic and antidepressive actions were noted f o r sulpiride.'s S ~ h - 1 2 ~ 6 7 (g) 9 reduced aggressive behavior i n mice and monkeys; however, a c l i n i c a l study indicated i t i s not a c l a s s i c a l neuroleptic." Chronic schizophrenics were improved by g-penicillamine.'s Prostaglandin like chlorpromazine, decreased CAR i n both naive and trained r a t s f r l A benzothienopyridine, EX 11-349 ( 1 ), decreased SMA i n mice and was e f f e c t i v e i n a f i g h t i n g mouse test ( q o + . 9 mg/kg, po)." Several members of a series of l-acylated-l,2-dihydroquinolines antagonized amphetamine actions, blocked a CAR, and caused neuroleptic-like effects i n mice and rats." The cis-,b u t not the t r a n s , aminoalcohol (g) was e f f e c t i v e i n several pharmacological tests f o r neuroleptic a ~ t i v i t y . ' ~ In mice, the benzothiazinone 16 was the most potent of a series of compounds i n causing depression, catatonia and decreased SMA.50
?s) , demonstrated
14
QQ X
11
14 H ..
4 N - + y N,Bo
16
17
18 -
Benzoquinolizine-like ( short-acting, selective) depletion of c e n t r a l and U-20,057 ,s2 catecholamines w a s produced by RO-8-2580 (17)51 compounds causing neuroleptic-like effects i n animals,
(2)
-
BenzodiazeDines and related compounds The c h d s t r y and s o m e aspects of the relationship between the s t r u c t u r e of 1,kbenzodiazepines and their anti-anxiety a c t i v i t y were reviewed i n 1971.53 In clinical studies, demethdiazepam (*, RO-5-2180, A-101) was more e f f e c t i v e than diazepam for the treatment of anxiety;54 however, Ro-5-3350 w a s less
(a)
10
Sect. 1
-
Engelhardt, Ed,
CNS Agents
e f f e c t i ~ e . ' ~ Several pharmacologicals6 ' s 7 and c l i n i c a l s 8 studies indicated lorazepam wy-4036) i s a potent anti-anxiety agent with a sedativehypnotic component. Sch-12,041 ( 1 d) showed evidence of anti-anxiety Methyloxazepam w a s t h e most a c t i v i t y i n an uncontrolled study+ potent of a series of benzodiazepines i n p o t e n t i a t i n g methamphetamineinduced stereotyped behavior i n rats.60 I n monkeys, Ro-5-4200 ( 1 f > was e f f e c t i v e i n causing EEG and behavioral e f f e c t s (20X diazepam) .6?-Various 7-sulfonamido-1, kbenzodiazepines (3,X = h N S 4 , (CHj l2 N S 0 2 , CHj So, NH; 1-H o r CHj) had a n t i n i c o t i n e a c t i v i t y i n mice, b u t they were much less potent than diazepam.62 Ro-5-6901/3 (3) was t h e most e f f e c t i v e of 8 benzodiazepines t e s t e d f o r anticonvulsant a c t i v i t y i n
(a,
(B)
21 -
X=C1, B r , N 4 20 -
a > x=cl; Y=H b) X = B r ;
&
=2-pyridyl
x=ci; y=ci; 3-OH d) X X 1 ; Y=H; l--CFj e> X=Cl; Y=H; l-CHj; 3 - 0 H f > X = N % ; Y-F; 1-CH5 g> X 4 1 ; Y=F; 1-(C14)2N(C2H5)2
C)
a ) R-4Hj; X=C1; Y=F b) R=CH,; X=Y=Cl C > RrCHj; X=C1; Y=H d) R=Y=H; X=C1 e) X=Y=H; RICHj f > X=H; Y=C1; R=CHj
c1
q$ 0
X=Halogen, CHj
, CHjO
22 I n an extensive series of benzo[6,7]-1, It-diazepino-C5, k-bjoxazoles several 9-methyl d e r i v a t i v e s and t h i a z o l e s r e l a t e d t o oxazolazepam,' (2) were more potent than diazepam a s antagonists of bemigride-induced convulsions i n mice.6' Triazolobenzodiazepines (21)demonstrated potent and s e l e c t i v e a c t i v i t y i n various pharmacological tests generally thought t o i n d i c a t e
Chap.
1
A n t i p s y c h o t i c s , A n t i - A n x i e t y Agents
Z i r k l e , Kaiser
11
anti-anxiety a c t i v i t y . S t r u c t u r e - a c t i v i t y data65 f o r a series o f t h e s e compounds i n d i c a t e s u b s t i t u t i o n of t h e 8-psi t i o n w i t h electron-withdrawi n g groups g e n e r a l l y enhances potency, a s does 1-methyl s u b s t i t u t i o n . S u b s t i t u t i o n of t h e 1-position w i t h a l k y l groups l a r g e r than e t h y l as w e l l a s i n t r o d u c t i o n of a para-methoxyl i n t o t h e 6-phenyl moiety caused a marked decrease of potency.66 S u b s t i t u t i o n of C 1 o r F a t t h e o r t h o posit i o n of t h e C-6 phenyl r i n g gave compounds w i t h d r a m a t i c a l l y enhanced a c t i v i t y i n many tests,65 e.g., & and 2 w e r e very p o t e n t (3OX diazepam) upon S.C. a d m i n i s t r a t i o n t o m i c e i n an a n t i - p e n t y l e n e t e t r a z o l test. Extensive pharmacologicald6'6 and biochemical6 d a t a a r e r e p o r t e d f o r D-65-MI' (3) , D-40-TA , U-31,957 and U-35,005 (21f).
'
(e)
A benzodiazepinone CT 5104 (22)was considerably less p r o t e c t i v e than chlordiazepoxide v e r s u s electroshock-induced convulsions i n mice.6 The benzodiazepindiones 3 were i n e f f e c t i v e a s a n t a g o n i s t s o f pentylenetetrazol-induced convulsions i n r a t s . 7 0 I n humans, O W 8063 e l i c i t e d e l e c t r o p h y s i o l o g i c a l and behavioral changes similar t o those had c l i n i c a l produced by diazepam.71 The pyrazolodiazepine C I 683 (3) anti-anxiety a c t i v i t y . I n r a t s , i t counteracted conflict-induced depression and antagonized pentylenetetrazol-induced convulsion^.^^
(2)
Several miscellaneous s t r u c t u r e s were examined f o r a n t i - a n x i e t y a c t i v i t y . Propranolol w a s e f f e c t i v e i n LSD-induced a n x i e t y i n humans.73 As both ( + > and (-)-isomers produced t r a n q u i l i z a t i o n i n rats, t h e a c t i o n i s n o t a t t r i b u t e d t o P-adrenergic b l ~ c k a d e . ~ ' Although pyridarone (3) was t h e most p o t e n t member of a series s t u d i e d f o r neurodepressant a c t i v i t y i n animals, anti-anxiety a c t i o n could n o t be confirmed i n a clinical study.75 Fenpentadiol (3)displayed anti-anxiety and s t i m u l a n t Meprobamate-like a c t i v i t y w a s noted i n pharmacop r o p e r t i e s i n animals.76 l o g i c a l s t u d i e s o f Insem-54 The pharmacology o f propanediol carbamates w a s reviewed r e ~ e n t l y . ~ '
27
26 -
28 -
bktabolism of benzodiazepine d e r i v a t i v e s - B i o l o g i c a l h a l f - l i f e s t u d i e s of chlordiazepoxide i n man showed desnethylchlordiazepxide (-1 and demoxepam t o be major metabolite^.^^ In dogs, metabolism of i n v o l v e s two o x i d a t i v e pathways. One l e a d s t o two phenolic products: 5-( 4-hydroxyphenyl) and 9-hydroxy d e r i v a t i v e s . The o t h e r i n v o l v e s l o s s of t h e N d x i d e f u n c t i o n t o give N-desoxy-2, oxazepam, and N-desoxy d e r i v a t i v e s of t h e phenolic products. A l s o , h y d r o l y s i s of demoxepam I n man, m e t a b o l i t e s o f demoxepam a f f o r d s an "opened lactam" ( Z > . ' O The pharmacologwere oxazepam conjugates, 30, and phenolic products.'l i c a l effects of diazepam i n mice were r e l a t e d t o b r a i n l e v e l s of i t s metaboli tes, p a r t i c u l a r l y oxazepam .82
a
-
12 -
c1
Sect. 1
-
CNS Agents
Engel h a r d t , Ed.
&-
a) X=NH
R
O
N*
a) R = q v ; Y=H
b) X=O
C>
b) R=Y=H
R = C % v ; Y=OH
Metabolism o f prazepam by human and animal l i v e r preparations gave mainly desalkylprazepam p l u s a small amount o f oxazepam, b u t no 3-hydroxyprazepam (jlc) I n c o n t r a s t , t h e p r i n c i p a l urinary metabolites of prazepam i n man were glucuronides of J & and oxazepam and small amounts of
u.''
Diazepam and phenolic diazepam d e r i v a t i v e s were s i g n i f i c a n t m e t a b o l i t e s of medazepam i n dog, r a t and man.e5
-
The r e s u l t s of extensive Hypotheses. Biochemistrv and Pharmacoloqy histochemical mapping by Swedish i n v e s t i g a t o r s 3 ' 5 " " o f catecholaminergic (CAI pathways i n t h e r a t b r a i n suggest t h a t these systems may play c r u c i a l roles i n t h e complex n e u r a l t r a f f i c which courses back and f o r t h between b r a i n s t e m c e n t e r s , hypothalamus, thalamus, basal ganglia (e.g., neostriaturn), limbic system and cortex, and provides the neural b a s i s f o r perception, arousal, motivation and emotional behavior. The most c l e a r l y defined t r a c t i s a n i g r o s t r i a t a l dopaminergic (DA) pathway ascending f r o m the s u b s t a n t i a nigra t o the neostriatum. Another DA system p r o j e c t s from the midbrain t o t h e limbic system. 'Jho noradrenergic (NA) pathways, o r i g i n a t i n g i n the r e t i c u l a r formation and ascending through t h e medial forebrain bundle, together innervate t h e hypothalmus, thalamus, areas of the limbic system and the cortex. Growing evidence i n d i c a t e s t h a t t h e antipsychotics e x e r t many of t h e i r pharmacological and c l i n i c a l e f f e c t s by a c t i o n s on these CA neural systems. The EPS produced by these drugs c l e a r l y i n d i c a t e an a c t i o n on t h e b a s a l ganglia. Lesions i n t h e nigros t r i a t a l pathway, attended by a loss of DA i n the neostriatum, appear t o be i n l a r g e p a r t responsible f o r t h e EPS of parkinsonism, and the EPS produced by reserpine probably a r e t h e consequence of t h e DA-depleting action of t h e drug.5 Although o t h e r types o f n e u r o l e p t i c s such a s the phenothiazines and butyrophenones do n o t have an appreciable e f f e c t on b r a i n l e v e l s of DA they too a f f e c t DA metabolism i n t h e neostriatum. Various biochemical effects of t h e s e agents, e.g., an increased l e v e l o f homovanillic acid, i n d i c a t e t h a t they a c c e l e r a t e t h e turnover of DA i n the neostriatum. It i s postulated t h a t the antipsychotics block postsynatic DA receptors and t h a t t h e r e s u l t i n g functional deficiency of DA a c t i v a t e s a feed-back mechanism t o stimulate synthesis o f t h e transmitter.25 ' The observation t h a t t h e n e u r o l e p t i c s do not appreciably i n c r e a s e turnover of DA u n l e s s nerve impulse flow i s i n t a c t seems t o favor a postsynaptic mechanism of DA blockadee6 r a t h e r than a presynaptic mechanisme7 l i k e t h a t of reserpine. These drugs a l s o i n c r e a s e turnover of DA i n t h e neurons which p r o j e c t t o t h e limbic system and s o m e accelerate turnover However, i n d i v i d u a l drugs of norepinephrine (NE) i n the NA system^.^
Chap, 1
A n tip s y c h o tic s ,
A n ti-A nxiety Agents
Z i r k l e , Kaiser
13
seem t o d i f f e r considerably i n t h e i r effects on t h e two types of neurons. I n an extensive study of a v a r i e t y o f neuroleptics, i t w a s found t h a t perphenazine accelerated turnover of both amines, spiroperidol increased turnover of only DA and pimozide increased turnover o f DA a t low doses and NE a t high doses.” Rats with u n i l a t e r a l l e s i o n s of t h e n i g r o s t r i a t a l pathway have been used a s a model f o r measuring the DA a c t i v i t y of drugs such as amphetamine and t h e DA blocking a c t i v i t y o f a n t i p s y c h o t i c s i n t h e n e o ~ t r i a t u m r. ~ Be70 These animals d i s p l a y motor asymmetries and a tendency t o t u r n toward t h e side of t h e l e s i o n ( i p s i l a t e r a l turning). Amphetamine enhances the turni n g behavior and t h e n e u r o l e p t i c s antagonize this effect. If t h e neostriatum i s lesioned o r removed, t h e n e u r o l e p t i c s cause c o n t r a l a t e r a l asymmetries. A s i m i l a r mouse model h a s been developed and used t o assess t h e a c t i v i t y o f various anti psychotic^.^' The c h a r a c t e r i s t i c cataleptogenic property of t h e antipsychotics has been thought t o be due t o an effect of these drugs i n t h e n e o ~ t r i a t u m . ~ ~ ~ ~ Consistent with this idea i s t h e f i n d i n g of a c o r r e l a t i o n between t h e potencies and t i m e courses of a c t i o n of drugs i n producing c a t a l e p s y and i n producing increased homovanillic a c i d l e v e l s i n t h e neostriatum o f rats.” However, a comparison of the effects of l e s i o n s i n t h e s u b s t a n t i a nigra, neostriatum o r globus p a l l i d u s upon antipsychotic- and cholinergicinduced c a t a l e p s y suggests t h a t i n t e g r i t y of t h e globus p a l l i d u s i s import a n t for t h e a c t i o n o f n e u r o l e p t i c s b u t n o t f o r t h e a c t i o n of choline r g i c s .9 ’9 5
‘
Antagonism of amphetamine- o r apomorphine-induced stereotyped behavior i s another c h a r a c t e r i s t i c effect of the antipsychotics. Fbst d a t a favor t h e hypothesis t h a t drug-induced stereotyped behavior i s the r e s u l t of DA a c t i v i t y i n t h e n e ~ s t r i a t u m . ” ~ ~However, a comparison o f t h e e f f e c t s of l e s i o n s i n the neostriatum o r i n t h e tuberculum olfactorium upon DA- and apomorphine-induced stereotyped behavior suggests t h a t DA a c t i v i t y i n t h e limbic f o r e b r a i n may be important f o r this drug effect i n the rat.96 The antipsychotics are a l s o noted for t h e i r a b i l i t y t o a t t e n u a t e Animals with e l e c t r o d e s implanted i n t h e septum b r a i n self-stimulation. ( i n t h e limbic system) o r t h e medial f o r e b r a i n bundle, through which CA neurons ascend t o t h e limbic system, repeatedly p r e s s a l e v e r to o b t a i n electrical stimulation of these areas. Thus the “reward o r pleasure” centers involved i n this behavior may be located i n areas of t h e limbic f ~ r e b r a i n . ~ ?A study extending earlier work o f SteinP7 s h o w s t h a t selfstimulation i s accompanied by release o f NE f r o m NA terminals i n t h e hypothalamus, p r e o p t l c area, and p a r t s of t h e limbic system.98 Another paper r e p o r t s t h a t self-stimulation also occurs when e l e c t r o d e s a r e placed i n regions near the s u b s t a n t i a n i g r a where DA neurons are located.99 Thus DA a s w e l l as NA pathways may be involved i n t h e effects o f reward on operant behavior and i n t h e a t t e n u a t i n g effects o f t h e n e u r o l e p t i c s on T h i s behavior i s a1 so attenuated when 6-hydroxydopaming self-stimulation. which causes degeneration o f CA neurons and depletion o f t h e amines, i s
14 -
Sect. 1
-
CNS Agents
E n g e l h a r d t , Ed.
given i n t r a c i s t e r n a l l y t o rats.’” S t e i n and W i s e ’ O ’ have proposed a novel e t i o l o g y of schizophrenia which involves t h e endogenous buildup o f 6-hydroxydopamine and a r e s u l t a n t d e t e r i o r a t i o n of NA pathways t h a t mediate reward. They p o s t u l a t e t h a t t h e a n t i p s y c h o t i c s produce t h e i r c l i n i c a l e f f e c t s by preventing t h e uptake of 6-hydroxydopamine i n t o the NA neurons. Several criticisms’02-’05of this hypothesis and a rebuttala have been published. These p o i n t o u t t h e problems of defining and c h a r a c t e r i z i n g mental disorders as w e l l as some of the experimental and i n t e r p r e t a t i o n a l d i f f i c u l t i e s of research i n this area. Hypotheses regarding a c t i o n o f the antipsychotics a t the c e l l u l a r and molecular l e v e l s range f r o m a view t h a t the drugs i n t e r a c t nons p e c i f i c a l l y with neuronal and s u b c e l l u l a r membranes to a p o s t u l a t e t h a t they s p e c i f i c a l l y block postsynaptic r e c e p t o r s of neurotransmitters, e.g., DA and NE. These drugs a r e potent surface-active agents and s t a b i l i z e c e l l u l a r and s u b c e l l u l a r membranes and i t has been proposed t h a t they act l i k e l o c a l a n e s t h e t i c s by a l t e r i n g membrane permeability and i n t e r f e r i n g with neural transmission.’ O 6 Consistent with t h i s v i e w are observations t h a t procaine, when i n j e c t e d i n t o the neostriatum of cats, produced e f f e c t s s i m i l a r to those of haloperidol’07 and t h a t ouabain, another agent which a l t e r s membrane function, produced many of t h e effects of t h e a n t i A n i n v i t r o study o f the psychotics when given intraventricularly.’O effects of promazine and t h i o r i d a z i n e on membrane preparations suggests t h a t i n h i b i t i o n of Na+-K+-ATPase by these agents i s secondary to more general a l t e r a t i o n s of the c e l l membranes.’ Another hypothesis proposes t h a t t h e a n t i p s y c h o t i c s prevent t h e access of neurotransmitters t o t h e i r r e c e p t o r s by forming a monomolecular f i l m on t h e postsynaptic noting t h a t t h e s o l i d - s t a t e s t r u c t u r e membrane,’ b u t Horn and Snyder,’ of DA i s superimposable upon a portion of the solid-state s t r u c t u r e o f chloropromazine, suggest t h a t t h e antipsychotics might s e l e c t i v e l y i n t e r act with CA receptors. The e f f e c t s of t h e antipsychotics upon b r a i n tissue l e v e l s o f c y c l i c AMP, which could be t h e mediator o f c e n t r a l CA actions, have been studied i n vivo and i n vitro.’ Trifluopera~ind’~ and haloperidol’ were more potent than chlorpromazine i n preventing the rise i n c y c l i c AMP levels produced by norepinephrine o r decapitation. The ” promethazine,’ and protripsulfoxides of t h e two phenothiazines,’ tyline’ were much less potent than chlorpromazine.
’
’
’’
’ ’’ ’
’
’
’ ’
’
If both antipsychotic and l o c a l a n e s t h e t i c a c t i v i t y are t h e result of nonspecific i n t e r a c t i o n of drugs with membranes, t h e c h a r a c t e r i s t i c CNS a c t i o n s of the antipsychotics must be due t o a p a r t i c u l a r drug d i s t r i b u t i o n i n t o v a r i o u s b r a i n regions, a s e l e c t i v e a f f i n i t y f o r c e r t a i n neurons, o r a d i f f e r e n t i a l s u s c e p t i b i l i t y t o drug a c t i o n by various i n t e r neuronal organizations. It has been observed t h a t d i f f e r e n t regions of t h e b r a i n take up d i f f e r e n t amounts of chlorpromazine, b u t no d i f f e r e n c e in the a f f i n i t y of t h e n e u r o l e p t i c s f o r t i s s u e from various b r a i n regions w a s detected i n i n v i t r o experiments.”‘ A study of phenothiazines showed t h a t the d i f f e r e n t potencies of t h e 1-, 2-, 3- and k h l o r o p r o m a z i n e s i n producing catalepsy i s not due to d i f f e r e n c e s i n t h e a v a i l a b i l i t y o f t h e In c o n t r a s t , a c a r e f u l study of f o u r f o u r isomers i n the brain.”‘ butyrophenones i n d i c a t e d t h a t t h e i r molar concentrations i n t h e b r a i n were
Chap. 1
Antipsychotics, Anti-Anxiety A g e n t s
Z i r k l e , Kaiser
JI
a bout t h e same a f t e r administration of Eq, doses f o r antagonism of Thus, i f amphetamine- and apomorphine-induced stereotyped behavior.’ t o t a l b r a i n l e v e l s of a n t i p s y c h o t i c s are an index of drug a v a i l a b i l i t y a t sites o f a c t i o n , t h e s e l i m i t e d observations suggest t h a t the differences i n t h e potencies of t h e a n t i p s y c h o t i c s can be accounted f o r by differences i n t h e i r a b i l i t i e s t o reach t h e i r d t e s o f a c t i o n i n t h e case of the four butyrophenones b u t not i n the case of t h e isomeric phenothiazines. Much more extensive s t u d i e s c o r r e l a t i n g b i o l o g i c a l a c t i v i t y w i t h t o t a l o r regional b r a i n l e v e l s of a v a r i e t y of a n t i p s y c h o t i c s o f d i v e r s e s t r u c t u r e and potencies must be c a r r i e d o u t before the s i g n i f i c a n c e o f t h e struct u r a l requirements f o r antipsychotic a c t i v i t y can be understood.
’
Although t h e r e a r e s o m e i n d i c a t i o n s t h a t Li,CO, in some way a f f e c t s CA metabolism,”‘ l i t t l e progress has been made i n explaining i t s specific therapeutic effects i n manic-depressive psychosis. Manic o r hypomanic states sometimes develop i n t h e course of L-dopa therapy, p a r t i c u l a r l y i n ” From t h e meager conf licp a t i e n t s w i t h a p r i o r h i s t o r y of mania.’ t i n g d a t a available” e i t cannot be s a i d y e t whether o r n o t Li, COJ i s e f f e c t i v e i n ameliorating Gdopa-induced mania.
’ ’
Additional d a t a support t h e i d e a t h a t effects of anti-anxiety agents upon CA pathways may a t least i n p a r t account f o r t h e i r c l i n i c a l action. A study of the effects o f chlordiazepoxide, diazepam and nitrazepam on C4 neurons of non-stressed and stressed r a t s using N s t o chemical and biochemical analyses of amines suggests t h a t these drugs decrease impulse a c t i v i t y i n NA neurons i n n e r v a t i n g t h e c o r t e x and hippocampus and i n DA neurons ascending t o t h e neostriatum and limbic foreThese r e s u l t s are c o n s i s t e n t with e l e c t r o p h y s i o l o g i c a l obserbrain.’ vations t h a t the anti-anxiety agents c o n t r o l abnormal a c t i v i t y i n various components of t h e limbic system a t doses which have l i t t l e o r no effect on the cortex.”’
’
REFERENCES
1. Anonymous, Chemical Week, =(lo), 41, March 8, 1972. 2. J. R. Cooper, I“. E. Bloom and R. H. Roth, The Biochemical Basis of Neurophamcology, O x f o n l University Press, New York, 1970.
3. W. G. Clark and J. d e l Giudice, Eds., P r i n c i p l e s of Psychopharmacology, Academic Press, New Yo*, 1970. 4. R. H. Rech and K. E. Moore, Eds., An Introduction t o Psychophamcology, Raven Press, New York, 1971. 5. K. Rxe, T. Hokfelt and U. Ungerstedt, Lnt. Rev. Neumbiol., 13 93 (1970). 6. F. S u l s e r and E. Sanders-Bush, Annu. Rev. Phamacol., ll, m Y 1 9 7 1 ) . 7. K. Rxe and T. Hokfelt, Triangle, 10, 73 (1971).
367,
8. U. Ungerstedt, Acta Physiol. Scand., Suppl. 1 (1971). 9. C. L. Zirkle and C. Kaiser, i n Medicinal Chemistry, 3rd Ed., A. Burger, Ed., Wiley-Interscience, New York, 1970, p. 1410. 10. S. J. Childress, i b i d . , p. 1498. 11. P. Deniker, D. Ginestet, P. Peron-Magnan, L. Colonna and H. Loo, Therapie, 26, 227 (1971). 12. J. R. Boissier and C. hrmont, ibid., 26, 481 (1971). 13. M. M. Broussolle, J. Grambert and M. Hodam, Ann. Med. Psychol., 129, 436 (1971). 14. C. Earchewitz and H. Helmchen, Pharmakopsychiat./Neuro-Psychpharmakol., 3, 293 (1970). 15. R. I. Fryer, Annual Reports Med. Chem.,1970, p. 1. 16. M; Nakanishi, T. Okada and T. Tsumagari, Yakugaku Zasshi, 90, 800 (1970).
16
Sect. 1
-
Engelhardt, Ed.
CNS Agents
17. Anonymous, Jap. Med. Gaz. $l), 10, NoV. 20, 1971. 18. U. Malm, Acta Psychiat. Sand., 225 (1970). 19. T. Itil and A. Keskiner, Dis. Nerv. Syst., Suppl. 2,37 (1970). 20. F. J. Ayd, Jr., Int. DNg IPher. Newsletter, z(1-21, 1 (1972). 22. J.O. Cole, Dis. Nerv. Syst., Suppl. 2,5 (1970). 22. C. Casagrande, A. Galli, R. Ferrini and G. Miragoli, Armeb.-Forsch., 2l, 898 (1971). 23. D. Lenke, B. Neteler and N. Brock, ibid., 2 l , 288 (1971). 24. L. Fontanella, L. Mariani, E. Occelli, B. Rosselli del Turco and A. Diena, Farmaco, Ed. Sci., 489 (1971). u / 25. K. Pelz, E. Svdtek, J. Metysova, F. Hradil and M. Protiva, Collect. Czech. Chem. Commun.,A, 2623 (1970). 26. P. J. Fowler, D. H. Tedeschi, C. Zirkle and E. Macko, Pharmacologist, 13, 235 (1971). 27. J. Angst, U. Jaenicke, A. PadNtt and C. Scharfetter, PhannakopsychiatTNeuro-Psychopharmakol., 4, 192 (1971); Chem. Abstr.,E, 196n (1972). 28. G. S t i l l e , H. Lauener and E. Eichenberger, Famco, Ed. Prat., 26, 603 (1971). 29. A. A. S u g e m , Curr. Ther. Res., C l h . Exp., l3, 549 (1971). 30. D. M. G a p a n t , R. Guerrerc-Figueroa an? M. P. Bishop, ibid.,l3, 469 (1971). 31. J. 0. Jilek, J. Pomyk<:ek, J. Metygova and M. Protiva, Collect. Czech. Chem. Commun.,*, 2226 (19711. 32. J. Mety$v< Acta Hem. Super. (Praha), 2,185 (1971). 33. J. 0. Jilek, K. &dele$< J. Metygov6, J. MetyG J. Pomyk&k and M. Protiva, Collect. Czech. Chem. C o q n . , 35, 3721 (1970). 34. K. S i n d e l z , J. MetyEova/and M. Protiva, ibid., 36, 3404 (1971). 35. M. Nakanishi, T. Tsumagari and A. Nakanishi, Armeh.-Forsch., 2, 391 (1971). 36. J. P. L i , R. G. Stein, J. H. Biel, J. A. Gylys and S. A. Ridlon, J. Med. Chem., 2, 1230 (1970). 197 (1971). 37. D. N. Johnson, W. H. Funderburk and J. W. Ward, Arch. Int. Pharmacodyn., 38. M. Bleiberg and J. W. Ward, Fed. Proc,, Fed. Amer. SOC.E x p . Biol., 2,390 Abs. (1971). 1008 (1971). 39. S. J. D o m i n k m i , R. P. Pioch and R. L. Young, J. Med. Chem., 40. E. T. Kimura, P. W. Dodge, P. R. Young and R. P. Johnson, Arch. Int. Pharmacodyn., 190, 124 (1971). 41. S. J. Dominimi, R. P. Pioch, R. L. Young and P. J. S t h r t , J. Med. Chem., 1009 (1971). 42. S. W. Holmes and J. A. Gylys, Fed. Proc., Fed. Amer. SOC. Exp. Biol., 30, 598 Abs. (1971). 43. A. E l i m r and S. Gershon, Curr. Ther. Res., Clin. Exp., l3, 5!34 (197117 44. A. Keskher, T. M. Itil, T. H. Han, B. Saletu and W. Hsu, ibid., l3, 714 (1971). 45. D. J. Mattke and M. Alder, D i s . New. Syst.,32, 3W (1971). 46. W. J. Potts and P. F. E a s t , Arch. Int. Pharmaccdyn., 191, 74 (1971). 47. F. P. Miller, G. Garske, and D. Gauger, Pharmacologist, 13, 207 (1971). 48. J. F. h r e n and A. Weissman, J. Med. Chem., 49 ( 1 9 7 1 r 49. B. Lal, J. M. Khanna and N. Anand, ibid., l5, 23 (1972). 50. N. D. Hehdel, J. R. Reid and J. E. Willis, ibid., l4, 453 (1971). 51. W. P. Burkard, M. Jalfre, J. E. Blum and W. Haefely, J. Pharm. Phamcol., 23, 646 (1971). 52. G. A. Johnson and A. D. liudsik, Pharmacologist, l2, 218 (1970). 53. L. H. Sternbach, Angew. Chem. Int. Ed. Engl., lo, 34 (1971). 54. G. P. Biscaldi, J. Hattab, N. Montanaro and R. Scoz, Curr. Ther. Res., C l i n . Exp., l3, 606 (1971). 55. W. R. Mckod, R. M. Mowbray and B. Davis, Clin. Pharmacol. Ther., 11, 856 (1970). 56. M. I. Gluckman, Arzneh-Forsch., 2 l , 1049 (1971). 57. L. Stein and B. D. Berger, ibid., 21, 1073 (1971). 58. 0. Schrappe, ibid., Z, 1079 ( 1 9 7 1 r 59. D. M. Gallant and M. P. Bishop, Curr. Ther. Hes., C l h Exp., l3, 107 (1971). 60. M. Bebbhi, N. Montanaro, P. Strocchi and M. Gaiardi, Eur. J. Phannacol., 13, 3 3 (1971). 61. R. I. Joy, A. J. Hance and K. F. K i l l a m , Jr., Neurophamacology, l o ,483 G 7 1 ) . 62. R. B. Moffett and A. D. liudzik, J. Med. Chem., 588 (1971). 439 (1971). 63. J. d'Armagnac, F. Boismare, G. Streichenberger and P. Lechat, Therapie, 64. T. MGadera, J. Terada, M. Fukunaga, Y. Kawano, 1. Kamioka, C. Tamura, H. Takagi, and R. Tachikawa, J. Med. Chem., & 5X, (1971). 65. J. B. Hester, Jr., A. D. mdzik and B. V. Kamdar, ibid., 1078 (1971). 66. R. Nakajima, C. Hattori and Y. Nagawa, Jap. J. Pharmacol., 2, 489, 497 (1971). 205 (1971). 67. A. D. Rudzik, J. B. Hester and W. Friis, Pharmacologist, 68. G. A. Johnson, E. G. K i m and S. J. Boukma, ibid., 13, 2% (1971).
46,
2,
2,
2,
2,
14,
2,
26,
fi,
x,
Chap. 1
Antipsychotics,Anti-Anxiety
Agents
17
Z i r k l e , Kaiser
69 M. Julia, N. Hurion and Huynh Dinh T., Chb. Ther., 2, 343 (1970). 70. N. D. Heindel, W. P. Fives, T. F. kmke, J. E. Rowe, H. W. Snady and R. A. Carrano, J. Med. Chem., l4, 1233 (1971). 747 (1971). 71. R. GuerrereFigueroa and D. M. Gallant, Curr. Ther. Res., Clin. Ew., 72. R. J. Santos, C. Bowling, L. Mudgil and J. H. Nodhe, Pharmacologist, 2, 205 (1971). 1039 (1971). 73. A. Linken, Lancet, I1 74. J. G. Bainbridge and D. T. Greenwood, Neurophamacology, l0, 453 (1971). 75. H. J. Ziegler, H. Inion, G. Aussems, A. Christiaens, F. Chaillet and R. Charlier, Chim. Ther., 159 (1971). 76. J. Ginet, J. C. Levy and D. Rolland, Arznek-Forsch., 2, 1 (1971). Bonvarlet, J.-C. C a s h and M. Cazin, Chh. Ther., 6, 14 (1971). 77. C. kspagnol, J.-C. 78. B. J. Ludwig and J. R. Potterfield, Adv. Pharmacol. and Chemotherapy, go 173 (1971). 1500 (19717. 79. M. A. Schwartz, E. Postma, and 2. Gaut, J. Pham. Sci., 80. M. A. Schwartz, E. Postma and S. J. Kolis, ibid., 60, 438 (1971). 81. M. A. Schwartz and E. Postma, ibid., 6 l , 123 ( 1 9 7 2 r 82. F. Marcucci, E. hhssini, A. Guaitani, R. Fanelli and S. Garattini, Eur. J. Pharmacol., l6, 311 (1971). 83. J.-P. Viau, J. E. Epps and F. J. DiCarlo, Fed. ploc., Fed. Amer. SOC. Exp. Biol., 2,225 Abs. (1971). 04. F. J. DiCarlo, J.-P. Viau, J. E. Epps and L. J. Haynes, C l h . Pharmacol. Ther., ll,890 (1970). 85. M. A. Schwftrtz and J. J. Carbone, Biochem. Pharmacol., 2,343 (1970). 86. N.-E. Anden, H. Corrodi, K. Rrxe and U. Ungerstedt, Eur. J. phamcol., l5, 193 (1971). 87. A. Tagliamonte, P. Tagliamonte and G. L. Gessa, J. Neurochem., 2,733 (1970). And&, S. G. h t c h e r , H. Cormdi, K. Fuxe and U. Ungerstedt, Eur. J. Fhamcol., ll,303 88. N.-E. (1970 1. e9. U. Ungerstedt, Acta Physiol. Scand., Suppl. 367, 49 (1971). 90. U. Ungerstedt, ibid., Suppl. 367, 69 (1971). Part I, 781 (1971). 91. V. J. L o t t i , Life Sci., 92. R. Fog, A. Randrup and H. Pakkenberg, Psychophamcologia, l8, 346 (1970). 93. G. S t i l l e and H. Lauener, Arzneim.-Forsch., 2, 252 (1971). 94. B. Costall and J. E. Olley, Neurophamcology, LO, 297 (1971). 95. B. Costall and J. E. Olley, ibid., lo, 581 (1973. 96. G. M. McKenzie, Pharmacologist, l3, 279 (1971). 97. L. Stein and C. D. Wise, Ref. 3, p. 313. 98. G. W. Arbuthnott, K. Fuxe and U. Ungerstedt, Brain Res., 27, 406 (1971). 406P 99. G. M. Anlezark, G. W. Arbuthnott, J. E. Christie and T. J. Crow, B r i t . J. Phamcol.,
2,
(m),
i,
g,
2,
(19711.
loo. G. R. Breese, J. L. Howard and J. P. Leahy, ibid., 101. 102. 103. 104. 105.
106. 107. 108.
log. 110.
111. 112.
113. 114. 115. 116. 117. 118.
119. 120.
5,
255 (1971). L. Stein and C. D. Wise, Science, 1032 (1971). S. M. Antelman, A. S. Lippa and A. E. Fisher, ibid., 175, 919 ( l 9 Z ) . M. B. Bowers, Jr. and M. H. Van Woert, ibid., 175, W?j1972). J. S. Strauss and W. T. Carpenter, Jr., ibid., 175, gU (1972). L. Stein and C. I). Wise, ibid., 175, p 2 (1972). W. 0. Kwant and P. Seeman, Biochem. Pharmacol., 2089 (1971). A. R. Cools, Arch. Int. Pharmacodyn., 259 (1971). N. S. Doggett and P. S. J. Spencer, B r i t . J. Pharmacol., 42, 242 (1971). K. Landmark and I. dye, Acta Pharmacol. Toxicol., 29, 1 (1971). P. A. J. Janssen, Int. J. Neuropsychiat., Suppl. 1, S10 (1967). A. S. Horn and S. H. Snyder, Roc. Nat. Acad. Sci. U.S.A., 63, 2325 (1971). G. C. Palmer, G. A. Robison and F. Sulser, Biochem. Phanoacol., 236 (1971). P. Uzunov and B. Weiss, Neuropharmacoloa, 10 697 (1971). A. L. Green, J. Pham. Phanacol., 2, 207 7i967). P. A. J. Janssen and F. T. N. Allewijn, Arzneb.-bsch., 199 (1969). W. E. Fann, J. M. k v i s , D. S. Janowsky, J. H. Cavanaugh, J. S. KauPmenn, J. D. Gfiffith and J. A. Oates, C l b . Pharmacol. Ther., 2, 71 (1972). F. K. Goodwin, J. h e r . Med. Ass., 2,1915 (1971). C. A. Pearlman, Jr., New Eng. J. Med., 285, 1326 (1971). H. Corrodi, K. Rrxe, P. Lidbrink and L. Olson, B r a i n Res., 1 (1971). S. Margolin and M. Kletzkin, Ref. 3, p. 93.
171,
194,
g,
2
g,
2,
3,
Chapter 2.
Antidepressives and Stimulants
C a r l Kaiser and Charles L. Z i r k l e Smith Kline & French Laboratories, Philadelphia, Pa. 19101
-
Introduction As i n p a s t years, this chapter reviews stimulants together with antidepressives. T h i s arrangement of t o p i c s seems not t o be j u s t i f i e d on c l i n i c a l grounds f o r t h e s p e c t r a of clinical u t i l i t y of t h e two c a t e g o r i e s of drugs are q u i t e d i f f e r e n t . Is t h e r e any reason f o r t r e a t i n g the two s u b j e c t s together o t h e r than one of convenience? Perhaps t h e answer i s yes i f t h e d e f i n i t i o n of *Istimulants" i s l i m i t e d to amphetamine and pharmacologically r e l a t e d agents. Most research reported i n the l a s t year supports t h e long held b e l i e f t h a t the antidepressives and t h e amphetamine-like drugs e x e r t many of t h e i r pharmacological and clinical effects by a c t i o n s on c e n t r a l monoaminergic, e s p e c i a l l y catecholaminergic, pathways. B u t t h e biochemical a c t i o n s of t h e t r i c y c l i c a n t i d e p r e s s i v e s are s t i l l poorly understood and t h e i r relevancy to t h e t h e r a p e u t i c effects has not been established. From the extensive s t u d i e s on amphetamine a more coherent, i f n o t clearer, p i c t u r e of i t s a c t i o n s is emerging. A sign of progress i s t h a t one can now with some assurance describe amphetamine a s a catecholaminergic agent w i t h a pronounced dopaminergic component o f action r a t h e r than a s a c e n t r a l l y - a c t i n g sympathomimetic amine. The 1971 l i t e r a t u r e describes t h e s y n t h e s i s and pharmacological evaluation of numerous p o t e n t i a l antidepressives, b u t p r e s e n t s no evidence t h a t new agents superior t o t h e e s t a b l i s h e d drugs are i n the offing.
-
Tricvclic compounds w i t h antidepressive a c t i v i t y An a m i t r i p t y l i n e d e r i v a t i v e , S D 2202-01 (In),exhibited a pharmacological p r o f i l e similar t o t h a t o f the parent.' Antidepressive and anti-anxiety p r o p e r t i e s were Other a m i t r i p t y l i n e r e l a t i v e s , a l s o noted f o r a monomethyl analog (&I.* some 5-methylene-4-substituted dibenzocycloheptenes (21,had l i t t l e a c t i v i t y i n a mouse a n t i r e s e r p i n e test.' A dibenzthiepin, dothiepin (prothiadine), was superior t o a m i t r i p t y l i n e i n a double b l i n d comparison f o r t h e treatment of depression.' Amoxapine (3, cL-67772), a dibenzoxazepine, although devoid of a n t i c h o l i n e r g i c p r o p e r t i e s , produced imipramine-like a c t i v i t y i n animals. C l i n i c a l l y , 3 was an e f f e c t i v e a n t i depressive agent; however, s i d e e f f e c t s (insomnia, d i f f i c u l t u r i n a t i o n ) were e n ~ o u n t e r e d . ~Several related dibenzodiazepines had antidepressive properties. SM-307 (41, an e t h y l s u l f o n y l analog of dibenzepin,6 produced
kCOCH, NRCH'
la:
lb: -
R=CH3 R=H
-2
Antidepressives, S t i m u l a n t s
Chap. 2
19 -
Kaiser, Z i r k l e
imipramine-like e f f e c t s i n animals.’ A r e l a t e d pyridobenzodiazepine, UP-106 (2), a l s o was a c t i v e i n various animal tests i n which most a n t i depressives a r e e f f e c t i v e and i t demonstrated clinical activity.’ The s t r u c t u r a l l y s i m i l a r U-17,660 (6)w a s t h e most potent a n t i a l l e r g i c and antianaphylactic compound i n a series of 5- and 10-aminoalkylated dibenzodiazepines
.’
Antidepressive a c t i v i t y was noted f o r s o m e t r i c y c l i c compounds having a six-rnembered c e n t r a l ring. A series of naphthyridones, C-29 c-42 (2). and C-45 (21, caused imipramine-like a c t i v i t y i n animals.’ The influence of 3 on c e n t r a l biogenic amine levels,’ as w e l l a s i t s absorption, d i s t r i b u t i o n and excretion,’ was investigated i n mice and rats, Several phenothiazine d e r i v a t i v e s had antidepressive a CF, analog of a c t i v i t y , III extensive clinical t r i a l s f l u o r a c i z i n e (&I, chloracizine,’ showed antidepressive e f f i c a c y equivalent to imipramine. It a l s o produced a n t i c h o l i n e r g i c effects,’ ” S t r u c t u r e versus antidepressive a c t i v i t y r e l a t i o n s h i p s were reported f o r a series of phenot h i a z i n e s and r e l a t e d compounds bearing a carbocyclic b a s i c s i d e chain. Che of these compounds (&) was considerably more potent than amitriptyOther l i n e i n preventing reserpine-induced p t o s i s i n mice and rats.” phenothiazines with antidepressive a c t i o n s included &, t h e l-chloroanalog of chlorpromazine, which produced imipramine-like a c t i o n s i n mice and r a t s , ’ and the azaphenothiazine-10-thiolcarboxylate 4 which induced antidepressive-like symptoms (mydriasis, increased s e n s i t i v i t y t o touch) i n mice.‘ The antidepressive e f f e c t s of phenothiazine d e r i v a t i v e s with 1- o r a-substituents may be associated with the steric influence of these groups i n i n t e r f e r i n g with attainment of a nearly f l a t conformation by the t r i c y c l i c system.’ 3
(A),
’
‘
’
0
-7 a> X=H b) X=OCH3
c> x 4 1
-a
2
a ) X=2-CF3 ; R=CO(CY N(C, H, l 2 b) X=Z-Cl; R = t r a n s - T C % N(CH, C > X-1-C1; R = m 3 N(CH3 1 2
Other t r i c y c l i c compounds with antidepressive a c t i v i t y w e r e maprotiline (10, Ciba 34276-Ba), which produced imipramine-like e f f e c t s
20 -
Sec t. I
i n dogs’
-
CNS Agents
E n g e l h a r d t , Ed.
,
and blocked r a t synaptoso.na1 uptake of norepinephrine’ (NE) which antagonized tetrabenazineI n mice, t h e phenanthinduced p t o s i s i n mice a t EL+o 20 mgkg, P , o . ~ O rene 12 had no a n t i r e s e r p i n e a c t i v i t g ’ and a 6,g-dihydro d e r i v a t i v e of imipramine f a i l e d t o antagonize tetrabenazine-induced depression .2 and t h e pyridobenzocyclooctane
(z),
7
@cH(q)2N(a3)2
\
(a%)3NHcH3 10 -
(q13 N(CH3 1 2
11 -
((33 1 2
12 -
Several diphenylmethane d e r i v a t i v e s had antidepressive a c t i v i t y . w a s well-tolerated and e f f e c t i v e i n p a t i e n t s with various Tofenacin (3) kinds of d e p r e ~ s i o n ‘.2~4 ~ Like imipramine, s o m e aminopropenes reversed reserpine-induced hypothennia i n mice .2 The (-1 -isomer of 2 caused c l i n i c a l antidepressive a c t i o n s , b u t these were accompanied by unwanted side e f f e c t s . 2 6
14
X=H,j-F,LF; R=H,CH3
14 -
15
Other compounds with antidepressive a c t i v i t y - It has been suggested t h a t rubidium s a l t s ( s e e below) may have antidepressive a c t i v i t y and a remarkable therapeutic response was noted i n an open clinical C l i n i c a l antidepressive a c t i v i t y was produced by A-25794 .2 A molindone r e l a t i v e , EN-3022 ( 9 1 , was e f f e c t i v e i n s e v e r a l tests (antagonism of tetrabenazine-induced p t o s i s i n mice; p o t e n t i a t i o n of pressor response t o NE i n dogs)30 i n which most antidepressives are a c t i v e . Nomifensine w a s more potent than imipramine i n antagonizing reserpineinduced catalepsy i n rats.” Quipazine had a pharmacological p r o f i l e similar t o t h a t of t r i c y c l i c anti depressive^.^^ I n a series of phenacylthioimidazolines, 2 was the most potent antagonist of reserpine-induced hypothermia i n mice (12X imipramine) .l3
(16)
(18)
(a)
Chap. 2
Antidepressives, Stimulants
21 -
Kaiser, Z i r k l e
0
M p r a m i n e - l i ke phannaco logica 1 a c t i v i t y , without a n t i cho l i n e r g ic properties, was noted f o r LG 152 i t also prevented synaptosomal reuptake of NE.35 Potent antitetrabenazine-induced p t o s i s a c t i v i t y , without anticholinergic effects, w a s produced by some e t h e r s of hexanophenone oxime, e.g. 2 3 3 6 The piperidinecarboxamide was equipotent with amitriptyl i n e i n a test f o r dopa-potentiation i n mice.)' A series o f phthalan derivatives having a pharmacological spectrum similar t o t h e tric y c l i c a n t i d e p r e s s i v e s was studied f o r i n h i b i t i o n of mitochondrial activity i n i n t a c t yeast cells a test which c o r r e l a t e s with c l i n i c a l antidepressive potency. Most potent a c t i v i t y was noted f o r Lu 3-04" (2&) , Lu 3-009 (24b) , Lu 3-074 3 X impramine))* and Lu 3-049 4.3X imipramine) C l i n i c a l antidepressive a c t i o n s were noted f o r HT 3261 (3)" and t h e choline d e r i v a t i v e panclar which was an e f f e c t i v e psychostimulant i n p a t i e n t s with schizophrenia, depression and Other compounds with c l i n i c a l antidepressive a c t i v i t y neuroses." included W I N 27,147-2 (271, which w a s devoid of s i d e effects a t e f f e c t i v e which w a s o f doubtful value i n humans dose levels.42 and 8 14.368 (g>,53 and caused untoward s i d e effects although i t produced antidepressive-like a c t i o n s i n animals. Short-lived antidepressive a c t i v i t y w a s observed with ~40pa.'~
(a
(2)
-
(a,
.r
(a,
(261,
(c4L C H 3
ss
c
=NO(CH2)2N% 22 -
24 -
3 HOPO) (% >,N(CH3
26 pcs
a) b) c) d)
X=CH,; R=CH3 X 4 ; R=CH3 X-S; R = C b X=C%; R=H
OH
Several amphetamine d e r i v a t i v e s displayed antidepressive properties. Fenfluramine, an a n o r e c t i c drug which depresses motor a c t i v i t y , showed an imipramine-like p r o f i l e of a c t i v i t i n various phamacological tests i n mice.'5 p3loroamphetamine (*IY6 and i t s N-methyl d e r i v a t i v e ,
22 -
Sect.
1
-
CNS Agents
E n g e l h a r d t , Ed.
RO-4-6861 (29b) ,47 produced c l i n i c a l a c t i v i t y resembling t h a t of the t r i c y c l i c a x d e p r e s s i v e s . BW 65-54 (2) e l i c i t e d antidepressive effects i n animals; i t potentiated responses to amphetamine, apparently by i n t e r f e r i n g with metabolic inactivation,'8 A number of new MA0 i n h i b i t o r s were described i n 1971; however, because of the l i m i t e d c l i n i c a l u t i l i t y of these agents i n t h e treatment of depression, they w i l l not be reviewed i n d e t a i l . Nonetheless, several was included i n a of these substances a r e noteworthy. Sydnophene (2)'9 series of sydnonimines examined f o r MAO-inhibitory a c t i v i t y . It demons t r a t e d m i l d stimulant and antidepressive a c t i o n s i n extensive c l i n i c a l s t u d i e s i n Russia.50 Another MAO-inhibitor, c l o r g i l i n e M&B 9302) had antidepressive a c t i v i t y ; i t s c l i n i c a l effects were s i m i l a r to those of i m i ~ r a m i n e . ~ ' Proportions of two forms of MA0 (Type A, B) were found to vary i n d i f f e r e n t a r e a s of r a t b r a i n . The type A enzyme, predominant i n sympathetic nerves, acted on both 5-HT and tyramine and was inhibited by and acted on tyramine, b u t 32, whereas type B-MA0 was i n s e n s i t i v e t o not 5-HT." I n humans, 32, tranylcypromine and isocarboxazid increased 5HT, NE and dopamine l e v e l s i n various b r a i n a r e a s ; however, t h e effect of tranylcypromine was s i g n i f i c a n t l y g r e a t e r than t h a t of the o t h e r two on dopamine i n t h e caudate nucleus and h y p o t h a l a m u ~ . ~In ~ vitro, Lilly 51641 (21, l i k e harmaline, p r e f e r e n t i a l l y blocked M A 0 oxidation of 5-HT, whereas tranylcypromine and pargyline s e l e c t i v e l y i n h i b i t e d the oxidation of tyramine .5'
(z,
-
Central Stimulants S t r u c t u r e - a c t i v i t y r e l a t i o n s h i p s o f c e n t r a l stimul a n t s were reviewed i n 1971.55 '56 The use of central stimulants, notably dextroamphetamine and methylphenidate, i n t h e therapy of hyperkinetic disorders i n children has increased, According t o NIMH estimates more than 200,000, o r about 1 s of hyperactive children, received amphetamine treatment i n 1969?' These agents reduce d i s t r a c t i b i l i t y and promote the c h i l d ' s a b i l i t y to focus on meaningful s t i m u l i and t o organize his bodily movements more purposefully.5 8 ' 5 9 Similar effects w e r e e l i c i t e d by treatment of untrainable hyperkinetic and aggressive dogs with dextroamphetamine."
(21,
N e w e r amphetamine r e l a t i v e s included pyrovalerone which w a s b e n e f i c i a l i n therapy of c h r o n i c a l l y fatigued patients," U-30,405A ( a) and U-28,926~ which caused CNS stimulation i n rhesus monkeys. 6% Amantadine produces amphetamine-like a c t i o n ( see below). An aminot e t r a l i n , ADT ( 6) afforded amphetamine-like e f f e c t s b u t decreased motor a c t i v i t y i n m i c S 3 Adenosine had a psychoanaleptic effect i n a mouse .65 maze test.64 Exploratory a c t i v i t y of mice was enhanced by P1961 (2) Other compounds f o r which CNS-stimulating a c t i v i t y was observed i n mice
(z),
Chap. 2
Ant idepress ives, S t i m u l a n t s
included 4864 ( 8) ,66 a benzocyclobutene % 1-69 and GYI 20238 (j
23 thiolactams,6 *
Kaiser, Z i r k l e
(2) ,6 several
a
c1
2
38
Several s t u d i e s r e l a t e d t o physical p r o p e r t i e s and metabolism of amphetamines. "he b a s i c i t y , t i s s u e d i s t r i b u t i o n and metabolism of p-f luoro-, p, p-dif luoroamphetamine, and amphetamine w e r e s t r i k i n g l y d i f f e r e n t i n rats.70 N m r studies of t h e conformational properties7' of amphetamine and r e l a t e d phenethylamines revealed a preference f o r trans phenylamino rotomers i n aqueous although s u b s t i t u e n t groups, steric and electronic f a c t o r s influence rotomer p o ~ u l a t i o n s . ~A~ quantum mechanical study indicated the folded form of amphetamine i s s l i g h t l y favored.72 Metabolism of amphetamine t o an oxime and subsequent hydrolys i s t o benzyl methyl ketone was shown t o c o n s t i t u t e a route of deaminat i ~ n . ~ ' In a r a b b i t l i v e r oxygenase system this conversion involves an intermediate a-hydroxyamine .75
-
of the various i d e a s about -theses. Biochemistry and Pharmacoloqy biochemical causes of a f f e c t i v e disorders,76 '77 the Vatecholamine (CAI hypothesis" is s t i l l t h e most frequently c i t e d . According to this p o s t u l a t e depression may be r e l a t e d t o a deficiency of CA (usually NE) a t functionally important c e n t r a l CA receptors, w h i l e mania r e s u l t s from excess CA. Perhaps an equally p l a u s i b l e case can be made f o r a "serotonin hypothesis of a f f e c t i v e disorders." Consistent with t h e CA hypothesis a r e the observations t h a t when a-methyltyrosine, an i n h i b i t o r of CA biosynthesis, was given to 7 m a n i c and 3 depressed p a t i e n t s under double b l i n d conditions, 5 of t h e m a n i c p a t i e n t s became less manic and t h e 3 depressed p a t i e n t s became more d e p r e s ~ e d . ~ " ~However, ~ attempts t o overcome t h e postulated deficits of CA o r serotonin (5-HT) by administration of t h e amino acid precursors, Gdopa, tryptophan, o r 5-hydroxytryptophan- a s t r a t e g y successful i n the treatment of parkinsonism have given generEven i n l a r g e a l l y disappointing r e s u l t s i n depressed patient^.^"^^ '13' doses equivalent t o those found t o be e f f e c t i v e i n parkinsonism, M o p a produced an antidepressive effect i n Only 4 of 16 p a t i e n t s . A l l of the p a t i e n t s who responded had retarded depressions; none of the 5 p a t i e n t s with a g i t a t e d depression improved. Five depressed p a t i e n t s who had p r i o r
-
24 -
Sect. 1
-
CNS Agents
Engelhardt, Ed.
h i s t o r i e s o f mania developed hypomania o r mania without a r e v e r s a l o f depression. It i s suggested t h a t CA, p a r t i c u l a r l y dopamine (DA), may be involved i n t h e genesis o f mania i n susceptible i n d i v i d u a l s b u t t h a t These depression and mania are not opposite poles of the same entity." r e s u l t s do not support t h e CA theory of depression b u t n e i t h e r do they rule i t out. Although L-dopa i n c r e a s e s DA i n b r a i n , i t may not i n c r e a s e NE. It also produces o t h e r c e n t r a l biochemical a c t i o n s , e.g., effects suggesting t h a t i t causes a decrease i n turnover o f b r a i n 5-HT i n However, t h e mostly negative clinical r e s u l t s with depressed patients." L a o p a seem t o cast f u r t h e r doubt on the v a l i d i t y of t h e behavioral syndrome and amine depletion induced by r e s e r p i n e (which i s reversed by L-dopa) a s a model of depression. The catechol theory of depression i s based i n p a r t on evidence t h a t the t r i c y c l i c antidepressives and ampheramine a f f e c t CA m e t a b o l i s m i n ways t h a t r e s u l t i n an increased a v a i l a b i l i t y o f t h e t r a n s m i t t e r s a t t h e i r receptor sites. It has been thought f o r s o m e t i m e t h a t t h e w e l l known i n h i b i t o r y a c t i o n o f t h e t r i c y c l i c a n t i d e p r e s s i v e s upon t h e uptake o f NE i n central noradrenergic (NA) neurons r e s u l t s i n an i n c r e a s e of t h e monoarnine a t t h e r e c e p t o r s and may account f o r antidepressive a c t i v i t y . Several observations may not be i n accord with this view. I n d i r e c t evidence has been adduced t h a t some t r i c y c l i c agents with t e r t i a r y amino groups (imipramine, chlorimipramine and a m i t r i p t y l i n e ) p r e f e r e n t i a l l y block 5-HT uptake i n 5-HT neumns w h i l e c e r t a i n secondary amines (desmethylimipramine , n o r t r i p t y l i n e and p r o t r i p t y l i n e ) p r e f e r e n t i a l l y i n h i b i t uptake o f NE. Recent s t u d i e s i n which i n vivo uptake o f NE and 5-HT was d i r e c t l y measured histochemically confirm t h e e a r l i e r data a s d i d funct i o n a l s t u d i e s using the extensor and f l e x o r r e f l e x e s t o assess t h e influence of t h e various drugs on 5-HT and NA receptor a c t i v i t y , respect i ~ e l y . ' ~ I n a d d i t i o n t h e antihistamine drugs, chlorpheniramine and e s p e c i a l l y brompheniramine were found t o be very potent blockers o f 5-HT uptake. However, these drugs, u n l i k e t h e t e r t i a r y amino t r i c y c l i c s , also showed a potent blocking a c t i o n on NE uptake. The questions arise whether t h e c l i n i c a l a c t i v i t y o f these drugs i s more c l o s e l y related t o effects on 5-HT o r on NE neurons o r whether t h e r e are two classes o f antidepressives a c t i n g by d i f f e r e n t mechanisms. Some clinicians feel t h a t t h e c l i n i c a l a c t i o n s of t h e t r i c y c l i c a n t i d e p r e s s i v e s can be divided i n t o a mood-elevating component and a psychomotor-activating component. They b e l i e v e t h e t e r t i a r y amines are more e f f e c t i v e i n brightening of mood, suggesting involvement of 5-HT neurons w h i l e t h e secondary amines are more e f f e c t i v e i n i n c r e a s i n g d r i v e o r producing psychomotor a c t i v a t i o n , suggesting t h a t NE neurons a r e mainly Seemingly a t odds with t h e blockade of amine-uptake hypotheses are the p r o p e r t i e s of one of t h e newer t r i c y c l i c s , iprindole. This drug produces c l i n i c a l effects resembling those of imipramine-like agents y e t i n s o m e pharmacological tests, e.g., r e v e r s a l o f reserpine-induced p t o s i s and hypothermia i n mice, i t i s considerably less potent than i~nipramine.'~ It i s a very weak i n h i b i t o r of uptake of NE and 5-HT &-I v i t r o and i n vivo i n mice and rats.86 Despite i t s weak uptake blocking a c t i v i t y , i t potentiated t h e awakening effect of Gdopa i n r e s e w z e d mice a s
Chap. 2
Antidepressives, Stimulants
Kaiser, Z i r k l e
25
imipramine does. Unlike the a n t i d e p r e s s i v e s which block amine uptake, i p r i n d o l e does not augment the pressor response t o NE o r block t h e blood pressure response t o tyramine i n man,'7 Differences i n t h e e f f e c t s of acute and chronic treatment with imipramine and p r o t r i p t y l i n e on c e n t r a l NE metabolism i n t h e r a t have been observed." The turnover of NE was decreased a f t e r acute administration but increased during chronic administration of these drugs. The i n c r e a s e i n NE turnover occurred sooner when thyroxine was administered with imipramine. It i s suggested t h a t these observations may help t o explain t h e delayed o n s e t of c l i n i c a l antidepressive effects and t h e a c c e l e r a t i n g and enhancing effects o f thyroid hormone on the c l i n i c a l e f f e c t s of imipramine. It has been suggested t h a t thyroxine may e x e r t s o m e o f i t s action by f a c i l i t a t i n g the action of NE i n c e n t r a l NA pathways.e9 Rats t r e a t e d with thyroxine became hyperactive and showed increased s e n s i t i v i t y t o the behaviorally a c t i v a t i n g e f f e c t s o f NE administered i n t r a v e n t r i c u l a r l y . Possibly r e l e v a n t t o the v a r i a t i o n i n effects on NE turnover noted under varied conditions of administration of t h e t r i c y c l i c s i s t h e observation t h a t spontaneous a c t i v i t y i n r a t s w a s decreased s h o r t l y after administration of imipramine but w a s increased over t h a t of c o n t r o l animals one day a f t e r a d m i n i s t r a t i ~ n . ~Much ~ more d a t a o f t h e kinds c i t e d above must be obtained f r o m s t u d i e s o f a v a r i e t y of t r i c y c l i c antidepressives, including i p r i n d o l e , before any conclusions about a r e l a t i o n s h i p between t h e clinical a c t i o n of t h e s e drugs and t h e i r effects on monoamine metabolism can be drawn. A study o f t h e effects of L-dopa and Li,CO, on u r i n a r y excretion o f c y c l i c AMP i n depression and mania has been r e p ~ r t e d . ~ ' Manic p a t i e n t s excreted t h e most c y c l i c AMP and severely depressed p a t i e n t s excreted t h e l e a s t ; c o n t r o l s and moderately depressed p a t i e n t s showed intermediate values. Depressed p a t i e n t s t r e a t e d with L-dopa showed marked i n c r e a s e s i n urinary c y c l i c AMP excretion. P a t i e n t s treated with U 2 C 9 showed changes i n c y c l i c AMP excretion i n t h e d i r e c t i o n o f clinical change; a s depression improved, c y c l i c AMP e x c r e t i o n increased and as mania improved i t diminished. It i s not possible t o a t t r i b u t e these changes i n excretion of c y c l i c AMP t o e i t h e r c e n t r a l o r peripheral mechanisms o r both.
Rubidium i o n seems t o have opposite effects from l i t h i u m i o n on CA metabolism and it has been suggested t h a t i t may have c l i n i c a l antidepressive a c t i v i t y . It produces an i n c r e a s e i n t h e r e l e a s e and turnover o f b r a i n stem NE and, u n l i k e l i t h i u m ion, i t induces an increase i n s t e a d of a decrease i n shock-elicited aggression i n rats.92 Further comparisons of rubidium and l i t h i u m i o n s may shed considerable l i g h t on t h e biochemistry of t h e a f f e c t i v e disorders i f t h e i n i t i a l c l i n i c a l observations t h a t rubidium has antidepressive a c t i v i t y a r e confirmed by c o n t r o l l e d studies?' Although t h e r o l e s o f NE and 5-HT i n t h e antidepressive a c t i o n o f the t r i c y c l i c s have n o t been e s t a b l i s h e d , t h e r e i s l i t t l e doubt b u t t h a t the stimulatory a c t i o n of amphetamine i s t o a l a r g e e x t e n t mediated through CA pathways. Early experiments emphasized effects of t h e drug on NA systems. Now t h e evidence i s stronger f o r a DA mechanism of central
26 -
Sect. 1
-
CNS Agents
Engelhardt, Ed.
a c t i o n than f o r a NA mechanism. Although t h e r e is some disagreement, most authors believe t h a t amphetamine produces i t s c e n t r a l e f f e c t s by r e l e a s i n g dopamine and NE a t nerve endings from labile i n t r a n e u r o n a l pools of newlysynthesized amines. Amphetamine i s thought t o induce stereotyped behavior by r e l e a s i n g DA whereas apomorphine produces this behavioral effect by a direct a c t i o n on DA receptors. The increase i n locomotor a c t i v i t y e l i c i t e d by amphetamine appears t o be mediated a t l e a s t i n p a r t by a NA action. Other behavioral effects of amphetamine may also involve NA and/or DA actions. The experimental b a s i s f o r t h e s e statements h a s been A f e w of the observations may be b r i e f l y extensively reviewed.53 summarized a s follows. Depletion of CA i n t h e i n t r a n e u r o n a l storage granules by r e s e r p i n e does not prevent t h e i n c r e a s e i n motor a c t i v i t y o r s t e r e o t y p i c a l behavior produced by amphetamine o r apomorphine. I n h i b i t i o n of CA s y n t h e s i s by a-methyltyrosine blocks the effects o f amphetamine b u t not those of apomorphine. I n h i b i t o r s of dopamine P-hydroxylase (e.g., d i e t h y l dithiocarbamate), which i n h i b i t t h e s y n t h e s i s o f NE but n o t DA, decrease amphetamine-stimulated motor a c t i v i t y , b u t do n o t i n h i b i t and even may enhance amphetamine-induced stereotypies. Recent s t u d i e s confirm these r e s u ~ t s . ~'9'J '95
"'
b s t evidence suggests t h a t amphetamine- and apomorphine-induced s t e r e o t y p i e s a r e t h e r e s u l t of enhanced DA a c t i v i t y i n t h e neostriatum. Consistent with this view i s t h e e f f e c t of amphetamine i n rats with u n i l a t e r a l l e s i o n s of t h e n i g r o s t r i a t a l DA pathway ( s e e Chapter 1, p 19. The drug causes i p s i l a t e r a l turning i n t h e s e animals, presumably as a consequence of release o f DA i n t h e neostriatum from t h e i n t a c t DA neurons of the c o n t r a l a t e r a l (non-lesioned) side. T h i s effect of amphetamine i s attenuated by pretreatment with a m e t h y l t y r o s i n e b u t n o t with reserpine.96 19' I n c o n t r a s t , apomorphine, which i s believed t o be a d i r e c t a c t i n g DA agent, induces c o n t r a l a t e r a l turning behavior, an e f f e c t a t t r i b u t e d t o denervation s u p e r s e n s i t i v i t y o f s t r i a t a l DA r e c e p t o r s i n t h e neostriatum on the lesioned side. T h i s e f f e c t of apomorphine i s not antagonized by e i t h e r r e s e r p i n e o r a-methyltyrosine. I n r a t s with u n i l a t e r a l l e s i o n s i n t h e neostriatum, amphetamine and apomorphine both e l i c i t i p s i l a t e r a l turning. Similar effects are observed i n mice with u n i l a t e r a l l e s i o n s o f t h e caudate nucleus. This preparation provides a simple and rapid model f o r studying effects of drugs on c e n t r a l DA systems.9e Possibly a t odds with t h e hypothesis t h a t drug-induced stereotyped behavior involves a DA mechanism are observations on t h e effects of s o m e stimulants on t h e turnover o f b r a i n CA i n the r a t . cJ-Amphetamine, aminorex and p-chloramphetamine a t doses which increased motor a c t i v i t y , but d i d not induce s t e r e o t y p i e s , caused an i n c r e a s e i n turnover o f DA b u t not of NE. These r e s u l t s a r e d i f f i c u l t to i n t e r p r e t , however, because phenmetrazine did n o t a l t e r turnover of DA o r NE a t a dose t h a t increased motor a c t i v i t y . 9 9 Although t h e c e n t r a l a c t i o n s of amphetamine may r e q u i r e an uninterrupted s y n t h e s i s of CA r a t h e r than reserpine-sensitive s t o r e s of the amines, this does n o t seem t o be true f o r a l l amphetamine-like stimulants.
Chap. 2
Antidepressives, Stimulants
Kaiser, Z i r k l e
27
A r e c e n t study, together with e a r l i e r d a t a , suggests that amphetamine-like
stimulants can be divided i n t o two groups according t o t h e ways i n which they i n t e r a c t with r e s e r p i n e and a-methyltyrosine. The e f f e c t s of members of one group - amphetamine, methamphetamine, ephedrine,phenmetrazine and phentermine - are i n h i b i t e d by a-methyltyrosine b u t not by reserpine; those of members of t h e second group benzphetamine, methylphenidate, pipradrol, It-dihydro-bxo-1,acocaine and amfonelic acid ( 7-benzyl-1-ethyl-1, naphthyridine-3-carboxylic acid) are i n h i b i t e d by r e s e r p i n e b u t n o t by m e t h y l t y r o s i n e , a t least i n moderate doses.”’ Although, a s t h e s e results suggest, stimulants may d i f f e r i n t h e i r a c t i o n s on i n t r a n e u r o n a l pools of CA, no d i f f e r e n c e i n t h e i r c l i n i c a l e f f e c t s has been observed. b t h y l p h e n i d a t e produced physiologic, s u b j e c t i v e and behavior effects t h a t w e r e not s i g n i f i c a n t l y d i f f e r e n t from those of amphetamine, methamphetamine, ephedrine and phenmetrazine.‘
-
-
’‘
Further s t u d i e s of t h e metabolism o f amphetamine and o f t h e effects of t h e drug and i t s metabolites on CA metabolism have n o t defined t h e biochemical e f f e c t s underlying t o l e r a n c e development t o t h e drug.102-104 A thorough study was made o f t h e psychomotor and anorexigenic effects of d-amphetamine upon chronic dosing.’ Tolerance development t o t h e drug occurred i n r a t s which w e r e dosed d a i l y s h o r t l y before t e s t i n g . Tolerance d i d not occur i n rats which received t h e same d a i l y doses o f amphetamine but were dosed a f t e r each d a i l y t e s t session. Subsequent dosing of t h e l a t t e r group with amphetamine p r i o r t o t e s t i n g produced psychornotor stimulation and anorexigenic e f f e c t s a s l a r g e a s those i n i t i a l l y observed i n t h e r a t s t h a t had always been dosed d a i l y p r i o r to t e s t i n g . The r e s u l t s suggest t h a t tolerance t o t h e s e effects of amphetamine r e p r e s e n t s a behavioral adaptation of the r a t s t o the. “drugged” state.
-
Several reports described effects of t h e methylxanthines and amantadine on b r a i n monoamine m e t a b o l i s m which may be involved i n t h e i r pharmacological actions. Caffeine and theophylline release b r a i n NE i n r a t s and guinea pigs.’o6 The i n c r e a s e i n c y c l i c AMP produced by these drugs, u s u a l l y a t t r i b u t e d t o i n h i b i t i o n of phosphodiesterase, could be I n mice due t o stimulation of adenyl cyclase by t h e released NE. c a f f e i n e and aminophylline appear t o i n c r e a s e turnover of b r a i n DA and NE.lo7 Other d a t a suggest t h a t t h e methylxanthines e i t h e r prevent t h e The antiparkinsonisn release o f b r a i n 5-HT o r i n c r e a s e 5-HT synthesis.”* e f f e c t s of amantadine have stimulated s t u d i e s o f i t s c e n t r a l actions. Extensive biochemical and pharmacological d a t a from s t u d i e s i n r a t s and mice i n d i c a t e t h a t this drug produces i t s effects, e.g. i n c r e a s e i n r o t a t i o n a l behavior i n t h e r a t turning model and i n c r e a s e i n motor a c t i v i t y , by r e l e a s i n g CA, e s p e c i a l l y DA, f r o m e x t r a g r a n u l a r (reserpiner e s i s t a n t ) s t o r e s . Thus amantadine appears t o have an amphetamine-like However, action b u t i t i s much less potent than unlike amphetamine, amantadine-induced i n c r e a s e i n motor a c t i v i t y i n mice was not a l t e r e d by a-rnethyltyrosine.l
’’
28 -
Sect. 1
-
E n g e l h a r d t , Ed.
CNS Agents
REFERENCES
El
1. J.4. Boissier, C. tumont and R. Ratouis, Therapie, 459 (1971). 2. W. B. Iacefield, J. Med. Chem., 82 (1971). 3. L. G. Humber, F. Herr, and M . 4 . Charest, J. Med. Chem., 982 (1971). 4. hi. S. Lipsedge, W. L. Rees and D. J. Pike, Psychophannacologb, 153 (1971). 5. D. M. Gallant, M. P. Bishop and R. (Xrerrero-Figueroa, Curr. Ther. Res., C l h . Exp., ?64 (1971). 6. J. Krapcho, Annual Reports Med. Chem., 19701 p. 15-23. 7. T. Nose and Y. Kowa, Jap. J. Phamacol., 2 l , 47 (1971). 8. J.-M. Lwoff, C. Iarousse, P. Simon and J.-R. Boissier, Therapie, 451 (1971). 9. M. E. Greig, A. J. Gibbons and G. A. Young, Arch. Int. Phannacodyn., 190, 299 (1971). 10. M. Filczewski, K. Oledzka, I. Ma3ecki and T. Paszek, Diss. ham. Fhanascol., g,263 (1970). 11. J. Wysokowski, ibid., 23, 646 (1971). 12. B. Szukalski and M. Kobylinska, ibid., 23, 640 (1971). 13. C. Kaiser and C. L. Zirkle, h "Medicha1 Chemistry," 3rd Ed., A. Burger, Ed., Wiley-Interscience, New York, 1970, pp. 1470-1497. 14. A. N. Gritsenko, 2. I. Emakova, S. V. Zhuravlev, T. A. Vikhlyaev, T. A. Klygul and 0. V. Ufianova, Khim.-Fam. Zh., 5, 18 (1971); Chem. Abstr. El 1407761 (1971). 15. G. N. Lakoza, Faxiikkol. Toksikol. (Moscow), 397 (1971); Chem. Abstr., 75, 139223s (1971). 16. C. Kaiser, D. H. Tedeschi, P. J. Fowler, A. M. Pavloff, B. 1. Laster and C. L. Zirkle, J. Med. 179 (1971). Chem., 17. E. R. Atkinson, P. L. Fhrss, M. A. Tucker and F. J. Rosenberg, ibid., 1005 (1971). 18. H. Brunner, P. R. Hedwall, M. Meier and H. J. Bein, Ag. Actions, 2,, 69 (1971); Chem. Abstr., 76, 10334~(1972). 19. L. MaZtre, M. S t a e h e l h and H. J. B e h , Biochem. Phamcol., g,2169 (1971). x). F. J. Vtllani, C. A. E l l i s and T. A. Mann, J. Pharm. Sci., 1566 (19zl). 21. J. 0. Jilek, V. Seidlov;, K. Pelz, B. K a k ~ ~J., Holubek, E. Svktek, 2. Sediv; and M. Protiva, Collect. Czech. Chem. Commun., 36, 3300 (1971). 22. W. A. Remers, E. N. Greenblatt, L. Ellenbogen and M. J. Weiss, J. L d . Chem., 331 (1971). 23. G. Bnun and N. Shanmuganathan, Curr. Ther. Res., C l h . Exp., l3, 625 (1971). 265 (1971). 24. R. Brasseur, Encephale, 25. G. Jones, R. F. Maisey, A. R. Somerville and B. A. Whittle, J. Med. Chem., 161 (1971). 26. H. H. Keaslhg and A. B. Moffett, ibid., 1106 (1971); R. B. Moffett and T. L. F%okering, ibid., 14 1100 (1971). 27. T'J. Carroll and P. T. Sharp, Science, 172, 1355 (1971). 28. S. R. Platman, Dis. Nerv. Syst., 32, 604711971). 29. A. Flemenbaum and B. C. Sohiele, Curr. Ther. Res., C l h . Exp., l3, 53 (1971). 33. M. Cohen, P. Milonas, 2. Weisberger, J. Thompson and A. A. &bin, Fhannacologist, 255 (1971). 31. I. Hofflpnn, G. Ehrhart and K. Schmitt, Arzneim.-Forsch., 21 1045 (1971). 32. R. Rodriquez and E. Pardo, Psychophamcologia, 211 89 ( 1 9 d . 33. C. J. Sharpe, R. S. Shadbolt, A. Ashford and J. W. Ross, J. Med. Chem., l4, 977 (1971). 34. A. Vagne, M. Manier, Y. A. Brunet and A. Boucherle, Therapie, 26, 553 (1971). 35. A. Vagne, 0. A. Nedergaard, M. A. Brunet and A. Boucherle, C. R. SOC. Biol., 1769 (1970). 36. H. B. A. Welle, J. van DGk, J. E. Davies, V. Claassen and T. A. C. Boschman, Chim. Ther., 5, 367 (1970). 37. M. N. Aboul-hein, L. Morgan and J. Sam, J. Pharm. Sci., 61, 127 (1972). 18. D. Lhstead and D. Wilkie, Biochem. Pharmacol., El 839 6 7 1 ) . 39. B. Cubinsky, K. Karpowicz and M. E. Goldberg, Pharmacologist, 2,255 (1971). 40. C. Barchewitz and H. Helmchen, Phamakopsychiat./Neur-F'sychophamcol., 2, 293 (1970). 41. G. Salomon, R. Wolf and A. Ma%re, Gaz. k d . France 78, 1040 (1971). Curr. Ther. Res., C l h . Exp., l4, 61 (1972). 42. D. M. Gallant, M. P. Bishop and R. Guerrer-Figueroa, 43. S. Park, S. Gershon, B. Angrist and A. Floyd, ibid., 65 (1972). 44. T. Persson and J. Walhder, Brit. J. P s y c h i a t . , M , 277 (1971). 45. R. C. Srimal, H. K. S h g h and B. N. Dhawan, Arch. Int. Phannacodyn., E,3x) (1970). 46. H. M. van Praag, J. Korf and F. van Woudenberg, Psychophannacologia, l8, 412 (1970). 47. P. Deniker, P. Peron-Magnan, C. Eliet-Le Guillou and M. Hanus, Therapie, 2lg (1971). 48. L. Lemberger, E. Sernatinger and R. Kuntzman, Biochem. Phannacol., 2, ?02l (1970). 49. V. G. Yashunskii, V. 2. Gorkh, M. D. Mashkovskii, A. A. Altshuler, I. V. Veryovkha and L. E. Kholodov, J. Med. Chem., 1013 (1971).
2,
2,
2,
2,
5,
2,
2,
2,
2,
2,
2,
2,
2,
2,
164,
2,
El
2,
Chap. 2
Antidepressives, Stimulants
50. R. A. Altshuler and B. I. Kochelaev, Khh.-Fam. Zh., 51. D. Wheatley, B r i t . J. Psychiat., 117, 573 (1970).
4,
29
Kaiser, Zirkle
59 (1971).
52. C. Goridis and N. H. Neff, Neuropharmacology lo, 557 (1971). J. Nicholson, K. R i c e and A. S. Stacey, Brit. Med. J., 5791, 17 (1972). 54. R. W. Fuller, B. J. Warren and B. B. Molloy, Biochem. Phamacol., 3 3 4 (1970). 55. E. Costa and S. Garatthi, Eds. lllilnphetamines and Related Compounds,11 Raven Press, N.Y., 1970. 56. J. M. van Rossum, Lnt. Rev. Neurobiology, l2, 307 (1970). 57. Anonymous, Wall Street Journal, Jan. 29, 1971. 58. D. X. Freedman, Children, l8, 111 (1971). 59. E. H. Ellinwood and S. Cohen, Science, 171, 420 (1971). 60. S. A. Corson, €3. OIL. Corson, V. Kirilcuk and L. E. Arnold, Fed. Proc., Fed. Amer. SOC. Exp. Biol.,
53. A. B. B. Jones, C. M. B. Pare, W.
2,
-' 30
206 (1971).
61. G. Gardos and J. 0. Cole, Curr. Ther. Res., C l h . Exp. l3, 631 (1971). 62. A. H. Tang and J. D. Kirch, Rychophannacologia, 2l, 139 (1971). 63. C. F. Barfknecht, D. E. Nichols, B. Olesen and J. A. Engelbrecht, Pharmacologist 2,233 (1971). 64. B. Hach and F. He& Arzneh-Forsch., 2l, 23 (1971). 65. 0. Nieschulz, h i d . , g,1497 (1970). 66. M. Julia and J. deRosnay, Chh. Ther., 2, 337 (1970). .l, 645 (1971). 67. A. A. Siciliano and K. A. Nieforth, J. Med. Chem., 4 68. E. J. Lien, L. L. Lien and G. L. Tong, h i d . , 846 (1971). 69. J. Borsy, I. Elekes, J. I. S&ely and L. Toldy, Acta. Physiol. Acad. Sci. Hung., 39, 275 (1971). 70. R. W. Fuller and B. B. Molloy, Pharmacologist, l3, 294 (1971). 71. G. A. Neville, R. Deslauriers, B. J. Blackburn, and I. C. P. Smith, J. Med. Chem., 717 (1971). 72. B. hllman, J.-L. Coubeils, P. Cwrriere and J.-P. Gervois, ibid., l5, 17 (1972). 73. K. Bailey, A. W. By, K. C. Graham and D. Verner, Can. J. Chem., 3143 (1971). 74. A. H. Beckett, J. P. Van Dyk, H. M. Chissick and J. W. Gorrod, J. Pharm. pharmacol., 23, 560 (1971). 75. C. J. Parli, N. Wang and R. McMahon, Biochem. Biophys. Res. Connnun., 43, 1204 (1971). 76. G. A. Aillon, Psychosomatics, l2, 260 (1971). 77. D. J. McClure, Can. Psychiat. Ass. J., l6, 247 (1971). 872 78. W. E. hnney, Jr., H. K. H. Brodie, D. L. k r p h y and F. K. Goodwin, Amer. J. Psychht., (1971). 79. H. K. H. Brodie, D. L. hrphy, F. K. Goodwin and W. E. Bunney, Jr., C l b . Pharmacol. Ther., 2, 228 (1971 1. 80. F. K. Goodwin, D. L. Murphy, H. K. H. Brodie and W. E. Bunney, Jr., Biol. Psychiat., 2, 341 (1970). 81. B. J. Carroll, C l h . Pharmacol. Ther., l2, 743 (1971). 82. F. K. Goodwin, D. L. h n n e r and E. S. Gershon, Life Sci., lo, Part I, 751 (1971). 83. P. Lidbrink, G. Jonsson and K. Fuxe, Neuropharmacology, 522 (1971). 84. F. Sulser and E. Sanders-Bush, Annu. Rev. Pharmacol., 11, 209 (1971). 85. M. I. Gluckman and T. hum, Psychop8harmacologia,l5, 169 (1969). 86. S. B. Ross, A. L. Renyi and S.-0. Ogren, Life Sci., l0, Part I, 1267 (1971). 87. W. E. Fann, J. Y. Davis, J. S. Kauflpann, J. D. Griffith, D. S. Janmsky and J. A. Oates, F'harmacologist, l3, 207 (1971). 88. J. J. Schildkraut, A. Winokur, P. R. Draskc6zy and J. H. Hensle, h e r . J. Psych&., In, 1032 (1971). 69. W. M e n , D. S. Segal and A. J. Mandell, Science, 2,79 (1972). 90. D. Meltzer and P. A. Fox, Psychophamcologia, 2l, 187 (1971). 91. M. I. Paul, H. Cremer and F. K. Goodwin, Arch. Gen. Psychiat., 24, 327 (1971). 92. J. M. Stolk, R. L. Conner and J. D. Barchas, Psychophamacologia, 2, 250 (1971). 93. T. H. Svensson, Naunyn-Schmiedebergs Arch. Phaxmak. Exp. Pathol., 271, 111 (1971). 94. U. S t h b e r g and T. H. Svensson, Psychopharmacologia, 2,53 ( 1 9 7 1 r 95. J. Maj, 1. Grabonska and E. Mogilnioka, Psychophannecologia,s, 162 (1971). 96. U. Ungerstedt, Acta Physiol. Scand., Suppl., 49 (1971). 97. U. Ungerstedt, ibid., Suppl., 69 (1971). 98. V. J. Lotti, Life Sci., 30., Part I, 781 (1971). 99. E. Costa, K. M. Nabzada and A. Revuelta, B r i t . J. Pharmacol., 43, 570 (1971). 100. J. Scheel-Kzger, Eur. J. Phaxmacol., 47 (1971). 101. W. R. Martin, J.W. Sloan, J. D. Sapira and D. R. Jasinski, C l i n . Phamacol. Ther., l2, 245 (1971). 102. T. Lewander, Naunyn-Sohmeidebergs Arch. Phaxmak. Exp. Pathol., 271, 221 (1971).
2,
2,
2
m,
2,
H,
z,
2,
30
Sect. 1
-
CNS Agents
E n g e l h a r d t , Ed.
103. G. A. Clay, A. K. Cho and M. Roberfroid, Biochem. Pharmacol., g,1821 (1971). 176 (1971). 104. H. C. Rbiger and E. G. McGeer, Eur. J. Phamcol., 105. R. T. H i l l , Abstracts, 7th Middle Atlantic Regional Meeting Amer. Chem. SOC., Feb. 14-17, 1972,
16,
p. B. B. B.
59.
A. Berkowitz, J. H. Tarver and S. Spector, Eur. J. Pharmacol., 2, 64 (1970). Waldeck, J. Pham. hamacol., 23, 824 (1971). A. Berkowitz and S. Spector, Eur. J. h a m c o l . , 322 (1971). U. Stramberg and T. H. Svensson, Acta Phamcol. Todcol., 161 (1971). L.-0. Farnebo, K. Fuxe, M. Goldstein, B. Hamberger and U. Ungerstedt, Eur. J. Fhamacol., (1971). 111. J. E. Thornburg and K. E. Moore, Pharmacologist, 2,202 (1971).
106. 107. 108. 109. 110.
E,
2,
2, 27
Chapter 3 .
Analgesics and Narcotic Antagonists
Franklin M. Robinson Merck Sharp & Dohme Research Laboratories, West Point, Pa. 19486 Literature reports over the last year indicate some decrease in the amount of chemical effort devoted to new analgesic structures, but a continued increase in investigation of biochemical mechanisms of analgesia and dependence. Interest in narcotic antagonists for the treatment and prevention of narcotic abuse has stimulated much current research on new compounds. In neither area was there evidence of a significant advance during the year. An extensive review of the literature on narcotic antagonists and analgesics from July, 1966 to April, 1970 appeared.’ I.
Strong Analgesics
A. New Clinical Studies
-
No clinical studies on new compounds were reported, but new studies on diviminolY2 tilidhe,, and bezitramide4y5 continue to indicate that these are orally effective analgesics in the codeine-morphine potency range which do not produce tolerance.
-
B. Structure-Activity Studies There is an increasing tendency to use the newer tests (inflamed foot, writhing, bradykin) for evaluation of analgesic potency but, unless otherwise specified, potency estimates in the following discussion are based on the mouse hot plate assay.
-
1. Compounds Related to Morphine New reports of the chemistry and activities of ethenothebaines and oripavines include a collated review of la structure-activity relationships containing previously unreported data. The importance of an R configuration at C19 for high analgesic activity has been established6 for the 7-8 as well as the 742 series. The primary ,CH3
~+$,~~ncs~T
7--@
om3
OH
I
IS\ OH
&*#I.. OH
OCH, I1
importance of a lipophilic binding site rather than that previously postulated for the (2-19 hydroxyl was shown by the finding that 11 is as potent (1000 times morphine in the rat tail pressure test) as etorphine (I). Structure-activity relationships in this series vary greatly according to the test used.la
32
Sect. 1
-
CNS Agents
Engelhardt, Ed.
Both natural and synthetic (2) forms of the cholinesterase inhibitor, galanthamine, were reported to be analgesics equipotent with morphine .7 ( 0 )
-
Synthesis and conformation of the 3- (111) and 4-methyl 2. Benzmorphans (IV) benzmorphans were reported.8 IVa (2 times codeine) was about three times as potent an analgesic as IIIa, but IVb, c and d surprisingly were
-
inactive, In the I11 series, all were active the cyclopropylmethyl analog (IIIc) about five times as active as the methyl (IIIa) analog ands without antagonist effect or physical dependence capacity in the monkey.
The benzmorphan analog (V) was comparable to codeine in the acetic acid writing test, but eleven other analogs oxygenated at the carbon 10 bearing the phenyl group were inactive.
-
3. Meperidine Analogs WY-22811 (VI)ll and both of its optical isomers were somewhat more potent analgesics than pentazocine, and both antagonized morphine, the (-) isomer being the more potent. Side effects were minima 1
.
%00C2H5
cH2m3
‘0
VI
VII
(b) n = 2
Chap.
3
Rob i nson
Analgesics, Narcotic Antagonists
33 -
The two dioxolanoalkyl meperidines (VII) shared activity in the meperidine range (VIIb was 3 times VIIa).12 The corresponding dioxane analogs were inactive at 50 mg./kg. but did potentiate meperidine.
VIII
LH2CH2 - @ H C O C H = C H C O O C 2 H j
IX The trans isomer of VIII showed weak analgesic activity while the cis was inactive, although it more closely approximates the structure of morphine than does the trans.13 A series of anileridine derivatives bearing substituents with potential alkylating ability was made in order to investigate the possibility of locating analgesic receptors by specific alkylation.14 The fumaryl derivative (IX) caused apparent inactivation which'could be prevented by naloxone pretreatment. Other analogs of IX were non-selective and toxic. An attempt to label receptors in brain homogenates by photolysis with [H3]-N-B-(p-azidophenyl)-ethylnorlevorphanol also showed insufficient specificity although the compound was a potent narcotic.15
-
New Compounds Extensive pharmacological studies of MZ-144 (X) and 16-19 It was limited data on 20 analogs (of 85 prepared) were reported.
C.
H X
XI
orally active, did not produce tolerance, was not antagonized by nalorphine and strongly potentiated morphine even in tolerant animals. At high doses, MZ-144 was nearly as effective as morphine in animal studies, and it was said to be clinically effective at doses of 0.15-0.3 g. Abbott 30360 (XI) was found to quilizer whose analgesic effect was data on 14 analogs indicated fairly analgesic potency, although the 8-c"
be an orally active analgesic-tranLimited in the morphine range.20 high structural specificity for analog was equally active.
34
Sect. 1
&.J
-
Engelhardt, Ed.
CNS Agents
1 R
XI1 Four quinazolones (XII) of a series of 19 were more potent ana-gesics than codeine. Substitution in the ring or modification of the R-group reduced activity. XIIa has been selected for clinical trial.21 WY-12157 (XIII) showed anal esic activity of the order of morphine as did both of its optical isomers.B2 It was not antagonized by naloxone and produced little or no tolerance, but CNS oxicity and blindness were seen during chronic administration to monkeys. &a
R I
R
t
(a) -H
XIV XIVa was found to be a centrally-acting analgesic more potent than codeine with little respiratory depressant action or physical dependence capacity.24 Twenty of 64 analogs made were also active. XIVb and c antagonized XIVa but potentiated morphine.
PJcH2NHcH3
0%
xv
c$(
IzOOH
0CH,
XVI
XV2’ and XV126 were reported to have significant analgesic activity, but data were limited.
Antiinflammatory Analgesics For complete coverage of this class of compounds refer to the chapter on Antiinflammatory Agents (Section 4). No new compounds with outstanding analgesic activity have appeared. 11.
Reports on new clinical studies27 on clonixin show equivalence of
600 mg. p.0. with 10 mg. of morphine parenterally in post-operative pain.
Chap. 3
Analgesics, Narcotic Antagonists
Rob inson
35
111. Biochemical Mechanisms Many new data concerning the role of neurohumoral agents in the actions of analgesics continue to appear. The conflict between different workers on the effect of morphine on brain serotonin turnover28929 may be due to differeniotime courses of the experiments, since it appears to be an acute effect. Evidence has been reported suggesting that the role of catecholamines in anal esia may depend mainly on dopamine or dopamine/norepinephrine Strong cross tolerance between the analgesic effects of ratios. "pS methamphetamine and morphine develops after 5 days 1 adrninistrati~n.~' Additional studies on the depression of brain acetylcholine release by analgesics34 have shown that morphine also facilitates its action at the neuromuscular junction.35 A review of knowledge concerning the harmacokinetics and sites of action of narcotics in the brain appeared.!36 IV. Narcotic Antagonists Over the past ten years, research on narcotic antagonists has been directed principally toward the discovery of new analgesics, since it was originally thought that such compounds would not have abuse liability. Work leading to thf introduction of pentazocine has been discussed in a , 37-40 Structurally, these antagonists were polynumber of reviews. cyclic potent analgesic molecules with the N-methyl group replaced by an allyl, cyclopropylmethyl or related moiety. The most potent analgesicantagonists did not attain practical utility because of hallucinogenic or other bizarre central nervous system effects that are usually associated with powerful antagonist activity. More recent research on analgesics has produced new types of compounds that will not support morphine dependence, and some of which pharmacologically behave as mild morphine antagonists. These are not related structurally to the antagonists mentioned above. Direct addiction studies on both types of antagonists demonstrated a capacity to produce physical dependence (e .g. pentazocine,*' nalbuphine,& profad01~~ and pro~iram*~) of a type which could lead to drug seeking behavior.44 (The potent antagonists with hallucinogenic effects can also produce a milder type of physical dependence not leading to drug seeking behavior.) Thus, it has been established that a component of antagonist activity does not necessarily eliminate abuse liability. TWO potent antagonists, naloxone (XvIIa) and cyclazocine (XVIII) were administered to selected groups of narcotic addicts in an attempt to Itcure" their addiction by blockin an pleasurable effect of narcotic of the series of preliminary self-administration. The results"*' studies were sufficiently favorable that large-scale controlled studies were begun to better evaluate this type of approach, Research in this
36
Sect. 1
-
Engelhardt, Ed.
CNS Agents
area is being expanded greatly as part of the effort47 now being directed toward alleviation of the drug abuse problem. Although some of the current research in this field has been discussed in newspapers and magazines, few data suitable for this review have been published. Data reported so far indicate that naloxone has too low an oral potency and too short a duration of action to be satisfactory, while the side effects of cyclazocine may be unacceptable.
tg
only reported narcotic antagonist without Naloxone (XVIIa) is other biological activity, This can be demonstrated by an acetylcholine release assay* which measures both agonist and antagonist actions of narcotics, as well as by pharmacological studies. In contrast, analogs
cH3
R
I
1
XVII
XVIII
XVIIb, c and d show both analgesic and antagonist properties. XVIIb (EN-1639) is currently being studied in addicts5' since it appears to be longer acting than naloxone, and shows fewer side effects than cyclazocine. Cyclazocine (XVIII) is a powerful antagonist and analgesic, and its many known analogs show both properties. Diprenorphine (XIXa) is a pure morphine antagonist (3-5 times naloxone) pharmacolo ically, but shows some agonist activity in the acetylcholine assay." In this series, structure around C-19 is critical, e.g. XIXb and c are not antagonists.52
& HO
HO
OCHs XIX
OH
0
xx
Chap.
3
Analgesics, Narcotic Antagonists
Robinson
37
XX shows mild antagonist activity which is unusual for an N-methyl compound la
.
Diphenoxylate and an analog SC-26100 (XXI) will prevent withdrawal symptoms in morphine-addicted animals, and the former has been reported to have the same effect in man. 53
4
0
Haloperidol has been reported to be useful in the treatment of withdrawal symptoms in addicts and also to reduce morphine self-administration in rats at the proper dose.54 REFERENCES
1. J. Lewis, K. Bently and A. Cowan, Ann. Rev. Pharmacol., ll, 241 (1970). (a) P. 249. 2. F. Nobili and G . Bernardi, Europ. J. Clin. Pharmacol., 2, 119 (1971). 3 . J. Klapetek, Med. Welt, 1523 (1971). 4. P. Janssen, C. Niemegeers, K. Schellekens, R. Marsboom, V. Herin, W. Amery, P. Admiraal, J. Bosher, J. Crul, C. Pearce and C. Zegveld, Arzneim. Forsch., 2 l , 862 (1971). 5. H. Knape, Brit. J. Anesthesia, 42, 76 (1971). 6. J. Lewis and M. Readhead, J. Chem. SOC. (C), 2296 (1971). 7. T. Kametani, G., 1043 (1971). 8. R. Parfit and S. Walters, J. Med. Chem., 14,965 (1971). 9. J. Villarreal and M. Seevers, Addendum to the minutes of the 33rd Meeting of the Committee on Problems of Drug Dependence, Nat. Acad. Sci., 1939 (1971). 10. W. Chang, L. Walter and R. Taber, J. Med. Chem., 14, 1011 (1972). 11. P. Goode and A. White, Brit. J. Pharmacol., 9, @P (1971). 12. D. Kriesel and 0. Giavold, J. Pharm. Sci., 60, 1250 (1971). 13. J. Greenhill, J. Hcd. Chem., 14,971 (1971). 14. P. Portoghese, V. Tchng, A . Takemori and G. Hayashi, g., &, 144
(1971).
s,
15. B. Winter and A . Goldstein, Fed. Proc., 528 (1972). 16. J. Knoll, Z. M&z&os, P. Szentmikl6si and S. Furst, Arzneim. Forsch., 21, 717 (1971). 17. 7 Knoll, S. Fursf and Z. Me/szB/ro8, g., 2 l , 719 (1971). 18. J. Knoll, S. Furst and Z. Me/s/ziros,E., 21, 727 (1971). 19. J. ~noll,K. Magyar and D. Banfi, E., 21, 733 (1971).
38
Sect. 1
-
CNS
Engelhardt, Ed.
Agents
20. E. Kimura, P. Dodge, P. Young and R. Johnson, Arch. Intern. Pharmacodyn., 190, 124 (1971). 21. M. Vincent, J. Poignant and G. Remond, J. Med. Chem., 714 (1971). 22. J. Malis, Fed. Proc., 2, 563 (1971). 23. Ref. 9, p . 1950. 24. G. Regnier, K. Canevari, J. LeDouarec, S . Holstrop and J. Daussy, J. Med. Chem., Q, 295 (1972). 25. T, Ohgah, N. Hirose, S . Sohda and S . Toyoshima, J. Pharm. SOC. Japan,
2,
603 (1971). 26. H. Hishmat, A. Hashim, M. Shalash and M. Nawito, Arzneim. Forsch., 21, 1026 (1971). 27. Finch and T. DeKornfeld, J. Clin. Pharmacol., 11, 571 (1971). 28. S. Algeri and E. Costa, Biochem. Pharmacol., 2 0 , @' (1971). 29. D. Cheney, A. Goldstein, S. Algeri and E. Costa, Science, IJl, 1169 09-711 30. G. Yarbrough, D. Buxbaum, M. Sanders and E. Bush, Life Sci., 10, 977 (1971) 31. K. Fukui and H. Takagi, Brit. J. Pharmacol., 44,45-51 (1972). 32. A . Takemori and Y. Maruyama, Fed. Proc., 1, 504 (1972). 33. B. Pleuvry, J. Pharm. Pharmacol., a,969 1971). 34. K. Jhamandas, J. Phillis and C. Pinsky, Brit. J. Pharmacol., 4J, 53 (19711 35. R. Frederickson and C. Pinsky, Nature New Biol., 231, 93 (1971). 36. A. Herz and H. Teschemacher, Advances in Drug Research, 6, 79 (1971). 37. W. Martin, Pharmacol. Rev., 2,463 (1967). 38. H. Frazer and L. Harris, Ann. Rev. Pharmacol., 1,277 (1967). 39. S. Archer and L. Harris, Prog. Drug Res., g, 261 (1965). 40. L. Harris and W. Dewey, Ann, Reports in Med. Chem. 1967, 36 (1968). 41. D. Jansinski, W. Martin and R. Hoeldtke, Clin. Pharmacol. Therap., 11, 385 (1970). Jasinski and P. Mansky, E.,Q, 78 (1972). 42. 43. D. Jasinski, W. Martin and R. Hoeldtke, G., 12, 613 (1971). 44. J. Inciardi and C. Chambers, N. Y. State J. Med., 71, 1727 (1971). 45. M. Fink, Science, 1005 (1970). 46. A. Zaks, T. Jones, M. Fink and A. Freedman, J. Am. Med. ASSOC., 3, 2108 (1971). 47'. J. Jaffe, Clin. Res., 2,612 (1971). 48. H. Blumberg, H. Dayton and P. Wolf, Proc. SOC. Exp. Biol. Med., B, 755 (1966) 49, A. Cowie, H. Kosterlitz and A. Watt, Nature, 220, 1040 (1968). 50. A. Hammond, Science, 503 (1971). 51. H. Kosterlitz and A. Watt, Brit. J. Phanaacol., z, 266 (1968).
.
f
.
a,
m,
52. Ref. 1, p. 254. 53. E. Dobrin, D. Krok and W. Potts, Fed, Proc., 2,503 (1972). 54. H. Hanson and C, Cimini-Venema, 503 (1972).
E.,
,
Chapter 4.
Sedatives, Hypnotics, Anticonvulsants and General Anesthetics A. D. Rudzik and W. Friis The Up john Company, Kalamazoo, Michigan 49001
-
Introduction Although an effort has been made in this chapter to exclude depressants classified in other chapters as antipsychotic and antianxiety agents, certain benzodiazepines will be considered here because of the number of compounds in this series which have been found clinically to possess sedative-hypnotic and anticonvulsant activity. In most cases, compounds with more than preliminary pharmacological data o r representatives of new structural types were selected for inclusion in this chapter.
-
Sedatives and Hypnotics Considerable research effort has been expended to elucidate the possible role of serotonin in the neuropharmacology of sleep: Administration of serotonin in proper dosage and by the proper route produces electroencephalographic and ocular signs of (slow wave) sleep. Nonspecific reduction of serotonin levels in the brain by reserpine reduced both rapid eye movement (REM) and non-rapid eye movement (NREM) sleep while sterotaxic destruction of serotonin-containing neurons has produced insomnia in animals.2 With the discovery of a specific inhibitor of serotonin synthesis, para-chlorophenylalanine, it has been possible to deplete brain serotonin without altering the catecholamine content markedly3. A dose dependent reduction in cerebral serotonin, induced by the administration of para-chlorophenylalanine, is followed by a dose-dependent reduction in total sleep lasting as long as 16 days.4 Injection of 5-hydroxytryptophan at the height of the para-chlorophenylalanine action restored slow wave sleep within 10 minutes and after a delay of 5 hours, paradoxical sleep. In man, para-chlorophenylalanine decreased rapid eye movement ( R E M ) sleep, with either no change or a slight increase in non-rapid eye movement (NREM) sleep5. L-Tryptophan, a precursor o f serotonin has also been shown in normal subjects to reduce sleep latency and increase sleep length without altering In a the qualitative characteristics of polygraphically recorded sleep'. double-blind study in hospitalized insomniac patients, doses of 4 to 5 g of L-tryptophan significantly increased sleep time, reduced sleep latency and reduced the number of awakenings
.'
Several reviews have recently appeared on the neurohumoral aspects of sleep control4 and on the chemical families which influence sleep patterns. Many benzodiazepine derivatives have been reported to possess sedative and hypnotic activity in both animals and man. Flurazepam (I) has been found to possess useful hypnotic activity in man without producing In animals flurasignificant "hangover" effects the following morning8". zepam was found to possess activity, in many tests systems, similar in potency and profile to diazepad'.
40
Sect. 1
-
CNS A g e n t s
E n g e l h a r d t , Ed.
I11
IV-X=H Y=H V’X’CH3 Y=H VI-XzCH3 Y 4 1
Flunidazepam (11) was found i n a l l - n i g h t human EEG sleep s t u d i e s and o t h e r e f f i c a c y s t u d i e s t o be a o t e n t h y p n o t i c approximately 15 t o 30 times more a c t i v e t h a n f lurazepam R e c e n t l y a n a n a l o g of oxazepam , lorazepam (111, WY-4036) was r e p o r t e d by Hedges e t a l l 3 t o p o s s e s s p o t e n t s e d a t i v e and d e p r e s s a n t a c t i v i t y i n man and was approximately 5 times more a c t i v e t h a n diazepam i n t h i s s t u d y . Perhaps t h e most s i g n i f i c a n t benzodiazepines r e p o r t e d i n t h e l a s t two y e a r s have been t h e t r i a z o l o b e n z o d i a z e p i n e s ( I V , V , V I ) . These compounds have been found t o p o s s e s s s e d a t i v e and h y p n o t i c a c t i v i t y i n a n i m a l ~ ~ * , ~ 5 , ~ 6 iannman17. d From e x p e r i m e n t a l d a t a i n man, Compound V was p r e d i c t e d t o have l o n g l a s t i n g a n t i a n x i e t y p r o p e r t i e s a t low d o s e s and s e d a t i v e - h y p n o t i c a c t i v i t y a.t h i g h d o s e s 17. Another benzodiazepine d e r i v a t i v e , V I I , has been r e p o r t e d t o possess h y p n o t i c a c t i v i t y i n animals and i s more p o t e n t t h a n diazepam i n t h i s r e g a r d la.
VII
VIII
While t h e most s i g n i f i c a n t s e d a t i v e s and h y p n o t i c s found r e c e n t l y have been benzodiazepine d e r i v a t i v e s , s e v e r a l i n t e r e s t i n g non-benzodiazepine d e r i v a t i v e s have a l s o been r e p o r t e d t o p o s s e s s s e d a t i v e and h y p n o t i c a c t i v i t y . One of t h e s e compounds, p e r l a p i n e ( V I I I ) , has been found t o be a u s e f u l h y p n o t i c i n man.lS
Chap. 4
Rudz i k,
Depressants
Fr i i s
41
c
Janssen et a12' has reported that etomidate (IX, R-16659) is a potent i.v. hypnotic in rats with a rapid onset of action and a duration of hypnosis dependent on the dose administered. The compound has a high safety margin with the toxic dose being approximately 30 times the efficacious dose. Three new pyridazone derivatives (X, XI, XII) were reported by Wermuth et a121 to possess sedative and hypnotic activity. The compounds were synthesized in an analgesic program but were poorly active in analgesic test systems.
--
& &. do X
'
0
-
CH2CH2
XI
I
-
CH2CH2
'- 0
CH2CH2 XI1
An interesting aporphine alkaloid, xylopine (XIII), isolated from the bark of Xylopia brasilienes, possesses both sedative and analgesic activity in mice at moderate doses22. In dogs the compound was found to possess hypotensive activity.
In contrast to many other classes of compounds, the activity of many CNS agents has been found clinical1y.Fenfluramine is an example of such a clinical finding. Fenfluramine (XIV) is presently marketed in 22 countries as an effective and safe anorexigenic drug. Though a phenethylamine derivative, the compound produced sedation and drowsiness in man as a side effect in the anorexigenic studies23. A ureide derivative, capuride (XV, McN-X-94) is a new addition to the nonbarbiturate sedatives. It is especially useful in aiding sleep in preoperative patients2*. Finally, a new derivative of cyclic 3'5' -adenosine monophosphate, HD-233(6-piperidino-purinoribosyl-3 '5'cyclic AMP) has been found to have a sedative effect in rats25. The compound does not alter either serotonin or 5-hydroxy-indoleacetic acid levels in the brain of rats but does increase the brain levels of barbiturates and prolongs barbiturate sleeping time.
-
Anticonvulsants During the past two years numerous compounds possessing anticonvulsant activity have been reported. Many of the compounds report-
42 -
Sect. 1
-
CNS Agents
Engelhardt, Ed.
ed were benzodiazepine derivatives and these will be reviewed briefly in this section. Chlorazepate (XVI, A-35616, 4306CB) possesses anticonvulsant activity in mice equipotent to diazepam2e. The monopotassium and the dipotassium salts possessed approximately the same activity and have the advantage of being water soluble. Although the pharmacology of clonazepam (XVII, Ro 5-4023) has been reported previously in this review, more recently numerous papers have appeared reporting the potent anticonvulsant activity in animals27 and man28’29. Clonazepam has been found to be 10 times more active than diazepam.
c 1’ \
XVI
XVII
XvIII-X=C1 XIX- x=C1 XX- X=H XXI- X=H
Y=c1 Y=H Y=H Y X l
A series of triazolobenzodiazepines were found to possess potent anticonvulsant activity in animals. U-33,030 (XVIII) and U-31,889 (XIX) were much more potent than diazepam in mice, rats and cats while U-31,957 (XX) and U-35,005 (XXI) were equipotent to 30. These compounds are extremely active against chemically induced seizures but only weakly active against seizures induced by electroshock. Removal of the chloro-group from position 7 in the diazepam molecule markedly decreased the pharmacologic activity while in the triaaolobenzodiazepine series the compound (XX) still was equipotent to diazepam, This points out the major differences in the triazolobenzodiazepine structure activity relationships compared to the diazepam series. Another benzodiazepine derivative possessing anticonvulsant activity is 0~~?-8063 (XXII). The compound inhibits maximal electroshock, pentylenetetrazol and thiosemicarbazide convulsions in laboratory animals31.
XXII
XXIII
XXIV
Chap.
4
Depressants
Rudzik, Friis
43 -
A series of 22 phenanthridine basic ethers reported by Ashford et a1 were found to possess anticonvulsant activity in mice=. Some of the derivatives, of which compound XXIII is a representative, were as active as diphenylhydantoin in antagonizing pentylenetetrazol and electroshock convulsions but in most cases possessed therapeutic ratios inferior to diphenylhydantoin. Funcke and Zandberg, evaluating a series of tricyclic compounds for anticonvulsant activity, found two compounds, BS7679 ( X X I V ) and BS7029 (XXV), worthy of further studyg3. The compounds were more efficacious than phenobarbital with a low neurotoxicity.
xxv A series of diphenylaminopropanols were evaluated for toxicity, anticonvulsant, anorexigenic and anticholinergic activity34. Several of the derivatives (XXVI , X X V r I ) were potent anticonvulsants against thiosemicarbazide, electroshock and nicotine induced convulsions without possessing anticholinergic activity.
XXVI
XXVI I
Alkoxymethyl derivatives of barbiturates and diphenylhydantoin are The compounds( X X V I I I ,XXIX) possess marked effective anticonv~lsants~~. activity against both maximal electroshock and pentylenetetrazol induced seizures
.
c2:Qi@cH3
CH3O-C H p
-
a CHgCH3
O 0
XXVIII
XXIX
The same authors also reported that acyloxymethyl, bis (acyloxymethyl) and bis (halomethyl) derivatives of 5- e t h y l - 5 - p h e n y l b a r b i t u r i c acid possessed marked anticonvulsant activityg6. Depakine (XXX) has been reported by DeBiolley and Sore1 in uncontrolled studies to be an effective anticonvulsant in the treatment of petit ma1 epilep~y~~’ Some ~ ~ .action was also noted in psychomotor seizures. Side effects in these studies were not a major problem.
44 -
Sect. 1
-
Engel h a r d t , Ed.
CNS Agents
XXX
CH3
XXXII
-
x=NH2 Y e 1
Finally, various compounds related to methaqualone have been found to possess anticonvulsant activity in mice=. Compound XXXI was found to be more active than methaqualone against maximal electroshock seizures. Compound XXXII also possessed potent anticonvulsant activity but was more toxic than Compound XXXI. General Anesthetics - Few new anesthetic agents were reported in the literature in the last two years. The pharmacology of a new dissociative anesthetic, etoxadrol (XXXIII, CL1848C, U-37,862A) in primates and other species= and an evaluation of etoxadrol in normal human volunteers40 has been reported. Etoxadrol has properties similar to ketamine (XXXIV) as an anesthetic. After intravenous administration in monkeys etoxadrol produces complete analgesia with retention of the light and corneal reflexes. In man, etoxadrol appears to be a useful drug in anesthesia and has a longer lasting activity than ketamine. Etoxadrol appears to be devoid of long term psychologic, biochemical or physiologic pathology. Furt er studies have been conducted on compound 347 (XXXV), now called Ethraneb The compound was administered to 250 patients as the major anesthetic41. Its physical properties and clinical characteristics are similar to those of halothane.
HCF&CF2CHFCl 0 C6H5
XXXIII
C2H5
XXXI v
XXXV
REFERENCES 1.
2.
3,
4. 5. 6. 7.
W. P. Koella, Sleep: Its Nature and Physiological Organization, C.C. Thomas, Springfield, Illinois, 1967. M. Jouvet, Advances in Pharmacology, S. Garattini and P. A. Shore; Eds., Academic Press, New York 1968, 265. B. K. Koe and A. Weisman, J. Pharmacol. Exptl. Therap. 499 (1968). W. P. Koella, Biol. Psychiatry 1, 161 (1969). R. J. Wyatt, K, Engelman, D. J. Kupfer, J. Scott, A. Sjoerdsma and F, Snyder, Electroenceph. Clin. Neurophysiol. 3 , 529 (1969). E. Hartmann, R. Chung and C. Chien, Psychopharmacologia 114 (1971). A. J. Mandell, C.E.Spooner and D.Brunet, Biol. Psychiatry 1, 13 (1969).
m,
a,
Chap. 4
45
Rudz i k, Fr i i s
Depressants
A. Kales, J.D. Kales, M.B. Scharf and T. Tan, Arch. Gen. Psychiat. 3, 219 (1970). 9. A.M.Zimmerman, Current Therap. Res. 12, 18 (1971). 10. L. 0. Randall, W. Schallek, C. L. Scheckel, P. L. Stefko, R. F. Banzig e r , W. Pool and R. A. Moe, Arch. I n t . Phannacodyn. 216 (1969). 11. I. Oswald, S. A. L e w i s and J. Tagney, I n t e r n a t i o n a l Symposium on Benzodiazepines, Raven P r e s s , New York, i n press. 12.. A. Kales, I n t e r n a t i o n a l Symposium on Benzodiazepines, Raven P r e s s , New York, i n p r e s s . 13. A. Hedges, P. Turner, T. V. A. Harry, J. Clin. Pharmacol. 11,423 (1971). 14. R. Nakajima, Y. Take, R. Moriya, Y. S a j i , T. Yui and Y. Nagawa, Japan. J. Pharmacol. 2l, 497 (1971). 15. J. B. Hester, A. D. Rudzik and B. V. Kamdar, J. Med. Chem. 1078
8.
m,
16.
14,
( 19711
A. D. Rudzik, J. B. Hester and W.
F r i i s , The Pharmacologist,
12,205
(1971)
17. T. M. I t i l ,
B. S a l e t u , J. Marasa and A. N. Mucciardi, D i s . Nerv. S y s t . , i n press. 18. R. Nakajima, Y. S a j i , S. Chiba and Y. Nagawa, J. Takeda Res. Lab 3, 153 (1970). 19. Chem. Drug. 192,228 (1970). 20. P.A.Janssen, C. J. E. Niemegiers, K. H. L. Schellekens and F. M. L e n a e r t s , Arzneimittel - Forsch. 21, 1234 (1971). 21. C. G. Wermuth, G. LeClerc and J. Schreiber, Chimie Therapeutique lOg
6,
(1971)
22. C. Casagrande and G. M e r o t t i , Farmaco, 3, 799 (1970). 23. B. W. E l l i o t t Current Therap. Res. l2, 502 (1970). 24. J. Katz, S.C. Finestone, M.T.Pappas and J. Fine, Current Therap. Res. 12, 255 (1970 25. L. Vargiu and P. F. Spano, Arch. Pharmakol. 269, 410 (1971). 26. J. Schmitt, P Comoy, M. Suquet, G. C a l l e t , J. LeMeir. T. C l i m , M. 239 Brumaud, J. Mercier, J. S a l l e and G. Siou, Chimie Therapeutique
. Armagnac,
( 1969)
27. J.
4,
F. Boismare, G.
Streichenberger and P. Lechat, Therapie 26,
439 (1971) 28. H. Gastaut, I n t e r n a t i o n a l Sumposium on Benzodiazepines, Raven P r e s s , New York, i n press. 29. G. F. Rossi, C. DiRocco, G. Maira and M. Meglio, I n t e r n a t i o n a l Symposium on Benzodiazepines, Raven P r e s s , New York, i n p r e s s . 30. A. D. Rudzilc, J . B. Hester, A. H. Tang, R. N. Straw and W. F r i i s , Int e r n a t i o n a l Symposium on Benzodiazepines, Raven P r e s s , New York, i n press. 747 31. R. Guerrero Figueroa and D. M. G a l l a n t , Current Therap. Res.
u,
-
(1971).
32. A. R. 33. A. 34. H. 35. C.
Ashford, G. R. Brown, P. J. Palmer, J. W. Ross, R. B. Trigg, and J. Ward, Arzneimittel - Forsch. 21, 937 (1971). B. Funcke and P. Zandberg, Arzneimittel Forsch. 20, 1896 (1970). H. Keasling and R. B. Moffett, J. Med. Chem 1106 (1971). M. Samour, J , F. Reinhard and J. A. Vida, J. Med. Chem. 187
-
(1971)
14,
0
36.
J. A.
Vida, W. R. Wilber and J. F. Reinhard, J. Med. Chem.
14, 14,190
46 -
Sect. 1
-
CNS Agents
Engelhardt, Ed.
( 19711
37. D. DeBiolley and L. Sorel, Acta Neurol. Belg. &, 909 (1969). 38. D. DeBiolley and L. Sorel, Acta Neurol. Belg. &, 914 (1969). 39.
J. Hildalgo, R. M. Dileo, M. T. Rikimaru, R. J. Guzman and C. R. Thompson, Anesthesia and Analgesia, 50, 231 (1971). 40. R. D. Wilson, D. L. Traker, E. Barratt, D. L. Creson, R. C. Schmitt, and C. R. Allen, Anesthesia and Analgesia &, 236 (1970). 41. M. H. Lebowitz, C. D. Blitt and J. B. Dillon, Anesthesia and Analgesia &, 1 (1970).
47 Chapter 5.
Recent Developments Relating Serotonin and Behavior
Albert Weissman and Charles A. Harbert, Pfizer Inc., Groton, Conn. 06340 The existing encyclopedic reviews on 5-HT1 make evident that techniques for modifying 5-HT kinetics are almost as varied and voluminously reported as those for studying behavior. As a result, few areas are more difficult to survey briefly than this, relating two such ill-defined yet exhaustively studied variables. We have accordingly chosen to focus on a limited number of issues with particular current importance. Techniques for Manipulating 5-HT Steady State Levels and Receptor Activity
It must be asserted at the outset that there are still no entirely satisfactory means to either elevate or reduce 5-HT steady state levels. Studies purporting to show altered behavior as a function of variations in 5-HT levels are inevitably tainted by factors that covary. For example, the elevation of brain 5-HT levels by administration of the dietary 5-HT precursor, Trp, leads a l s o to the metabolism of excess substrate through other pathways, particularly the kynurenine pathway. Administration of the immediate precursor of 5-HT, 5-HTP, leads to a non-physiological distribution of 5-HT in brain, owing to the ubiquitous distribution of aromatic amino acid decarboxylase. 5-HT derived from either precursor may decrease catecholamine stores by amine displacement, and Trp derivatives also inhibit tyrosine hydroxylase. Conclusions based on high 5-HT levels in selected animal strains, at certain times of day, or at certain ages are confounded by multiple genetic, circadian or ontogenetic effects that covary, Similar problems apply to conclusions drawn from carcinoid victims or other examples of human pathology where 5-HT is elevated. MA0 inhibitors, even those relatively specific for that isoenzyme for which 5-HT is a primary substrate, exert actions other than elevating 5-HT. Comparable lack of specificity plagues known methods of depleting 5-HT from brain: reserpine and similar amine-releasing drugs block the intraneuronal vesicular uptake of catecholamines as well as of 5-HT.4 Lesions in the nucleus Raphe, the medial forebrain bundle and other tracts,5 which deplete 5-HT from brain, deplete NE as well. Prolonged Trp deficient diets6 cause general nutritional deficits and an inefficient decrease in 5-HT levels. Substituted phenethylamine derivatives, such as p-chloromethamphetamine and fenfluramine, have usually been reported to exert relatively small effects on brain 5-HT and the mechanism
______________-__-----------------Abbreviations used in this paper: 5-HT = 5-hydroxytryptamine (serotonin); Trp = tryptophan; 5-HTP = 5-hydroxytryptophan; 5-HIAA = 5-hydroxy-3indoleacetic acid; MA0 = monoamine oxidase; PCPA = p-chlorophenylalanine; NE = norepinephrine
48
Sect. 1
-
CNS Agents
Engelhardt, Ed.
of their action is unclear. The recent disclosure that intraventricularly administered 5,6-dihydroxytryptamine causes selective degeneration of 5-HT neurons in rat brain7 is exciting, but will require confirmation. The selectivity and activity problems inherent in the above techniques explain why PCPA8 has been seized upon as a tool for studying behavioral and neurophysiological effects after brain 5-HT is depleted. PCPA is perhaps both the most selective and effective depletor of 5-HT known. Nevertheless, it also slightly, but significantly, depletes the brain of catecholamines for a few hours after its administrationY8and several authors have dwelled on this effect in accounting for some of its By blocking phenylalanine hydroxylase ,8,10 PCPA physiological actions. elevates phenylalanine and its metabolitesll and "experimental PKU" may account for certain behavioral effects of PCPA. Other biochemical complications after PCPA include reduced uptake of Trp and phenylalanine.12 Furthermore, 5-HT depletion after PCPA is not "complete", and residual amounts of 5-HT that are synthesized after PCPA may account for its unexpected effects or lack of effects.13 It is unnecessary to alter steady state levels of 5-HT in order to alter 5-HT receptor activity. Blockade of 5-HT reuptake into presynaptic terminals may prolong high extraneuronal concentrations of 5-HT .I4 Agents believed t o exert such an effect -- tertiary tricyclic antidepressants, particularly chlorimipramine -- also have selectivity problems, since all exert at least some effect on NE uptake. Alternatively, it may be possible to stimulate or to block 5-HT receptors specifically. It is suggested that quipazine (2-[l-piperazinyl]quinoline)(III) exerts 5-HT mimetic properties based on its smooth muscle spasmogenic profilei15a its behavioral effects in animal tests also suggest similarities with 5-HT.15b From the plethora of agents exerting peripheral antiserotonin properties some may exert comparable effects in brain; the often-cited anti-5-HT activity of LSD in brain, however , may be complicated by 5-HT mimetic properties as well .I6 Keeping specificity limitations in mind, let us nevertheless focus on the behavioral effects associated with a reduction in brain 5-HT levels caused by the tryptophan hydroxylase inhibitor PCPA or its methyl ester. Where possible the behavioral effects reported to occur after PCPA are related to those produced when 5-HT levels or receptor activity are altered by other means. Behavioral Effects of PCPA-Elicited Serotonin.Depletion in Animals Symptoms - A corollary to the familiar Brodie and Shore h y p ~ t h e s i s ~ ~ that 5-HT mediates a central parasympathetic ("trophotropic") system is that suppression of 5-HT biosynthesis should result in central stimulation because of the dominance of the central sympathetic ("ergotropic") system. Initial symptomatological observations after PCPA, however, included only mild irritability and aggressiveness in isolated rats, without clear evidence of motor stimulation.8 These observations of absent or mild symptomatic effects in rats have frequently been confirmed.18 Quantitative
Chap. 5
Serotonin and Behavior
We i ssman , Ha rbert
49
locomotor activity studies in rodents usually report no elevation, and sometimes decreases in motor activity following PCPA at doses effective in depleting 5-HT.I4 Nevertheless, animals have exhibited elevated activity during prolonged exposure to an activity chamber, as if the novelty of the activity box is sustained.20 In unrestrained larger animals, especially rabbits, cats and rhesus monkeys, irritability and aggressiveness without frank motoric excitement, are observed.21 Consummatory Behavior - Rats treated with moderate doses of PCPA consume laboratory food and water normallyY18b,19c~22 but appear to be more finicky or responsive than controls in their consumption of solutions of alcohol,22~23saccharin,23c dextroselgb or quinine,lgb suggesting that gustatory or olfactory thresholds may be lowered by PCPA. Sleep - Many sleep researchers have found that PCPA causes prolonged EEG activation and sleep disturbances. In rats, there is a significant decrease of both REM and slow wave sleep correspondin to reduced 5-HT levels in brain, but not with PCPA levels.18a,20a,2'f This diminution in REM sleep in rats is most unusual in that no REM rebound occurs.24 Related to the sleep findings is the observation that PCPA inhibits hibernation in squirrels.25 Extensive studies in the laboratories of Jouvet,26 KoellaY2' Dementzla and others have shown that PCPA has the ability to block slow wave sleep and produce prolonged insomnia in cats, effects that are rapidly reversed by 5-HTP. Titration of PCPA and 5-HTP can lead to normal sleep. In rhesus monkeys depleted of brain 5-HT by PCPA, however, REM sleep may be unchanged, and in this respect PCPA effects appear to differ from those seen in rats and cats. The amount of time spent in slow wave (and hence, total) sleep decreases si nificantly, but "total insomnia", as often reported for cats, is not seen.28 Dement et a1,21a however, have been able to produce sleep loss in 2 monkeys resembling the effect in cats. To the extent that conclusions may be drawn from the data available, a different picture occurs in man. In patients seriously ill with carcinoid, Huntington's chorea, migraine, or dystonia, REM sleep is markedly depressed, but slow wave sleep is either unchanged or slightly increased.29 A study of PCPA in normal volunteers revealed no subjective complaints of insomnia.30 The rat and cat sleep results with PCPA, even considered alone, would suggest that 5-HT is functionally involved in normal sleep mechanisms, but these findings are in fact only the latest in a long chain of circumstantial evidence linking 5-HT to sleep.26b Y 27 Exogenous 5-HT, given intraventricularly or in the carotid, and 5-HT precursors -- either Trp or 5-HTP -- given peripherally, have frequently been reported to produce electrophysiological, behavioral and clinical evidence of sedation and sleep. Among other established means of reducing slow wave sleep are administration of reserpine and methysergide. Circadian variations in 5-HT brain levels in animals are positively correlated with circadian variations in sleep. Ablation of the 5-HT-rich Raph6 nuclei also produces insomina. Sensitivity to Pain and Shock Avoidance Behavior - PCPA is hyperalgesic
50
Sect. 1
-
CNS A g e n t s
Engel h a r d t , Ed.
i n r a t s , l g c , 3 1 an e f f e c t r e v e r s i b l e by 5-HTP, b u t n o t by 5-HT a d m i n i s t r a t i o n . 5-HT-depleting l e s i o n s of t h e m e d i a l f o r e b r a i n bundle exert a s i m i l a r e f f e c t . 31a Heightened r e s p o n s i v e n e s s t o p a i n may account f o r enhanced avoidance a c q u i s i t i o n a f t e r PCPA.19c,32 I t i s a l s o l i k e l y t h a t e l e v a t i o n s i n avoidance r e s p o n s e r a t e a f t e r PCPA33 d e r i v e i n p a r t from i n c r e a s e d s e n s i t i v i t y t o f o o t shock. PCPA b l o c k s t h e a n a l g e s i c a c t i o n s of morphine, methadone, propoxyCNS phene and m e ~ e r i d i n e . ~ ~ e f f e c t s of morphine o t h e r t h a n a n a l g e s i a are blocked by PCPA,35 b u t t h e f i n d i n g s of Way e t a136 t h a t PCPA b l o c k s symptoms accompanying morphine w i t h d r a w a l have n o t been confirmed. 37
The h y p e r a l g e s i c and a n a l g e s i c - b l o c k i n g e f f e c t s of PCPA are cons i s t e n t w i t h l i t e r a t u r e r e p o r t s showin i n c r e a s e d s e n s i t i v i t y t o p a i n a f t e r lesion-induced d e p l e t i o n of 5-HT3la o r a f t e r r e s e r p i n e - l i k e d r u g s , and an a n a l g e s i c r e s p o n s e f o l l o w i n g MA0 i n h i b i t o r s p l u s 5-HTP.38
-
S e n s i t i v i t y t o Convulsant Treatments PCPA f a c i l i t a t e s c o n v u l s i o n s e l i c i t e d by h y p e r b a r i c oxygen,3Y p e n t y l e n e t e t r a z o l , 4 0 e l e c t r o c o n v u l s i v e shock, 40a,41 a u d i o g e n i c c o n v u l s a n t s t i m u l i , 4 2 f l u r o t h y l 4 3 and w i t h d r a w a l from b a r b i t u r a t e s .44 A s u b s t a n t i a l o l d e r l i t e r a t u r e , o r i g i n a t i n g w i t h t h e work of Chen e t a145 on r e s e r p i n e , d e a l s w i t h t h e r o l e of b i o g e n i c amines i n e x p e r i m e n t a l s e i z u r e s . The preponderance of t h e s e r e p o r t s i n d i c a t e t h a t s t i m u l a t i o n of 5-HT r e c e p t o r a c t i v i t y d e c r e a s e s s e i z u r e s u s c e p t i b i l i t y , and t h a t d e p r e s s i o n of 5-HT r e c e p t o r a c t i v i t y e x e r t s t h e o p p o s i t e e f f e c t , S e n s i t i v i t y t o Other Non-Social E x t e r o c e p t i v e S t i m u l i - S e v e r a l s t u d i e s i n d i c a t e t h a t PCPA i n c r e a s e s v a r i o u s b e h a v i o r a l o r n e u r o l o g i c a l e f f e c t s of e l e c t r i c a l s t i m u l a t i o n . T h r e s h o l d s of c u r r e n t r e q u i r e d t o r e i n f o r c e s e l f s t i m u l a t i o n b e h a v i o r are lowered by PCPA i n r a t s , 4 6 and PCPA h a s been rep o r t e d t o c a u s e s t r o n g e x c i t a t o r y e f f e c t s on i n t r a c r a n i a l s e l f - s t i m u l a t i o n rates i n rats 3 days a f t e r t r e a t m e n t . 4 7 5-HT-depleted animals have b e e n r e p o r t e d t o b e more a c t i v e t h a n c o n t r o l s under c o n d i t i o n s of e x t r a environmental s t i m u l a t i o n , p a r t i c u l a r l y “novel” s t i m u l a t i o n . 1 8 b 9 1 9 ~ Cats “overr e a c t t o s l i g h t n o i s e s ,’I48 s e n s o r y t h r e s h o l d s are lowered,29 t h e r e s p o n s i v e n e s s t o a s t a r t l e s t i m u l u s of rats w i t h low b a s a l r e s p o n s i v e n e s s i s i n c r e a s e d , 4 9 and h a b i t u a t i o n t o an a u d i t o r y - e l i c i t e d s t a r t l e r e s p o n s e , as measured by c o r t i c a l e l e c t r i c a l r e s p o n s e s , is reduced.50 S e x u a l i t y - D e s p i t e o c c a s i o n a l d i s s e n t 5 I t h e r e can now b e l i t t l e doubt t h a t PCPA d r a m a t i c a l l y enhances s e x u a l i t y i n s u i t a b l e animal p r o t o c o l s . 52 L i k e o t h e r e f f e c t s of PCPA, h y p e r s e x u a l i t y i s a b r u p t l y r e v e r s i b l e by low doses of 5-HTP.52a PCPA h a s b e e n observed t o a c t i v a t e l o r d o s i s , a prime i n d i c a t o r of e s t r u s b e h a v i o r , i n o v a r i e c t o m i z e d r a t s t r e a t e d w i t h e s t r o gen and exposed t o a v i g o r o u s male a r t n e r . 5 3 PCPA d r a m a t i c a l l y i n c r e a s e s s e x u a l b e h a v i o r i n cats21a,E4 and r a b b i t s ; 5 5 i n t h e s e s p e c i e s , a l s o , t h e e f f e c t of PCPA i s r e v e r s e d by 5-HTP. Aggression and Other Non-sexual S o c i a l Behavior - Mouse k i l l i n g (muricide) i n rats i s enhanced by PCPA.22b “Cats who normally i g n o r e l a b o r a t o r y rats b e g i n t o k i l l them w i t h a r a p i d i t y and c o n c e n t r a t e d s a v a g e r y t h a t
Chap. 5
Serotonin and Behavior
Weissman, Harbert
51 -
evoke images of the jungle".2la Mice or rats can be extremely aggressive to one another.18a~22b~56 Much of this social behavior is reversed by administration of 5-HTP.22b,52c Summary of Behavioral Effects of Depleting 5-HT with PCPA in Animals - Although isolated animals treated with PCPA show few symptomatic effects, exposure of animals to novel exteroceptive stimulation evokes behavioral hyperresponsiveness. Animals overreact to painful, electrical, auditory, visual, gustatory, olfactory and especially social stimuli. The sustained wakefulness of animals treated with PCPA may feasibly be considered one manifestation of this generalized hyperresponsiveness. The animal behavioral data from PCPA, taken as a whole, may be loosely interpreted as suggesting that 5-HT subserves behavioral inhibitory functions, and that a relative absence of 5-HT produces hypersensitivity to environmental cues. Both the rapid reversal of electrophysiological and behavioral changes following smalldoses of 5-HTP, and the parallel time course of PCPA actions with brain 5-HT levels clearly associate 5-HT with its effects. The PCPA data are also consistent with findings from less selective means of modifying brain 5-HT, such as reserpine or MA0 inhibitor treatment, treatment with 5-HT precursors, lesion-elicited 5-HT depletion, and the use of animal strains, ages, or times of day associated with variations in 5-HT. Implications of PCPA-Elicited Clinical Symptomatology Many clinical investigators who have studied altered attention, sensory and perceptual characteristics in man believe that schizophrenics respond to sensory inputs that do not affect normals.57 In view of this, and the preceding analysis of the role of 5-HT in behavior, one might expect aberrant clinical behavior after selective depletion of 5-HT. Limited reports of such aberrations after PCPA have appeared. In the course of successful trials of PCPA in patients with carcinoid tumor, pronounced behavioral aberrations, ranging from depression to florid hallucinations and paranoia occurred.58 A comparison of sleep patterns in both schizophrenics and PCPA-treated cats revealed several similarities.21a It thus appears at least feasible that the animal behavioral findings after PCPA are manifested in humans as depression and paranoia. This speculation is provocative since abnormalities of 5-HT synthesis and metabolism have been implicated in several psychopathological conditions. We shall accordingly now focus on the role of 5-HT in depression, mania, and schizophrenia and shall emphasize experimental therapeutic approaches current and speculative - which involve an attempt to manipulate brain 5-HT. Indoleamine Dysfunction in Human Behavior Depression - The controversy surrounding the relative importance of catecholamines and indoleamines in depression has culminated in divergent
52
Sect. 1
-
CNS Agents
Engelhardt, Ed.
"catecholamine"59 and "5-HT"60 hypotheses. However, recent reviews on the role of brain monoamines in psychopathological disorders emphasize the need for understanding their complex interaction.61 Evidence cited to support 5-HT dysfunction in depression includes 1) decreased levels of 5-HT and 5-HIM in the brains of depressed patients who commit suicide,62 2) sub-normal concentrations of 5-HT metabolites in the cerebrospinal fluid (CSF) of depressives,63 and 3) diminished rates of 5-HT turnover, manifested as deficient 5-HIM accumulation in the CSF following treatment with the efflux blocker, probenecid.64 The 5-HT precursors Trp and 5-HTP have been explored most extensively by proponents of the 5-HT deficiency hypothesis, in efforts to increase brain 5-HT levels.65 The earliest trials of Trp in depression found it to potentiate the beneficial effects of MA0 inhibitors.66,67 Ensuing reports have claimed that D L-Trp is as effective as electroconvulsive shock therapy68 or imipraminebg and it has been successfully used "as a last res0rt".7~ In other studies, however, L-Trp has been less impre~sive.7~ Early studies of 5-HTP were limited to low doses given over short periods of time.72 Recent, more prolonged trials, have yielded conflicting results.73 Several recent findings may have an important bearing on the future use of 5-HT precursors in depression. Evidence from CSF experiments suggests an abnormally low rate of 5-HT synthesis in the CNS of some depressed patients,63 perhaps due to impaired Trp-5-hydroxylase activity.74 If this were true, L-Trp would inefficiently elevate brain 5-HT in this population, explaining the divergent clinical results obtained with L-Trp. The use of L-5-HTP, which enters the 5-HT pathway subsequent to the rate-limiting Trp hydroxylation step, might seem a logical alternative. Recent reports, however, indicate that this precursor leads to indiscriminate and non-physiologic elevations of brain 5-HT. 2 75 To what extent these findings apply to the chronic administration of this amino acid to man is not known, but van Praag and Korf73b recently reported L-5-HTP to be effective in depressives who showed evidence of a 5-HT synthesis defect. The continued viability of the 5-HT precursor approach to the treatAdditional definitive research ment of depression is thus questionable. concerning 1) the relationship of change in levels of 5-HIAA in CSF to brain 5-HT turnover, 2) the biochemical classifications of depression, and 3 ) the effects of chronic L-5-HTP on levels of physiologically active 5-HT are needed to determine the future direction of this approachOther potentially significant approaches to the treatment of depression based on the 5-HT hypothesis have emerged during the past few years. These include: 1) selective 5-HT reuptake blockade, 2) selective inhibition of MAO, and 3) 5-HT mimetic activity. Although these approaches may not suffer from the obvious disadvantages of the precursor approach, each possesses unique and challenging problems of its own.
Chap. 5
Serotonin and Behavior
We i ssman , Ha rbert
53
The concept of selective blockade of monoamine reuptake has been studied extensively by Carlsson and associates76 who have shown that tricylic mines such as imipramine and chlorimipramine are selective inhibitors of 5-HT uptake. Furthermore, they have suggested that blockade of 5-HT reuptake is associated with the "mood-elevating" action of the tricyclic antidepressants and that blockade of NE reuptake promotes "drive" in depressed patients. This is consistent with the fact that chlorimipramine, the most potent and selective inhibitor of 5-HT reuptake in this series, has encouraging antidepressant activity in humans77 with at least one report of a selective mood-elevating effect .78
&
At least four different molecular forms of MAO, with different substrate specificities, occur in human brain79 suggesting that depression might be treated by selective inhibition of 5-HT oxidation .80 Several c1
c1 I
I1
I11
selective inhibitors have been reported to date81 and at least two, clorgyline82 (I) and Lilly 51641 (11),83 have been reported to possess antidepressant activity. It is not clear whether they possess sufficient selectivity to obviate the autonomic side effects commonly seen with other non-selective MA0 inhibitors. Another conceivable approach to the problem of 5-HT and depression is the development of an agent that selectively stimulates 5-HT receptors. Such a 5-HT mimetic would require a high degree of CNS selectivity, but this problem does not seem insuperable. Quipazine (111), a smooth muscle stimulant with 5-HT-mimetic properties ,15a possesses a characteristic "antidepressant" profile in animals15b and, depending on clinical activity, may be a significant development toward this end. Mania - Mania has been viewed historically as "the other affective disorder," and emphasis has tended to focus on the polarity of certain manic depressive symptoms. Kety6lc has recently hypothesized that a central indoleamine deficiency permits the occurrence of either mania or depression, and that an accompanying change in adrenergic activity determines the polarity of the affective disorder, adrenergic activity being intensified in mania and diminished in depression. Thus, within the context of this discussion, Kety ' s hypothesis suggests a similar "pro-indole" therapeutic approach to both depression and mania. Clinical trials of 5-HT precursors in mania have been rare, but two recent reports indicate a moderately beneficial effect from L-Trp. 71b ,84 Methysergide has a deleterious effect in manic patients .85
54
Sect. 1
-
CNS Agents
Engel hardt, Ed.
Schizophrenia - Schizophrenia is almost certainly a class of behavioral disorders and not a single disease entity, which perhaps explains in part the numerous theories and conflicting clinical findings,61 Several theorists invoke defective indoleamine metabolism and transport as key etiological factors in schizophrenia.6la,b Woolley86 suggested that 5-HT concentrations might be elevated in schizophrenics, consistent with observations that L-Trp in combination with an MA0 inhibitor exacerbates psychoses.87 Similar exacerbations and recurrences of individual psychotic patterns are seen following administration of the methyl donors, methioninegg and betaine.89 These findings, together with the known psychotomimetic effects of dimethyltryptaminego and bufotenin91 led several authors88992 to suggest that abnormal methylation of indoleamines, leading t o the endogenous formation of methylated indole(ethyl)amines, may be a primary causative factor in the pathogenesis of schizophrenia. This has been supported by the recent isolation of a specific indoleamine Nmethyltransferase from rat and human brain,93 and the demonstration that tryptamine is converted to dimethyltryptamine in rat and human brain.94 This theory is also compatible with a recent a-2 globulin theoryYg5which postulates an enzyme abnormality that permits excess Trp to enter brain. Clinical attempts to elevate CNS 5-HT levels in schizophrenics have generally had deleterious effects, particularly when L-Trp is combined with an MA0 inhibitor.87 Reports of mild beneficial effects of L-Trp74 and L-5-HTP96 in schizophrenics have appeared recently. Other Behavioral States - Elucidation of the role of 5-HT in sleep26b,27 has prompted numerous clinical studies with L-Trp and L-5-HTP. L-Trp appears t o sedate normals and insomniac patients97 and has recently been described as a "natural sedative".98 Clinical studies of L-5-HTP in sleep have not been as impressive.99 Several behavioral disturbances including psychoses frequently accompany Hartnup's disease, Wilson's disease, porphyria and pellagra, diseases in which indoleamine abnormalities have been identified.100 These behavioral aberrations generally recede during clinical remission of the primary metabolic abnormality. References 1. a) 5-Hydroxytryptamine and Related Indolealkylamines, ed. V. Erspamer, Springer-Verlag, Berlin (1966); b) Advances in Pharmacology, ed. E. Costa and M. Sandler, Academic Press, New York (1968); c) S. Garattini and L. Valzelli, Serotonin, Elsevier, Amsterdam (1965) 2. A. T. B. Moir and D. Eccleston, J. Neurochem., 15, 1093 (1968). 3 . D. K. Zhelzaskov, M. Levitt, and S. Udenfriend, Molec. Pharmacol., 4, 445 (1968).
Chap.
4. 5. 6.
7. 8. 9.
10. 11. 12. 13.
14. 15.
5
S e r o t o n i n and Behavior
We i s sma n , Ha r be r t
55
A. C a r l s s o n , P . 529 i n r e f . l a . U. U n g e r s t e d t , Acta P h y s i o l . Scand. S u p p l . , (1971). E . M. G a l , P . A . D r e w e s , and C . A. B a r r a c l o u g h , i n P r o c e e d i n g s of t h e F i r s t I n t e r n a t i o n a l Pharmacology M e e t i n g , v o l . 8 , 1 0 7 , Pergamon Press, Oxford (1962) H. G. Baumgarten and L. Lachenmayer, B r a i n R e s . , 38, 228 ( 1 9 7 2 ) . B . K . Koe and A. Weissman, J . Pharmacol. Exp. T h e r . , 499 ( 1 9 6 6 ) . a ) A . S . Welch and B . L. Welch, J . Pharm. P h a r m a c o l . , 19,632 (1967) ; b ) F. P . Miller, R. H . Cox, J r . , W . R. S n o d g r a s s , and R . P . M a i c k e l , Biochem. Pharmacol. 9, 435, 1970. G . G u r o f f , Arch. Biochem. Biophys. 134,610 ( 1 9 6 9 ) . M. L i p t o n , K . Gordon, G. G u r o f f , and S . U d e n f r i e n d , S c i e n c e , 156, 248 ( 1 9 6 7 ) . A. T a g l i a m o n t e , P . T a g l i a m o n t e , and J , Perez-Crue t , J . Pharmacol. Exp. T h e r . , 475 ( 1 9 7 1 ) . B . B . B r o d i e and W . D. R e i d , Adv. P h a r m a c o l . , @, 97 ( 1 9 6 8 ) . A. C a r l s s o n , J . J o n a s o n , M. L i n d q u i s t , and K . Fuxe, B r a i n R e s . , 456 ( 1 9 6 9 ) . a ) E . Hong, L. F. S a n c i l i o , R. V a r g a s , and E . P a r d o , E u r . J . Pharmac o l . , 6, 274 ( 1 9 6 9 ) ; b ) R. R o d r i g u e z and E . G . P a r d o , Psychopharmacologia, 89 ( 1 9 7 1 ) . G . K . A g h a j a n i a n , Fed. P r o c . &, 9 1 ( 1 9 7 2 ) . B . B . B r o d i e and P . A . S h o r e , Ann. N . Y . Acad. S c i . , 66, 6 3 1 ( 1 9 5 7 ) . a) V. F l o r i o , A . S c o t t i - D e - C a r o l i s , and V. G. Longo, P h y s i o l . Behav., 3 , 8 6 1 (1968) ; b ) J . F. Brody, J r . , P s y c h o p h a r m a c o l o g i a , 1 4 (1970) c) J . C. D e L a T o r r e , H . M. Kawanaga, and S . M u l l e n , Arch. I n t . Pharmacodyn., 298 ( 1 9 7 0 ) . a) M. H o l l i n g e r , Arch. I n t . Pharmacodyn. T h e r . , 2 ,419 ( 1 9 6 9 ) ; b ) J . K . S a l e n s , G. B . K o v a c s i c s , and M. P . A l l e n , i b i d , 1 7 3 , 411 (1968) ; c) S . S . Tenen, P s y c h o p h a r m a c o l o g i a , 10,204 ( 1 9 6 7 ) . 434 ( 1 9 6 9 ) ; b ) a ) J . H . P i r c h , Arch. I n t . Pharmacodyn. T h e r . , H . C. F i b i g e r and B . A. Campbell, Neuropharmacology, 25 ( 1 9 7 1 ) . a ) W . Dement, V . Z a r c o n e , J . F e r g u s o n , H . Cohen, T . P i v i k , and J . B a r c h a s , I n S c h i z o p h r e n i a . C u r r e n t Concepts and R e s e a r c h , e d . D. V . S i v a S a n k a s , P J D P u b l i c a t i o n s , L t d . , H i c k s v i l l e , N . Y . ( 1 9 6 9 ) , p . 775; b ) J . A. Wada and A. T e r a o , Exp. N e u r o l . , 28, 5 0 1 (1970) ; c) W. P . K o e l l a , A. F e l d s t e i n , and J . S . Czicman, E l e c t r o e n c e p h a l o g r . C l i n . N e u r o p h y s i o l . , 25, 481 ( 1 9 6 8 ) ; d) L . S a a r n i v a r a , Ann. Med. Exp. B i o l . 113 (1969). Fenn., a) K . O p i t z , Arch. Pharmak. Exp. P a t h o l . , 259, 56 ( 1 9 6 7 ) ; b ) M. H . Sheard, Brain Res., 524 ( 1 9 6 9 ) . a ) T . J . C i c e r o and S . Y . H i l l , P h y s i o l . Behav., 1,787 ( 1 9 7 0 ) ; b) H . H . F r e y M. P . Magnussen, and C. K . N i e l s e n , Arch. I n t . Pharmacodyn. T h e r . , 183, 1 6 5 ( 1 9 7 0 ) ; c) M. Nachman, D. Lester, a n d J . LeMagnen, S c i e n c e , 168,1244 (1970) ; d) K . O p i t z , P h a m a k o p s y c h i a t r i e , 2, 202 (1969) ; e ) R. D. Myers and T . J . C i c e r o , P s y c h o p h a m a co!.ogia, 373 ( 1 9 6 9 ) . J . Mouret , P . B o b i l l i e r , and M. J o u v e t , E u r . J . Pharm., 5 , 1 7 ( 1 9 6 8 ) . D. C . S p a f f o r d and E . T . P e n g e l l e y , Comp. Biochem. P h y s i o l . , 38, 239 ( 1 9 7 1 ) .
367,
.
154,
177,
12,
2,
16. 17. 18.
z,,
188,
19.
20. 21.
181,
47,
22. 23.
15,
15,
24. 25.
10,
56 26. 27. 28. 29. 30. 31.
Sect. 1
-
a) M. Jouvet, Adv. Pharmacol.,
163,
32 (1969).
160,
1361 (1968).
Engelhardt, Ed.
CNS Agents
E, 265
(1968); b) M. Jouvet, Science,
W. P. Koella, Biol. Psychiat., L, 1 6 1 (1969). E. D. Weitzman, M. M. Rapport, P. McGregor, and J. Jacoby, Science, R. J . Wyatt, K. Engleman, D. Kupfer, J . Scott, A. Sjoerdsma, and F. Snyder, Electroencephalogr. Clin. Neurophysiol., 27, 529 (1969). V . Y. Cremata and B. K. Koe, Clin. Pharmacol. Ther. , 7, 768 (1966). a) J. A. Harvey and C. E. Lints, J . Comp. Physiol. Psychol., 74, 28 (1971); b ) B. D. Garlitz and H. H. Frey, Arch. Pharmakol., R43
270.
(1971). 32.
33. 34.
35. 36. 37.
38.
39. 40.
C. Y. Schlesinger, R. A. Schreiber, and G. T. Pryor, Psychonom. Sci.,
11, 225
12,
Exp. Ther., 180, 136 (1972). G. G. Yarbrough, D. M. Buxbaum, and E. Sanders-Bush, Pharmacologist, 13, 681 (1971). E. L. Way, H. H. Loh, and F. H. Shen, Science, 162, 1290 (1968). a) S. Algeri and E. Costa, Biochem. Pharmacol., 20, 877 (1971); b ) D. L. Cheney and A. Goldstein, J . Pharmacol. Exp. Ther., 177,309 (1971); c) D. L. Cheney, A. Goldstein, S . Algeri, and E. Costa, Science, 1 7 1 , 1169 (1971); d) I. G. Marshall and D. G. GrahameSmith, Nature, 228, 1206 (1970); e) Y. Maruyama, G. Hayashi, S. E. Sonits, and A. E. Takemori, J . Pharmacol. Exp. Ther., 178,20 (1971); f) A . S. Schwartz and E. Eidelberg, Life Sci., 9 Part I, 613 (1970). M. Herold and J . Cahn, in Pharmacology of Pain, ed. R. K. S. Lim, D. Armstrong and E. G. Pardo, Pergamon Press, Oxford, (1968). S. H. Ngai and Lofstrandh, in Abstracts, Annual Meeting, American Society of Anesthesiologists (19691, p. 5 . a) A. D. Rudzik and G. A . Johnson, In Amphetamines and Related Compounds, ed. E. Costa and S . Garattini, Raven Press, New York, (1970) p . 715; b) J. C. De La Torre and S . Mullan, J . Pharm. Pharmacol.,
22,
41. 42.
(1968).
S . Takaori and C. Tanaka, Jap. J . Pharmacol., 20, 607 (1970). a) S. S. Tenen, Psychopharmacologia, 278 (1968); b) C. F. Major and B. J. Pleury, Brit. J. Pharmacol., 40, 143P (1970); c) W. L. Dewey, L. S . Harris, J . F. Howes, and J . A . Nuite, Pharmacologist, 10, 199 (1968); d) M. R. Fennessy and J. R. Lee, J . Pharm. Pharmacol., 22, 930 (1970); e) T. Oka, M. Nozaki, and E. Hosoya, J . Pharmacol.
858 (1970).
a) B. K. Koe and A. Weissman, Adv. Pharmacol., 6 B , 29 (1968); b) W. D. Gray and C. E. Rauh, J . Pharmacol. Exp. T her.17, - 206 (1971). K. Schlesinger, W. 0. Boggan, and D. X. Freedman, Life Sci., 9 Part I, 721 (1970).
43.
44. 45.
J. W. Prichard and G. Guroff, J . Neurochem., 1 8 , 1 5 3 (1971). P. Norton, J . Pharm. Pharmacol., 22, 763 (1970). G. Chen, C . R. Ensor, and B. Bohner, Proc. SOC. Exp. Biol. Med., 86,
507 (1954). 46. 47. 48.
a) S. Gibson, E. G. McGeer, and P. L. McGeer, Exp. Neurol., 27, 283 (1970); b) K. Blum and I. Geller, Fed. Proc., 28, 794 (1969). B. P. H. Poschel and F. W. Ninteman, Physiol. Behav. 1, 39 (1971). J. Ferguson, S. Henriksen, H. Cohen, G. Mitchell, J . Barchas, and W. Dement, Science, 168,499 (1970).
Chap. 5 49. 50. 51.
52.
53. 54. 55. 56.
57.
S e r o t o n i n and Behavior
We i s sma n , Ha r b e r t
J. A. Rosecrans, P h y s i o l . Behav., 5, 453 (1970). A. K. Swonger, W. F. Chambers and R. H. Rech, P h a r m a c o l o g i s t , 207 (1970). 1000 (1970); b) A. a ) R. E. Whalen and W. G . L u t t g e , S c i e n c e , Z i t r i n , F. A. Beach, J . D. Barchas, and W. C. Dement, S c i e n c e , 170, 868 (1970). a ) A. Tagliamonte, P. Tagliamonte, G. L. Gessa, and B. B. B r o d i e , Science, 1433 (1969); b ) E. E. S h i l l i t o , B r i t . J . Pharmacol., 38, 305 (1970); c ) N a t u r e , 398 (1971); d ) P . J . S a l i s and D. A. Dewsbury, Nature, 23, 400 (1971). a ) B. J . Meyerson and T . Lewander, L i f e S c i . , 9 P a r t I , 661 (1970); 60 (1971). b ) L . H. Lindstriim, Eur. J . Pharmacol., U. J . Hoyland, E. E. S h i l l i t o , and M. Vogt, B r i t . J. Pharmacol., 40, 659 (1970). D. Tagliamonte, J . Perez-Cruet, A. Tagliamonte, and G. Gessa, Pharmacologist, 205 (1970). E. Lycke, K. Modigh, and B . E. ROOS, E x p e r i e n t i a , 25, 951 (1969). a ) A. F. Mirsky and C. Kornetsky, i n Psychopharmacology, A Review of P r o g r e s s , ed. D. H. Efron, P . H. S . P u b l i c a t i o n , Washington, (1968); b ) J. Silverman, Psychol. Rev., 352 (1964). a ) K. Engelman, E. J e q u i e r , W. Lovenberg, and A . Sjoerdsma, C l i n . Res., 316 (1967); b) A. Sjoerdsma, W. Lovenberg, K. Engleman, W. T. C a r p e n t e r , R. J. Wyatt, and G . L. Gessa, Ann. I n t e r n . Med., 73, 607 (1970). J . J. S c h i l d k r a u t , Am. J . P s y c h i a t . , 509 (1965). I. P . Lapin and G. F. Oxenkrug, Lancet 1 132 (1969). a ) Biochemistry, S c h i z o p h r e n i a s and A f f e c t i v e D i s o r d e r s , e d . H. E. Himwich, The Williams and Wilkins Co., B a l t i m o r e , (1970). b ) Bioc h e m i s t r y of B r a i n and Behavior, ed. R. P. Bowman and S . P. D a z , Plenum P r e s s , New York (1970); c ) S. Kety, B r a i n Chemistry i n Ment a l Disease, i n B. T . Ho and W. M. McIsaac, Eds., Plenum P r e s s , New York, N.Y. (1971). a ) D. M. Shaw, F. E. Camps, and E. E c c l e s t o n , B r i t . J . P s y c h i a t . , 113, 1407 (1967); b) H. R. Bourne, W. E. Bunney, R. W . Colburn, J. M. Davis, J . N. Davis, D . M. Shaw, and A. Coppen, Lancet 2 , 805 (1968). H. M. van P r a a g , J . Korf, and J . P u i t e , Nature, 1259 (1970). H. M. van Praag and J . Korf, Psychopharmacologia, 19, 148 (1971). 743 (1971); b ) A. J . Copa ) B. J . C a r r o l l , C l i n . Pharm. Ther., (1968). pen, Adv. Pharmacol. A. Coppen, D. M. Shaw, and J . P . F a r r e l l , Lancet 1, 79 (1963). A. H. Glassman and S. R. Platman, J . P s y c h i a t r . Res., L, 83 (1969). A. Coppen, D. M. Shaw, B. Herzberg, and R. Maggs, Lancet, 2, 1178 (1967). A. J . Coppen, P. C . Whybrow, R. Noguera, R. Maggs, and A. J . Prange, J r . , Arch. Gen. P s y c h i a t r y , 26, 234 (1972). A . D. B r o a d h u r s t , Lancet 1, 1392 (1970). a ) B. J. C a r r o l l , R. M. Mzwbray, and B. M. Davies, Lancet L, 967 (1970); b ) W. E. Bunney, H. K. H. Brodie, D . L. Murphy, and F. K. Goodwin, Am. J . P s y c h i a t r y , 872 (1971).
12,
169,
166,
232,
15,
12,
71,
58.
59. 60. 61.
62.
63. 64. 65. 66. 67. 68. 69. 70.
71.
57
15,
122,
225,
12,
s,
127,
Sect. 72. 73.
74. 75. 76.
1
-
CNS Agents
E n g e l h a r d t , Ed.
S a c k s , and G. M. Simpson, Am. J . P s y c h i a t r y , 129, 379 ( 1 9 6 4 ) . a) H . K . H . B r o d i e , R . S a c k , and L . S i e v e r , C o n f e r e n c e on S e r o t o n i n and B e h a v i o r , P a l o A l t o , C a l . , J a n . 1972 , i n p r e s s ; b ) H . M. van P r a a g and J . K o r f , 3. M. B . Bowers, Neuropharmacology, 9 , 599 ( 1 9 7 0 ) . G. K . A g h a j a n i a n , A. Graham, and E. S h e a r d , S c i e n c e , 169, 1100 ( 1 9 7 0 ) . a) A. C a r l s s o n , H . C o r r o d i , K . Fuxe, and T . H s k f e l t , Europ. J . Pharma c o l . , 5 , 357 ( 1 9 6 9 ) ; b ) A. C a r l s s o n , J . J o n a s o n , and M. L i n q v i s t , J . Pha;. Pharmacol., 769 ( 1 9 6 9 ) . Drug T h e r a p . B u l l . , 2, 99 ( 1 9 7 1 ) . M. H . Synies, S n t . J . N e u r o p s y c h i a t r y , 3 , 60 ( 1 9 6 7 ) . G. G. S . C o l l i n s , M. S a n d l e r , D. E . W i l l i a m s , a n d M . B . H . Yondim, Nature, 817 ( 1 9 7 0 ) . R . W. F u l l e r , Arch. I n t . Pharmacodyn., 1 2 , 32 ( 1 9 6 8 ) . a ) I). W . R. H a l l , B . W . Logan, and G . H . P a r s o n s , Biochem. P h a r m a c o l . , _18, _ 1447 ( 1 9 6 9 ) ; b ) R. W . F u l l e r , B . J . Warren, and B . B . M o l l o y , Riochem. Pharmacol. , 19,2934 ( 1 9 7 0 ) . J . A . H e a r d , C l i n . T r i a l s J . , 6 , 219 ( 1 9 6 9 ) . G . M. Simpson, C . J . I q b a l , a n d F. l q b a l , C u r r . T h e r a p . R e s . , 8, 400 ( 1 9 6 6 ) . A. J . P r a n g e , J . L. S i s k , I . C . W i l s o n , C . E . M o r r i s , C . D . H a l l , and J . S . Carman, C o n f e r e n c e on S e r o t o n i n and B e h a v i o r , P a l o A l t o , J a n . 1972, i n p r e s s . A . Coppen, A. J . P r a n g e , P . C . Whybrow, R. Noguera, and J . M. P a e z , L a n c e t 2, 338 ( 1 9 6 9 ) . D . W . Woolley, The B i o c h e m i c a l Bases of Psycho=, J o h n Wiley and S o n s , Tnc., New York, 1 9 6 2 , p . 1 4 . W . P o l l i n , P . Cardon, J r . , and S . K e t y , S c i e n c e , 122,104 ( 1 9 6 1 ) . G . G . Brune and H . E . Himwich, J . Nerv. Ment. D i s . , 134,447 ( 1 9 6 2 ) . G . G. Brune and H . E . Hirnwich i n R e c e n t Advances i n B A o l o g i c a l P s y c h i a t r y , e d . J . W o r t i s , Vol. 5 , Plenum Press, New York, 1963, 1 4 4 . S . S z a r a , E x p e r i e n t i a , 12, 441 ( 1 9 5 6 ) . H . D. Fabing and J . R. Hawkins, S c i e n c e , 123,886 ( 1 9 5 6 ) . J . A x e l r o d , S c i e n c e , 134,343 ( 1 9 6 1 ) . A . J . Mandell and M. Morgan, N a t u r e , 230, 85 ( 1 9 7 1 ) . J . M. S a a v e d r a and J . A x e l r o d , S c i e n c e , 175,1 3 6 5 ( 1 9 7 2 ) . C . E . Frohman, K. A. Warner, C . T . B a r r y , and R . E . A r t h u r , B i o l . P s y c h i a t . , 1,201 ( 1 9 6 9 ) . R . J . W y a t t , T . Vaughan, J . K a p l a n , M. G a l a n t e r , and R . G r e e n , i n Conf e r e n c e on S e r o t o n i n and B e h a v i o r , P a l o A l t o , J a n . 1 9 7 2 , i n p r e s s . E . Hartmann, R. Chung, and C h i e n , P s y c h o p h a r m a c o l o g i a , 19, 114 ( 1 9 7 1 ) . R. J . Wyatt, K . Engleman, D . J . K u p f e r , D . H . Fram, A. S j o e r d s m a , and F. S n y d e r , L a n c e t 2 , 842 ( 1 9 7 0 ) . I. Oswald, G . W . A s h c r o f t , R. J . B e r g e r , D . E c c l e s t o n , J . I. E v a n s , 391 ( 1 9 6 6 ) . and V . R . T h a c o r e , B r . J . P s y c h i a t . , G. G . Brune i n B i o c h e m i s t r y , S c h i z o p h r e n i a s and A f f e c t i v e I l l n e s s e s , e d . H . H i m i c h , The W i l l i a m s & W i l k i n s Co., B a l t i m o r e , 1 9 7 0 , p . 43. N . S . K l i n e , W.
z,
77.
78. 79. 80. 81.
82. 83. 84.
85. 86. 87. 88. 89. 90. 91. 92. 93. 94. 95. 96. 97. 98. 99. 100.
?c,
112,
Section I I - Pharmacodynamic Agents Editor:
John G. Topliss, Schering Corp., Bloomfield, New Jersey Chapter 6 .
Antihypertensive Agents
Anthony M. Roe, Smith Kline and French Research Institute, Welwyn Garden City Hertfordshi re, England Introduction - No major advance n our understanding of the nature of hypertension has been made this year, and it remains true that "until the mysteries of the etiology of essential hypertension are unravelled, treatment must remain empiric and pall iativel'.l Several review^^-^ have discussed various aspects of the clinical conditions which are associated with an elevated blood pressure, and which are the target for so much research. Other review^^-^ have described the cl inical benefits achieved by lowering elevated blood pressure; it is possible that this benefit is obtained by the reversal of the increased ratio of the vascular wall thickness to the diameter of the lumen which is a characteristic of essential hypertension. l o The spontaneously hypertensive rat (SHR) continues to gain attention as a rode1 with which to assess antihypertensives.10-12 The extent to which different anesthetics reduce cardiovascular responses of cats has been studied,13 and the danger of assuming that drug solvents such as polyethylene glycol have no effect on these resporises has been pointed out. l4 Developments in clinically useful antihypertensives - There has been a great deal of discussion15 on work carried out to evaluate the therapeutic potential of combining a vasodilator with a B-adrenoreceptor blocker in order to counteract the tachycardia associated with the former. The combination of hydralazine with propranolol (p.0.) is effective in hypertensive patients at doses which separately do not give a satisfactory hypotensive effect;16 a similar situation holds for dih~dra1azine.l~ Alprenolol (i .v.) also reduced the cardiac stimulation observed in normotensive and hypertensive patients after dihydratazine (i .v.) .18 Minoxidi 1 (PDP), in combination with propranolol and hydrochlorothiazide, appears to be more effective in refractory hypertensive patients than hydralazine. l 9 Practolol effectively blocks the tachycardia in normotensive dogs treated with hydralazine (i.v.) without potentiating the hypotensive effects, which suggests that tachycardia does not diminish the hypotens i ve effect of hydra 1 az i ne . 2o Guancydine has been examined in further cl inical tria1s,21,22 and shown to have no effect on the pressor response of angiotensin in hypertensives.22 The mode of action of guancydine has been studied in vitro leading to the conclusion that its hypotensive properties result
60
Sect. I I
-
T o p l i s s , Ed.
Pharmacodynamic Agents
from i t s n o n - s p e c i f i c i n h i b i t o r y e f f e c t on smooth muscle.23 The c a r d i o v a s c u l a r responses o f p a t i e n t s r e c e i v i n g p r o p r a n o l o l have been compared t o those r e c e i v i n g b e t h a n i d i n e , guanethidine and u - m e t h y l d ~ p a ; no ~ ~ advantage i s gained by combining p r o p r a n o l o l w i t h these sympathetic inhibitor^.^^ Propranolol i s thought t o a c t as an a n t i h y p e r t e n s i v e by decreasing the c a r d i a c o u t p u t and c o n d i t i o n i n g the baroreceptors t o f u n c t i o n a t a lower i n addition t o cardiac B-blockade, t h e r e may be a component o f adrenergic neurone blockade i n t h i s a c t i o n . 2 6 I n c o n t r a s t , t h e a n t i h y p e r t e n s i v e a c t i o n o f p r a c t o l o l may be due t o v a ~ o d i l a t i o n . ~ The ~ problems i n v o l v e d i n t h e c l i n i c a l e v a l u a t i o n of these drugs have been discussed.28 There has been a succession o f r e p o r t s t h i s year on t h e c l i n i c a l e f f e c t s o f c l o n i d i n e ( I ) , which can be used w i t h advantage i n c o n j u n c t i o n with c h l o r t h a l i d ~ n e . ~ ~ ~unique ~~ The and complex mechanism o f a c t i o n o f t h i s drug i s now becoming c l e a r . 3 1 When a l l sympathetic transmission i s blocked, a p e r i p h e r a l vasodi l a t i n g a c t i v i t y has been uncovered,32 i n a d d i t i o n t o i t s p e r i p h e r a l a-receptor s t i m u l a n t a c t i o n which r e s u l t s i n a b r i e f hypertensive response a f t e r i . v . a d m i n i s t r a t i o n a t low doses. The a c t i o n which predominates and makes c l o n i d i n e such a u s e f u l drug i s i t s a b i l i t y t o s t i m u l a t e c e n t r a l a-receptors l e a d i n g t o an i n h i b i t i o n o f sympathetic An e f f e c t on the c e n t r a l c o n t r o l o f vagal a c t i v i t y , a t l e a s t i n dogs, has a l s o been ~ u g g e s t e d . ~ ~
I
Ill
II
Studies on the h e m ~ d y n a m i c sand ~ ~ central s i t e s o f action37 o f several a-receptor s t i m u l a n t s , i n c l u d i n g c l o n i d i n e ( I ) , t h e oxazol i n e ( 1 1 , LD2855), and x y l a z i n e ( I l l , BAY 1470) have been reported. Adrenergic neurone blockers - Several m e t h y l p y r r o l i d i n e analogs ( I V , R = (CH3)2 o r (CH3)3) o f guanethidine have a c t i v i t i e s comparable t o t h a t o f guanethidine when t e s t e d p.0. and S . C . i n renal hypertensive r a t s . ( I V , R = cis-2,4-(CH3)2) i s l e s s a c t i v e than guanethidine as a sympathomirnetic i n dogs and c a t s ( i . v . ) . 3 8
N-CH2CH2NHC //NH NH2
'
IV
\
m N - C C N H
NH2 V
VI
Chap. 6
A n t i h y p e r t e n s i v e Agents
61 -
Roe
The N-carbamidoxime ( V ) lowers the blood pressure o f renal hypertensive dogs a t 2 and 8 mg/kg and i s a l s o r e p o r t e d t o be an e f f e c t i v e a n t i h y p e r t e n s i v e i n neurogenic dogs, as w e l l as r e n a l and spontaneously hypertensive r a t s . T h i s compound resembles guanethidine and debrisoquine ( V I ) i n i t s adrenergic neurone b l o c k i n g and catecholamined e p l e t i n g a c t i v i t y , but i t may have an a d d i t i o n a l c e n t r a l e f f e c t . l l ~ ~ ~ Debrisoquine has now been shown t o d e p l e t e t h a t small p a r t o f the norepinephrine s t o r e which has been p o s t u l a t e d as e s s e n t i a l f o r t h e proper f u n c t i o n i n g o f adrenergic neurones , 4 0 A comparison o f the a n t i h y p e r t e n s i v e e f f e c t o f guanethidine w i t h t h r e e o f i t s m e t a b o l i t e s i n renal h y p e r t e n s i v e r a t s leads t o t h e conclusion t h a t guanethidine p e r se, and not i t s m e t a b o l i t e s , i s responsible f o r i t s hypotensive e f f e c t s . 4 1 Gang1 i o n b l o c k e r s - A t 10 mg/kg, d e r i v a t i v e s o f 4-azahomoadamantane ( V I I ) and (VIII) lower the blood pressure o f anesthetized dogs by a t l e a s t 15% f o r two hours o r more, a p p a r e n t l y by g a n g l i o n blockade.42 The monomethoxymecamylamines ( I X , R1, R2, o r R 3 CH,O) a r e about as a c t i v e as mecamylamine i n l o w e r i n g t h e blood pressure o f r e n a l h y p e r t e n s i v e r a t s , t h e corresponding hydroxy d e r i v a t i v e s a r e l e s s a c t i v e . 4 3
-
R = H = C2H4NHC (NH)NH2
R = NH2 = NHaryl = C H N(alkyll2
= C H COC H F - 4 2 4 6 4
2 4
viI
IX
VI I I
X
H3
-
XI
F u r t h e r d e t a i 1s have now appeared44 on t h e or-Adrenoreceptor b 1ocke r s c a r d i o v a s c u l a r e f f e c t s o f the a-blocker (X, NC 7197) mentioned l a s t year.45 The t r i c y c l i c guanidine ( X I ) , which s i g n i f i c a n t l y lowers t h e blood pressure o f m e t a c o r t i c o i d r a t s a t 5 mg/kg, and conscious normotensive o r neurogenic hypertensive dogs a t 2.5 mg/kg, probably has or-blockade as i t s main mechanism o f a c t i o n . However, s i n c e t h e r e i s no o r t h o s t a t i c hypotension i n the r a b b i t t i l t t e s t , i t s mechanism o f a c t i o n must be complex.46
62 -
Sect.
II
-
Pharmacodynamic Agents
Top1 i s s , Ed.
lndoramine ( X I I , Wy 21901) a b o l i s h e s e p i n e p h r i n e - and ouabai ninduced c a r d i a c a r r y t h m i a s by a combinat i o n o f a - a d r e n o r e c e p t o r b l o c k a d e and membrane s t a b i l i ~ a t i o n . These ~ ~ e f f e c t s have a l s o been s t u d i e d electrophysiological iy.48 l n d o ra m i n e has a PA, o f 7.4 as a c o m p e t i t i v e a - b l o c k e r on a o r t i c s t r i p , and a PA, o f 8.2 as an a n t i h i s t a m i n e o n guinea p i g ileum.49 The b l o o d p r e s s u r e o f c a t s and consci ous r e n a l h y p e r t e n s i v e r a t s i s lowered b y i n d o rami ne a t 20-40 mg/kg (p.0.) ; s e v e r a l analogs a r e a l s o a c t i v e b u t r a t h e r t o x i c . 5 0 A d o s e - r e l a t e d r e d u c t i o n i n b l o o d p r e s s u r e accompanied by an i n c r e a s e i n h e a r t r a t e a f t e r a d m i n i s t r a t i o n o f i n d o ra mi n e has been observed i n man.51 The new compound ( X I 1 1 , AH 5158A) i s p a r t i c u l a r l y i n t e r e s t i n g because i t combines s i g n i f i c a n t B -a d r enoreceptor b l o c k i n g a c t i v i t y w i t h a - b l o c k i n g a c t i v i t y b o t h i n a n i m a l s and i n man.52
IN
H
XI I
XI II
Compounds a f f e c t i n g a d r e n e r g i c t r a n s m i t t e r s - F u s a r i c a c i d amide ( X I V , Sch 10595) i s a v e r y a c t i v e i n h i b i t o r o f doparnine-6-hydroxylase i n v i v o ( b u t n o t i n v i t r o ) , and i t l o w e rs t h e b l o o d p r e s s u r e o f DOCA h y p e r t e n s i v e r a t s f o r many h o u rs i n a d o s e - r e l a t e d manner.53 The c y c l o h e x y l a m i n o o x a z o l i n e ( X V , BAY a6781) p r o b a b l y e x e r t s i t s h y p o t e n s i v e e f f e c t by p r e v e n t i n g t h e r e l e a s e o f c a te c h o l a mi nes f r o m t h e a d r e n a l gl and.54 3-Ethyl-a-methyltyrosine (XVI) i s a competitive i n h i b i t o r o f t y r o s i n e h y d r o x y l a s e and e x h i b i t s s i g n i f i c a n t a n t i h y p e r t e n s i v e a c t i v i t y i n DOCA r a t s a t 25 mg/kg. I t may be p r e f e r a b l e t o a - m e t h y l t y r o s i n e because i t s h o u l d n o t be m e t a b o l i s e d i n t o a ~ a t e c h o l a m i n e . ~ ~
--
CH
[
N ), 3 - H C2H5
XIV
xv
CH
FH3 1 3
1
I 2'NH22
xv I
The mechanism o f t h e c e n t r a l h y p o t e n s i v e e f f e c t s of L-dopa, a-methyldopa and m - t y r o s i n e has been s t u d i e d w i t h t h e a i d o f p e r i p h e r a l dec ar box y las e i n h i b i t o r s . 5 6 3 7 The e f f e c t s o f L-dopa on t h e c a r d i o v a s c u l a r system have been re v i ew ed.5* A c o m p a r a t i v e s t u d y o f t h e dose-dependent a n t i h y p e r t e n s i v e a c t i o n s , and t h e n o r e p i n e p h r i n e d e p l e t i n g a c t i v i t i e s , o f a - m e t h y l t y r a m i n e and a-methyl octopami ne i n r e n a l r a t s has been pub1 i shed. 5 9
Chap. 6
A n t i h y p e r t e n s i v e Agents
63
Roe
A s e r i e s o f hydrazones has been shown t o have a n t i h y p e r t e n s i v e and monoamine o x i d a s e i n h i b i t o r y a c t i v i t y , a l t h o u g h t h e r e was no c o r r e l a t i o n between th e s e a c t i o n s . The most a c t i v e compound ( X V I I ) caused a p r o l o n g e d f a l l o f 40-60 mn Hg i n t h e b l o o d p r e s s u r e o f a n e s t h e t i z e d dogs and c a t s a t 1 mg/kg ( i . v . 1 , and a l s o i n G o l d b l a t t h y p e r t e n s i v e r a t s a t 30 mg/kg (p.0.) when g i v e n f o r 10 d a y s . 6 0 I n a n o t h e r s t u d y , t h e compounds ( X V I I l a and X V l l I b ) were t h e most a c t i v e o f a s e r i e s o f a n t i h y p e r t e n s i v e monoamine o x i d a s e i n h i b i t o r s . 6 1 CH
' 3
XVI I I a) X = -CH=Nb) X = -CH2NHOZN
0 0
0
XVI I
-
N a t u r a l l y o c c u r r i n g and r e l a t e d compounds The s t r u c t u r e and s y n t h e s i s o f oudenone ( X I X ) , t h e h y p o t e n s i v e menti oned l a s t y e a r , 4 5 has now been r e p o r t e d . 6 2 A c e ty l a n d ro me d o l ( X X , g r a y a n o t o x i n I ) , o b t a i n e d from v a r i o u s s p e c i e s o f Rhododendron, i s h y p o t e n s i v e i n c a t s a t 0.04 mg/kg ( i . v . ) ; a r t e f a c t s w i t h r e l a t e d s t r u c t u r e s are a l s o hypotensive i n cats o r r a t s . 6 3 R =
ATS) CH3
-OH
xx
x IX
xx I
i;)
R = , ,
H
Analogs o f n i c o t i n e and anabasine i n w hi ch t h e p y r i d i n e r i n g has been r e p l a c e d by q u i n u c l i d i n e (XXla and b o t h d i a s t e r e o i s o m e r s o f XXlb) show h y p o t e n s i v e e f f e c t s when g i v e n i . v . t o dogs.64 The h y d r a z i d e o f yo him boic a c i d , w h i c h i s c o n s i d e r a b l y l e s s t o x i c t h a n t h e m e t h y l e s t e r ( y o h i m b i n e ) , causes p r o l o n g e d h y p o t e n s i o n a t 1 mg/kg ( i.v.) i n chloralosed dogs.65
-
Prostaglandins The e f f e c t s o f p r o s t a g l a n d i n s on c a r d i o v a s c u l a r responses would appear t o be c r i t i c a l l y dependent on dose l e v e l s : i n f u s e d i n t o humans a t t h e a p p r o p r i a t e dose, PGA, and P G E l cause a f a l l i n b l o o d p r e s s u r e and r e n a l d i l a t a t i o n w i t h o u t t h e r e l e a s e o f r e n i r ~ . ~ However, ~ , ~ ~ th e s e e f f e c t s a r e n o t s i m p l y dose r e l a t e d . 6 8 Ex per im ent s on t h e c a t s p l e e n have l e d t o t h e s u g g e s t i o n t h a t t h e r e i s a continuous basal s e c r e t i o n o f vasodi l a t i n g p r o ~ t a g 1 a n d i n s ; ~ g a t very low i n f u s i o n r a t e s o f PGA, and PGEl i n t h e dog, e f f e c t s due t o d i r e c t v a s o d i l a t i o n can be s e p a ra te d from s y m p a t h e t i c i n h i b i t i ~ n . ~ ~
64 -
-
Sect, I I
Pharmacodynamic Agents
T o p l i s s , Ed.
Compounds a c t i n g d i r e c t l y on vascular smooth muscle o r by unknown The 1,3,4-oxadiazole ( X X 1 1 ) 7 1 and t h e a c e t o n i t r i l e mechanisms ( X X 1 1 1 ) 7 2 cause b r i e f v a s o d i l a t i o n i n c a t s and i n dogs r e s p e c t i v e l y .
-
u1- c Hi-(d) 0
O
0
\ / I
XXI I
q - Nc H2c NO
XXlJ I
NHNH2
XXIV
C H CON-Ph 2 5
CH2CH20H
The benzoquinol i z i n e ( X X I V ) i s a hypotensive v a s o d i l a t o r i n i t lowers the blood pressure of conscious anesthetized dogs and c a t s ; renal hypertensive dogs a t 10 mg/kg/day (p.0.) . 7 3 s 7 4 The hypotensive e f f e c t o f the hydrazine ( X X V , L6150) i n conscious o r a n e s t h e t i z e d dogs (0.5 o r 0.01 mg/kg, i . v . ) appears t o be due t o p e r i p h e r a l v a s o d i l a t i o n . 7 5 The pyrazole ( X X V I ) i s a potent v a s o d i l a t o r which reduces t h e blood pressure o f c a t s and dogs by 40-50 mm Hg f o r 2 hours a t 0.25 mg/kg (i.v.), I t i s a l s o a c t i v e i n renal hypertensive rats.76
a
CH2NH (CH2) TX-NHn
CH3
XXVI I a)
CH3
b) c) d)
Ar
xxv I I
I
4-m-Chlorophenyl-1-piperazino
c6H5 C6H5 c6H5
n 1 2 2
2,6-Me2C6H3
2
11
L c o 2 c pH
R = N - 1 ,2,3,4-Tetrahydroisoquinol i n o 4-Benzyl-1-piperazino
I
Ar
RCH CH C 2 2-
1
X Cti
CH N
CH CH XXlX
A s e r i e s o f twenty-nine 3-pyrrolemethylamines ( X X V I I ) show e) hypotensive a c t i v i t y i n conscious and anesthetized dogs; ( X X V I I , a reduce t h e blood pressure o f t h e l a t t e r by 20 mm Hg a t 1 mg/kg ( i . v , ) o r less.77 Other compounds r e p o r t e d t o be hypotensive i n anesthetized
-
Chap. 6
Antihypertensive A g e n t s
65
Roe
c a t s o r d o g s a r e t h e piperazines ( X X V 1 1 1 ) , 7 8 t h e prenylamine analog ( X X I X , HOE 674), 7 9 t h e hydroxamic acid ( X X X ) e O and t h e amidinium salt ( X X X I ) . a 1
NHOH
xxx
xxx I
XXXI I
T h e highly substituted tetrahydroisoquinol ines ( X X X I I , R = PhCH, and CH3) lower t h e blood pressure o f anesthetized d o g s b y 30 mm Hg for 1 hour at 10 and 4 mg/kg (i.v.) respectively;82 a reduction o f 40% or more for a t least 4.5 hours occurs a f t e r giving several ‘+-substituted * aminoquinol ines ( X X X I I I ) .83 T h e benzocycloheptenes ( X X X I V , a and b) s h o w hypotensive activity in rats a t 10 and 20 mg/kg (i.v.) respectively. 8 4 R HR I XXXI I I
QQ
R = e.g. H, al kyl, furfuryl
m
xxx I v
a) R = 4-(l-methylpiperazinyl.) b) R = N(Ph)CH2CH2N(CH3)2
CHJ09cH2<1 N
xxxv
CH30’
O
H
xxxv I
T h e amidine analog (XXXV, A r = 2,6-C1,C6H3) o f clonidine, and several related compounds (e.g. X X X V , A r = C6H , 2-CH3C6H4, 3’CH3C6~4, are active 2,3-(CH3) ,C,H?, 2,4- ( C H ~ ) Z C ~ H and ~ , 2,2-C12!6H3CH,) antihypertensives in DOCA rats at 10 mg/kg intragastrical ly.85 A detailed study has been made o f t h e unique combination of properties exhibited by t h e hypotensive imidazol idine ( X X X V I , R o 7-2956). In dogs, a direct peripheral vasodilation i s combined w i t h a nonadrenergic myocardial stimulant activity reminiscent o f theophyll ine.86
66
Sect.
I 1 - Pharmacodynamic Agents
T o p l i s s , Ed.
RE FERENC E S
I . R.W.
G i f f o r d , J r . , i n "Drugs o f Choice, 1970-1971", W. M o d e l l , Ed., C . V . Mosby, S t . L o u i s . 2. Symposium on Mechanisms o f H y p e r t e n s i o n , F.M. Abboud and R . Reader, Suppl. 2, 1 - 1 and 1 1 - 1 (1970). Eds., C i r c . Res., 3. J.M. Ledingham, P r a c t i t i o n e r , 207, 5 (1971). 4. J . J . Brown, R . F r a s e r , A.F. L e v e r , and J . I . S . R obertson, A b s t r . 45, 549 and 633 (1971). World Med., 5. E.D. F r e i s , C i r c . Res., Suppl. 2, 11-70 (1971). 6. C.J. B u l p i t t and C.T. D o l l e r y , P r a c t i t i o n e r , 207, 43 (1971). 7. E d i t o r i a l , L a n c e t, 217 (1971). 8. R. Nagle, P r a c t i t i o n e r , 52 (1971). 9. " Hy per t ens i o n " , O f f i c e o f H e a l t h Economics, London (1971). 10. B. Folkow, M. H a l l b a c k , Y . Lundgren, and L . Weiss, A c t a P h y s i o l . Scand., 83, 280 (1 9 7 1 ). 1 1 . H. Lape, D . F o r t , R . F r e r i n g , and T. Skulan, P h a r m a c o l o g i s t ,
27,
28,
r,
207,
-
13,
191 (1971).
20. 21.
I . Nagatsu, T . Nagatsu, K. M i z u t a n i , H. Umezawa, M. M a t s u z a k i , and T. T ak euc h i , N a t u r e , 230, 381 (1 971). D . A . A . Owen, B r i t . J . P h a r m a c o l . , 43, 668 (1971). R.D. Heilman, E . Bauer, and J.P. D x a n z o , P h a r m a c o l o g i s t , 13, 298 (1971). L . Werko, Eur. J . C l i n . Pharmacol., 3 , 61 (1971). R . Z ac es t , E . G i l m o r e , and J . Koch-Weser, C l i n . Pharmacol. T h e r . , 12, 305 (1971). M. K a t i l a and M.H. F r i c k , I n t e r n . J . C l i n . Pharmacol. Ther. T o x i c o l . , 4, 1 1 1 (1970). S anner s te d t, J . Stenberg, G. Johnsson, and L . Werko, Amer. J . C a r d i o l . , 28, 316 (1971). T . G o t t l i e b a n d C . Chidsey, C i r c u l a t i o n , 44, Suppl. 2, 11-129 (1971). A.S. Dahr, C.F. George, and C.T. D o l l e r y , E x p e r i e n t i a , 27, 545 (1971). J . Stenberg, R . S a n n e r s t e d t , and L. Werko, E ur. J. C l i n T P h a r m a c o l . ,
22.
g.
12.
13. 14.
15. 16.
17. 18. 19.
K.
-
3 , 63 (1971).
23. 24. 25. 26. 27. 28. 29. 30.
V i l l a r r e a l , H. A r c i l a , M.A. Ramirez, and P. S i e r r a , C l i n . Pharmacol. T h e r . , 838 (1971). M. Worcel, A. P a p a d i m i t r i o u , and P . Meyer, J . Pharmacol. Exp. Ther., 179, 42 (1971). W.C. P r i c h a r d , P.M.S. G i l l a m , and B.R. Graham, I n t e r n . J . C l i n . Pharmacol. T h e r . T o x i c o l . , 4, 131 (1970). G.M. Day and B.N.C. P r i c h a r d , B r i t . J . Pharmacol., 41, 408P (1971). S. E l i a s h and M . Weinstock, B r i t , J. Pharmacol. 43, n 7 (1971). G . Bodem, H.L. Brammell, J . W e i l , and C . C h i d s e y T C i r c u l a t i o n , 44, Suppl. 2, 11-143 (1971). B.N.C. P r i c h a r d , Arch. I n t . Pharmacodyn., S uppl ., 193 (1971). G . O n e s t i , A . B . Schwartz, K.E. K i m , V . M a r t i n e z Paz, and C . Swartz, Circ, Res., Suppl. 2, 11-53 (1971). G. O n e s t i , K.D. Bock, V . Heimsoth, K.E. K i m , and P . Merguet, Amer. J . C a r d i o l . , 28, 74 (1971).
12,
-
192,
28, -
Chap. 6
A n t i h y p e r t e n s i v e Agents
67
Roe
207,
431 (1971). 32. J . Shaw, S.N. Hunyor, and P . I . K o rner, E ur. J . Pharmacol., 101 ( 1 9 7 1 ) . 33. P . Bolme and K. Fuxe, Eu r. J . Pharmacol., 13, I 6 8 (1971). 34. H. S c h m i t t , H. S c h m i t t , and S . Fenard, E ur. J . Pharmacol., 14, 98 (1971). 35. W. Kobinger and A. Walland, Eur , I . Pharmacol . , 120 (1971). 36. A.M. A u t r e t , H. S c h m i t t , S. Fenard, and N. P e t i l l o t , E u r . J . Pharmacol , 208 (1971). 37. H. S c h m i t t and S. Fenard, A rc h . I n t . Pharmacodyn., 229 (1971). 38. B.P. Curwain, C.S. Fake, J . L . Gordon, M.D. Mehta, D . M i l l e r , R.H. Poyser, and E . A . W a tts , J . Med. Chem., 14, 737 (1971). 39. M. L e v i t t , W. Cumiskey, T. Skulan, and F. Rosenberg, Pharmaco o g i s t ,
3 1 . B.A. Callin g h a m, P h a rm a c e u ti c a l J . ,
14,
5,
. 13,
190,
1 3 , 191 (1971). 40. K I . Robe rts o n and E.T. Abbs, J . Neurochem., 18, 1999 (1971). 41. L. M a i t r e , M. S t a e h e l i n , and H. Brunner, J . P ' 6 r m . Pharmacol. 23 , 327 (1971). 42. V.G. K e i z e r and J.G. K o r s l o o t , J. Med. Chem., 14, 411 (1971). 43. M.E. H e r r , H . C . M u rra y , and G . S . Fonken, J . M e Z C h e m . , 842
-
14,
(1971).
44. P.J. P r i v i t e r a , T. B l i c k e n s t a f f , T.E. Gaffney and S. Mohammed, J. Pharmacol. Exp. T h e r . , 655 (1971). 45. F.M. Hershenson, Ann. Reps. Med. Chem., 52 (1970). 46. B. Loev, T. Jen, and R . A . McLean, E x p e r i e n t i a , 27, 875 (1971). 47. B.J. A l p s , M. H i l l , K. F i d l e r , E . S . Johnson, a n d A . B . W i l s o n , J . Pharm. Pharmacol., 23, 678 (1 971). 48. D . J . C o l t a r t , S.J. Meldrum, and R . B . Royds, B r i t . J . Pharmacol ., 42, 664P (1971). 49. E J . A l p s , M. H i l l , E . S . Johnson, and A.B. W i l son, B r i t . J . Pharmacol., 44, 52 (1972).
176,
50. J . L . A r c h i b a l d , B.J. A l p s , J.F. C a v a l l a , and J.L. Jackson, J. Med. Chem., 1054 (1971). 51. D.J. C o l t a r t , J.D.F. L o c k a r t , R . B . Royds, and P. T u r n e r , B r i t . J . Pharmacol , 43, 467P (1971 ) 52. J.G. C o l 1 i e r N . A . H . Dawnay, Ch. Nachev, and B.F. Robinson, J . Pharmacologie, 194 (1971). 53. C.A. Korduba, J . V e a l s , A. Wohl, S . Symchowicz, and I . I . A . T abac hnic k , P h a r m a c o l o g i s t , 192 (1971). 54. H.J. Schtmann and U . Werner, Naunyn-Schmiedebergs A rch. Pharmakol Exp. P a t h o l . , 268, 71 (1971). 55. R.E. C o u n s e l l , P. D e s a i , A . I d e , P . G . K u l k a r n i , P . A . Weinhold, and V.B. Ret h y , J. Med, Chem., 789 (1971). 56. A . Rubenson, J . Pharm. Pharmacol., 23, 412 (1971). 57. M.W. Osborne, J.J. Wenger, and W. WTlems, J . Pharmacol. Exp. T her . , 517 (1971). 58. H.A. Car r a s c o , J . Lozano, T-W Lang, and S . Meerbaum, G e r i a t r i c s , 26, 100 (1 9 7 1 ). 59. M a i t r e and H. Brunner, Biochem. Pharmacol., 20, 351 (1971). 60. T. George, C.L. K a u l ? R . S . Grewal, and D . V . MehG, J . Med. Chem., 14, 909 (1971).
14, .
.
2,
13,
-
14,
178,
-
.
68 -
Sect. I I
-
61. T. George, C.L. Kaul, R.S. 14, 913 (1971).
Pharmacodynamic Agents
T o p l i s s , Ed.
Grewal, and R. Tahilramani, J. Med. Chem.,
M. Ohno,
M. Okamoto, N. Kawabe, H. Umezawa, T. Takeuchi, H. I inuma, and S. Tikahashi, J. Amer. Chem. SOC., 93, 1285 (1971). 63. S . von Kurten, S . auf dern K e l l e r , P . Pachaly, F. Zymalkowski, G. Tauberger, and M. Moussawi, Arch. Pharm. (Weinheim), 304, 753
62.
-
(1971).
14,
64. F.D. Reed and A. Burger, J. Med. Chern., 554 (1971). 65. N.P. Buu-Hoi, Pham-Huu Chanh, G. S a i n t Ruf, Pharmacologist, 66.
67. 68. 69. 70.
71. 72.
73.
74. 75. 76.
77. 78. 79. 80.
81. 82.
83.
2,
.
.
14,
14,
14,
14,
84. 85. 86.
13,
298 (1971). E . E . Westura, H. Kannegiesser, J.D. O'Toole, and J.B. Lee, C i r c . Res., 27, 1 - 1 3 1 (1970). A.A. Carr, Ann. I n t e r n . Med., 74, 830 (1971). J.B. Lee, J.C. M c G i f f , H. K a n n g i e s s e r , Y.Y. Aykent, J.G. Mudd, and T.F. Frawley, Ann. I n t e r n . Med., 74, 703 (1971). S.H. F e r r e i r a and S . Moncada, B r i t . JTPharmacol., 43, 419P (1971). P.J. Kadowitz, C.S. Sweet, and M.J. Brody, J. P h a r m z o l . Exp. Ther., 179, 563 , (1971). R. Rips, C . Derappe, M. Dupont, and M. C r u c i f i x , Chim. Ther., 6, 45 (1971). K. Hashimoto, N. T a i r a , M. H i r a t a , and M. Kokubun, Arzneim.-Forsch., 21, 1329 (1971). H. V i d r i o , A. Viveros, and R. Vargas, Arzneim.-Forsch., 941 (1971). J.W. Van Dyke, J r . , H.J. Havera, R.D. Johnson, H. V i d r i o , and A. Viveros, J. Med. Chem., 5, 91 (1972). E. B a l d o l i , A . Sardi, and G. Bianchi, Naunyn-Schmiedebergs Arch. Pharmakol Exp. Pathol , 269, 391 (1971). V . P . Arya, R.S. Grewal, C T Kaul, and S.P. Ghate, E x p e r i e n t i a , 27, 1186 (1971). T H . T i l f o r d , W.J. Hudak, and R.E. Lewis, J . Med. Chem., 328 (1971). P.C. Das, B.B. Patra, S.B. Chaudhuri, U.P. Basu, B.N. Kolay, and S.R. M a i t r a , J. Med. Chem., 890 (1971). E. Marmo, Arzneim.-Forsch., 21, 476 (1971). H. Kehl, J. Pharm. Sci., 6 3 T 3 9 (1971). N.A. Kogan and E . I . Boksiner, Khim.-Farmatsevt. Zh., 21 (1971). 584 J . F i n k e l s t e i n , E . Chiang, and A. B r o s s i , J. Med. Chem., (1971). G.Cl Wright, E.J. Watson, F.F. Ebetino, G . Locheed, B.J. Stevenson, A. W i n t e r s t e i n , R.K. B i c k e r t o n , R.P. H a l l i d a y , and D.J. Pals, J . Med. Chem., 1060 (1971). Z.J. Vejdelek and M. P r o t i v a , C o l l e c t . Czech. Chem. Comun., 1611 (1971). F.M. Hershenson and L.F. Rozek, J. Med. Chem., 907 (1971). M.W. Osborne, J.J. Wenger, and R.A. Moe, J. Pharmacol. Exp. Ther., 176, 174 (1971).
36,
14,
-
Chapter 7.
Antianginal Agents
Charles F. Schwender , Warner-Lambert Research I n s t i t u t e Morris Plains, N.J. Angina pectoris i s a painful symptom of myocardial ischemia occurring when the oxygen supply cannot meet the requirements of the heart. During ischemia, pain and abnormalities of heart metabolism, l e f t ventricular function and electrocardiograms are observed. Blood flow through the myocardium i s the main determinant of oxygen supply.2 The heart extracts oxygen from i t s blood supply a t near maximal efficiency so t h a t any i n crease in oxygen requirements must be met by an increase i n blood flow. Ischemia caused by an i n s u f f i c i e n t oxygen supply may be improved by agents such as n i t r a t e s which increase myocardial perfusion and reduce oxygen utilization. 3 Early work wi t h n i troglyceri n i ndi cated a coronary vasodi 1 a t o r action which led t o a concerted e f f o r t t o find more potent, longer acting vasodi 1 ators s e l e c t i v e f o r the coronary vascul a r bed. These newer agents have been disappointing since l i t t l e r e l i e f of ischemia or anginal pain has been observed. Another more recent approach t o treatment of angina4 includes the reduction of myocardi a1 oxygen requi remen ts through reduced cardi ac work. Also, improved circulation of blood t o ischemic areas by s e l e c t i v e dilation of certain l a r g e r supply vessels appears t o restore normal oxygen and nutrient supply. Circulation through the l e f t ventricle involves epicardial (superficial regions) and endocardial (deeper regions) pathways which compete f o r available blood flow from larger intramural supply vessels. Further branching of the supply vessels leads t o p r e a r t e r i o l a r , a r t e r i o l a r and capillary beds which have a n u t r i t i v e function i n the t i s s u e s . I t has been suggested t h a t circulation in the endocardium i s probably inadequate, thus establishing a r e l a t i v e l y ischemic r e g i ~ n . ~ , ~ Compared w i t h the epicardium, the endocardial region has a lower oxygen tension and a lower level of circulating nutrients. When coronary artery disease r e s t r i c t s blood flow, the endocardial region may be prone t o wocardial insufficiency. Since the endocardium i s r e l a t i v e l y ischemic, autoregulatory responses cause an average a r t e r i o l a r and precapi 1 l a r y sphincter d i l a t i o n of about 91%. The vessels of the better perfused epicardium are only opened about 68% and can b e t t e r t o l e r a t e a decreased flow through compensatory mechanisms. Nitroglycerin - Nitroglycerin i s the oldest and most e f f e c t i v e antianginal agent i n use today. Used prophylactically o r f o r immediate r e l i e f of anginal pain, nitroglycerin acts by reducing heart work and by redist r i b u t i n g blood flow t o the ischemic areas of the myocardium. The beneficial e f f e c t of nitroglycerin on the myocardial circulation of dogs i s the r e s u l t of a number of a c t i o n s . 6 ~ 7 ~ 8The ~ 9 reduced ischemia i s probably the r e s u l t of a decreased oxygen requirement due t o a reduced heart work, f i l l i n g pressure and stroke volume. The major mechanism of action appears
70
Sect.
I I - Pharrnacodynarnic A g e n t s
Top1 i s s , Ed.
t o be an i n c r e a s e d oxygen t e n s i o n i n t h e endocardium due t o a r e d i s t r i b u blood flow t i o n o f b l o o d from t h e e p i c a r d i ~ m . ' + ~ While ~ , ~ ~myocardial ~ ~ ~ i s decreased by n i t r o g l y c e r i n , endocardia1 p e r f u s i o n i s m a i n t a i n e d a t p r e t r e a t m e n t l e v e l s b y t h e r e d i s t r i b u t i o n o f b l o o d f r o m t h e epicardium. Endocardia1 oxygen t e n s i o n r i s e s as a r e s u l t o f t h e r e d i s t r i b u t e d b l o o d f l o w and decreased oxygen requirement. N i t r o g l y c e r i n r e d i s t r i b u t e s b l o o d f l o w t o t h e endocardium b y d i l a t i n g t h e l a r g e r s u p p l y o r i n t r a m u r a l vessels c o n t r o l l i n g t h e f l o w d i s t r i b u t i o n between t h e i n n e r and o u t e r r e g i o n s o f t h e myocardium. The i n t r a m u r a l vessels do n o t appear t o be c o n t r o l l e d by t h e a u t o r e g u l a t o r y mechanism s o t h a t t h e y respond d i f f e r e n t l y t o drugs than a r t e r i o l e s . Measurements o f changes i n l a r g e vessel r e s i s t a n c e and oxygen t e n s i o n c o r r e l a t e we1 1 w i t h t h e e f f e c t s caused by n i t r o g l y c e r i n . Microsphere d i s t r i b u t i o n s t u d i e s i n t h e dog a l s o i n d i c a t e d a r e d i s t r i b u t i o n o f f l o w t o t h e endocardium due t o n i t r o g l y c e r i n a c t i o n . I n c o n t r a s t t o n i t r o g l y c e r i n and p e n t a e r y t h r i t o 1 t e t r a n i t r a t e coronary v a s o d i l a t o r s such as d i p y r i d a m o l e 4 and chromonar12 i n c r e a s e d t o t a l coronary b l o o d f l o w i n dogs w i t h o u t r e d i s t r i b u t i n g b l o o d f l o w o r improvi ng endocardi a1 oxygen tens ion. The coronary vasodi 1a t o r s , d i p y r i damole, chromonar, l i d o f l a z i n e , i p r o v e r a t r i l , papaverine and prenylamine were a l l shown t o e x e r t a s e l e c t i v e d i l a t o r a c t i o n on s m a l l coronary a r t e r i e s and a r t e r i o l e s . l 3 I t has been suggested1'+ t h a t t h e smooth muscle r e l a x a n t a c t i o n o f n i t r o g l y c e r i n may be r e l a t e d t o i t s i n i t i a l b l o o d c o n c e n t r a t i o n s r a t h e r than a c e r t a i n optimum b l o o d l e v e l . N i t r o g l y c e r i n appears t o be most e f f e c t i v e i n a b o l i s h i n g e x i s t i n g c o n t r a c t i o n s o f v a s c u l a r smooth muscles r a t h e r than p r e v e n t i n g t h e i r c o n t r a c t i o n . This may i n d i c a t e why n i t r o g l y c e r i n i s t h e r a p e u t i c a l l y more e f f e c t i v e sub1 i n g u a l l y o r by subcutaneous i n j e c t i o n than o r a l l y .
Blum15 was unable t o demonstrate a r e l a t i o n s h i p between reduced oxygen u t i l i z a t i o n , i n h i b i t i o n o f m i t o c h o n d r i a 1 r e s p i r a t i o n and d i l a t a t i o n o f l a r g e coronary a r t e r i e s u s i n g a s e r i e s o f o r g a n i c n i t r a t e s . B i o chemical e v a l u a t i o n d i d n o t c o n s i s t e n t l y p r e d i c t which agents would a f f e c t b l o o d f l o w t o t h e endomyocardium. Coronary V a s o d i l a t o r s - Continued i n t e r e s t i n t h i s approach t o a n t i a n g i n a l agents has been r e f l e c t e d by t h e numerous r e p o r t s o f agents i n c r e a s i n g coronary b l o o d f l o w and oxygen s u p p l y . These agents p r o b a b l y a c t b y i n t e r f e r i n g w i t h m e t a b o l i c a u t o r e g u l a t i o n o f coronary b l o o d f l o w . l6 3 1 7 A u t o r e g u l a t i o n i s a mechanism by which t h e h e a r t m a i n t a i n s s u f f i c i e n t b l o o d f l o w and n u t r i e n t supply f o r i t s m e t a b o l i c a c t i v i t y . Some vasod i l a t o r agents appear t o be s p e c i f i c d i l a t o r s o f s m a l l e r coronary b l o o d vessels by an adenosine-sparing mechanism. The end p r o d u c t o f adenosine t r i p h o s p h a t e (ATP) breakdown i n t h e h e a r t appears t o be adenosine w h i l e i n o t h e r t i s s u e s such as s k e l e t a l muscle, i n o s i n e i s t h e p r o d u c t . Adenosine, a p o t e n t v a s o d i l a t o r , has been shown t o be p r e s e n t i n t h e dog h e a r t i n n u c l e o s i d i c and n u c l e o t i d i c forms. D u r i n g ischemic c o n d i t i o n s , b o t h myocardial and b l o o d l e v e l s o f adenosine a r e increased.
Chap.
7
Ant iang ina 1 A g e n t s
Schwende r
71
A1 though n o t proven c o n c l u s i v e l y , adenosine has been i m p l i c a t e d as a t l e a s t one m e d i a t o r o f a u t o r e g u l a t o r y c o n t r o l o f myocardial b l o o d f l o w . Oxygen t e n s i o n , potassium i o n c o n c e n t r a t i o n , b l o o d pH and a myogenic response a l s o may be i n v o l v e d i n a u t o r e g u l a t i o n . However, a change i n adenosine c o n c e n t r a t i o n as a r e s u l t o f ischemia can f u l l y account f o r vasodi 1 a t o r responses through a u t o r e g u l a t o r y c o n t r o l . l7 Any t h i n g which may h e l p c r e a t e an oxygen d e f i c i e n c y such as a c t i v e t r a n s p o r t processes, i n c r e a s e d h e a r t work o r i m p a i r e d coronary c i r c u l a t i o n due t o o c c l u s i o n or c a r d i o v a s c u l a r disease a l s o decreases t h e ATP s u p p l y i n t h e myocardium. D u r i n g ischemia, t h e e q u i l i b r i u m between ATP and adenosine diphosphate (ADP) f a v o r s ADP f o r m a t i o n and adenosine. The h i g h e r i n t r a c e l l u l a r adenosine c o n c e n t r a t i o n promotes d i f f u s i o n o f adenosine through c e l l u l a r membranes i n t o t h e b l o o d o f t h e myocardium. A r e s u l t i n g l o c a l i z e d v a s o d i l a t i o n i n c r e a s e s t h e b l o o d f l o w and oxygen s u p p l y t o t h e ischemic area. The i n c r e a s e d ATP/ADP r a t i o p e r m i t s more work.and m e t a b o l i c processes t o be supported. B l o o d f l o w i s m a i n t a i n e d a t a g i v e n l e v e l o f m e t a b o l i c a c t i v i t y and adenosine c o n c e n t r a t i o n . Coronary v a s o d i l a t o r s i n t e r a c t w i t h t h e adenosine-mediated vasod i l a t i o n response by p r e v e n t i n g t h e deamination o r r e a b s o r p t i o n o f adenosine p r e s e n t i n t h e blood. Such agents a r e d i p y r i d a m ~ l e , ~ ~ , ~ ~ hexobendine,2 l i d o f l a z i n e , l 8 2 - a l k y l t h i o a d e n o s i n e s ,2 and o t h e r subs t i t u t e d - a d e n o s i n e s 2 2 i n dogs and p t e r i d i n e r ' analogs i n k i t t e n s . A l though these agents a r e i n h i b i t o r s o f i n t r a c e l l u l a r adenosine deaminase, i t i s b e l i e v e d t h a t t h e i r p r i m a r y a c t i o n i s t h e i n h i b i t i o n o f adenosine d i f f u s i o n across c e l l u l a r membranes where i t i s deaminated.16 Adenosine uptake may i n v o l v e a membrane-bound k i n a s e enzyme which r e l e a s e s adenosine as i t s monophosphate w i t h i n t h e c e l l . 2 4 Dipyridamole i n h i b i t s t h i s membranal k i n a s e i n guinea p i g s t o a g r e a t e r degree than s o l u b l e i n t r a c e l l u l a r adenosine deaminase o r k i n a s e enzymes. Dipyridamole, i n r a t s , does n o t p r e v e n t uptake o r p o t e n t i a t e t h e v a s o d i l a t o r e f f e c t s o f adenosine due t o a l a c k o f t h e membranal k i n a s e t r a n s p o r t mechanism. Thus, species v a r i a t i o n i n adenosine uptake mechanism may t e n d t o confuse s t u d i e s i n mechanisms o f a c t i o n w i t h v a s o d i l a t o r s i n t e r f e r i n g w i t h aden 0s in e
.
Ischemia may cause d e t e r i o r a t i o n o f myocardial f u n c t i o n through excessive l o s s o f ATP and t h e myocardial pool o f p u r i n e n u c l e o s i d e s . The enzyme, x a n t h i ne oxidase, ir r e v e r s i b l y c o n v e r t s p u r i n e s t o u r i c a c i d. A f t e r p e r i o d s o f asphyxia, an i n f u s i o n o f adenosine caused a markedly a c c e l e r a t e d r e s t o r a t i o n o f normal myocardial n u c l e o t i d e s . 2 5 I n coronaryl i g a t e d dogs and sheep, t h e x a n t h i n e oxidase i n h i b i t o r a l l o p u r i n o l p r e vented o r r e v e r s e d n u c l e o t i d e l o s s from t h e myocardium, ST-depression and c a r d i a c arrhythm; 35 due t o myocardial ischemia.26 Hexobendine2 causes a m e t a b o l i c a c i d o s i s which may c o n t r i b u t e t o i t s v a s o d i l a t o r a c t i o n i n humans. Other acje:l?t,z such as amiodarone ,2
bencycl an ,z
chromonar,
72
Sect.
II
-
Pharmacodynamic Agents
Topliss, Ed.
d i a z o x i d e Y 3 l i p r o v e r a t r i l , 3 0 perhexiline,32 and diazepam33 have been shown i n dogs t o e x e r t a v a s o d i l a t o r y a c t i o n on small coronary blood vessels. The mechanisms o f a c t i o n have n o t been f u r t h e r e l u c i d a t e d . These agents a l s o possess a p e r i p h e r a l v a s o d i l a t o r a c t i o n which may be b e n e f i c i a l i n anginal p a t i e n t s by decreasing blood pressure, venous r e t u r n and h e a r t work. An understanding o f t h e m i c r o c i r c u l a t o r y responses o f t h e h e a r t t o n i t r o g l y c e r i n and coronary v a s o d i l a t o r s c l e a r l y i n d i c a t e s why n i t r o g l y c e r i n i s an e f f e c t i v e a n t i a n g i n a l agent, w h i l e v a s o d i l a t o r s are g e n e r a l l y i n e f f e c t i v e o r d e l e t e r i o u s i n ischemic c o n d i t i o n s . 4 ~ 5 N i t r o g l y c e r i n d i l a t e s l a r g e r coronary a r t e r i e s n o t c o n t r o l l e d by a u t o r e g u l a t i o n mechanisms. A r e d i s t r i b u t i o n o f blood f l o w r e s u l t s which d i v e r t s b l o o d from the normal epicardium t o the ischemic endocardium. L i t t l e change i n t o t a l coronary f l o w i s observed. Since coronary v a s o d i l a t o r s a c t by i n t e r ference o f a u t o r e g u l a t i o n mechanisms i n s m a l l e r coronary vessels, v a s o d i l a t i o n o f t h e normal e p i c a r d i a l vessels probably predominates. The smal l e r vessels i n t h e ischemic endocardium are probably maximally d i l a t e d due t o anoxia. Thus, an enhanced e p i c a r d i a l f l o w must d i v e r t b l o o d f l o w from ischemic areas since they compete f o r a v a i l a b l e flow. Coronary v a s o d i l a t o r s could n o t be expected t o be b e n e f i c i a l b u t may be harmful when used t o t r e a t nlyocardial ischemia and angina p e c t o r i s . I n very severe ischemia, h i g h doses o f dipyridamole a c t u a l l y induced anginal a t t a c k s i n man. 3 4
ami odarone
d
bencyclan
H
perhexi lene
hexobendi ne
-
Treatment o f angina p e c t o r i s w i t h BBeta-Adrenergic B l o c k i n q Agents b l o c k i n g agents i s a more r e c e n t !approach which appears t o be o f therap e u t i c value. Exercise and s t r e s s tend t o increase catecholamine l e v e l s and c a r d i a c sympathetic d r i v e i n anginal p a t i e n t s . Excessive sympathetic s t i m u l a t i o n creates an oxygen wasting e f f e c t by i n c r e a s i n g oxygen use i n the myocardium more than i s r e q u i r e d t o perform a d d i t i o n a l work. BBlockade prevents t h i s excessive oxygen consumpti on and reduces c a r d i a c The lower c a r d i a c work and oxygen requirement allows t h e h e a r t t o perform more e f f i c i e n t l y d u r i n g moderate exercise a t a lower h e a r t r a t e .
Chap.
7
Antianginal Agents
73
Schwender
A number o f 8-adrenergic blockers have r e c e n t l y been r e p o r t e d i n the l i t e r a t u r e . Two previous reviews have covered a l l b u t t h e most c u r r e n t analogs. 36 , 3 7 Ring s u b s t i t u t i o n o r t h o t o the oxypropanolamine s i d e chain by cyclopropyl (SD-2124-01) has 1a n o n s e l e c t i v e 8-blocker o f potency s i m i l a r t o p r i n d o l o l and g r e a t e r than p r o p r a n o l o l i n dogs. This analog 1acks s igni f icant B-sympathomi meti c and c a r d i odepress ant a c t i v i ty b u t is capable o f r e v e r s i n g ouabain-induced cardiac arrhythmias p o s s i b l y by f a c i l i t a t i n g a t r i o - v e n t r i c u l a r conduction. 38 Two n i t r i l e - s u b s t i t u t e d analogs, Ko-1313 and Ko-1366, have been reO as nonselective 8-blocking agents which were more p o t e n t than ported39,'+ propranolol i n dogs and a l s o reversed ouabain-induced c a r d i a c arrhythmias. However, s i g n i f i c a n t depression o f a t r i o - v e n t r i c u l a r conduction was observed a t a n t i a r r h y t h m i c dosage l e v e l s . This Another analog s i m i l a r i n potency t o propranolol i s D-69-12. agent i s a c t i v e i n the guinea p i g . 4 1 The compound D563 o r 1-3-methoxy-w(l-hydroxy-l-phenyl isopropy1amino)-propiophenone i s a @-blocker i n dogs.42 I n a d d i t i o n t o p r a c t o l o l , o t h e r p a c y l a m i n o analogs43 were shown t o be c a r d i o s e l e c t i v e 8-blockers and more p o t e n t than t h e parent compound. Para-a1 l y l and -a1 l y l o x y s u b s t i t u t e d analogs o f a1 r e n o l o l and oxprenolol have been reported t o be c a r d i o s e l e c t i v e i n cats. !4 RI
Rz
t-butyl
SD-2 124-01
KO-1 313
2-CN
isopropyl
KO-1 366
2 -CN
-t - b u t y l
D-69-12
2-c1
t -b u t y 1 -
0 , C H Z CHOHCHzNHRz
practolol
4-NHCOCH3
isopropyl
alprenolol
isopropyl
oxp reno l o 1
isopropyl
KL-255
2-C1,
5-CH3
t-butyl
B-Adrenergic blockers remain c o n t r a i n d i c a t e d i n those p a t i e n t s s u f f e r i n g from some n y o c a r d i a l decompensation o r h e a r t f a i l u r e . 4 5 I n those cases, B-blockade o f normal sympathetic support o f h e a r t f u n c t i o n may p r e c i p i t a t e c a r d i a c f a i l u r e . Several studies concerning the cause o f tqyocardial depression and i n d u c t i o n o f h e a r t f a i l u r e have been r e ported. % - 4 9 6-61 ockers whi ch possessed s i g n i f ic a n t c a r d i ac depress a n t p r o p e r t i e s may have i n t e r f e r e d w i t h calcium t r a n s p o r t across membranes o f the mitochondria and sarcoplasmic r e t i c u l u m i n dog h e a r t muscle. This r e s u l t e d i n a depression o f the c o n t r a c t i l e s t a t e o f t h e myocardium.
74
I
Sect.
II
-
Phariiiacodynamic A g e n t s
T o p l i s s , Ed.
N a ~ l e rproposed ~ ~ t h a t agents which have s i g n i f i c a n t 8-sympathomimetic a c t i o n d i d n o t i n t e r f e r e w i t h c a l c i u m t r a n s p o r t and t h e c o n t r a c t i l e s t a t e . They were l e s s depressant on t h e myocardium t-han 6 - b l o c k e r s n o t h a v i n g as t i m u l a n t a c t i o n . The depressant e f f e c t was n o t r e l a t e d t o a - b l o c k i n g potency. A t h i g h c o n c e n t r a t i o n s , Noack and G r e e f f 4 7 demonstrated t h a t ab l o c k a d e was n o t i n v o l v e d i n i n h i b i t i o n o f c a l c i u m t r a n s p o r t . Using an v i t r o model, d- and 1-a1 p r e n o l o l were equal l y e f f e c t i v e i n h i b i t o r s o f calcium transport. A f t e r a s t u d y o f t h e c a r d i a c depressant a c t i o n o f KL-255, i t was suggested t h a t m y o c d r d i a l depression may be a r e s u l t of @-blockade o f t h e basal t o n e e s t a b l i s h e d b y endogenously r e l e a s e d catecholamines. 4 8 Catecholamine d e p l e t i o n b y g u a n e t h i d i n e r e s u l t e d i n a l o s s o f t h e dep r e s s i o n o f c o n t r a c t i l e f o r c e n o r m a l l y observed w i t h KL-255. The depress a n t e f f e c t s d i d n o t appear t o he d o s e - r e l a t e d t o l o c a l a n e s t h e t i c a c t i o n . I n t r i n s i c a-sympathomimetic a c t i v i t y o f some B - b l o c k e r s d i d n o t appear t o p r e v e n t t h e onset o f c a r d i a c f a i l u r e i n h e a r t s dependant upon sympathetic d r i v e . I t was suggested t h a t r;-blockers w i t h s i g n i f i c a n t 6sympathomimetic a c t i o n , such as DCI, m i g h t be l e s s l i k e l y t o p r e c i p a t a t e h e a r t f a i l u r e . The more depressant p r o p r a i i o l o l l a c k s 6-sympathomimetic a c t i v i t y . No d i f f e r e n c e was observed between DCI and p r o p r a n o l o l when i n t r o d u c e d d u r i n g t h e sympathomimetic-dependant phase o f e x p e r i m e n t a l h e a r t f a i l u r e i n guinea p i g s . 4 9 Although u - b l o c k e r s t e n d t o reduce coronary b l o o d f l o w , t h e y may n o t be harmful t o p a t i e n t s w i t h myocardial ischemia. I n t h e dog, p r o p r a n o l o l reduces b l o o d f l o w t o normal b u t n o t t o ischemic areas o f t h e h e a r t . Using RbE6 uptake, Xe133 c l e a r a n c e and l a b e l l e d microsphere d i s t r i b u t i o n s t u d i e s , experiments show t h a t p r o p r a n o l o l , l i k e n i t r o g l y c e r i n , r e d i s t r i butes b l o o d f l o w i n t o ischemic r e g i o n s o f t h e h e a r t . 1 0 , 5 0 - 5 2 WinburyS3 used oxygen t e n s i o n t o r e f l e c t i n c r e a s e d r e g i o n d l p e r f u s i o n and decreased m e t a b o l i c requirement o f oxygen. The 6 - b l o c k e r s , b u n o l o l and propranolo'l , i n c r e a s e d oxygen OCHzCHOHCHzNHC(CH3 )3 t e n s i o n i n ischemic areas o f t h e dog endocardium. R e d i s t r i b u t i o n o f b l o o d f l o w i n t o deeper areas of t h e endocardium appears t o be a common a c t i o n o f b o t h n i t r o g l y c e r i n 0 bunolol and a t l e a s t some @ - b l o c k e r s .
Q3
C l i n i c a l Therapy - The v a r i a b l e s i n c l i n i c a l e v a l u a t i o n agents a r e w e l l documented. Unless t h e d r u g s t u d i e d i s judgement o f t h e r a p e u t i c e f f i c a c y i s l i k e l y t o be mixed s u b j e c t t o v a r i e d i n t e r p r e t a t i o n s among i n v e s t i g a t o r s . see agents e f f e c t i v e i n some s t u d i e s b u t no b e t t e r than
o f antianginal 100% e f f e c t i v e , with bias or I t i s common t o placebo i n others.
V a r i a t i o n s i n dosages s t u d i e d , as w e l l as d u r a t i o n o f a c t i o n , o f t e n l e a d t o i n c o n s i s t e n t r e s u l t s . I s o s o r b i d e d i n i t r a t e i s an a c t i v e a n t i a n g i n a l agent w i t h a d u r a t i o n o f a c t i o n s i m i l a r t o n i t r o g l y c e r i n . Some r e p o r t s o f i n e f f e c t i v e n e s s may have been due t o t h e i n e f f e c t i v e dosage
Chap.
7
A n t i a n g i na 1 A g e n ts
Sc hwende r
-75
s t u d i e d o r t h e a g e n t ' s s h o r t d u r a t i o n of a ~ t i o n . ~ ' Chronic ~ - ~ ~ treatment w i t h i s o s o r b i d e d i n i t r a t e d i d n o t cause a c r o s s t o l e r a n c e w i t h n i t r o g l y c e r i n t o develop.57 N i t r o g l y c e r i n c o n t i n u e s t o p r o v e u s e f u l i n angina t r e a t m e n t . Using reduced ST-depression as a c r i t e r i o n f o r agent e f f e c t i v e n e s s i n ischemia, i t was shown t h a t n i t r o g l y c e r i n was b e n e f i c i a1 w h i l e s e v e r a l c o r o n a r y v a s o d i l a t o r s i n c l u d i n g chromonar, d i p y r i d a m o l e and hexobendine were i n e f f e c t i v e i n l o n g t e r m the rap^.^^,^^ 6-Adrenergic b l o c k i n g agents c o n t i n u e t o show u t i l i t y i n t h e t r e a t ment o f angina i f a d m i n i s t e r e d t o c a r e f u l l y s e l e c t e d p a t i e n t s . 3 5 , 5 8 , 6 0 ~ 6 1 Anginal p a i n induced by i s o p r o t e r e n o l o r e x e r c i s e was p r e v e n t e d o r e l i m i n a t e d upon t r e a t m e n t w i t h p r o p r a n o l o l o r o x p r e n o l o l . Ischemic changes n o t e d as ST-depressions were reduced by B - b l o c k e r t h e r a p y . A l p r e n o l o l , however, was r e p o r t e d i n e f f e c t i v e i n a s e p a r a t e study.62 I n a t r i a l w i t h p a t i e n t s h a v i n g m y o c a r d i a l i n f a r ~ t i o n ,t h~ e~ c a r d i o s e l e c t i v e B - b l o c k e r p r a c t o l o l showed p o s s i b l e v a l u e i n t h e p r e v e n t i o n o f arrhythmias a s s o c i a t e d w i t h severe ischemia w h i l e i t d i d n o t induce c l i n i c a l d e t e r i o r a t i o n o r f a i 1u r e o f t h e myocardi um. P r o p r a n o l o l , however, d i d cause d e t e r i o r a t i o n i n some p a t i e n t s . Combination therapy w i t h B - b l o c k e r s and n i t r a t e s has c o n t i n u e d . 3 5 3 , h 4 Combined t h e r a p e u t i c e f f e c t s have reduced t h e p o s i t i v e i n o t r o p i c and c h r o n o t r o p i c e f f e c t s o f n i t r o g l y c e r i n and t h e v a s o c o n s t r i c t i v e a c t i o n o f 6 - b l ockers . Benefi c i a1 s y n e r g i s t i c e f f e c t s upon reduced c a r d i ac work , oxygen requirements, and improved f l o w t o ischemic areas o f t h e myocardium have been observed. Combinations o f a l p r e n o l o l o r p r o p r a n o l o l and i s o s o r b i d e d i n i t r a t e s i g n i f i c a n t l y i n c r e a s e d work t o l e r a n c e and delayed p a i n and ST-depression i n some angina p a t i e n t s . The i n d i v i d u a l drugs were l e s s e f f e c t i v e . However, i n another s t u d y , i s o s o r b i d e d i n i t r a t e was i n e f f e c t i v e alone o r i n combination w i t h p r o p r a n ~ l o l . ~I ~n t h e same s t u d y , p r o p r a n o l o l induced h e a r t f a i l u r e i n some p a t i e n t s where no c l i n i c a l d e t e r i o r a t i o n had been d e t e c t e d e a r l i e r .
A s m a l l synergism was n o t e d when e r y t h r i t o l t e t r a n i t r a t e was coinb i n e d w i t h p r o p r a n o l o l o r a l p r e n o l o l . I t was suggested t h a t f u r t h e r i n v e s t i g a t i o n s i n v o l v i n g l a r g e r numbers o f p a t i e n t s a r e needed t o e v a l u a t e t h e p o s s i b l e s i g n i f i c a n c e of combined t h e r a p y . 6 6 References
1. 2.
3.
R. S. ROSS, Myocardial Ischemia, R. S. Ross and F. Hoffman, eds., pp. 1-6, Excerpta Medica, P r i n c e t o n , New Jersey, 1971. R. Kadatz,' Problems i n L a b o r a t o r y E v a l u a t i o n of A n t i a n g i n a l Agents, M. M. Winbury, ed., p. 3, North-Holland, Amsterdam, The Netherlands, 1967. M. M. Winbury, B . B. Howe and H. R. Weiss, J . Pharmacol. Exp. Ther. , 176, 184 (1971).
76 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34.
Sect.
II
-
Pharmacodynamic Agents
Topliss, Ed.
M. M. Winbury, Problems i n Laboratory E v a l u a t i o n of A n t i a n g i n a l Agents, M. M. Winbury, ed. , p. 1 , North-Holland, Amsterdam, The Ne t h e r l ands , 1967. M. M. Winbury, C i r c . Res., 28, (Suppl. I.) 140 (1971). J. K. Vyden, M. Carvalko, E. Boszormenyi, T.-W. Lang, H. B e r n s t e i n and E. Corday, Amer. J. C a r d i o l . ,*25-, 53 (1970). R. A. G i l l i s and K. I. M e l v i l l e , i b i d . , 28, 38 (1971). R. A. O'Rourke, V. S. Bishop, P. A. K o t and J. P. Fernandez, J. Pharmacol. Exp. Ther., 177,426 (1971). R. A. G i l l i s and K. I. M e l v i l l e , Eur. J. Pharmacol., 13,15 (1970). N. J. F o r t u n i , S. Kaihara, L. C. Becker and B. P i t t , Cardiovasc. Res., 5, 331 (1971). P. Mathes and J. R i v a l , i b i d . , 5, 54 (1971). H. R. Weiss and M. M. Winbury, Fed. Proc., 30, ( 2 ) 631 (1971). M. M. Winbury, B. B. Howe and M. A. Hefner, J. Pharmacol. Exp. Ther. , 168, 70 (1969). M. G. Bogaert, A. G. Herman and A. F. De Schaepdryver, Eur. J. Pharmacol , 215 (1970). S. W. Blum, J. B. Quinn, B. B. HOwe, M. A. H e f n e r and M. M. Winbury, J. Pharmacol. Exp. Ther., 176,684 (1971). W. Kubler, P. G. Spieckermann and H. J. B r e t s c h n e i d e r , J. Mol. C e l l . C a r d i o l , 1,23 (1970). R. M. Berne, R. Rubio and B . R. Duling, Myocardial Ischemia, R. S. Ross and F. Hoffman, eds., pp. 28-43, Excerpta Medica, P r i n c e t o n , New Jersey, 1971. N. B i t t a r and T. J. Pauly, E x p e r i e n t i a , 27, 153 (1971). N. Kolassa, K. P f l e g e r and W. Rummel , Eur. J. Pharmacol. , 2, 265 (1970). G. Raberger and 0. Kraupp, i b i d . , 13,312 (1971). M. H. Maguire, D. M. Nobbs, R. E i n s t e i n and J. C. M i d d l e t o n , J. Med. Chem., 415 (1971). J. A. Angus, L. B. Cobbin, R. E i n s t e i n and M. H. Maguire, B r i t . J. Pharmacol., 41, 592 (1971). M. W. N o t t , B r i t . J. Pharmacol., 39, 287 (1970). S. V. Hopkins and R. G. Goldie, Bzchem. Pharmacol., 8, 3359 (1971). W . I s s e l h a r d , D. H. H i n z i n , E. Geppert, W . Maurer, D. Ammermann and I.Sunder-Plassmann, P f l u g e r s Arch. , 320, 195 (1970). R. A. DeWall, K. A. Vasko, E. L. S t a n l e y and P. Kezdi, Amer. H e a r t J., 82, 362 (1971). W. Rudolph and I . Marko, Arzneim.-Forsch., 20, 1190 (1970). J. M. P e t t a and V . J. Zacchio, J. Pharmacol. Exp. Ther. , 176,328 (1971). 1370 (1970). G. Molnar and L. K e l l e r , Arzneim.-Forsch., K. Seta, Jap. C i r c . J., 34, 499 (1970). J. C. S c o t t and A. W. Cowley, Amer. J. C a r d i o l , 24, 865 (1969). G. G. Rowe, D. A. S p r i n g and S. Afonso, Arch. n t . Pharmacodyn. , 187, 377 (1970). R. M. Abel, R. L. Reis and R. N. S t a r o s i c k , B r t. J. Pharmacol , 38, 620 (1970). 0. Mantero and F. C o n t i , C i r c u l a t o r y Drugs, A. B e r t e l li , ed. , pp. 118123, North-Holland, Amsterdam, The Netherlands 1969.
. 12,
.
14,
a,
.
Chap.
35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66.
7
Ant iang i na 1 Agents
Schwender
77
D. C. Harrison, Myocardial Ischemia, R. S. Ross and F. Hoffman, eds., p. 97, Excerpta Medica, P r i n c e t o n , New Jersey, 1971. W. M. McLamore, Ann. Rep. Med. Chem., 1969, C. K. Cain, ed. , p. 63, Academic Press, New York, 1970. C. F. Schwender, i b i d . , 1970, p. 80, 1971. J. R. B o i s s i e r , J . F. G u i d i c e l l i , P. V i a r o , C. Advenier, P. M o u i l l e and S. Larno, Eur. J . Pharmacol., 15,151 (1971). T. Baum, G. Rowles, A. T. Shropshire and M. I.Gluckman, J. Pharmacol. Exp. Ther., 176,339 (1971). T. Baum, G. Rowles and A. T. Shropshire, ibid., 176, 350 (1971). K. Takagi, I.Takayanogi , Y . Kaziwara, Y . Hiramatsu and A. Izumi , Jap. J. Pharmacol., 20, 504 (1970). K. Sakai, i b i d . , 20, 306 (1970). A. F. Crowther, RFHowe and L. H. Smith, J. Med. Chem., 14, 511 (1971). B. Ablad, M. Brogard, E. Carlsson and L. Ek, Eur. J. P h a z a c o l . , 13, 59 (1970). P. G. Lund-Larsen and E. S i v e r t s s e n , Acta Med. Scand., 186, 187 11969). W. G. Nayler, Postgrad. Med. J., 46, (Nov. Suppl.) 90 (1970). E. Noack and K. G r e e f f , E x p e r i e n t i a , 27, 810 (1971). t R. G. Pendleton, J. M. P e t t a and R. ArHahn, Arch. I n t . Pharmacodyn. , 187, 75 (1970). A . M . B a r r e t t and B. Nunn, i b i d . , 189, 168 (1971). B. P i t t and P. Craven, Cardiovasc. Res., 4, 176 (1970). L. C. Becker, N. J. F o r t u n i and B. P i t t , c i r c . Res. , 28, 263 (1971). P. Mathes and J. R i v a l , i b i d . , 5, 54 (1971). M. M. Winbury, H. R. Weiss and B. B. Howe, Eur. J. Pharmacol., 16, 271 (1971). R. E. Goldstein, D. R. Rosing, D. R. Redwood, G. D. B e i s e r and S. E. Epstein, C i r c u l a t i o n , 43, 629 (1971). H. J. Semler and H. H. O r v i s , C u r r e n t Ther. Res., C l i n . Exp., 13, 523 (1971). W. S. Aronow and H. M. Chesluk, C i r c u l a t i o n , 42, 61 (1970). W. S. Aronow, Myocardial Ischemia, R. S. Ross and F. Hoffman, eds., p. 73, Excerpta Medica, Princeton, New Jersey, 1971. M. Kal tenback, Arzneim.-Forsch. , 20 , 1304 (1970). J.-M. R. D e t r y and R. A. B r u i c e , T i r c u l a t i o n 43, 155 (1971). K. Ushiyama, E. Kinwia, H. K i k u c h i and G. Mabuchi, I s r . J. Med. Sci., -5, 736 (1969). B. Sharma and S. H. Taylor, B r i t . J. Pharmacol., 43, 470P (1971). A. J. Wasserman, J. D. P r o c t o r , F. J. A1 l e n and E. V. Kemp, J. C l i n . Pharmacol. J. New Drugs, 10,37 (1970). D. E. J e w i t t , P. A. Burgess and J. P. S h i l l i n g f o r d , Cardiovasc. Res., 4, 188 (1970). L. Adolfsson, N.-H Areskog and T. Rosmunson, Eur. J. Clin. Pharmacol., 3, 68 (1971). A. N. Goldberg, J. F. Moran, T. K. B u t t e r f i e l d , R. Nemickes and G. A. Bermudez , C i r c u l a t on, 40, 847 (1969). G. A. Dogenais, B. P i t t T n d R. S. ROSS, Amer. J. C a r d i o l . , 28, 10 (1971).
Chapter 8.
A n t i t h r o m b o t i c Agents
Leonard J . Czuba, P f i z e r , I n c . , Groton C o n n e c t i c u t
06340
A s u r v e y of r e s e a r c h on p l a t e l e t a g g r e g a t i o n i n h i b i t o r s 1 was p r e s e n t e d i n t h i s s e r i e s i n 1971. A more comprehensive review of a g e n t s a f f e c t i n g thrombosis2 a p p e a r e d d u r i n g t h e p r e c e d i n g y e a r . The p r e s e n t r e p o r t i s i n t e n d e d a s a c o n t i n u a t i o n of t h e s e e a r l i e r works and a t t e m p t s t o summarize t h e s i g n i f i c a n t r e c e n t r e s e a r c h on a l l t y p e s of d r u g s f o r t h e management of thromboembolic d i s e a s e . Rue t o s p a c e limi t a t i o n s , i m p o r t a n t r e l a t e d r e s e a r c h on d i a g n o s t i c t e c h n i q u e s and e x p e r i m e n t a l models of thrumbosis w i l l n o t be reviewed. A roaches t o _Eg---.--..--.
A n t i t h r o m b o t i c Therapy ___(
A s Schor2 p o i n t e d o u t , t h e r e are t h r e e t h e r a p e u t i c a p p r o a c h e s t o t h e t r e a t m e n t of thrombosis : i n h i b i t i o n of p l a t e l e t a g g r e g a t i o n , i n h i b i t i o n of b l o o d c o a g u l a t i o n , and enhancement of t h e f i b r i n o l y t i c p r o c e s s . The a g e n t s i n v o l v e d a f f e c t p l a t e l e t f u n c t i o n , o r a c t on t h e b l o o d c o a g u l a t i o n mechanisms e i t h e r by i n h i b i t i n g t h e f o r m a t i o n o r e n h a n c i n g t h e breakdown of f i b r i n . I n t h i s r e g a r d , i t i s i m p o r t a n t t o d i f f e r e n t i a t e between a c l o t and a thrombus.3-5 A c l o t is a r e l a t i v e l y d is o r g an ized , dark-red s t r u c t u r e t h a t r e s u l t s from t h e c o a g u l a t i o n of whole b l o o d and i s u s u a l l y a s s o c i a t e d w i t h venous c i r c u l a t i o n . The s t r u c t u r a l i n t e g r i t y of t h e c l o t i s m a i n t a i n e d by a f i b r i n network and t h e p r i n c i p a l e v e n t i n c l o t f o r m a t i o n i s t h e a c t i v a t i o n of f i b r i n o g e n t o f i b r i n . I t c o n t a i n s r e d c e l l s , w h i t e c e l l s and p l a t e l e t s i n r o u g h l y t h e same p r o p o r t i o n s as they o c c u r i n whole b l o o d . Thrombi a r e s i m p l e r , more h i g h l y o r g a n i z e d s t r u c t u r e s t h a t o c c u r w i t h v a r y i n g d e g r e e s of ~ o m p l e x i t y ,b~u t t h e u s u a l form on t h e a r t e r i a l s i d e of t h e c i r c u l a t i o n i s a w h i t e h e a d composed a l m o s t e n t i r e l y of a g g r e g a t e d p l a t e l e t s , t o which is a t t a c h e d a r e d t a i l of f i b r i n c o n t a i n i n g r e d c e l l s . The p r i n c i p a l e v e n t s i n thrombus f o r m a t i o n a r e i n i t i a l a d h e r e n c e and t h e p r o p a g a t i o n of p l a t e l e t a g g r e g a t i o n by ADP r e s u l t i n g from t h e p l a t e l e t release r e a c t i o n . 6
A v a r i e t y of c l i n i c a l s t a t e s are a s s o c i a t e d w i t h t h r o m b o s i s . The p r e s e n t d i s c u s s i o n i s l i m i t e d t o a few of t h e more prominent thromboembolic d i s e a s e s ; f u r t h e r i n f o r m a t i o n on t h i s s u b j e c t may b e found i n several r e v i e w s . 3 97-9 The most common c l i n i c a l s t a t e s which i n v o l v e c l o t - l i k e , venous thrombi a r e deep v e i n t h r o m b o s i s , p a r t i c u l a r l y as a p o s t s u r g i c a l c o m p l i c a t i o n , and pulmonary embolism. A n t i c o a g u l a n t s s u c h as h e p a r i n and t h e coumarins have been known f o r y e a r s t o b e e f f e c t i v e i n t h e p r e v e n t i o n of t h e s e t y p e s of thrombi and more r e c e n t e x p e r i e n c e h a s d e m o n s t r a t e d t h e e f f i c a c y of f i b r i n o l y t i c a g e n t s such as s t r e p t o k i n ase f o r t h e i r d i s s o l u t i o n . 3 , 9 P l a t e l e t a g g r e g a t i o n i n h i b i t o r s h a v e o n l y r e c e n t l y been e v a l u a t e d c l i n i c a l l y i n t h e p r e v e n t i o n of venous t h r o m b o s i s . These s t u d i e s a r e c r u c i a l t o t h e r e s o l u t i o n of t h e c o n t r o v e r s y as t o whether p l a t e l e t s p l a y a v i t a l r o l e i n t h e i n i t i a t i o n of venous thrombi.10 There i s p e r s i s t e n t h i s t o l o g i c a l e v i d e n c e t h a t i n d i c a t e s venous thrombi b e g i n as p l a t e l e t a g g r e g a t e s .I1 Myocardial i n f a r c t i o n and s t r o k e are
Chap. 8
A n t i t h r o m b o t i c Agents
Czuba
79
t h e major c l i n i c a l m a n i f e s t a t i o n s of a r t e r i a l t h r o m b o s i s . A n t i c o a g u l a n t s have b e e n found t o o f f e r l i t t l e , i f a n y , b e n e f i t t o t h e s u r v i v o r s of m y o c a r d i a l i n f a r c t i o n , and p r o p h y l a c t i c t r e a t m e n t w i t h t h e s e a g e n t s i s overshadowed by t h e d a n g e r of hemorrhage. 3 L a r g e s c a l e c l i n i c a l s t u d i e s of t h e f i b r i n o l y t i c a g e n t s t r e p t o k i n a s e i n m y o c a r d i a l i n f a r c t i o n h a v e b e e n u n d e r t a k e n i n r e c e n t y e a r s . 1 2 Although a s t a t i s t i c a l l y s i g n i f i c a n t improvement is i n d i c a t e d by t h e s e t r i a l s , t h e commitment t o f u r t h e r s t u d i e s t o v e r i f y e f f i c a c y h a s b e e n c r i t i c i z e d on t h e b a s i s of t h e l i m i t e d p o s s i b l e b e n e f i t s of f i b r i n o l y s i s t o t h e p a t i e n t due t o t h e c r i t i c a l t i m e element involved i n myocardial i n f a r c t i o n , S i n c e t i s s u e n e c r o s i s d i s t a l t o t h e c o r o n a r y o c c l u s i o n o c c u r s w i t h i n a few h o u r s , i t h a s b e e n a r g u e d t h a t l i t t l e i s t o b e g a i n e d by r e s t o r a t i o n of b l o o d f l o w a f t e r t h i s i r r e v e r s i b l e damage i s done, and t h a t c l i n i c a l e f f o r t s would b e b e t t e r expended on p r o p h y l a c t i c a g e n t s . 1 3 The r e s u l t s of s t r e p t o k i n a s e trials currently i n progress should resolve t h e controversy and e s t a b l i s h a n i m p o r t a n t p r e c e d e n t i n r e g a r d t o t h e f e a s i b i l i t y o f f i b r i n o l y t i c therapy i n arterial thrombosis. I n g e n e r a l , t h e r e appears t o b e agreement t h a t p l a t e l e t a g g r e g a t i o n i n h i b i t o r s are t h e most r a t i o n a l t y p e of a g e n t f o r t h e p r o p h y l a x i s of a r t e r i a l t h r o m b o s i s . A s p i r i n , t h e p y r i m i d o - p y r i m i d i n e s r e l a t e d t o d i p y r i d a m o l e ( P e r s a n t i n e ) and d e x t r a n are t h e most n o t a b l e a g e n t s f o r which a n t i - p l a t e l e t a c t i v i t y h a s b e e n d e m o n s t r a t e d i n v i v o i n man. However, no m a j o r c l i n i c a l t r i a l s of p l a t e l e t a g g r e g a t i o n i n h i b i t o r s i n p a t h o l o g i c s t a t e s s u c h as m y o c a r d i a l i n f a r c t i o n h a v e b e e n r e p o r t e d . Moreover, s e l e c t i v e p l a t e l e t a g g r e g a t i o n i n h i b i t o r s t h a t a r e l a c k i n g o t h e r m a j o r d r u g e f f e c t s , s u c h as a n t i i n f l a m matory o r h y p o t e n s i v e a c t i v i t y , h a v e n o t undergone c l i n i c a l e v a l u a t i o n . I t i s t h i s l a t t e r c l a s s of a g e n t s t h a t a p p e a r s t o h o l d t h e most p r o m i s e f o r t h e p r e v e n t i o n of a r t e r i a l t h r o m b o s i s . P l a t e l et A g g r e g a t i o n . I n h i b it o r s
P r o s t a g l a n d i n s and C y c l i c AMP - The e f f e c t s of n a t u r a l p r o s t a g l a n d i n s on p l a t e l e t f u n c t i o n h a v e b e e n s t u d i e d e x t e n s i v e l y . A s a g r o u p , t h e y are gene r a l l y i n h i b i t o r s of ADP-induced p l a t e l e t a g g r e g a t i o n . P G E l i s by f a r t h e most p o t e n t b y a t l e a s t two o r d e r s of m a g n i t u d e . PGE2 d i f f e r s i n t h a t i t e x h i b i t s a b i p h a s i c a c t i v i t y ; a t c o n c e n t r a t i o n s less t h a n t h o s e r e q u i r e d f o r i n h i b i t i o n , i t p o t e n t i a t e s p l a t e l e t a g g r e g a t i o n . 1 4 PGEl a l s o i n h i b i t s c l o t r e t r a c t i o n . 1 5 T h i s p o t e n t e f f e c t may b e a t t r i b u t e d t o i n h i b i t i o n of t h e p l a t e l e t release r e a c t i o n . 1 5 The p o s s i b l e c l i n i c a l u t i l i t y of P G E l h a s been s u g g e s t e d , a l t h o u g h s h o r t d u r a t i o n of a c t i o n The l e t h a l e f f e c t of i n t r a v e n appears t o b e an important limitation.16 o u s l y a d m i n i s t e r e d ADP t o r a t s , which a p p e a r s t o c a u s e d e a t h by o c c l u s i o n of t h e c e r e b r a l a r t e r i e s w i t h p l a t e l e t t h r o m b i , w a s p r e v e n t e d by PGE1. T r a n s i e n t t h r o m b o c y t o p e n i a i n d u c e d by ADP i n j e c t i o n w a s a l s o i n h i b i t e d . I 7 The growth of a p a r t i c u l a r t y p e of p l a t e l e t thrombus formed b y e l e c t r i c s t i m u l a t i o n i n c o r t i c a l v e i n s w a s i n h i b i t e d by l o c a l l y a d m i n i s t e r e d PGE1.18 PGEl i s s t a b l e and r e t a i n s p l a t e l e t a c t i v i t y on i n c u b a t i o n w i t h whole human b l o o d . 1 4 R e c e n t l y , a p r o c e d u r e h a s b e e n d e v e l o p e d f o r s t a b i l i z i n g p l a t e l e t f r a c t i o n s w i t h PGEl i n b l o o d b a n k s . P l a t e l e t s t r e a t e d i n t h i s manner e x h i b i t e d n o r m a l h e m o s t a t i c f u n c t i o n f o l l o w i n g t r a n s f u s i o n i n man.19
80 -
Sect.
II
-
Pharmacodynamic A g e n t s
T o p l i s s , Ed.
Two r e p o r t s d e s c r i b e a n a l o g s more p o t e n t t h a n PGE1. The w-homolog of P G E l h a s been shown t o b e about 4 times more p o t e n t t h a n P G E l i n t h e i n h i b i t i o n of p l a t e l e t a g g r e g a t i o n i n v i t r o . 1 7 S i m i l a r l y , an a n a l o g of PGEl w i t h a trans double bond a t t h e 2 - p o s i t i o n was found t o b e 2 1 1 2 times more p o t e n t t h a n PGE1. I t i s i n t e r e s t i n g t h a t a number of isomers of t h i s compound w i t h t h e double bond a t d i f f e r e n t p o s i t i o n s i n t h e s i d e c h a i n s , i n c l u d i n g n a t u r a l PGE2, were a l l much less p o t e n t t h a n PGE1.20 Perhaps t h e most s i g n i f i c a n t event i n p r o s t a g l a n d i n r e s e a r c h d u r i n g t h i s p a s t y e a r was t h e d i s c o v e r y t h a t a s p i r i n i n h i b i t s t h e s y n t h e s i s of p r o s t a g l a n d i n s i n a v a r i e t y of t y p e s of c e l l s , and t h a t t h i s e f f e c t may account f o r many of t h e f a m i l i a r a c t i o n s of a s p i r i n . 2 1 The p r o s t a g l a n d i n s PGE2 and PGF2, are p r o d u c t s of t h e p l a t e l e t release r e a c t i o n induced by thrombin. Although a s p i r i n i n h i b i t s t h e release r e a c t i o n , r e l a t i v e l y high c o n c e n t r a t i o n s of thrombin caused unimpaired release of p l a t e l e t c o n s t i t u e n t s i n t h e p r e s e n c e of a s p i r i n w i t h o u t t h e concomiT h i s i n h i b i t i o n of p r o s t a g l a n d i n product a n t release of PGE2 and PGF2,. t i o n was a l s o demonstrated w i t h p l a t e l e t s from donors dosed w i t h a s p i r i n 1 hour b e f o r e blood was taken.22 Presumably, i n h i b i t i o n of p r o s t a g l a n d i n s y n t h e s i s does n o t c o n t r i b u t e s u b s t a n t i a l l y t o t h e i n h i b i t i o n of p l a t e l e t a g g r e g a t i o n by a s p i r i n . Evidence c o n t i n u e s t o s u p p o r t t h e h y p o t h e s i s t h a t p l a t e l e t aggregat i o n and t h e release r e a c t i o n are i n h i b i t e d by r a i s e d l e v e l s of i n t r a c e l l u l a r c y c l i c AMP.1 The i n h i b i t o r y e f f e c t s on p l a t e l e t f u n c t i o n of such d i v e r s e a g e n t s as P G E l , d i p y r i d a m o l e , t h e m e t h y l x a n t h i n e s and p a p a v e r i n e a l l appear t o b e mediated by t h i s c y c l i c n u c l e o t i d e . 2 3 - 2 8 A s p i r i n - S e v e r a l n o n - s t e r o i d a l anti-inflammatory a g e n t s are known t o i n h i b i t p l a t e l e t a g g r e g a t i o n by p r e v e n t i n g t h e release r e a c t i o n . T h e r e f o r e , a g g r e g a t i o n induced by a g e n t s such as c o l l a g e n , e p i n e p h r i n e and low conc e n t r a t i o n s of thrombin i s i n h i b i t e d , b u t ADP-induced a g g r e g a t i o n i s n o t a f f e c t e d . Among known i n h i b i t o r s of t h i s k i n d , which i n c l u d e s a l i c y l a t e , p y r a z o l e and i n d o l e a c e t i c a c i d t y p e anti-inflammatory a g e n t s , t h e most n o t a b l e are indomethacin and a s p i r i n . 1 9 3 Although r e p o r t s on t h e p l a t e l e t e f f e c t s of indomethacin29 and a n a l o g s such a s "BLR-43"30 c o n t i n u e t o app e a r , t h e v a s t m a j o r i t y of t h e l i t e r a t u r e i n t h i s area i s devoted t o s t u d i e s of a s p i r i n . Although a s p i r i n and s a l i c y c l i c a c i d e x h i b i t h a l f - l i v e s i n man of only 1 3 t o 1 9 min. and 3.5 t o 4.5 h r s . , r e s p e c t i v e l y , 3 1 t h e e f f e c t of a s p i r i n on p l a t e l e t s i n v i v o h a s a d u r a t i o n which approximately p a r a l l e l s p l a t e l e t s u r v i v a l t i m e of 2-7 days. The c u r r e n t l y a c c e p t e d h y p o t h e s i s t o e x p l a i n t h i s a c t i o n h o l d s t h a t a s p i r i n i r r e v e r s i b l y alters p l a t e l e t funct i o n by a c e t y l a t i o n of a p r o t e i n component of p l a t e l e t membrane. A subs t a n t i a l amount of e x p e r i m e n t a l evidence c o n s i s t e n t w i t h t h i s h y p o t h e s i s h a s accumulated. 1 9 3 2 Although a s p i r i n does n o t i n h i b i t ADP-induced a g g r e g a t i o n i t s e f f e c t on t h e release r e a c t i o n d e c r e a s e s p l a t e l e t r e s p o n s e and a b o l i s h e s t h e "second wave'' of a g g r e g a t i o n i n t h e p r e s e n c e of ADP. I t a p p e a r s t h a t a n o t h e r component of a s p i r i n a c t i o n is an e f f e c t on a plasma c o f a c t o r of ADP-induced a g g r e g a t i o n . 3 3 , 3 4 Evidence h a s been
Chap.
8
Antithrombotic Agents
Czuba
81 -
p r e s e n t e d t h a t Hageman f a c t o r i s n e c e s s a r y f o r p l a t e l e t - a g g r e g a t e s t a b i l i t y . I n a d d i t i o n , t h e a g g r e g a t i n g p l a t e l e t s u r f a c e h a s been proposed as a s i t e of Hageman f a c t o r a c t i v a t i o n . A s p i r i n may i n h i b i t t h e s e i n t e r a c t i o n s by b l o c k i n g t h e a p p r o p r i a t e s i t e on t h e p l a t e l e t s u r f a c e . 35 ,36 The a n t i t h r o m b o t i c e f f e c t of a s p i r i n h a s been demonstrated i n a numb e r of e x p e r i m e n t a l animal models. The d e a t h r a t e due t o pulmonary thromboembolism induced i n mice by i n f u s i o n of a c o l l a g e n s u s p e n s i o n w a s d e c r e a s e d r e p r o d u c i b l y by a s p i r i n . 3 7 A s p i r i n provided s i g n i f i c a n t prot e c t i o n a g a i n s t t h e v a s o c o n s t r i c t i v e e f f e c t s and m o r t a l i t y of pulmonary embolism caused by i n j e c t i o n of f r e s h , a u t o l o g o u s c l o t s i n t o r a b b i t s 3 8 o r dogs .39 Presumably, s u p p r e s s i o n of t h e v e n o c o n s t r i c t i v e component of pulmonary embolism by a s p i r i n w a s due t o t h e i n h i b i t i o n of s e r o t o n i n release from p l a t e l e t s .38 O c c l u s i v e thrombus f o r m a t i o n induced i n i s o l a t e d a r t e r i e s of dogs by mechanical o r chemical i n j u r y w a s s u b s t a n t i a l l y reduced by a s p i r i n i n g e s t i o n . I n t h i s model dipyridamole had no e f f e c t . 4 0 Myocardial n e c r o s i s induced i n dogs by i n f u s i o n of e p i n e p h r i n e i s b e l i e v e d t o b e caused by t h e f o r m a t i o n of p l a t e l e t thrombi. Both a s p i r i n and dipyridamole have a s i g n i f i c a n t p r o t e c t i v e e f f e c t a g a i n s t t h i s phenomenon.41 A new m i c r o i o n t o p h o r e t i c t e c h n i q u e h a s been developed f o r q u a n t i t a t i n g p l a t e l e t a g g r e g a t i o n i n v i v o . T h i s p r o c e d u r e , w a s used t o demonstrate t h a t a s p i r i n w a s s e v e r a l times more e f f e c t i v e i n t h e i n h i b i t i o n of hamster p l a t e l e t a g g r e g a t i o n i n v i v o than i n v i t r o . 4 2 A number of c l i n i c a l t r i a l s w i t h a s p i r i n as an a n t i t h r o m b o t i c a g e n t were r e p o r t e d d u r i n g t h e p a s t y e a r . Some of t h e s t u d i e s have i n v o l v e d venous thrombotic s t a t e s i n which t h e importance of p l a t e l e t a g g r e g a t i o n i s uncertain a t present. The outcome of t h e s t u d i e s r e p o r t e d t h u s f a r
does n o t f u r n i s h an adequate answer t o t h i s i m p o r t a n t q u e s t i o n . I n e f f o r t s t o determine e f f e c t i v e d o s e l e v e l s f o r t h e p r e v e n t i o n of p o s t o p e r a t i v e deep v e i n thrombosis , no a n t i t h r o m b o t i c e f f e c t w a s observed f o l l o w i n g t h e i n g e s t i o n of a s h i g h as 2.4 g of a s p i r i n d a i l y . 4 3 A comparative s t u d y of a s p i r i n , dipyridamole , d e x t r a n and w a r f a r i n w a s c a r r i e d o u t i n 169 p a t i e n t s undergoing h i p r e c o n s t r u c t i v e s u r g e r y . The high rate of o c c u r r e n c e of deep v e i n thrombosis which accompanies t h i s t y p e of s u r g e r y w a s s i g n i f i c a n t l y reduced by a s p i r i n , d e x t r a n and w a r f a r i n , b u t n o t by dipyridamole.44 A c o n t r o l l e d s t u d y of m o r b i d i t y and m o r t a l i t y among 430 aged p e o p l e i n d i c a t e d t h a t a s p i r i n had no e f f e c t on thromboemb o l i c d i s e a s e i n t h i s p a r t i c u l a r group.45 I n hemodialysed p a t i e n t s asp i r i n w a s found t o p r e v e n t f i s t u l a c l o t t i n g which i s c h a r a c t e r i z e d by i n c r e a s e d p l a t e l e t a d h e s i v e n e s s and thrombin p r o d u c t i o n . 4 6 P l a t e l e t consumption a s s o c i a t e d w i t h thromboembolic c o m p l i c a t i o n s of p r o s t h e t i c h e a r t v a l v e s w a s found t o b e uniformly p r e v e n t e d by d i p y r i d a m o l e , b u t a s p i r i n had l i t t l e o r no e f f e c t . 4 7 Some f u r t h e r examples of c l i n i c a l s t a t e s i n which a s p i r i n w a s found t o have s i g n i f i c a n t a n t i t h r o m b o t i c e f f e c t are spontaneous p l a t e l e t a g g r e g a t i o n as a c a u s e of i d i o p a t h i c thrombosis and r e c u r r e n t p a i n f u l t o e s and f i n g e r s , 4 8 t h e r e t i n a l - a r t e r y embolism of amaurosis f ~ g a x and , ~ ~thrombotic thrombocytopenic p ~ r p u r a . ~ ~ The p r e s e n t c l i n i c a l e v i d e n c e f o r t h e a n t i t h r o m b o t i c e f f e c t of asp i r i n i s e q u i v o c a l . Much f u r t h e r s t u d y w i l l b e r e q u i r e d t o d e m o n s t r a t e
82
Sect. I I
-
Topliss, Ed.
Pharrnacodynamic Agents
e f f i c a c y , and once e s t a b l i s h e d , any a n t i t h r o m b o t i c b e n e f i t w i l l have t o b e s u f f i c i e n t t o outweigh t h e r i s k of g a s t r i c b l e e d i n g 5 1 7 5 2 on c h r o n i c a d m i n i s t r a t i o n t o p a t i e n t s w i t h thromboembolic disease.
-P l r L m i d o p y r i m i d i n e s -
D i p y r i d a m o l e and two a n a l o g s , RA233 and RA433, h a v e been s t u d i e d e x t e n s i v e l y as p l a t e l e t a g g r e g a t i o n i n h i b i t o r s i n v i t r o and i n v a r i o u s a n i m a l models of t h r o m b o s i s . 5 3 ~ 5 ~ tThe mechanism of a c t i o n of t h e s e compounds on p l a t e l e t s a p p e a r s t o i n v o l v e i n h i b i t o r y e f f e c t s o n g l u c o s e metabolism53155 and c y c l i c AMP p h o s p h o d i e s t e r a s e . 2 7 C l i n i c a l t r i a l s w i t h d i p y r i d a m o l e f o r t h e r e d u c t i o n of thromboembol i c c o m p l i c a t i o n s a f t e r p r o s t h e t i c c a r d i a c v a l v e replacement c o n t i n u e t o show e n c o u r a g i n g r e s u l t s . 4 7 I n a c o n t r o l l e d s t u d y o f 1 6 3 p a t i e n t s , d i pyridaniole ( 4 0 0 mg d a i l y ) s i g n i f i c a n t l y r e d u c e d t h e f r e q u e n c y of a r t e r i a l emboli.56 O n t h e o t h e r h a n d , d i p y r i d a m o l e was found t o have no s i g n i f i c a n t e f f e c t on p o s t o p e r a t i v e d e e p v e i n t h r o m b o s i s .44 New Agents - R e p o r t s of new s t r u c t u r a l t y p e s of p l a t e l e t a g g r e g a t i o n i n h i b i t o r s have i n c r e a s e d d u r i n g t h e p a s t y e a r . The 5 ,SO-dihydro-3-phenylt h i a z o l o [ 3 , 2 - b ] [ 2 , 4 ] b e n z o d i a z e p i n e 1. and f i v e p h e n y l - s u b s t i t u t e d a n a l o g s i n h i b i t e d ADP- i n d u c e d human p l a t e l e t a g g r e g a t i o n i n v i t r o a t c o n c e n t r a to rabbits resulted i n I n t r a v e n o u s a d m i n i s t r a t i o n of t i o n s n e a r lo-5%. i n h i b i t i o n of ADP-induced a g g r e g a t i o n i n s u b s e q u e n t l y drawn b l o o d s a m p l e s , and an o r a l d o s e of i n mice c a u s e d a s i . g n i f i c a n t i n c r e a s e i n b l e e d i n g t i m e . 5 7 Compound 2- w a s t h e most p r o m i s i n g member of a l a r g e g r o u p of a n a l o g o u s a c r i.d i n e de r i v a t i v e s t h a t i n h i b i t e d ADP - i n d u c e d p 1.a t e 1e t a g g r e g a t i o n . T h i s a g e n t was a c t i v e on human p l a t e l e t s i n v i t r o a t conc e n t r a t i o n s of 10-5M. JiIi v z a c t i v i t y was d e m o n s t r a t e d i n r a b b i t s . 5 8 E x t e n s i v e s y n t h e t i c m a n i p u l a t i o n of t h e r i n g s u b s t i t u e n t s and t h e a c r i d i n e n u c l e u s gave a number of a c t i v e a n a l o g s , b u t none w a s found t o b e s u p e r i o r t o 1 . 5 9 The anti.throriibotic a c t i v i t y of a new b e n z o [ c ] [ 1 , 6 ] n a p h t h y r i d i n e 2 w a s d e s c r i - b e d , T h i s compound i n h i b i t e d ADP-induced agThe e f f e c t was n o t g r e g a t i o n i n v i t r q a t c o n c e n t r a t i o n s of 10-51. Rat carotid r e v e r s e d , b u t was s i g n i f i c a n t l y p o t e n t i a t e d by e p i n e p h r i n e . a r t e r y thrombus fozmati.on i n d u c e d by i n s e r t i o n of s y n t h e t i c t u b i n g w a s 2 1 . ~ 0j nlii1,ite.d 60
1
L
p\\,fb-y7 C . N
OCH3 2
-
q ,
A c o m p a r a t i v e s t u d y o€ t h e i n h i b i t o r y a c t i v i t y of 5 and 5 on b i p h a s i c ADP-induced a g g r e g a t i o r t of human p l a t e l e t s i n v i t r o h a s b e e n d e s cribed. Compound 4 i n h i b i t e d b o t h p h a s e s of a g g r e g a t i o n b u t was most e f f e c t i v e on t h e s e c o n d p h a s e . I n c o n t r a s t , i n h i b i t e d o n l y t h e second
Chap.
8
A n t i thrornbot i c Agents
Czuba
83
p h a s e which i s a s s o c i a t e d w j t h t h e reLease r e a c t i o n . Compound 5 was a b o u t 400 t i m e s as e f f e c t i v e as oxyphcnburazone . 6 1 M o n o d a n s y l c a d a v e r i n e (6), which i s an e f f e c t i v e i n h i b i t o r of t h e f i b r i n c r o s s - l i n k i n g enzyme f i b r i n o l i g a s e , 5 7 ~ s f o u n d t o i n h i b i t ; t h e s e r o n d p h a s e of ADP-induced p l a t e l e t aggregation. A l k y l a t i o r , of t h e p r i m a r y aiuirie f u n c t i o n r e s u l t e d i n analogs t h a t r e t a i n e d v l a t e l e t a c t i v i t y but f i b r i n n l i g a s e i n h i b i t o r y a c t i v i t y was abo 1iThed .5 2
0 0 M ( CH ) 7
CgNA(>> 1
c'lI2CO2
{:I
Na
\
'>'
c f l y
CHJ
SO2NH (CH2 ) 5NI12
m 3 i N (CH3)
*
-2d,.
4 __
5
6 -
1
The a n i l i n e d e r i v a t i v e w a s found t o b e a p o t e n t i n h i b i t o r of ADP-, c o l l a g e n - and t h r o m b i n - i n d u c e d a g g r e g a t i o n of human p l a t e l e t s i n v i t r o . O r a l a d m i n i s t r a t i o n of 2 t o g u i n e a p i g s p r o d u c e d a n i n h i b i t o r y e f f e c t on p l a t e l e t a g g r e g a b i l i t y . I n v i t r o c o n c e n t r a t i o n s of L c o m p a r a b l e t o & v i v o p l a t e l e t i n h i b i t o r y c o n c e n t r a t j o n c h a d no e f f e c t on p l a s m a c o a g u l a t i o n f a c t o r s , b u t h i g h e r c o n c e n t r a t i o n s were f o u n d t o i n h i b i t p r o t h r o m b i n and p a r t i a l t h r o m b o p l a s t i n t i m e s . 6 3 ~ 6 4 A c l o s e a n a l o g o f p r e v i o u s l y d i s c l o s e d a n t i c o a g u l a n t s , 2 compound S , has r e c e n t l y b e e n r e p o r t e d a s a n i n h i b i t o r o f ADP- and c o l l a g e n - i n d u c r d p l a t e l e t a g g r e g a t i o n and c l o t retraction. P l a t e l e t i n h i h i t o i y c o 1 i i e n t r a t i o n s of 8 d i d n o t a f f e c t b l o o d c o a g u l a t i o n . 65
7-
8 __
I t h a s b e e n shown r e c e n t l y t h a t c o n c e n t r a t i o n s of c o l l a g e n , i n s u f f i c i e n t t o i n d u c e a g g r e g a t i o n , p o t e n t i a t e ADP-induced a g g r e g a t i o n of r a b b i t p l a t e l e t s . The noveL t e t r a h y d r o t h i e n o p y r i d i n e d e r i v a t i v e 2, which w a s d e s c r i b e d p r e v i o u s l y ac; an i n h i b i t o r of ADP-induced a g g r e g a t i o n , l i n T h i s o b s e r v a t i o n was i n t e r p r e t e d as e v i d e n c e hibited this potentiation. t h a t 9 a c t s by i n h i b j t i o n of tlie r e l e a s e r e a c t i o n . 6 6 B r i e f m e n t i o n h a s b e e n made of t h e t a c t t h a t some d e r i v d t i v e s of t h e n o v e l t h i a z o l o (3,2-a)pyrrolo(2,3-d) p y r i m i d i n e r i n g s y s t e m are h i g h l y a c t i v e i n h i b i t o r s of ADP-induced p l a t e l e t a g g r e g a t j o n , 67
(10)
84 -
Sect. I I
6’
-
Pharmacodynamic A g e n t s
Topliss, Ed.
NH2
9 -
10 Anticoagulants
The physiology and b i o c h e m i s t r y of blood c o a g u l a t i o n have been t h e Anticoagulants s u b j e c t s of s e v e r a l reviews d u r i n g t h e p a s t year.68-70 i n t e r r u p t i n some manner t h e complex mechanisms c o n t r o l l i n g t h e enzymatic conversion of a s o l u b l e blood p r o t e i n f i b r i n o g e n i n t o i n s o l u b l e f i b r i n . Direct a n t i c o a g u l a n t s , such as h e p a r i n , i n h i b i t t h e conversion of prothrombin t o thrombin and t h e thrombin-fibrinogen r e a c t i o n . Because of e f f i c a c y only by p a r e n t e r a l a d m i n i s t r a t i o n , h e p a r i n i s used i n t r a v e n o u s l y u n t i l o r a l a n t i c o a g u l a n t s b e g i n .to t a k e e f f e c t . 9 The o r a l l y e f f e c t i v e coumarin and indandione t y p e a n t i c o a g u l a n t s a c t i n d i r e c t l y by i n h i b i t i n g s y n t h e s i s i n t h e l i v e r of blood c l o t t i n g f a c t o r s of t h e prothrombin comp l e x . Vitamin K i s e s s e n t i a l f o r t h e s y n t h e s i s of c l o t t i n g f a c t o r s i n t h e l i v e r , and a d e f i c i e n c y produces an a n t i c o a g u l a n t e f f e c t s i m i l a r t o t h a t of t h e coumarin d r u g s . The s i t e of a c t i o n of v i t a m i n K and o r a l a n t i c o a g u l a n t s i n v o l v e s one of t h e f i n a l s t e p s i n t h e p r o d u c t i o n of c l o t t i n g f a c t o r subsequent t o p o l y p e p t i d e c h a i n s y n t h e s i s on t h e ribosomal l e v e l . I n q u i r y i n t o t h e n a t u r e of t h e s e s t e p s and t h e p r e c u r s o r s of t h e rothrombin complex i s c u r r e n t l y an a c t i v e area of i n v e s t i g a t i o n . 71-7t The comprehensive review by Douglas9 p r o v i d e s a r e c e n t d i s c u s s i o n of t h e c l i n i c a l l y u s e f u l a n t i c o a g u l a n t s . Recent s t u d i e s have shown h e p a r i n t o b e c l e a r l y e f f e c t i v e i n c l i n i c a l s t a t e s i n which d i s s e m i n a t e d i n t r a v a s c u l a r c o a g u l a t i o n was i n d i c a t e d to b e a p a t h o l o g i c f a c t o r .75 The most commonly employed o r a l a n t i c o a g u l a n t s are of t h e coumarin t y p e such as w a r f a r i n and nicoumalone. The o r a l a n t i c o a g u l a n t s a p p e a r t o b e of v a l u e i n t h e p r e v e n t i o n of thromboembolic c o m p l i c a t i o n s a f t e r myocardial i n f a r c t i o n . g p 7 6 However, a n t i c o a g u l a t i o n t h e r a p y h a s been found t o have no e f f e c t on d e a t h - r a t e i n t h e s e p a t i e n t s . 7 7 W a r f a r i n h a s been shown t o b e e f f e c t i v e i n t h e p r e v e n t i o n of p o s t o p e r a t i v e venous thrombosis .44 The e f f e c t i v e n e s s of o r a l a n t i c o a g u l a n t s i n t h e p r e v e n t i o n of thromboembolism from p r o s t h e t i c h e a r t v a l v e s i s s t i l l open t o q u e s t i o n . Recent e x p e r i e n c e w i t h acenocoumarol and sodium w a r f a r i n i n h e a r t v a l v e p r o s t h e s e s i n d i c a t e d a low i n c i d e n c e of thromboembolic c o m p l i c a t i o n s .78 P a t i e n t s on o r a l a n t i c o a g u l a n t s are a t c o n s i d e r a b l e r i s k b e c a u s e of p o s s i b l e hemorrhage and t h e dangerous i n t e r a c t i o n s between t h e s e a g e n t s and common drugs s u c h as a s p i r i n and t h e b a r b i t u r a t e s . The complex subj e c t of drug i n t e r a c t i o n s w i t h coumarin a n t i c o a g u l a n t s h a s been e x t e n s i v e l y i n v e s t i g a t e d . 79,80
Chap. 8
Antithrombotic Agents
Czuba
85 -
Reports bf new a n t i c o a g u l a n t s have been r e l a t i v e l y rare. A new s t r u c t u r a l t y p e found t o have a n t i c o a g u l a n t a c t i v i t y i s t h e sodium s a l t of 2,3,5,6-tetrachloro-4-pyridinol. A number of analogs were found t o b e a c t i v e , b u t less p o t e n t . 81 Some novel 4-hydroxycoumarin d e r i v a t i v e s r e l a t e d t o dicoumarol have been r e p o r t e d t o have a n t i c o a g u l a n t a c t i v i t y . The most p o t e n t was about h a l f as a c t i v e a s dicoumarol.82 Aromatic d i a m i d i n e s , which a r e known p o t e n t i n h i b i t o r s of t r y p s i n , i n h i b i t e d human thrombin c l o t t i n g a c t i v i t y and markedly i n c r e a s e d prothrombin and p a r t i a l thromboplastin times of human plasma. These compounds are a l s o much more p o t e n t a n t i - f i b r i n o l y t i c a g e n t s t h a n E-aminocaproic a c i d . 83 F i b r i n o l y t i c Agents A g e n e r a l d i s c u s s i o n of f i b r i n o l y s i s i s a v a i l a b l e i n r e c e n t reviews.9,68,84 The o l d e s t and most thoroughly s t u d i e d f i b r i n o l y t i c agent i s s t r e p t o k i n a s e , a p r o t e i n i s o l a t e d from hemolytic s t r e p t o c o c c i . S i m i l a r t o human a c t i v a t o r , i t d i r e c t l y a c t i v a t e s plasminogen t o plasmin. Although s t r e p t o k i n a s e is a n t i g e n i c and f r e q u e n t l y pyrogenic, t h e s e e f f e c t s have n o t been s u f f i c i e n t l y d e l e t e r i o u s t o p r e c l u d e c l i n i c a l u t i l i t y . 3 9 9 C l i n i c a l e x p e r i e n c e w i t h t h i s agent has been gained now i n most t y p e s of thromboembolic d i s e a s e s , 8 5 w i t h g e n e r a l l y f a v o r a b l e r e s u l t s i n t h e t r e a t m e n t of deep v e i n thrombosis ( w i t h i n 96 hours of o n s e t of A major e f f o r t h a s been expended symptoms) and pulmonary embolism.9,85,86 i n r e c e n t y e a r s t o i n v e s t i g a t e t h e u s e f u l n e s s of s t r e p t o k i n a s e i n myoc a r d i a l i n f a r c t i o n , b u t r e s u l t s i n t h i s a r e a a r e s t i l l open t o ques t i o n . 13 3 85S87-90 Urokinase i s a plasminogen a c t i v a t o r p r e p a r e d from human u r i n e . I t i s produced by kidney c e l l s and h a s been shown t o d i f f e r from v a s c u l a r plasminogen a c t i v a t o r i n terms of immunologic r e a c t i o n , enzymatic a c t i v i t y , and molecular ~ e i g h t . 9 ~Although u r o k i n a s e does n o t e x h i b i t t h e a n t i g e n i c s i d e e f f e c t s a s s o c i a t e d w i t h s t r e p t o k i n a s e , development of t h i s agent h a s been h i n d e r e d by t h e expensive p r o c e s s r e q u i r e d f o r e x t r a c t i o n from u r i n e . However, i t a p p e a r s t o have s u p e r i o r t h e r a p e u t i c potent i a l , and t h e c l a i m h a s been made t h a t c o s t could b e reduced s h a r p l y i f a l a r g e - s c a l e demand were t o develop.90 A c l i n i c a l t r i a l t o s t u d y t h e e f f e c t s of u r o k i n a s e on pulmonary embolism i s c u r r e n t l y i n p r o g r e s s under t h e a u s p i c e s of t h e N a t i o n a l Heart and Lung I n s t i t u t e . 9 2 A r e c e n t s t u d y has demonstrated t h e f e a s i b i l i t y of e v a l u a t i n g u r o k i n a s e i n myocardial infarction.93 S e v e r a l o t h e r h i g h molecular w e i g h t n a t u r a l p r o d u c t s have been i n v e s t i g a t e d a s f i b r i n o l y t i c a g e n t s .2 A t e r o i d i s a n a t u r a l mucopolysacc h a r i d e w i t h f i b r i n o l y t i c a c t i v i t y . The a c t i v a t i o n of f i b r i n o l y t i c processes w i t h t h i s agent i n man h a s been demonstrated i n c l i n i c a l s t u d i e s . I n a d d i t i o n , experiments i n r a t s and r a b b i t s have s u g g e s t e d t h a t i t may a c t by t h e i n h i b i t i o n of endogenous a n t i - a c t i v a t o r s . Recent evidence i n d i c a t e s one important component of t h e f i b r i n o l y t i c a c t i o n may b e due t o n e u t r a l i z a t i o n of antiplasmin.94 A r e l a t i v e l y n o n - s p e c i f i c p r o t e o l y t i c enzyme from A s p e r g i l l u s oryzae, b r i n a s e , c a u s e s l y s i s of e x p e r i m e n t a l thrombi f a s t e r t h a n o t h e r c l i n i c a l t h r o m b o l y t i c a g e n t s . Reduction of
86
Sect.
II
-
Pharrnacodynamic Agents
Topliss,
Ed.
serum a n t i p l a s m i n a c t i v i t y by b r i n a s e may a c c o u n t f o r much of t h e i n v i v o f i b r i n o l y t i c e f f e c t . F i b r i n o l y t i c e f f e c t i v e n e s s and a l a c k of untoward s i d e e f f e c t s h a s b e e n d e m o n s t r a t e d w i t h b r i n a s e i n a number of c l i n i c a l s t a t e s .95 A r v i n and r e p t i l a s e are enzymes w i t h similar a c t i o n i s o l a t e d from t h e venom of Malayan p i t v i p e r , A g k i s t r o d o n rhodostoma, and a S o u t h American s n a k e , B o t h r o p s a t r o x , r e s p e c t i v e l y . T h e s e a g e n t s c o n v e r t f i b r i n o g e n t o an abnormal f i b r i n - l i k e s u b s t a n c e , which i s more r e a d i l y b r o k e n down t o f i b r i n o p e p t i d e s t h a n f i b r i n and d o e s n o t form i n t r a v a s c u l a r c l o t s . For t h e most p a r t , c l i n i c a l s t u d i e s h a v e d e m o n s t r a t e d p r o p h y l a c t i c e f f e c t i v e n e s s , b u t l y s i s of venous o c c l u s i o n s h a s a l s o b e e n c l a i m e d w i t h a r v i n . Both a r v i n and r e p t i l a s e i n h i b i t t h e s e c o n d p h a s e of ADP-induced p l a t e l e t a g g r e g a t i o n . 3996 A c o m p i l a t i o n of s y n t h e t i c d r u g a p p r o a c h e s t o f i b r i n o l y s i s h a s b e e n p r o v i d e d by Schor.97 A v a r i e t y of s i m p l e s y n t h e t i c compounds a r e known t o c a u s e l y s i s of p r e f o r m e d c l o t s . The m a j o r i t y of t h e s e compounds a r e a n t i i n f l a m m a t o r y a g e n t s and s t r u c t u r a l l y s i m i l a r o r g a n i c a c i d s . They do n o t e f f e c t f i b r i n d i r e c t l y , b u t r e q u i r e t h e p r e s e n c e of serum p r o t e i n s f o r c l o t l y s i s . C u r r e n t e v i d e n c e is c o n s i s t e n t w i t h a mechanism of a c t i o n t h a t i n v o l v e s i n h i b i t i o n of a n t i a c t i v a t o r o r a n t i p l a s m i n a c t i v i t y ; b u t t h e p o s s i b l e d i r e c t a c t i v a t i o n of plasminogen h a s n o t b e e n e x c l u d e d . 9 7 398 T h i s g r o u p of compounds a l s o i n h i b i t s p l a t e l e t a g g r e g a t i o n w i t h v a r y i n g d e g r e e s of e f f e c t i v e n e s s . A c o m p a r a t i v e s t u d y of t h e f i b r i n o l y t i c and p l a t e l e t i n h i b i t o r y e f f e c t s h a s been c a r r i e d o u t t o t r y t o o p t i m i z e b o t h a c t i v i t i e s i n t h e d e s i g n of one h i g h l y e f f e c t i v e a n t i t h r o m b o t i c a g e n t .99 B i s o b r i n (EN-1661) i s a & t e t r a h y d r o i s o q u i n o l i n e d e r i v a t i v e t h a t h a s promising f i b r i n o l y t i c a c t i v i t y i n animals;2,97 e x t e n s i v e s t r u c t u r e a c t i v i t y s t u d i e s h a v e b e e n r e p o r t e d r e c e n t l y .loo A p e r i p h e r a l v a s o d i l a t o r , bencyclane, h a s r e c e n t l y been r e p o r t e d t o have p o t e n t f i b r i n o l y t i c a c t i v i t y and t o i n h i b i t p l a t e l e t a g g r e g a t i o n . Io1
References _____ 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14.
15.
L. N. J. N. J. A. J. J.
M. F. J. A. S.
J. J. S. G.
N. E.
J . Czuba, Ann. R e p o r t s i n Med. C l e m . , 1Y70, C . K . C a i n , E d . , Academic P r e s s , New Y o r k , Y., 1971, p . 60. M. S c h o r , Ann. R e p o r t s i n Med. Chem., 1969, C . K . C a i n , E d . , Academic P r e s s , New Y n r k , Y., 1570, p. 237. R . Hampton, Am. J . C a r d i o L o g y , 2, 659 ( 1 9 7 1 ) . B . C h a n d l e r , i n T h r o m b o s i s , e d . by S . S h e r r y , K . M . B r i n k h o u s e , E . C e n t o n a n d M. S t e n g l e , N a t i o n a l Academy of S c i e n c e s , W a s h i n g t o n , D . C . , 1969, P . 2 7 9 . E . French, i n Thrombosis, p. 300. B . Z u c k e r , i n T h r o m b o s i s , G., p . 407. J. K azm i er , Thromb. D i a t h . Haemorrh. S u p p l . , 44, 1 2 7 ( 1 9 7 1 ) . R . A. M i t c h e l l , Thromb. D i a t h . Haemorrh. S u p p l . , 285 (1970). S . D ougl as , S e m i n a r s i n Haemat., 95 ( 1 5 7 1 ) . S h e r r y , New E n g l . J . Med., 284, 1325 ( 1 9 7 1 ) . C . P a t e r s o n , i n T hroinbos is , e d . by S . S h e r r y , K . M. B r i n k l i o l l s e , E . (;enLon and M. S t e n g l e , N a t i o n a l Acadeiny of S c i e n c e s , W a s h i n g t o n , D.D., 1965. S h e r r y , Am. H e a r t J . , 427 (1.972). R . F e a r n l e y , L a n c e t , 2, 473 ( 1 9 7 1 ) . C handr a S e k h a r , Thromb. D i a t h . Haemorrh. S u p p l . , 42, 305 ( 1 9 7 0 ) . H . Miirer, N a t u r e , L22, 113 ( 7 9 7 1 ) .
u., t,
83,
40,
Chap. 8 16.
17. 18. 19. 20.
Antithrombotic Agents
Czuba
G. HOKnStKa, EUKO. J. Pharmacol ., 15,343 (1971). J. Kl o e z e . Thromb. D i a t h . Haemorrh., 2, 286 (1970). J. Kl o e z e , Thromb. D i a t h . HaemOKKh., 3,293 (1970).
( a ) H. S h i o and P. W. R a m e l l , S c i e n c e . 175. 536 ( 1 9 7 2 ) ; ( b ) G. A. B e c k e r , M. K . Cha los , M. T u c o e l l i and R. H. A s t e r , 538 (1972); ( c ) C. R. Valeri, C. G. Z a n o u l i s , J. C . Rogers, R. I . Handin and L. D. Marchionni, 539 (1972). R. K . B e e r t h i u s , D. H. Nugt eren, H . J. J. Pabon. A. Ste e nhoe k and D. A. Van D o K ~ . Rec.
w.,
w.,
Tr a v . Chem., 3,943 (1971). H. 0. J. C o l l i e r , N a t u r e , 232. 17 (1971). J. G. Smith and A. L. W i l l i s , N a t u r e New B i o l . , 231, 235 (1971). B . Cole, G. Robison and R. C. Hartman, Annals N . Y . Acad. S c i . , 185,477 ( 1 9 7 1 ) . J. Moskowitz. J. P. H a w o o d , W . D. Reid and G. K r i s h n a , Biochem. Biophys . Acta, 230, 279 (1971). 25. S . - Y . Song and W. U. Cheung, Biochem. B i ophys . A c t a , 593 (1971). 26. R. L. Vi g d a hl , J. Mongin Jr. and N . R. Marquis , Biochem. Biophys. R e s . Comm., 42, 1088 (1971). 27. D. C. B. Mills and J. B. S m i t h , Biochem. J . , 121, 185 (1971). 28. E . H. Miirer, Biochem. B i ophys. Acta., 237, 310 (1971). 29. G. deGaetano, M. B . D o n a t i , J. Vermylen. I n t . J. C l i n . Pha rma c ol. , 5 , 196 (1971). 30. H. H . B i c h e r , Thromb. d i a t h . Haemorrh. S u p p l . , 42, 197 (1970). 31. M. Rowland and S . Riegelman. J. Pharm. S c i . , 57, 1313 (1968). 32. F. J. Rosenberg, P . E . G i m b e r - P h i l l i p s , G. E. G roble w s ki, C. D a vis on, D. K. P h i l l i p s , S . J. G o r a l n i c k and E . D. C a h i l l , J. Pharmacol. Exp. T h e r . , 179, 410 (1971). 33. K. B r e d e l i n , J. SChaKKeK and M. Scheppi ng, Thromb. D i a t h . Haemorrh. S u p p l . , 9, 241 (1970). 34. P. Okonkwo and H . S . S i s e . Thromb. D i a t h . Haemorrh., 25, 279 (1971). 35. I . E . S a r j i and P. G. I a t r i d i s , Fed. P KOC. , 30, 285 (1971). 36. P. G. I a t r i d i s , S . G. I a t r i d i s and J. H . Fe rgus on, Thromb. D i a t h . Haemorrh., 25, 98 (1971). 37. E. E . N i sh iz awa, D. J. Wynalda, T . K . Sawa, and D. E . Suydam, C i r c u l a t i o n , 3 T S u p p l . 2 , 11-56 ( 1 9 7 1 ) . 38. C. B. Rosoff and E . W. Salzman, C i r c u l a t i o n , 44, Suppl. 2. 11-56 (1971). 39. P. D. A l l e n , F. G. Congdon and G. R. D a i c o f f , C i r c u l a t i o n , 3, S u p p l . 2 , 11-54 (1971). 40. C. A. Danese, Ch. D. V o l e t i and H . J. Weiss, Thromb. D i a t h . Haemorrh., 2,287 (1971). 41. J. I . H a f t , K. Gershengorn. P. Kranz and R. OeStKeiCheK, C l i n . Res.. 2,709 (1971). 42. N . A. Begent and G.. V. R. Born, BK. J. Pharmac., 42, 580 (1971). 4 3 . J. R. O'Brien. V. T u l e v s k i and M. E t h e r i n g t o n , L a n c e t , 1,399 (1971). 44. E . W . Salzman, W . H . Harris and R. W. Harris and R. W. D e S a n c t i s , New Eng. J. Med., 284, 1287 ( 1 9 7 1 ) . 45. R. Heikenheirno and K . J I r v i n e n , J. Am. Geriatrics S o c . , 2,403 (1971). 46. K. Andrassy, E . R i t z . W. S c h o e f f n e r , G . Hahn a nd K . Walter, K l i n . Wschr., 67,166 (1971). 47. L. A. Ha r k e r and S . J. S l i c h t e r , C i r c u l a t i o n . 3, Suppl. 2 , 11-66 (1971). 48. ( a ) J. Vreeken and W . G. van Aken, L a n c e t , 2. 1394 (1971); ( b ) R. Bierm6, B . Boneu, B. Boneu, B . Gui raud and J. h i s , H., 1;, 432 (1972). 49. M. J. G. H a r r i s o n , J. C. Meadows, J. M a r s h a l l and R . W. Ross R u s s e l , L a n c e t , 2, 743 (1971) 5 0 . L . R. Z a c h a r s k i , A. Walworth and 0. R. McIntyre , New Eng. J. Med., 285, 408 (1971). 51. G. E . Shambaugh, Jr.. J. Am. Med. A s s o c . , 218, 1573 (1971). 52. J. R. Leonard8 and G. Levy, Arch. I n t e r n . Med., 129, 457 (1972). 53. (a) V. Horch, R. Kadat z, 2. K o p i t a r , J. F i t s c h a r d a nd H. We is e nbe r, Thromb. D i a t h . Haemorrh. S u p p l . , 41, 253 (1970); ( b ) A. A. H a s s a n e i n , A. G. G. T u r p i e , G. P. McNicol, C . D. F o r b e s and A. S . Douglas, 277 (1970); ( c ) P . D idis he im and C . A. Owen, J K . , . ibid., i b i d . , 267 ( 1 9 7 0 ) . 5 4 . M. P. Cucuianu. E . E . Nishizawa and J. F. Mus ta rd, J. Lab. C l i n . Med., 77, 958 (1971). 55. M. C. Rozenberg, C. M. Ledwidge, D. E . L . Wilcken and M. McKeon, J. L a b T C l i n . Med., 7 7 , 88 ( 1 9 7 1). 56. J. M. S u l l i v a n . D. E . Harken and R. G o r l i n , New Eng. J. Med., 284, 1391 ( 1 9 7 1 ) . 5 7 . E . F. E l s l a g e r , J. R. McLean, S . C . P e r r i o n e , D o r i s Potoc z a k. H . V e los o, D. F . Worth and R. H . Wheelock. J. Med. Chem., 397, (1971). 58. E . F. E l s l a g e r , N . F. Hal ey. J. R. McLean, S . C . P e r r i c o n e , D . P o t o c z a k , H . Veloso. D. F. Worth and R . H . Wheelock, J. Med. Chem., 14,782 ( 1 9 7 1 ) . 59. E . F. E l s l a g e r , N . F. Hal ey, J. R . McLean, D o r i s P o t o c z a k , H . Veloso. and R . H . Wheelock, J. Med. Chem., 15, 6 1 (1971). 60. H . O t t and G . M . S m i t h , B K . J. Pharmacol. 2, 460P (1971). 61. F. J o b i n and F. T . Gagnon, Can. J. P h y s i o l . Pha rma c ol. , 49, 479 (1971). 21. 22. 23. 24.
242,
.
14,
88 62.
Sect.
-
Top1 i s s , Ed.
Pharmacodynamic Agents
R . L u n d h , A. H a r t k o o r n , J . L . G. N i l s s o n , P . S t e n b e r g , J. Bruner-Lorand and L . Lora nd,
J. Med. Chem., 63.
II
y,98
(1972).
E . De u t sc h , K. Lechmer, K . Moser and L. S t o c k i n g e r , Thromb. D i a t h . Haemorrh.,
22, 143
(1971).
64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89.
R . D. MacKenzie and T . R . Blohm, Thromb. D i a t h . Haemorrh. If?, 577 (1971). R. D. MacKenzie, T. R . Blohm. E . M. Auxi er, J . G. Henderson and J. M. S t e i n b a c h , P r o c . SOC. Exp. Bio. Med.. 137, 662 (1971). M. n a k a n i s h i , H . Imamura and K . Goto, Biochem. Pha rma c ol. , 0, 2116 (1971). G. Bormann and F. T r o x l e r , Hel v. Chim. Acta , 3, 1687 (1971). N . Heimburger and H . T r o b i s c h , Angew. Chem. I n t . Ed., lo, 85 (1971). W. H . S e c g e r s , Thromb. D i a t h . Haemorrh. S u p p l . , 56, 63 (1971). E . F. Mammen. i n Thrombosis and B l e e d i n g D i s o r d e r s , e d . by N . U. Bang, F. K . Beller, E . Deutsch and E. F. Hammen, Academic P r e s s , N. Y . . 1971, p. 1. R. A. O ' R e i l l y , Am. J. of P h y s i o l o g y , 3 ,1327 (1971). M. P e r e i r a and D. C o u r i , Biochim. Biophys. Acta, 237, 348 (1971). J . J. Veltkamp, H. Muis, A. D. M u l l e r , H . C . Hanker and E . A. L e l i g e r , Thromb. D i a t h . Haemorrh., 25, 312 (1971). G. Rez and H . P rydz; Biochim. Biophys. Acta, 244, 495 (1971). S. S. Lo, W . H . H i t z i g and P. G. F r i c k , Acta Haemat., 5, 1 (1971). B. J . Maurer, R. Wray and J. P . S h i l l i n g f o r d , L a n c e t , 2, 7739 (1971). C. A. Van D i j k , W. B. Dominicus, H. d e j o n g e and J . Ross, Acta Med. Sc a nd. , 189, 269 (1971). B. F r i e d l i , N . A e r i c h i d e . P. Grondin and L . Campeau, Am. Heart J . , 8 l , 702 (1971). J . Koch-Weser and E . M. S e l l e r s , New Eng. J. Med., 285, 487 and 547 (1971). R. A. O ' R e i l l y , M. A . Sahud and P . M. A g g e l e r , Ann. N . Y . Acad. S c i . , 179, 1 7 3 (1971). F. N . M a r s h a l l , P r o c . SOC. Exp. Bio. and Med., 139, 223 (1972). J . S u l k o , I1 Farmaco, 3,147 (1971). J . D. G e r a t z , Thromb. D i a t h . Haemorrh., 2fr. 391 (1971). ( a ) D. L . K l i n e , Thromb. D i a t h . Haemorrh. S u p p l . 51, 5 (1971); ( b ) K . C . Robbins and L. Summaria, 9 (1971). S. S h e r r y , Ann. I n t . Med., 2, 437 (1971). J . H i r s h . I. G. McDonald, G. A. Hale, E . F. O ' S u l l i v a n and V. M. J e l i n e k , Can. Med. Assoc, J . , 104,488 (1971). J. M. S u l l i v a n , N e w Eng. J . Med., 286, 432 (1972). European Working P a r t y , B r . Med. J . , 2. 325 (1971). R. Heikinheimo, P. Ahrenberg, H . Honkapohja, E . I i s a l a , V. K a l l i a , Y. K o n t t i n e n ,
-.,
0 . Le sk i n e n, H. Must ani emi , M.
R e i n i k a i n e n and L. S i i t o n e n , A c ta Ned. S c a n d . ,
189, 7
(1971). 90. A. P. F l e t c h e r in Thrombosis, e d . by S . S h e r r y , K . M. Brinkhous e , E . Genton and J . M. S t e n g l e , N a t i o n a l Academy of S c i e n c e s , Washington, D . C . , 1969, p. 710. 91. N . Aoki and K . N . von D a u l l a , J. Lab. C l i n . Med., 78, 354 (1971). 2163 (1970); 92. Urokinase-Pulmonary Embolism T r i a l S t udy Group: J . Am. Med. h s o c . , 9, 165 (1971). Thromb. D i a t h . Haemorrh. S u p p l . , 93. G. I. Litman, R. B. S mi l ey, J r . and N . K. Wenger, Am. J. C a r d i o l o g y , G. 636 (1971). 94. M. Mantovani and G. P r i n o , European J . Pha rma c ol. . 13,108 (1970). 95. W. H . E . R oschl au, Thromb. D i a t h . Haemorrh. S u p p l . , 5 6 , 229 (1971) and 57, 315 (1971). 96. (a) H. C. Kwaan and G. H . Barlow, Thromb. D i a t h . Haemorrh. S u p p l . , 57, 361 (1971); ( b ) W. R. Bell, %., 371 (1971). 97. Chemical C o n t r o l of Fibrinolysis-Thrombolysis, e d . by J . M. S c h o r , W i l e y - I n t e r s c i e n c e , New York, N . Y . , 1970. 98. ( a ) K . N . von K a u l l a , N . Aoki and E . von K a u l l a , Thromb. D i a t h . Haemorrh. S u p p l . , 57, 51 (1971); ( b ) W. Baumgarten, 61 (1971). 99. K . N . von D a u l l a and D. T h i l o , Thromb. D i a t h . Haemorrh. S u p p l . , 42, 345 (1970). 100. L. J. F l i e d n e r , J r . , J . M. S c h o r , M. J . Myers, and I. J. P a c h t e r , J . Med. Chem., 580 (1971). 1553 (1971). 101. I . B. KOVLCS, L . Csal ay and G. CsLkvdry, Arzneim.-Forsch.,
z,
u..
c,
a,
Chapter 9. S.
Pulmonary and A n t i a l l e r g y A g e n t s
Tozzi, Schering Corporation,
B l o o m f i e l d , New J e r s e y
-
I n a r e v e r s i b l e airway o b s t r u c t i v e disease, Introduction s u c h as asthma, r e s p i r a t i o n i s i m p a i r e d b y bronchospasm, vasod i l a t i o n , e x c e s s i v e mucous and edema. V a r i o u s t h e o r i e s have been proposed t o e x p l a i n t h e e t i o l o g y and p a t h o g e n e s i s o f asthma. I t has b e e n c a t e g o r i z e d a s a n i m m e d i a t e t y p e " h y p e r s e n s i t i v i t y " r e s u l t i n g from a n a n t i g e n - a n t i b o d y ( r e a g i n ) r e a c t i o n w i t h s u b s e q u e n t r e l e a s e o f h i s t a m i n e , s e r o t o n i n , bradyk i n i n , slow- r e a c t i n g s u b s t a n c e (S R S - A ) a n d p o s s i b l e o t h e r bronchoconstrictor substances. S i n c e s t r e s s and b r a i n les i o n s a l t e r immunological r e a c t i v i t y and s i n c e e m o t i o n a l fact o r s can e x a c e r b a t e t h e c l i n i c a l s i t u a t i o n , t h e c e n t r a l nerv o u s s y s t e m and c o n d i t i o n i n g may p l a y a r o l e i n asthma.. V a g a l s t i m u l a t i o n a n d c h o l i n e r g i c d r u g s c a n i n d u c e b r o n c h i a l cons t r i c t i o n by e x c e s s i v e p a r a s y m p a t h o m i m e t i c t o n e a n d b l o c k a d e by a n t i c h o l i n e r g i c d r u g s h a s b e e n u s e f u l i n t h e t r e a t m e n t o f asthma. S z e n t i v a n y i ' s l work h a s l e d t o h i s t h e o r y o f " b l o c k ade o f t h e a d r e n e r g i c I3 r e c e p t o r s ' ' i n t h e l u n g s as a p o s s i b l e c a u s e o f b r o n c h i a l asthma. He p o s t u l a t e s t h a t t h e a s t h m a t i c h a s a d e f e c t a t t h e I3 a d r e n e r g i c r e c e p t o r s i t e w h i c h i n d u c e 6 a s t a t e of hyperreactivity. T h i s t h e o r y has b e e n q u e s t i o n e d because i f a s t h m a t i c s have a n i n t r i n s i c B r e c e p t o r blockade, t h e y s h o u l d f i n d no r e l i e f w i t h B a d r e n e r g i c b r o n c h o d i l a t o r s . A new h y p o t h e s i s a b o u t b r o n c h i a l asthma h a s b e e n i n t r o duced which i s s u p p l e m e n t a r y t o t h e c l a s s i c a l t h e o r i e s o f t h e I t v i e w s t h e d i s e a s e a s t h e end r e s u l t o f i n t e r disease. a c t i o n b e t w e e n decreased c i r c u l a t i n g e p i n e p h r i n e and a p a t h o l o g i c a l l y a l t e r e d h y p e r a c t i v e b r o n c h i a l t r e e 2 . Some c l i n i c a l data3'4 i n b r o n c h i a l a s t h m a d o e s i n d i c a t e t h a t t h e r e i s a dec r e a s e i n c i r c u l a t i n g e p i n e p h r i n e and t h i s may be s e c o n d a r y t o a l t e r e d u p t a k e o r enzyme a c t i v i t y (COMT a n d MAO), o r dec r e a s e d r e l e a s e o f e p i n e p h r i n e from t h e a d r e n a l m e d u l l a . The d e c r e a s e d r e l e a s e o f e p i n e p h r i n e from t h e a d r e n a l m e d u l l a may i n v o l v e t h e hypothalamus t h e r e b y l i n k i n g t h e c e n t r a l nervous s y s t e m w i t h asthma. Drugs commonly u s e d f o r s y m p t o m a t i c management a c t by a v a r i e t y o f mechanisms. Sympathomimetic a g e n t s ( i s o p r o t e r e n o l ) m a i n l y a c t by s t i m u l a t i n g b e t a a d r e n e r g i c r e c e p t o r s t o c a u s e b r o n c h o d i l a t i o n a n d some ( e p h e d r i n e and e p i n e p h r i n e ) a l s o s t i m u l a t e a l p h a a d r e n e r g i c r e c e p t o r s t o cause vasoconstriction. The e f f e c t i v e n e s s o f x a n t h i n e derivat i v e s ( a m i n o p h y l l i n e , t h e o p h y l l i n e ) i s b a s e d on t h e i r a b i l i t y t o r e l a x t h e smooth m u s c l e o f t h e t r a c h e o b r o n c h i a l t r e e a n d r e d u c e edema o f t h e b r o n c h i a l mucosa. Their bronchodilator a c t i v i t y may i n v o l v e t h e i n h i b i t i o n o f l u n g c y c l i c AMP phosphodiesterase. Corticosteroids a c t through t h e i r a b i l i t y t o r e d u c e i n f l a m m a t i o n and edema a n d a l t e r t i s s u e r e a c t i v i t y t o
90
L
Sect.
II
-
T o p l i s s , Ed.
Pharmacodynamic Agents
allergens. I n a n a n t i g e n - a n t i b o d y r e a c t i o n , h i s t a m i n e i s rel e a s e d and w h i l e d r u g s t h a t b l o c k h i s t a m i n e a r e s u c c e s s f u l i n t r e a t i n g o t h e r a l l e r g i c d i s o r d e r s , they have been i n e f f e c t i v e i n t h e t r e a t m e n t o f asthma. T h i s i n e f f e c t i v e n e s s c o u l d b e rel a t e d t o t h e i n h e r e n t a b i l i t y of a n t i h i s t a m i n e s t o c o n s t r i c t smooth m u s c l e s s . R e c e n t l y , t h e development o f d i s o d i u m cromog l y c a t e has d i r e c t e d a t t e n t i o n t o w a r d a n o t h e r p o t e n t i a l l y usef u l mechanism f o r t h e t r e a t m e n t o f r e v e r s i b l e a i r w a y o b s t r u c t i v e disease. Disodium c r o m o g l y c a t e i s n o t a b r o n c h o d i l a t o r , antihistamine o r antiinflammatory agent. I n s t e a d , it i s thought t o a c t by blocking t h e release of a l l e r g y mediating s u b s t a n c e s s u c h as h i s t a m i n e , and SRS-A r e s u l t i n g f r o m a n t i gen- a n t i b o d y r e a c t i o n . The p r o s t a g l a n d i n s , a s e r i e s o f natur a l l y o c c u r r i n g hydroxy u n s a t u r a t e d f a t t y a c i d s , have b e e n reported t o possess potent stimulatory o r i n h i b i t o r y properties on r e s p i r a t o r y smooth m u s c l e and i n d e e d may o f f e r a new c l a s s of d r u g t o t h e e x i s t i n g g r o u p o f b r o n c h o d i l a t o r s .
-
The d i v e r s i t y Bronchodilators: Beta Adrenergic Stimulants of a c t i o n s of catecholamines a t 8 adrenergic receptors led Landse t o p o s t u l a t e t h a t t h e r e a r e two B r e c e p t o r p o p u l a t i o n s ; f31 m e d i a t i n g l i p o l y s i s a n d c a r d i a c s t i m u l a t i o n , a n d 82 media t i n g b r o n c h o d i l a t i o n and v a s o d i l a t a t i o n . Isoproterenol, a p o t e n t b r o n c h o d i l a t o r , a c t i v a t e s Be a d r e n e r g i c r e c e p t o r s b u t it a l s o s t i m u l a t e s c a r d i a c adrenergic r e c e p t o r s t o cause tachycardia. P r o b a b l y as a d i r e c t r e s u l t o f t h e c a r d i a c s t i m u l a t i o n , t h e hypoxaemia o f t h e a s t h m a t i c p a t i e n t c o u l d become worse when t h e d r u g i s a b u s e d a n d v e n t r i c u l a r f i b r i l l a t i o n o r T h i s c a r d i a c s t i m u l a t i o n has b e e n i m p l i a s y s t o l e may o c c u r . c a t e d i n t h e r e c e n t r i s e i n asthma m o r t a l i t y t h u s i n d i c a t i n g a n e e d f o r a d r u g t h a t has l i t t l e 191 a c t i v i t y . I n a d d i t i o n , isoproterenol i s a comparatively short a c t i n g bronchodilator b e c a u s e i t i s r a p i d l y m e t a b o l i z e d b y t h e enzyme c a t e c h o l - 0 S u b s t i t u t i o n o f o t h e r groups o r m e t h y l t r a n s f e r a s e (COMT). r e a r r a n g e m e n t s o f e x i s t i n g g r o u p s i n t h e b e n z e n e r i n g have res u l t e d i n compounds more r e s i s t a n t t o COMT w i t h g r e a t e r d u r a t i o n o f a c t i o n , a n d c h a n g e s i n t h e s i d e c h a i n have i n c r e a s e d t h e i r s p e c i f i c i t y f o r Be, o r b r o n c h i a l , as o p p o s e d t o t h e 81, o r cardiac, receptors. The c l i n i c a l , c h e m i c a l and pharmacol o g i c a l c o n s i d e r a t i o n s o f t h e newer B a d r e n e r g i c s t i m u l a n t s h a v e r e c e n t l y b e e n reviewed7. Examples o f d r u g s c l a i m e d t o h a v e more s e l e c t i v e 82 s t i m u l a n t a c t i o n s t h a n i s o p r o t e r e n o l a r e ; salbutamo18, t e r b u t a l i n e s , T h 1 1 6 5 a l 0 , hexo r e n a l i n e ” , clorprenalinel2, t r i m e t h o q u i n o l l 3 , q u i n t e r e n o l l q , WG 2 5 p and s o t e r e n o l l e . S t r u c t u r e a c t i v i t y r e l a t i o n s h i p s of salig e n i n a n a l o g s o f sympathomimetic c a t e c h o l a m i n e s a n d t h e r e s o l u t i o n o f i s o m e r s o f t h e ‘most p r o m i n e n t of t h e s e a n a l o g s , salb u t a m o l , have r e c e n t l y b e e n r e p o r t e d ’ 7r1
,
C l i n i c a l l y some o f t h e s e s e l e c t i v e a d r e n e r g i c bronchod i l a t o r s have s u c c e e d e d i n d e m o n s t r a t i n g l e s s c a r d i o v a s c u l a r
Chap. 9
Pulmonary, A n t i a l l e r g y A g e n t s
Isoproterenol S a l b u t amo 1 Terbutaline Sote r eno1 Clorprenaline Metaproterenol Th 1165a H e x o p r e n a l i ne
3- OH 3- C H 2 O H 3- OH 3- N H S 0 2 C H 3
4-OH
2- C 1
H
3- OH 3- O H 3- OH
5- OH
91 -
Tozz i
4- OH 5- OH 4- OH 5- O H
4- OH
OH
Q u i n te r e n o l 0C H 3
WG 253
T r i m e t hoqui no1
e f f e c t s than isoproterenol. T h e s e d r u g s a r e e f f e c t i v e as a e r o s o l s and u n l i k e i s o p r o t e r e n o l , t h e y a r e a l s o e f f e c t i v e orally. SalbutamolLs'2s has b e e n compared i n d o u b l e b l i n d ~ ~ e t, a p r o t e r e n ~ l ~ ~ r ~ ~ ' ~ ~ . s t u d i e s w i t h i s o p r ~ t e r e n o l ~o r~ m A t 0.2 mg, it i s e q u i a c t i v e t o i s o p r o t e r e n o l and has a l o n g e r d u r a t i o n of a c t i v i t y . T e r b u t a l i n e has demonstrated o t e n t b r o n c h o d i l a t o r a c t i ~ i t y ~ ~when , ~ ' g i v e n o r a l l y ( 5 mgp o r as a n a e r o s o l ( 0 . 2 mg). I t has b e e n compared t o p r o x y p h y l l i n e 4 5 i ~ o p r o t e r e n o la n ~ d~ m e t a p r o t e r e n o l * 4 - 4 7 . Th 1165a a e r o s o l a t 0.2 mg i s f o u r t i m e s as p o t e n t a s i t s a n a l o g u e m e t a p r o t e r e n o l Hexoprenaline and i s a r e l a t i v e l y s a f e b r o n c h o d i l a t o r 4 8 ' s o . i s e f f e c t i v e a s a n a e r o s o l (0.4$) o r o r a l l y (0.5 mg), has a l o n g d u r a t i o n o f a c t i ~ i t y ' ' ~ ~ ~ -a~n d? ,a l l o w s f o r t h e r e d u c t i o n o f c o r t i c o s t e r o i d r e q u i r e m e n t s 4 9 5 5 . Oral d o s e s of t r i m e t h o q u i n o l (1 rng)se,57 and q u i n t e r e n o l (0.4 m g ) s 8 a n d a e r o s o l d o s e s o f WG 253 ( 1 . 5 m g ) 1 5 , 5s a n d s o t e r e n o l ( 0 . 2 2 5 mg)eo h a v e bronchodilator efficacy equivalent t o isoproterenol w i t h a g r e a t e r d u r a t i o n o f a c t i v i t y and lessB1 s t i m u l a t i o n . Clorp r e n a l i n e has f32 b r o n c h o d i l a t o r p r o p e r t i e s i n d o g s 1 2 a n d ratse1. Sympathomimetic amines c a n a l s o i n h i b i t t h e r e l e a s e
92
Sect.
II
-
Pharrnacodynarnic Agents
Topliss, Ed.
o f p h a r m a c o l o g i c a l m e d i a t o r s of t h e immediate t y p e a l l e r g i c reactionse2re3. I n a s e r i e s o f t e s t s y s t e m s i n c l u d i n g pass i v e c u t a n e o u s a n a p h y l a x i s (PCA) a n d d e x t r a n r e s p o n s e i n t h e r a t , i s o p r o t e r e n o l w a s a t l e a s t 1000 times as p o t e n t a s d i s o dim c r o m o g l y c a t e (DSCG)@4. T h e r e f o r e , B a d r e n e r g i c stimul a n t s are a l s o p o t e n t p r o t e c t i v e a g e n t s a g a i n s t a n a p h y l a c t i c r e a c t i o n s and s h o u l d n o t b e c o n s i d e r e d o n l y a g e n t s p r o d u c i n g sympathomimetic r e l i e f o f bronchospasm i n asthma.
Non-Adrenergic B r o n c h o d i l a t o r s - S e v e r a l new b r o n c h o d i l a t o r s have b e e n r e p o r t e d which do n o t d e p e n d on a d r e n e r g i c s t i m u l a t i o n as t h e i r mode o f a c t i o n . P i q u i z i l , 4- (6,7-dimethoxyq u i n a z o 1 i n ) - 4- p i p e r a z i n e - 1-c a r b o x y l i c a c i d i s o b u t y l e s t e r , a new o r a l b r o n c h o d i l a t o r , has b e e n shown t o be e q u a l i n a c t i v i t y t o a c o m b i n a t i o n o f t h e o p h y l l i n e , e p h e d r i n e and phenobarbitale5. Sch 1000, a n a t r o p i n e d e r i v a t i v e , d e c r e a s e s pulmona r y r e s i s t a n c e i n o b s t r u c t i v e pulmonary d i s e a s e when i n h a l e d as a n a e r o s o l (0.025$)saree. D e c l o x i z i n e , a d e c h l o r i n a t e d d e r i v a t i v e of h y d r o x y z i n e , h a s marked a n t i s e r o t o n i n a n d papav e r i n e - l i k e p r o p e r t i e s a n d i s c l a i m e d t o be a n e f f e c t i v e o r a l Fenspiride, an alpha adrenerb r o n c h o d i l a t o r a t 50 mge7-ee g i c b l o c k i n g d r u g , has b e e n c l a i m e d t o b e of v a l u e i n t h e treatment of a ~ t h m a ~ ~ - 7 ~ .
.
S c h 1000
I
C02CH2CH ( C H a ) 2 Piquiz i1
(CH2)20(CH2)20H
Fenspiride
Decloxizine
-
PGEl a n d PGE2 a r e e f f e c t i v e b r o n c h o d i l a t o r s , Prostaglandins c a p a b l e o f r e v e r s i n g t h e i n c r e a s e d a i r w a y r e s i s t a n c e and dec r e a s e d a i r w a y c o m p l i a n c e i n d u c e d by c h o l i n e r g i c s t i m u l a t i o n i n t h e c a t . A d m i n i s t r a t i o n by a e r o s o l produces t h e g r e a t e s t b r o n c h o d i l a t i n g r e s p o n s e w i t h l i t t l e o r no c a r d i o v a s c u l a r The c a r d i o v a s c u l a r e f f e c t s of hypotension and tachycardia. e f f e c t s were most p r o n o u n c e d a f t e r i n t r a v e n o u s a d m i n i s t r a t i o n .
Chap.
9
Pulmonary, Antiallergy Agents
93 -
Tozz i
PGE2 b r o n c h o d i l a t o r e f f e c t s were n o t b l o c k e d b y b i l a t e r a l vagotomy, a d r e n a l e c t o m y , b e t a a d r e n e r g i c o r g a n g l i o n i c b l o c k ade. T h e s e a g e n t s may r e p r e s e n t a new a n d n o v e l c l a s s o f pot e n t b r o n c h o d i l a t o r agents74.
-
Phosphodiesterase I n h i b i t o r s Catecholamines i n c r e a s e t h e c o n c e n t r a t i o n o f c y c l i c AMP b y s t i m u l a t i n g t h e enzyme a d e n y l cyclase. M e t h y l x a n t h i n e s i n c r e a s e t h e c o n c e n t r a t i o n o f cyc l i c AMP b y i n t e r f e r i n g w i t h i t s i n a c t i v a t i o n by p h o s p h o d i e s t e r a s e and t h i s i s t h o u g h t t o b e t h e b i o c h e m i c a l b a s i s f o r t h e bronchodilator a c t i o n of theophylline.
AT’
++
---------------> Mg
Bronchodilation 4 c y c l i c $‘,5’ AMP
adenyl cyclase
Mg
----------------> 5’ ++
AMP
phosphodiesterase
T
T
I n h i b i t e d by t h e op hy 11i ne
S t i m u l a t e d by c a t e c h o l a m i ne s
I C I 58 3 0 1 (3- a c e t a m i d o - & m e t h y l - 8- n - p r o p y l - s- t r i a z o l o [ & , + a ] p y r a z i n e ) i s a new compound t h a t i s a g r e a t e r i n h i b i I n animals, I C I t o r of phosphodiesterase t h a n theophylline. 58 301 i s f a r more p o w e r f u l fn p r e v e n t i n g b r o n c h o s p a s m t h a n i n acting as a bronchodilator. T h i s a c t i v i t y h a s b e e n confirmed i n asthmatic patients7s. P r o x y p h y l l i n e , 7- (2- hydroxyp r o p y l ) t h e o p h y l l i n e , a d m i n i s t e r e d a s a s u p p o s i t o r y ( 5 0 0 mg) i s e f f e c t i v e i n e n h a n c i n g pulmonary f u n c t i o n i n c h r o n i c asthmatic patients76. OH NHCO C H 3
+I
P r o x y p h y l l i ne
ICI
-
58 3 0 1
Disodium C r o m o g l y c a t e (DSCG) T h i s compound a p p e a r s t o b l o c k a s t e p i n t h e c h a i n o f e v e n t s t r i g g e r e d by t h e u n i o n o f a n t i g e n w i t h r e a g i n i c a n t i b o d y which l e a d s t o t h e r e l e a s e o f s p a s mogens and o t h e r m e d i a t o r s o f t h e a n t i p h y l a c t i c and h a s been found u s e f u l i n t r e a t i n g asthma and a l l e r g i c r h i n i t i s . I t d i f f e r s from e x i s t i n g t h e r a p y i n t h a t i t h a s no sympathomimetic, a n t i i n f l a m m a t o r y o r a n t i h i s t a m i n i c a c t i v i t y . DSCG i s a d m i n i s t e r e d by i n h a l a t i o n as a d r y powder i n a spec i a l i n s u f f l a t o r which p e r m i t s c o n t r o l l e d d o s a g e . I n a dose r a n g e o f 20-80 mg d a i l y , i t h a s b e e n u s e d i n t h e t r e a t m e n t o f
94
Sect. I I
-
Pharmacodynamic Agents
T o p l i s s , Ed.
OH I
NaOgC
Disodium c r o m o g i y c a t e ( D S C G ) a l l e r g i c r h i n i t i s and has b e e n f o u n d t o be e f f e c t i v e b y I n e x t r i n s i c asths o m e 7 8 0 0 and i n e f f e c t i v e by o t h e r s a l - 8 3 . m a i n c h i l d r e n , i t has b e e n f o u n d t o be e f f e c t i v e by most i n v e s t i g a t 0 r s ~ 4 -a~n d~ a l l o w s f o r a d e c r e a s e i n t h e r e q u i r e m e n t a n d b r o n c h o d i l a t o r s 8 4 98 D S C G c a n preof s t e r o i d s 93' v e n t a s t h m a t i c a t t a c k s 94 p S T , r e d u c e h i s t a m i n e s e n s i t i v i t y 8 8 3 e@ and e x e r c i s e - i n d u c e d a i r w a y o b s t r u c t i o n l o o i n a s t h matics. The o n l y s i d e e f f e c t r e p o r t e d has b e e n a pharyngeal a n d t r a c h e a l i r r i t a t i o n l o L r L o e a n d a l t h o u g h t h e r e i s no evid e n c e o f d r u g - d e p e n d e n c e t h e r e may b e a loss o f e f f i c a c y a f t e r some months o f u s e L O8.
,
.
-
Antihistamines A n t i h i s t a m i n e s b l o c k h i s t a m i n e a t t h e recept o r s i t e and a r e u s e f u l i n t h e t r e a t m e n t o f u r t i c a r i a and rhinitis. U n f o r t u n a t e l y , t h e m a j o r i t y o f a n t i h i s t a m i n e s produce a n i n c r e a s i n g degree of s e d a t i o n w i t h i n c r e a s e d t h e r a peutic activity. Two new a n t i h i s t a m i n e s , m e c l a s t i n e l o 4 and a z a t a d i n e l o s , have b e e n r e p o r t e d t o be c l i n i c a l l y e f f e c t i v e . Clinical s t u d i e s show t h a t a z a t a d i n e i s a p o t e n t , l o n g a c t i n g a n t i h i s t a m i n e w i t h l o w s e d a t i v e l i a b i l i t y a t d o s e s o f 1 - 2 mg t w i c e daily10er107. A z a t a d i n e , a t 0.009-0.0024 mg/kg p.o., has b e e n r e p o r t e d t o b e more p o t e n t t h a n c y p r o h e p t a d i n e as a n a n t i h i s It t a m i n e and a n t i a n a p h y l a c t i c a g e n t i n m i c e a n d g u i n e a p i g s . i s g e n e r a l l y l e s s t o x i c t h a n c y p r o h e p t a d i n e and p o s s e s s e s s i g n i f ic a n t a n t i c h o l i n e r g i c and a n t i s e r o t o n i n a c t i v i t y 1 05.
n '
I
CH3
0- CH2- C H s - [ z
Meclas t i ne
A z a t a d i ne I t has l o n g b e e n a c c e p t e d t h a t h i s t a m i n e i s formed by t h e enzymatic decarboxylation of h i s t i d i n e . A drug t h a t inh i b i t s h i s t i d i n e - d e c a r b o x y l a s e would d e c r e a s e t h e amount o f
Chap. 9
95
Tozz i
Pulmonary, A n t i a l l e r g y Agents
h i s t a m i n e a v a i l a b l e and t h u s b e o f u s e i n t h e t r e a t m e n t o f allergic disorders. T r i t o q u a l i n e h a s b e e n r e p o r t e d t o have non- s p e c i f i c a n t i s p a s m o t i c and a n t i i n f l a m m a t o r y a c t i v i t y beIt h a s b e e n s i d e s i n h i b i t i n g histidine-decarboxy1aselo8. shown t o b e e f f e c t i v e i n t h e t r e a t m e n t o f hay f e v e r and unl i k e most a n t i h i s t a m i n e s , i t h a s no s e d a t i v e e f f e c t ’ 09. References 1. 2.
3. 4. 5. 6. 7.
8. 9. 10. 11. 12.
13
14. 15. 16.
18.
19 20. 21. 22. 23 24. 25. 26. 27
9
42,
A. S z e n t i v a n y i , J. A l l e r g y , 203 (1968). A.A. Mathe, J. P s y c h o s o m a t i c Res. 349 (1971). A.A. Mathe and P.H. Knapp, New Engl. J. Med. 281, 234
s,
(1969 I *
A.A. Mathe and P.H. Knapp, Am. P s y c h o s o m a t i c S o c i e t y , C i n c i n n a t i , 31 March, 1969. D.F. Hawkins, B r . Med. J. 10, 230 (1967). A.M. Lands, A. A r n o l d , J.P. M c A u l i f f , F.P. Luduena, a n d T.O. Brown, N a t u r e , 597 (1967). R.T. B r i t t a i n , D. J a c k a n d A.C. R i t c h i e , Ad. D r . Res., 3, 197 ( 1 9 7 0 ) . R.T. B r i t t a i n , J . B . Farmer, D. J a c k , L.E. M a r t i n a n d W.T. Simpson, Nature, 9,862 (1968). H. P e r s s o n and T. O l l s s o n , A c t a Med. Scand. s u p p l . , 512, 11 ( 1 9 7 0 ) . S . R . O’Donnell, Eur. J. Pharm., 12, 3 5 ( 1 9 7 0 ) . F. Witek, Wein. K l i n . Wschr., 8 -3, 1 1 4 (1971). T. I g a r a s h i , T. Wakabayashi, T. S h o j i and T. Tomiugam, Arzneim. F o r s c h . , 20, 1738 ( 1 9 7 0 ) . F. Fogelman and H.F. Grundy, B r i t . J. Pharm., 2, 416 (1970)Lab. F i l e s of C h a r l e s P f i z e r a n d Co., Groton, Conn. J . P . G r i f f i n a n d P. T u r n e r , J. C l i n . Pharm., ll, 280
e,
(1971 1
P.M. L i s h , J.H. W e i k e l and K.W. Dungan, J. Pharm. Exp. 1 6 1 (1965). Ther., D.T. C o l l i n , D. H a r t l e y , D. J a c k , L.H.C. Lunts, J.C. P r e s s , A.C. R i t c h i e and P. Toon, J. Med. Chem., 3, 674, ( 1 9 7 0 ) . D. H a r t l e y , D. M i d d l e m i s s , J. Med. Chem., 895 (1971). P.L. Kamuroff and F.J. Rime, B r i t . J. D i s . C h e s t , 64, 46 ( 1 9 7 0 ) . 8 2 (1971). R.L. F r e i s l e b e n , P o s t g r a d . Med. J. (1971). P. Dano and W. F a l h o l t , Ugeskr L a e gsupplo’ er, 81971) D. J a c k , P o s t g r a d . Med. J. s u p p l . , Y. Kawakami, Jap. J. A l l e r g y , 20, 233 (1971). Y. Kawakami, P o s t g r a d . Med. J. s u p p l . 71 (1971). Y. Nakayama, P o s t g r a d . Med. J. s u p p l . , 2, 118 (1971). F.J. Prime, P o s t g r a d . Med. J. s u p p l . , 88 (1971). A. Schumann and H. Herxheimer, P o s t g r a d . Med. J. s u p p l . , 47, 9 2 (1971).
149,
2,
36,
9, , $, 9,
-
96 -
Sect. I I
28.
S.S.
-
Pharrnacodynamic A g e n t s
C h a t t e r j e e and A.E.
Perry,
Topliss, Ed.
P o s t g r a d . Med. J. s u p p l . ,
47, 53 (1971).
7
S t r e e t o n and E.B. Morgan, P o s t g r a d . Med. J. suppl., 1 2 5 (1971). K.N. Palmer, J.S. Legge, W.F. H a m i l t o n and M.L. Diament, B r i t . Med. J., 2, 2 3 ( 1 9 7 0 ) . J.W. P a t e r s o n , P o s t g r a d . Med. J. s u p p l . , 47, 38 (1971). A.D. M i l n e r and D. Ingram, Arch. Dis. C h i l d . , 46, 502
J.A.
29
47,
30
31 32.
(1971).
Hambleton and E . A . S h i n e b o u r n e , Arch. D i s . C h i l d . , 766 ( 1 9 7 0 ) . F. Lustman, P r a c t i t i o n e r , 205, 213 ( 1 9 7 0 ) . D.A. W a r r e l l , D.G. R o b e r t s o n , J . N . Howes, M.E. Conolly, J.W. P a t e r s o n , L . J . B e i l i n and C.T. D o l l e r y , B r i t . Med. J., 2, 65 ( 1 9 7 0 ) . A.E. T a t t e r s f i e l d and M.W. McNicol, N e w Eng. J. Med., 281, 1323 (1969). T.V. O'Donnell, G.M. B u t l e r and M.D. Tocker, P o s t g r a d . Med. J. s u p p l . , 1 1 5 (1971). C. Racoveanu, e t a l . , P o s t g r a d . Med. J. s u p p l . , 83 G.
33
%,
34. 35. 36
37. 38.
-
9,
9,
(1971).
39
0
40.
41. 42.
43
6
44. 45 46. 47. 48. 49 50
51 52.
53
9,
P. Dano, P o s t g r a d . Med. J. s u p p l . , 86 (1971). B. Arner, A. B e r t l e r , T. K a r l e f o r s and H. W e s t l i n g , A c t a Med. Scand. s u p p l , , 512, 4 1 ( 1 9 7 0 ) . U. H e d s t r a n d , Scand. J. Resp. D i s . , 51, 188 ( 1 9 7 0 ) . C.H. Hagelund, Nord. Med., 728 (1971). R. E s p i n o z a , Nord. Med., 729 (1971). H. Formgren, Scand. J. Resp. D i s . , 203 ( 1 9 7 0 ) . H. Formgren, Scand. J. Resp. D i s . , 2, 195 ( 1 9 7 0 ) . B, A r n e r , A c t a Med. Scand. s u p p l . , 512, 45 ( 1 9 7 0 ) . M.J. M a t t i l a and A . M u i t t a r i , Ann. Med. Exp. B i o l . Fenn., 47, 298 (1969). H.K. Tweel, Ann. A l l e r g . , 3, 1 4 2 (1971). J. Hamm and H. Wusthofen, K l i n . Wschr., 48, 415 ( 1 9 7 0 ) . H.P. S c h u s t e r and P. Baum, Arzneim. F o r s c h . , 1p, 1905
a,
3,
-
(1969 1
3,
98 (1971). F. Wilk. Wein. K l i n . Wschr., D. T h i e d e , G. S t e m p e l and W.T. Ulmer, Arzneim. F o r s c h . , 21, 416 (1971). H. P a l l and W. S c h l i c k , Wein. K l i n . Wschr., &, 117
-
(1971
54 55. 56 57. 58.
59. 60.
z,
a,
B. S c h r e i n e r , Wein. K l i n . W ~ c h r . , 80 (1971). R. T i t a c h e r , Wein. K l i n . Wschr., 121, 146 (1971). I. Ando e t a l . , J a p a n Med. News, & ' 1 2 (1971). A. Kiyomoto, Y. Iwasawa and S. H a r i g a y a , Arzneim. F o r s c h , 1, 46 ( 1 9 7 0 ) . E. B l e e c k e r , W. McKinney, H. Lyons and S . N . S t e e n , Anesth. Analg., 48, 7 (1969). I. Carney, M . J . Daly, L.E. L i g h t t o w l e r and R.W. Pickering, Arch. Int. Pharmacodyn., 334 (1971). B.M. Cohen, Curr. T h e r . Res., 11, 713 (1969).
-
194,
Chap. 9
61.
Pulmonary, Antiallergy Agents
Tozz i
97 -
T.
I g a r a s h i , Y. S u s u k i and K. Miyao, Arzneim. F o r s c h . , 234 ( 1 9 7 1 ) . E.S.K. Assem and H.O. S c h i l d , N a t u r e , 3,1 0 2 8 ( 1 9 6 9 ) . E.S.K. Assem and H.O. S c h i l d , I n t . Arch. A l l e r g y , 40,
21, 62.
63
64. 65. 66. 67. 68. 69 70
a, J.
553 (1971).
Pernod and J. B a t i m e ,
J. Fr.
Med.
C h i r . Thorac.,
24,
783 (1970).
Rev. Lyon Med., 395 ( 1 9 7 0 ) . J. D u h a u l t and M. L a u b i e , Arzneim. F o r s c h . , 4, 1263 (1969). M.E. R o s e n t h a l e , A. D e r v i n i s and J. K a s s a r i c h , J. Pharm. Exp. Therp., 541 (1971). A. J. R i c h a r d s , S.R. Walker and J . W . P a t e r s o n , B r i t . J. D i s . Chest., 247 (1971). P. I n d a , S.S. C h a t t e r j e e , W.D. R i d i n and T. S i n g h , B r i t . J. C l i n . P r a c t . , 3, 5 0 5 (19697. J.S.G. Cox, J . E . Beach and P. S h e a r d , Ad. D r . Res., 3, 197 ( 1 9 7 0 ) . J. C e n t n e r , A r s Medici, 26, 715 (1971). E. H o l o p a i n e n , A. Backman and O.P. S a l o , L a n c e t , 1, 5 5 P. Galy e t a l . , J. C. LeDouaree,
72
73 74
178,
75.
76. 77. 78 79
3
(1971).
80.
81. 82.
83 84.
85 86. 87. 88.
89
-
-4,
71
90
576 (1971).
E.S.K. A s s e m a n d A.W. R i c h t e r , Immun., 21, 729 (1971). K . J . B e r e n y i and S . N . S t e e n , Canad. A n a e s t h . S o c . J., 17, 522 ( 1 9 7 0 ) . W.T. U l m e r , Med. K l i n . , 66, 326 (1971). A. M u i t t a r i , M . J . M a t t i l a and J. P a t i a l a , Ann. A l l e r g . , 274 (1969). J. Van Mechelen, A c t a T u b e r c . Belg., 2, 667 (1968). W.D. L i n e h a n , I b i d . , 3, 549 (1968). M.J. C h a r p e n t i e r , K. B r e u i l and G. Beauchant, Bord. Med.,
.
91. 92.
Pelikan, W.J. Snoek, H. Booij-Noord, N. O r i e and K. d e V r i e s , Ann. A l l e r g . , 28, 548 ( 1 9 7 0 ) . L.H. Cape1 and P. McKelvie, L a n c e t , 1, 575 (1971). R.H. Champion, L a n c e t , 1, 187 (1971): J.M. Smith, L a n c e t , 2, 1 9 5 (1971). I.L. B e r n s t e i n e t al., J. A l l e r g . , 95 (1971). H e Booij-Noord, N.G.M. O r i o , C. Berg and K. d e V r i e s , J. A l l e r g . , 46, ( 1 9 7 0 ) . S. B e d f o r d and J . A . Kuzemko, C l i n . P e d i a t . , 2, 719 (1970 A. Meyer, N. Donat a n d A.M. C l a u z e l , Presse. Med., D, Z.
2,
519 (1971).
D.R. McCourtie, N.M. L e f c o e and J . H . Toogood, Therap e u t i c s , 2, 40 (1971). R.M. S l y , Ann. A l l e r g . , 28, 299 ( 1 9 7 0 ) . T.E. Van Metre, J.Y.L. Chen, S.M. Nagy, P.S. Norman, M. S c h w a r t z and A. Turk, J. A l l e r g - , 131 ( 1 9 7 0 ) . J.S. Hyde, B. B u r a n a k u l and V i t h a y a s a i , Ann. A l l e r g . , 28, 449 ( 1 9 7 0 ) . W.F. Hughes, K.S. Tse and C.E. Arbesman, J. A l l e r g . , Q,
3,
-
98 93
94 95. 96 97 98.
99. 100. 101. 102. 103. 104. 105. 106. 107.
108. 109.
Sect.
II
-
Pharrnacodynarnic Agents
Topliss, Ed.
1 3 2 (1970). H. Chai, L. Molk a n d C . J . F a l l i e r s , A m e r . Med. Ass. 1 1 9 t h . Meeting, Chicago ( 1 9 7 0 ) . 8, 2 8 1 ( 1 9 7 0 ) . J.S. Hyde and B. B u r a n a k u l , C h e s t , O.R. McCarthy, L a n c e t , 2 , 9 8 0 (1970% I,. Molk, H. Chai and C . J . F a l l i e r s , J. A l l e r g . , 132 (1970). 141 (1971). S.C.L. S h o r e , S. A f r . Med. J., J . W . Kerr, M. G o v i n d a r a s and K.R. P a t e l , B r i t . Med. J., 2, 139 ( 1 9 7 0 ) U.Y. Ryo, B. Kang and R.G. Townky, J. A l l e r g . , 96
3,
9,
-
9,
(1971)
a,
S l y , Ann. A l l e r g . , 362 (1971). Mathison, J. J. Condemli, F.W. Lovejoy, Jr. and J.H. Vaughan, J A M , 216, 1 4 5 4 (1971). C.W.M. Cooper, P r a c t i t i o n e r , 205, 230 ( 1 9 7 0 ) . R. Munro-Ford, Ann. A l l e r g . , 2,8 (1971). A. Roncevich, Curr. Ther. Res., 11, 6 2 5 (1969). S. T o z z i , M. d e l Prado, R. L u t z , F.E. Roth and I . I . A . T a b a c h n i c k , Fed. P r o c e e d i n g s , 1972. A. Sabbah, L a V i e M e d i c a l e , 5401 (1969). B. S i g a l and M. H e r b l o t , Gaz. Med. F r a n c e , 77, 364 (1970). F. Hahn a n d H.J. T e s c h e n d o r f , Arzneim. F o r s c h . , 10, 1490 ( 1 9 7 0 ) . C. E b e r h a r t i n g e r a n d H. Ebner, Wrn. Med. Wsche., 119, R.M. D.A.
3,
783 (1969 1
.
Section I11 Editor:
-
Chemotherapeutic Agents
Kenneth Butler, Pfizer Inc., Groton, Connecticut Chapter 10. Antibiotics
Frank C. Sciavolino, Pfizer Inc., Groton, Connecticut
-
General A symposium commemorating thirty years of penicillin therapy was held in May surveyin presently active areas of sc entific research in the penicillin field Commercial 6-APA processes ,la chemical relationships between penicillins and cephalosporins,Ib mechanism of action,lc bacterial resistance,ld and immunological propertiesle of penicillins were discussed, as were current clinical aspects of penicillin therapy .If The physicochemical properties and biological activities of clinically significant 6-lactam antibiotics were reviewed with particular commentary on 8-lactamases.2 A chapter on the chemistry of cephalosporin antibiotics appeared. The Second International Symposium on Gentamicin brought up to date scientific and clinical information relating to this antibiotic, placed gentamicin in perspective among other aminoglycosides and defined areas in which further investigative efforts are needed.4 Structure-activity relationships among chemically and microbially modified lincomycin antibiotics were reviewed. A treatise on bacterial resistance to the macrolide antibiotics and lincomycins was published. The chemistry, biological activity and biosynthesis of the ansamycins were r e ~ i e w e d . ~Detailed accounts of totally synthetic approaches to the tetracycline antibiotics appeared. A monograph on the biochemistry of antimicrobial agents has united significant developments in this area and orients readers to major literature reviews u to 1971.9 A theory on the formation of antibiotics was A symposium11 held in March surveyed recent developments proposed in many areas of the vast field of antibiotics.
.
Aminoglycosides - Comparative in vitro evaluations of tobramycin (nebramycin factor 6) continue to indicate it is two to four times more active than entamicin against clinical isolates of Pseudomonas aeruginosa;l5-I5 mean MIC values of 0.42 and 3.54 y/ml, respectively, were reported.12 Conversely, gentamicin proved four times as potent as tobramycin against isolates of Serratia marcescens ;I4 both antibiotics demonstrated compargble-activity against the majority of other gramnegative pathogens .lz-l' Detailed accounts of the structure elucidations of the gentamicin C components16-18 and sisomicin19s20 were published. Chemical syntheses of 3'-d xykanamycin,21 3' ,4'-dideoxykanamycin B22 and 3 ' ,4'-dideoxyneamine" were announced along with preliminary biological data indicating their in vitro activity against Escherichia and 3. aeruginosa strains which inactivate the parent antibiotics by 3'-0-
100
Sect. I l l
-
Chemotherapeutic Agents
Butler, Ed.
phosphorylation. Among new naturally occurring aminoglycosides, structures were proposed for b u t i r ~ s i n s ~A(k) ~ - ~ ~and B(1b) and lividomycins A(2a)27928 and B(2b) .29 The butirosins, which were isolated from a bacterial fermentation, represent the first reported examples of aminoglycosides containing an N-acylated-2-deoxystreptamine moiety; an account of their biological profiles has not been reported. The lividomycin structures revealed their chemical immunity to enzymatic inactivation by 3'-O-phosphorylation, but 0-phosphorylative inactivation of lividomycin A by strains of g.aeruginosa has been observed3' and apparently occurs at a site other than the 3'-position.
L
HOCHp
Y Rl
NH
'4
OH
k0
I
R, OH
Enzymatic inactivation of gentam' in by cell-free extracts from clinical isolates of g. aeruginosa31,35 and R-factor carrying Klebsiella pneumoniae33~34was described. The mechanism of this pseudomonas resistance to gentamicin was established by showing that acetylation occurs on the +amino group of the 2-deoxystreptamine ring.32 All gentamicin C components and sisomicin were reported to be excellent substrates €or the inactivating enzyme gentamicin acetyltransferase, whereas tobramycin and kanamycin B proved to be poor substrates. A number of gentamicin-resistant aeruginosa from various parts tobramycin-sensitive clinical isolates of of the world have been studied and claimed to contain gentamicin acetyltransferase.32 The klebsiella resistance to gentamicin was
a.
Chap. 10
Antibiotics
Sciavol ino
101 -
reported to occur adenylylation and further the presence of an Rfactor which mediates gentamicin resistance in these klebsiella strains was demonstrated by transfer of this resistance in vitro to E. coli recipients subsequently designated E. & JR66lW677 and M L l ~ l O ~33o,34 A tentative structure for gentamicin C1 adenylate has been pr~posed.~' E. coli JR661W677 has also been shown to adenylylate 3',4'-dideoxykanam y c D 6 and the structure of the inactivated product established as 3 ' ,4'-dideoxykanamycin B-2"-adenylate. 37 A report presenting clinical and laboratory evid nce for the inactivation o.fOgentamicin by carbenicillin appeared.38 However, chemical ,39 kinetic and clinica141 data was published indicating that although gentamicin and carbenicillin can mutually inactivate each other, the reaction requires conditions that are not present in most patients requiring these agents.
Spectinomycin became available in the U.S. for single dose treatment of acute gonorrheal infections; clinical studies indicate IM administration of 2.0 or 4.0 g of spectin m in results in cure rates of over 90% in males and 96% in females.49J3 Ansamycins - Rifampicin became available in the U.S. during 1971 for use in the treatment of tuberculosis. Reviews containing discussions of clinical findings ntimicrobial activity and pharmacology of rifampicin were pubThrombocytopenia, apparently arising an immunological lished.44* mechanism, has been reported as a potentially serious side ef ct resulting from high-dose (1200 mg) twice-weekly rifampicin therapy .Eg The structure of streptovaricin C wt~,igvisedin accord with results of new 49 periodate oxidation experiments and X-ray crystallographic studies. Gross structures for six other naturally occurring streptovaricins were proposed.50 The antiviral properties of the ansamycins are discussed in Chapter 12.
''
+
6-Lactams - Announcements of the discoveries of four novel naturally occurring cephalossprf,i C variants highlighted the year's developments in B-lactam research. The new cephalosporins are uniquely substituted at positions C3 and/or C7 (cf. Table I) and were isolated from Streptomyces fermentations. In general, biological profiles suggest 7methoxycephalosporins are more active than cephalosporin C against most gram-negative bacteria, but show poor activity against g.aeruginosa; they are essentially inactive against penicillin-resistant staphylococci. An elegant tranacylation process for cleaving the aminoadipoyl moiety of 5 with simultaneous introduction of new acyl side chains was reported.55 Synthetic routes to 7-methoxycephalosporins and 6-methoxypenicillins which depart from benzhydryl 7-diazocephalos oranate and benzyl 6-diazopenicillinate, respectively, were described.g6 In related work, 7amethyl-7-phenoxyacetamido cephalosporanic acid and methyl 6amethylbenzylpenicillinate were synthesized as close mimics of the 2-alanyl-g-alanine end of acetylmuramylpentapeptide, but were reported to be substantiall less active than the parent compounds against gram-postive organisms.57
102 -
Sect. I l l
-
Chemotherapeutic Agents
TABLE
-3
Butler, Ed.
I
= Cephamycin A
I
OCH3
4 =
Cephomycin 6
5 =
Cephomycin C (A168868) =
-NH2
& = A16884 Cephalexin (KeflexR ) has proven to be safe and effective in treating commonly encountered in general practice.58 It a variety is reported that successful therapy of urinary tract infections with cephaloglycin (KafocinR) must be mainly attributed to the antibacterial activity of its metabolite desacetylcephaloglycin which is 4-8 times leas active against gram-negative bacilli than cephaloglycin itself. Orally administered acetoxymethyl and pivaloyloxymethyl esters of cephaloglycin were reported to be enzymatically cleaved following absorption from the gastro-intestinal tract and to affor higher blood and urine levels than an equivalent dose of cephaloglycin." Cephapirin (BL-Pl322) ( I ) ,a parenteral ce halosporin, has antibacterial activity equivalent to of 1 g of cephapirin sodium gave serum c e p h a l ~ t h i n . ~ ~IM - ~injection ~ ;61 an 88% levels of 7.2-25 y/ml and urine concentra ions of 1-2.5 mg cure rate was reported for urinary tract6' and respiratory6"infections caused by susceptible organisms. Less pain and phlebitis following i.v. administration is reported to be the mt4or advantage of cephapirin over cephalothin.61 BL-S217 (8) is claimed to be 20 times more effective than cephalothin against Streptococcus pyogenes and Diplococcus pneumoniae infection. infections in mice and 3-4 times more efficacious in an E. ubstitutedStructure-activity relationships among a group of 7-[a-(N,N' amidinothi0)-acetamido cephalosporanic acids were described.3
offinfections
Chap, 10
Antibiotics
S c i a v o l ino
103
Among semi-synthetic penicillins, BL-Pl597 (2)and BL-P1654 were reported to be more active than carbenicillin against Pseudomonas, inhibiting 90% of 150 isolates at 12.5 y/ml; conversely, carbenicillin was more active than both compounds against indole-positive p r ~ t e u s . ~Sulfo~ cillin was reported to have essentially the same in vitro spectrum and potency as carbenicillin.68
-8 . R
Orally administered indanyl carbenicillin (10)is absorbed and hydrolyzed in animals and man to provide carbenicillin activity generally equivalent to parenteral ~arbenicillin;~~ the metabolism of 10 in rats, dogs and humans was reported.70 Satisfactory clinical results have been reported for indanyl carbenicillin therapy f rinary tract infections caused by Pseudomonas and Proteus species.7p-7y Results of a multi-center clinical evaluation of epicillin indicate this orally active ampicillin congener was generally effective in 84% of 683 patients with respiratory, gastro-intestinal or soft-tissue infections caused by a variet ampicillin-sensitive gram-positive and gram-negative bacteria.Y40f Chemical properties of penicillin polymers derived from ampicillin, 6-APA and benzylpenicillin on standing in aqueous solution were described.75 These polymers have been s own to combine covalently with An enzymatic synthesis of protein and to elicit immune ampicillin from 6-APA and various phenylglq5ine esters in the presence of Kluyvera citrophila KY-3641 was described. Evidence has been published be suggesting that the physiological effects of penicillin on E. &may due to interaction with at least two specific targets, both of which are
response^.^'
104 -
Sect. I l l
-
Chemotherapeutic Agents
Butler, Ed.
enzymes. 78 The application of multiparameter regression analysis techniques to the design of semisynthetic penicillins was discussed at length.79 A monograph concerned mainly with chemical reactions and physiologi681 properties of natural and synthetic 6-lactams was published. LincomycinlClindamycin - The clinical efficacy of clindamycin81 and lincomycinBL against infections caused by nonspore-forming anaerobic bacteria was announced. Clindamycin was reported to inhibit 96% of 257 Bacteroides clinical isolates at 3.1 y/ml or less.83 A quantitative structure-activity study among lincomycin/clindamycin analogs suggests that the relative potency of members of these two sets of compounds depends only on the lipophilic nature of the pyrrolidine ring and not that of the molecule as a whole.84 Relative enzymatic hydrolysis rates for different positional and structural esters of lincomycin in dog serum and simulated intestinal fluid were determined as part of a search for a lincomycin congener with superior pharmaceutical and kinetic properties; -in vivo activity correlated with hydrolysis rates but no gross differences in esterase specificity were observed between dog serum and s 8:8.1' and ed intestinal fluid.85 Microbial transformations of clindamycin& N-demethylclindamycin88 by Streptomyces species, in general, lead to prodrug forms of the parent antibiotics.
-
Macrolides Stereochemical problems in the macrolide area were reviewed in depth.-Structures and interrelationships between the leucomycins, maridomycins, espinomycins,SF-837 and YL-704 macrolides were summarized.90 Two reports on syntheses of erythromycylamine indicate the 9-aminoerythromycin con ener can now be conveniently prepared in kilogram quantiA series of chalcomycin analogs were described several of which demonstrated in vitro and in viva activity against staphylococci comparable to the parent antibioticT3 Narbomycin aglycone, narbonolide , was isolated from a Streptomyces fermentation and its biogenetic relationship to narbomycin and picromycin established .94
tie^.^^,'^
Peptide antibiotics were reviewed with respect to biosynthesisg5 and the relationships between primary structure, conformation and antibacterial activity.96 The elusive structure of viomycin was further resolved.97 However, some doubt concerning the peptide sequence remains owing to an X-ray structure determination on closely related antibiotic tuberactinomycin 0 . 9 8 The 65lationship between viomycin and capreomycins 1 A and 1B was established. Tuberactinomycin N was reported to be as active as viomycin against experimental tuberculosis infections in mice and less ototoxic than both viomycin and capreomycin in guinea-pigs. loo The structure ofOfegamycin, a novel broad-spectrum hydrazide antibiotic, was solid-phase determined. An improved synthesis of gramicidin S synthesis and azide cyclization was carried out in 43-51% overall yield.Io2
-
Tetracyclines The disposition of doxycycline by man, dog and rats was investigated.103~104 Results in dog and rats indicate doxycycline passes relatively easily through the intestinal wall and is less
Chap. 10
Antibiotics
105
Sciavol ino
dependent upon normal r e n a l f u n c t i o n € o r i t s e l i m i n a t i o n t h a n o t h e r t e t r a c y c l i n e s of lesser l i p o p h i l i c i t y ; t h e s e f i n d i n g s are c i t e d t o h e l p explain t h e c l i n i c a l observation t h a t doxycycline u n l i k e o t h e r tetrac y c l i n e s does n o t accumulate i n p a t i e n t s w i t h r e n a l i n s u f f i c i e n c y ,105*106 Reports on s t r u c t u r e a c t i v i t y r e l a t i o n s h i p s among t e t r a c y c l i n e a n t i b i d e r i v e d by quantum mechanical c a l c u l a t i o n s 1 0 7 and m i c r o b i a l k i n e t i c s were d e s c r i b e d . An improved s y n t h e s i s of minocycline 4MinocinR) u t i l i z i n g 9-nitro-6-demethyl-6-deoxytetracycline w a s r e p o r t e d , 10
18biCs
References
1.
-
A D i s c u s s i o n of P e n i c i l l i n and R e l a t e d A n t i b i o t i c s P a s t , Present and F u t u r e , E. Chain and J . S t o k e s , O r g a n i z e r s , London, May 20-21, 1971. P r o c . R. Soc. Lond. B., a) T. R. C a r r i n g t o n , 321; b ) D. H. R. B a r t o n and P. G. Sammes, 345; c ) J . L. S t r o m i n g e r , P. M. Blumberg, H. Suginaka, J. Umbreit and G. G. Wickus, 369; d ) G. N . R o l i n s o n , 403; e ) S . S h a l t i e l , R. M i z r a h i and M. S e l a . 411 (1971); f ) C l i n i c a l p a p e r s , J . Roy: C o l l . Phys. Lond. NO, 2
179;
5,
2. 3. 4.
(1972). J . P. Hou and J . W. P o o l e , J . Pharm. S c i . , 60, 503 (1971). R. B. Morin and B. G. J a c k s o n , F o r t s c h r . Chemie Org. N a t u r s t . , 28, 343 (1970). Second I n t e r n a t i o n a l Symposium on Gentamicin, An Aminoglycoside A n t i b i o t i c , U n i v e r s i t y of C a l i f o r n i a , School of Medicine, Los Angeles, C a l i f o r n i a , January 25-26, 1971; J . I n f e c t . D i s . , Supp. (1971). B. J . Magerlein, Advan. Appl. M i c r o b i o l . , 185 (1971) “Drug Action and Drug Resistance i n Bacteria, 1. Macrolide A n t i b i o t i c s and Lincomycin,” S . M i t s u h a s h i , Ed., U n i v e r s i t y P a r k Press, B a l t i m o r e , Md., 1971. K. L. R i n e h a r t , J r . , Accounts. Chem. R e s . , 5, 57 (1972). D. H. R. B a r t o n and P. D . Magnus, J . Chem. SOC. (C), 2164 (1971). T. J . F r a n k l i n and G . A. Snow, “Biochemistry of A n t i m i c r o b i a l Action,’‘ Academic P r e s s , N.Y., N . Y . , 1971. M. M. Dhar and A. W . Khan, N a t u r e , 233, 182 (1971). Symposium on A n t i b i o t i c s , S t e M a r g u e r i t e , Quebec, Canada, March 1-3, 1971; P u r e Appl, Chem., 28, 399 (1971). A b s t r a c t s , E l e v e n t h I n t e r s c i e n c e Conference on A n t i m i c r o b i a l Agents and Chemotherapy, A t l a n t i c C i t y , N . J . Oct. 19-22, 1971; N . Moreland, M. B . Pearson and T . W. W i l l i a m s , J r . , p . 42. R. D. Meyer, L. S . Young and D . A m s t r o n g , Appl. M i c r o b i o l . , 22, 1147 (1971). W. H. Traub and E. A . Raymond, E., 23, 4 (1972). J . D i e n s t a g and H. C . Neu, Antimicrob. Ag. Chemother., 1,4 1 (1972). D. J. Cooper, M. D. Yudis, R. D. G u t h r i e and A . M. P r i o r , J . Chem. SOC* (C), 960, (1971). D. J. Cooper, M. D. Yudis, H. M. M a r i g l i a n o and T . T r a u b e l , 2876 (1971). D. J. Cooper, P . .I.L. D a n i e l s , M. D. Yudis, H. M . M a r i g l i a n o , R. D. G u t h r i e and S. T. K. Bukhari, 3126 (1971).
124,
5. 6.
7. 8. 9.
10. 11 * 12. 13.
14. 15. 16. 17. 18.
14,
w.,
m.,
106 19 20. 21. 22. 23. 24. 25.
26. 27. 28. 29.
30. 31. 32. 33. 34. 35. 36. 37.
38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50.
Sect. I I I
-
B u t l e r , Ed.
Chemotherapeutic Agents
D. J . Cooper, R. S. Jaret and H. Reimann, Chem. Comm., 285 (1971). H . Reimann, R. S . Jaret and D. J . Cooper, 924 (1971). S. Umezawa, T . Tsuchiya, R . Muto, Y. Nishimura and H . Umezawa, J . A n t i b i o t i c s (Tokyo), 274 (1971). H. Umezawa, S. Umezawa, T , Tsuchiya and Y. Okazaki, 485 (197l). 711 S, Umezawa, T . Tsuchiya, T . J i k i h a r a , and H. Umezawa, (1971). P . W. K. Woo, H. W. Dion and Q. R. B a r t z , T e t r a h e d r o n L e t t . 2617 (1971). P. W . K. Woo, 2621 (1971). P. W. K. Woo, H. W. Dion and Q. R. B a r t z , 2625 (1971). T. Oda, T. Mori and Y. Kyotani, J . A n t i b i o t i c s (Tokyo), 3, 503 (1971) T. Oda, T , Mori, Y. Kyotani and M. Nakayama, 511 (1971). T. Mori, Y. Kyotani, I. Watanabe and T. Oda, 25, 149 (1972). F. Kobayashi, M. Yamaguchi and S. M i t s u h a s h i , Antimicrob. Ag. Chemother., 1 7 (1972). S. M i t s u h a s h i , F. Kobayashi and M. Yamaguchi, J . A n t i b i o t i c s (Tokyo), 24, 400 (1971) M. B r z e z i n s k a , R. B e n v e n i s t e , J . Davies, P . J . L. D a n i e l s and J. W e i n s t e i n , Biochemistry, 761 (1972). F. Kobayashi, M. Yamaguchi, J . Eda, F. H i g a s h i and S . M i t s u h a s h i , J . A n t i b i o t i c s (Tokyo), 3, 719 (1971). R. B e n v e n i s t e and J . Davies, Febs L e t t . 293 (1971). F. LeGoffic, M. Chevereau and J . TrbfouEl, Compt. Rend. (C) , 274 535 (1972). M. Yagisawa, H. Naganawa, S. Kondo, N. Hamada, T. Takeuchi and H. Umezawa, J . A n t i b i o t i c s (Tokyo), 24, 911 (1971). H . Naganawa, M. Yagisawa, S . Kondo, T. Takeuchi and H. U m e z a w a , w . , 914 (1971). J. E. McLaughlin and D. S. Reeves, Lancet, I , 261 (1971). J . A. Waitz, C. G. Drube, E . L. Moss, J r . , E . M. Oden, J. B a i l e y and G. H . Wagman (Ref. 12) p. 66. L. R i f f and G. G. J a c k s o n , p . 65. P. Noone and J . R. P a t t i s o n , Lancet, 11, 575 (1971). W . R. Holder, D. P. R o b e r t s , W. C. Duncan and J , M. Knox (Ref. 12) p. 48. K. K. Holmes, A. H . B. Pedersen, P . J . Wiesner, L . T . Gutman and D. M. Bear, M.,p . 49. G. Binda, E. Domenichini, A. G o t t a r d i , B. O r l a n d i , E . O r t e l l i , B. P a c i n i , and G. Fowst, Arzneim. F o r s c h . , 21, 1907 (1971). 354 (1971). Anonymous, Drugs, G. P o o l e , P. S t r a d l i n g and S . Worlledge, B r i t . Med. J . 2, 343 (1971). K. S a s a k i . K. L. R i n e h a r t , J r . , F. J. h t o s z , J . A n t i b i o t i c s (Tokyo), 25, 68 (1972). K. L . R i n e h a r t , J r . , and F. J . Antosz, 7 1 (1972). A. H . J . Wang, I . C. P a u l , K. L. R i n e h a r t , J r . , and F . J . Antosz, J . Am. Chem. SOC., 93, 6275 (1971). K. L. R i n e h a r t , J r . , M. L. Maheshwari, F. J . Antosz, H. H . Mathur, K. S a s a k i and R . J . S c h a c h t , 6273 (1971).
u.,
24,
u., w,
-.,
w.,
m., m.,
L,
-
11,
14,
u.,
L,
-
u.,
u.,
Chap. 10
51. 52. 53. 54.
Antibiotics
Sciavol i n o
107
R. Nagarajan, L. D. Boeck, M. Gorman, R. L. H a m i l l , C . E . Higgens, M. M. Hoehn, W. M. S t a r k and J . G . Whitney, 2308 (1971). R. L. H a m i l l , C . B. Carrell, M. M. Hoehn, W. M. S t a r k , L . D. Boeck and M. Gorman (Ref. 1 2 ) p. 7. M. Gorman, M. M. Hoehn, R. Nagarajan, L. D. Boeck, E. A. P r e s t i , J . G. Whitney and R. L. H a m i l l , p. 7. E. 0. S t a p l e y , D . Hendlin, S . Hernandez, M. Jackson, J . M. Mata, A. K. Miller, H. B. Woodruff, T . W . Miller, R. T . Goegelman, R. G. Weston, I . P u t t e r , F. J . Wolf, G . Albers-Schonberg, B . H . Arison and J . L . Smith, p . 8. S. Karady, S. H . P i n e s , L. M. Weinstock, F. E . R o b e r t s , G. S . Brenner, A. M. Hoinowski, T. Y . Cheng and M. S l e t z i n g e r , J . Am. Soc., 2, 1410 (1972). L. D. Cama, W . J . Leanza, T . R. Beattie and B . G . C h r i s t e n s e n , -*i b i d ' 1408 (1972). E. H. W. Bohme, H. E. Applegate, B. T o e p l i t z , J . E . D o l f i n i and J . Z. Gougoutas, 93, 4324 (1971). J. E. Murphy, P r a c t i t i o n e r , 392 (1971). W. E. Wick, W. E. Wright and H . V . Kuder, Appl. M i c r o b i o l . , 21,
s.,
w.,
w.,
55. 56. 57. 58. 59.
w.,
206,
426 (1971). E. Binderup, W. 0. G o d t f r e d s e n , and K , R o h o l t , J . A n t i b i o t i c s (Tokyo), 24, 767 (1971). 61. J. L. Bran, M. E. Levison and D. Kaye, Antimicrob. Ag. Chemother., -1 35 (1972). 62. R. C. Gordon, F. F. Barrett, D. J . C l a r k and M. D . Yow, C u r r . Ther. R e s . , 13,398 (1971). 63. J, Axelrod, B. R. Meyers and S . Z . Hirschman, Appl. M i c r o b i o l . , 22, 904 (1971). 64. C. E. Cox and W. W. King (Ref. 12) p. 33. 65. R. E. Buck, F. L e i t n e r and K . E. P r i c e , Antimicrob. Ag. Chemother. -1, 67 (1972). 66. M. M i s i e k , T. A . P u r s i a n o , L. B. Crast, F. L e i t n e r and K . E . P r i c e , i b i d ' 54 (1972). 67. G. P . Bodey and D. S t e w a r t , Appl. M i c r o b i o l . , 2, 710 (1971). 68. K. T s u c h i y a , T . O i s h l , C. I w a g i s h i and T . I w a h i , J . A n t i b i o t i c s (Tokyo), 24, 607 (1971). 69. ( a ) A. R. E n g l i s h , J . A. Retsema, V . A. Ray and J . E . Lynch, (Ref. 12), p. 84; (b) K. B u t l e r , A. R . E n g l i s h , A. K. Knirsch and J . J . K o r s t , Delaware Med. J . , 43, 366 (1971). p . 43. 70. D. C. Hobbs, 71. G. R. Hodges and R. L . P e r k i n s , p . 32. 72. C. E. Cox, p . 33, 73. J. L. Bran, D. M. Karl and D. Kaye, C l i n . Pharmacol. T h e r . , 12, 525 (1971). 74. J. E. Beck, J . A. Hubsher and D. L . Caloza, C u r r . Thera. R e s . , 13, 530 (1971). 75. H. Smith and A. C. M a r s h a l l , N a t u r e , 232, 45 (1971). 76. A. C. Munro, J . M. Dewdney, H . Smith and A. W. Wheeler, J . Immun. 1971; i n p r e s s . 77. T. Nara, R. Okachi and M. Misawa, J . A n t i b i o t i c (Tokyo), 24, 321 (1971). 60.
w.,
m.,
w.,
108 78.
79. 80
81. 82. 83. 84. 85.
86. 87. 88. 89. 90.
91. 92. 93. 94.
Sect, I l l
-
B u t l e r , Ed.
Chemotherapeutic A g e n t s
235,
R. Hartmann, J . V. Haltje and U. Schwarz, Nature, 426 (1972). A. E. Bird and J . H. C. Nayler i n "Drug Design," Vol. 11, E. J . AriOns, Ed., Academic P r e s s , New York, N. Y . , 1 9 7 1 , Chap. 8. M. S. Manhas and A. K. Bose, "$-Lactams N a t u r a l and S y n t h e t i c , ' ' P a r t I , Wiley-Interscience, New York, N. Y., 1971, R. M. Swenson, T. Michaelson and E . H . Spaulding, (Ref. 12) p. 50. J . G. B a r t l e t t and S. M. Finegold, p. 51. W. J . Martin, M. Gardner and J . A. Washington 11, Antimicrob. Ag. Chemother., 1,148 (1972). Y. C. Martin and K . R. Lynn, J . Med. Chem., 2,1162 (1971). M. J . Taraezka, J . Pharm. S c i . , 60, 1414 (1971). J. H. Coats and A. D. Argoudelis, J . B a c t e r i o l . , 459 (1971). A. D. Argoudelis and J . H. Coats, .I.Am. Chem. SOC., 93, 534 (1971). A. D. Argoudelis, R. D. Birkenmeyer, J. H. Coats and B. J . Magerlein, (Ref. 1 2 1 , p. 1 0 . W. D. C e l m e r , P u r e Appl. Chem., 413 (1971). Y . Yagieawa, J a p . Med. Gaz., 9, No. 2 (1972). G. H. T i m and E. Wildsmith, Tetrahedron L e t t . , 195 (1971). E. Wildsmith, M., 29 (1972). R. D. Westland and T . H. H a s k e l l , A b s t r a c t , 162nd N a t i o n a l Meeting of t h e American Chemical S o c i e t y , Washington, D . C . , S e p t . 13-17, 1971; MEDI-48. T. H o r i , I . Maezawa, N. Nagahama and M. Suzuki, Chem. Conrm., 304
u.,
108,
2,
(19 71)
.
D. Perlman and M. Bodanszky, Ann, Rev. Biochem., 40, 449 (1971). C. Toniolo, Famaco. Ed. S c i , , 26, 741 (1971). B. W. B y c r o f t , D. Cameron, L. R. C r o f t , A. Hassanali-Walji, A. W . Johnson and T. Webb, E x p e r i e n t i a , 27, 501 (1971). 98. H. Yoshioka, T. Aoki, H. Goko, K. Nakatsu, T. Noda, H . Sakakibara, T. Take, A. Nagata, J. Abe, T . Wakamiya, T . Shiba and T . Kaneko, Tetrahedron L e t t . , 2043 (1971). 99. B. W. B y c r o f t , D. Cameron, L. R. C r o f t , A. Hassanali-Walji, A. W. Johnson and T. Webb, Nature, 231, 301 (1971). 100. T. Ando, K, Matsuura, R. Izumi, T. Noda, T . Take, A. Nagata and J . Abe, J . A n t i b i o t i c s (Tokyo), 24, 680 (1971). 101. S. Kondo, S . S h i b a h a r a , S. Takahashi, K. Maeda, H . Umezawa and M. Ohno, J , Am. Chem. SOC., 93, 6305 (1971). 102. M. Ohno, K. Kuromizu, H. Ogawa and N . Izumiya, 5251 (1971). 103. M, Schach von Wittenau and T. M. Twomey, Chemotherapy, l6, 217 (1971). 104. M. Schach von Wittenau, T. M. Twomey and A. C. S w i n d e l l , 26 (1971). 105. C. Revaz, B. Goldenberg and H. A c h t a r i , Schweiz. Med. Wschr., 101, 1 2 7 (1971). 106. R. B. S c o t t , J. S. Cameron, C. S . Ogg and P . Toseland, Lancet, 11, 95. 96. 97.
w.,
E. 17, ,
-
1378 (1971). 107. 108, 109.
F. P e r a d e j o r d i , A. N. Martin and A. Cammarata, J . Pharm. S c i . , 60, 576 (1971). G. H. M i l l e r , S . A. K h a l i l and A. N . Martin, 60, 33 (1971). R. F. R. Church, R. E. Schaub and M. J . Weiss, J . Org. Chem., 36, 723 (1971).
m.,
Chapter 11.
Antifungal Agents
J. Allan Waitz, C. 0 . Drube Schering Corporation, Bloomfield, New Jersey
-
A review of the treatment of mycoses by use of Reviews antibiotics including griseofulvin, nystatin, amphotericin B, pimaricin, 5 -fluoro-cytosine, trichomycin, cycloheximide, clotrimazole and miconazole, also covers the source of the antibiotic, chemistry, in vitro effects, clinical dosages, A recent text,2 together with indications and side effects.l while not specifically related to antifungal agents presents aspects of mycology, of preservation techniques and detailed descriptions of methods related t o diagnosis and culture of dermatophytes and subcutaneous and deep seated mycoses.
-
A new animal model for acute oral candidiasis i n Methods rats may provide an additional system for the preclinical evaluation of new antifungal agents.= Experimentally induced blastomycosis and histoplasmosis tend to mimic natural infecUse of tions and are susceptible t o amphotericin B therapy.* analogue-resistant mutants t o increase levels of end products, has been directed towards biosynthesis of pyrrolnitrins Strains were utilized which were resistant t o 5-fluorotryptophane and 6-fluoro-tryptophane. These studies suggest a possible biosynthetic pathway far pyrrolnitrin i n which D-tryptophane and reduced pyrrolnitrin are intermediates; 3-chloroindole appears to be a by-product since it markedly inhibits pyrrolnitrin synthesis.5 The currently used procedure of cutting out antibiotic producing colonies from the agar i n plugs, and placing them onto bioassay plates has been modified for kasugamycin producing strains. In the "agar piece method" the colonies are cut out prior t o heavy growth, preventing extensive antibiotic diffusion.6
.'
f3-Alanine has been shown to increase the yield of antifungal antibiotic AYF produced by Streptomyces aureofaciens. 7 W light and X-ray generate low-producing mutants as well as high producing mutants of Streptomyces nigrifaciens, with reference t o antifungal production.8 mystatin has been successfully used in the selection of amino acid auxotrophs of Saccharomyces.s Neutron activation analysis for determination of chlorine has been utilized for an assay of griseofulvin i n capsules and in tablet f o r m a l o
-
Intravenous administration of amphoterClinical Experience icin B continues t o be the mpjor therapy for the treatment of systemic mycoses. nebulization of amphotericin B was used t o avoid some aspects of toxicity associated with intravenous use. Nebulization produced an aerosol with 80-90$ of the drug
110
Sect. I l l
-
Butler, Ed.
Chemotherapeutic Agents
particles smaller than 8 microns, a diameter which should be retained in the peripheral bronchi. The successful treatment of 4 patients with coccidioidomycosis by this method, without toxicity, is reported.11 Extracorporeal dialysis has been successful in extracting amphotericin B after intravenous administration in dogs, and in 3 patients with acute renal insufficiency.12 The successful treatment of a case of primary aspergilloma of the cheek due to Aspergillus flavus with intravenous amphotericin B has been reported.13 Rapid intravenous infusion of amphotericin B has been shown to produce higher peak serum levels of amphotericin than slow intravenous infusion, without greater t0xi~ity.l~ The enhancement of fungal keratitis seen with steroid anti-inflammatory agents was not observed in experimental Aspergillus keratitis of the cornea in rabbits when low levels of dexamethasone were combined with pimaricin. It appears that this topical combination may be effective and also avoid the aggravation of fungal keratitis observed with the steroids Pimaricin topically, in combination with the antitrichomonal agent metronidazole orally, appears useful in the elimination of Trichomonas and prevention of the Candida overgrowth which frequently follows antitrichomonal therapy.ls Topical pimaricin therapy of Candida vaginal infections and mixed Candida and Trichomonas infections yielded satisfactory results in approximately 805 of 286 women.17 Several additional clinical reports have appeared on the use of 5-fluorocytosine. The successful therapy of Cryptococcus meningoencephalitis when the drug was given at a level -rams per day for 45 days has been reported. Relapse occurred after withdrawal of the drug; cultures became positive and additional therapy was judged unsuccessful.1* Several other documented relapses while patients are under therapy with 5-fluoro-cytosine for cryptococcal meningitis have been described,” and, in some cases have been attributed to development of resistance during therapy. Oral doses of 2 to 5 grams a day of 5-fluorocytosine have been successful in reducing urinary counts of Candida in some instances, and have apparently eliminated urinary candidiasis in other cases.20 Serum binding of 5-fluorocytosine w a s calculated to be approximately 50%; however the fungicidal effect of 5-fluorocytosine on Candida was enhanced in vitro by the addition of serum to the media. Urine appeared to inhibit the in vitro action of 5 -fluorocytosine.2 O
--
--
Clotrimazole (Bay b 5097) has been the object of additional clinical and laboratory evaluation. In children with C. albicans pyelonephritis who were dosed at a level of 70-200 m g / m o r 10 t o 40 days, good response was noted in all patients although relapses frequently occurred after the
Chap. 1 1
Waitz, Drube
A n t i f u n g a l Agents
111 -
cessation of therapy.21 Contrary to initial reports, a recent study found a number o f z . albicans strains which were not sensitive to obtainable serum levels of clotrimazole.22 Further investigations have shown Candida to be more sensitive -in vitro than Cryptococcus.23 The in vitro activity of clotrimazole against Blastomyces, Histoplasma, Sporothrix, Cryptococcus and Coccidioides was shown to be comparable to amphotericin B, while its activity against Candida and Aspergillus was less than that of amphotericin B, Against dermatophytes clotrimazole had activity comparable to pyrrolnitrin2’ but less than tolnaftate2’ and greater than that of griseofulvin.24’25 Some in vitro activity against In gram-positive bacteria has also been demonstrated.25 guinea pigs experimentally infected with Trichophyton mentagrophytes, topical therapy with clotrimazole wa8 less successful than with tolnaftate; oral therapy gave results similar to that seen with gri~eofulvin,~’ In experimental infections in mice infected with Aspergillus, Blastomyces or Candida, therapy with clotrimazole was unsuccessful, however some protection was obtained in Cryptococcus and Coccidioides infections at high oral dose regimens.26 A drug induced mechanism for in vivo drug inactivation has been
--
--
Thiabendazole, at 25 mg/kg/day orally for 1.5 -22 months, appeared successful in 1/3 of 14 patients with chromomycosis. However, hypersensitivity reactions manifested by elevated serum bilirubin and transaminase levels developed in several patients.27 Griseofulvin continues to be the main oral therapy for a number of dermatophyte infections, and attempts to improve the speed and degree of absorption of griseofulvin following oral administration have continued. Dispersions of griseofulvin in a solid matrix of polyethylene glycol 6000, was demonstrated to lead to higher serum levels in man than those obtained with commercial micronized griseofulvin.2B The vasodilator effect of griseofulvin has been utilized in the treatment of Raynaud’s Phenomenon.29930 The use of dimethyl sulfoxide as a vehicle for griseofulvin has been shown to increase the penetration of griseofulvin into the subkeratinous tissue. Topical therapy with griseofulvin in DMSO was successful in 10 cats with Microsporum canise3’ Miconazole nitrate. previously shown to be effective in topical treatment of Trikhophyton infections, was effective when used topically for 1 to 3 weeks as a 2 % cream in 44 of 46 cases of Candida vaginitis, bbt it was without effect in 2 cases of vaginal Torulopsis glabrata.32
-
Tetranactin, a new macrotetrolid antiNew Antifungal Agents biotic similar to nonactin and produced by a strain of Strep-
112 -
Sect. I l l
-
Chemotherapeutic Agents
B u t l e r , Ed.
tomyces aureus shows i n vitro activity against some fungi and gram-positive bacteria as well as insecticidal activity. The Flavomycoin acute toxicity of tetranactin i n mice is is a new polyene antifungal, isolated from Streptomyces roseoflavus, containing a pentaene system in conjugation with a lactone carbonyl group. It has the partial formula, 1.34'35
'\CH-
I
Tetramycin variety of 34HS 3O14N yeasts and tetramycin
-
CH-CHs I
CHz -CH
I
is another new polyene antifungal produced by a Streptomyces noursei; it has an empirical formula and good in vitro activity against a variety of filamentous fungi. The acute intravenous L D 5 0 of in mice is 50 mg/kge3'
Three new antibiotics related t o phleomycin and bleomyc i n have been isolated from fermentations of' S t r e o t o m m e s bikiniensis variety zorbonensis These products hav; in-vitro activity against gram-positive and gram-negative bacteria as well as-various fungi.- The empirical formulae for the antibiotics are: zorbomycin, CS6H1 00N28024S2C~; zorbonomycin B, C HB 8O S2 C u ; z orb onomyc in C has not b ee n c omple t e ly A new antibiotic, characterized but also contains 24010, possible related t o tunicamycin has activity against a variety of phytopathogenic fungi, Candid8 and Saccharomyces.~8
.
,
Prumycin, has an empirical formula C ~ H l s N ~ 0 5it ; is a new water soluble, basic antibiotic active against some bacteria and fungi and it is produced by a strain of Streptornyces.3s Tunicamycin is a new antibiotic isolated from Streptomyces lysosuperificus which has activity against animal and plant viruses and gram-positive bacteria as well as yeasts and fungi.40 Hikizimycin, produced by a new Streptomyces strain has some antibacterial as well as antifungal activity and appears to be the first example of an antibiotic with cytosine and kanosamine as s ~ b s t i t u e n t s . 4 ~ Cladosporin, 2, is a new antifungal metabolite produced by Cladosporium cladosporioides; it has modest in vitro activity against a variety of' derma-
Chap. 1 1
tophytes
Antifungal Agents
OH
Waitz, Drube
0
HO Amongst a series of semi-synthetic $-lactam compounds, the cephalosporin derivative, 2, and the penicillin derivatives, k,z, showed unexpected antifungal activity i n vitro; compound 3 was ineffective, however, in an experimental systemic Cryptococcus neoformans infection i n S
4 R'
= CsHsOCH(CH3)CO;R"
-5 R'
= C6HsOCH2CO; R" = CHO
= COSK
k, 5 A series of substituted carbamate esters (6-14), have in vitro
R
-6 7
RS02
NHC02Ar
CH3 CH3 2HS
Ar
2,4,6 -tricholorophenyl pent ac hlor op henyl pentachlorophenyl pentachlorophenyl pentachlorophenyl pentachlorophenyl pentachlor ophenyl pent ac hlor op henyl pentachlorophenyl
1 I4 -
Sect.
Ill
-
B u t l e r , Ed.
Chemotherapeutic Agents
activity against C. albicans and Aspergillus niger. The most actibe were 9 and &. The corresponding trichlorophenyl A series of derivatives of 8, 10, 3 2 , 2 were inactive.44 griseofulvin analozes, derived from transformation of 5'formyl griseofulvin, 15 through 24, have good in vitro activity against a number of dermatophytes; 24 was more active 0
CH30
OCH3
R =
cH3
c1 24 -
-in vitro
than griseofulvin. All were without activity in considerably 1 ~ 9 sactive than griseofulvin a g a i n z M. canis in guinea pigs. A series of unsymetrical caTbonyl disulfides, RC (O)SSR', were tested vitro against Histoplasma capsulatum; the most active were those where both R and R' were short unbranched alkyl or unsubstituted phenyl moieties. No meaningful in vivo activity was observed in the series.*' In a large series of thiosemicarbazones and 4-substituted thiosemicarbazones made from through 30, have interesting heterocyclic aldehydes, vitro activity.47 X Y R
vivo except 20 which was
--
a
H
kx
CHoNNHCSNHR
I
Y
-
Chemical and Physical Studies of Antifungal Agents The previous total synthesis of antimycin A3 provided a diasteriomeric mixture. A total synthesis of natural antimycin A2 has
Chap. 1 1
A n t i f u n g a l Agents
W a i t z , Drube
115
now b e e n r e p o r t e d . 4 8 The s t r u c t u r e s of t h e a u t o o x i d a t i o n p r o d u c t s of f i l i p i n and l a g o s i n have been shown t o b e t h e . 4 9 The p o l y e n e s c o r r e s p o n d i n g t e t r a e n e e p o x i d e s 31 and x
OH OH R
OH
OH
OH
OH
OH
OH
t e t r i n A and t e t r i n B have been shown t o have s t r u c t u r e s 2 and 2 r e s p e c t i ~ e l y . ~ ~The ' ~ s~t r u c t u r e of l i p o x a m y c i n h a s
"1; OH R
HO
'OH
OH
CH3
0
CH3 HO
OH
2
R=H
2
R-OH
NH2 b e e n shown t o have s t r i i c t u r e 35.'* Versico lin , an a n t i f u n g a l a n t i b i o t i c i s 2, 3, 6 - t r i h y d r o x y - t o l u e n e , and t h i s h a s b e e n c o n f i r m e d by s y n t h e s i s a 5 3 0 0 OH 0
L i n e a r f r e e e n e r g y r e l a t i o n s , c o r r e l a t i n g d a t a from more t h a n 30 s t r u c t u r a l t y p e s of a n t i f u n g a l a g e n t s w i t h h y d r o p h o b i c and e l e c t r o n i c p a r a m e t e r s have b e e n f o r m u l a t e d . I n a number of t h e s e examples, t h e a n t i f u n g a l a c t i v i t y c l o s e l y p a r a l l e l e d a n t i b a c t e r i a l and h e m o l y t i c a c t i v i t y , s u g g e s t i n g t h a t t h e s e f u n g i c i d e s may b r i n g a b o u t t h e i r a c t i o n by membrane e f f e c t a . 5 4
116
Sect. I I I
-
Chemotherapeutic Agents
Butler, Ed.
-
BiOlOgiCal Studies of Antifungal Agents The primary site of mentagrophytes appears to be the action of siccanin on succinate dehydrogenase system of terminal electron transport. This suggests that siccanin inhibits fungal growth by inhibiThe tion of the respiratory electron transport system.55 primary action of pyrrolnltrin against Microsporum gypseum has been shown to be blockage of the electron transfer between the flavo protein of NADH dehydrogenase and the cytochrome B of the respiratory chain.56 The mode of action of yemenimycin against 2. albicans is suggested to be interference with DNA synthesis. 5 7
r.
The polyenic antibiotic dermostatin which possesses i n vitro activity against dermatophytes and Candida has been re-examined with a view towards its in vitro and in vivo activity against Cryptococcus, Blastomyces and Histoplasma in a variety of test systems. Dermostatin was less active 2 vivo than amphotericin B against C. albicans and go capsulatum while the activities of the 2 antibiotics were comparable against C. neoformans and Blastomyces dermatitidis infections in mice.58
-
Saramycetin has been shown to retard the clearance of sulphobromophthalein (BSP) in man. This may be due to inhibition of the hepatic enzyme which conjugates BSP to reduced glutathione, or to the anticholeretic activity of saramyB has been shown to increase the perme~ e t i n . Amphotericin ~~ ability of frog skin to potassium, chloride and urea.60 It has been suggested that the differential activity of griseofulvin in vitro may against 2. mentagrophytes and Trichophyton rubrum -be useful in the differential diagnosis of these two specieso61 _In vitro studies with Saccharomyces, Candida and several strains of Cryptococcus have shown synergistic activity with a combination of amphotericin B and 5-fluorocytosineo~2 Natural resistance of Candida to nystatin and amphotericin B may not occur;however resistance can be developed in vitro to these agents as well as candicidin, pimaricin and filipin.63 REFERENCES 1. 2.
3. 4,
5. 60
R. Vanbreuseghem, Maroc. Med., 51, 156 (1971). C. Booth, Ed., "Methods in Microbiology", Academic Press, New York (1971). D. Adams and J. H. Jones, J. Dent. Res., 5, 643 (1971). J. W. Ebert, V. Jones, R. D. Jones, R. J. Weeks and F. E. Tosh, Mycopathol. Mycol. Applicata, 45, 285 (1971). R. P. Elander, J. A. Mabe, R e L. Hamill, and M. Gorman, Folia Microbiol., l6, 156 (1971). T. Ichikawa, M. Date, T. Ishikura and A. Ozaki, ibid., 16 218 (1971).
-,
Chap. 1 1
Antifungal Agents
117
Waitz, Drube
A. A. Abou-Zeid and A. E. A. Jousef, Zentralbl. Bakteriol., 126, 14 (1971). K. C. Basu Chaudhary and S o Gupta, Experientia, 3, 706
7. 8.
(1971) 9. 10.
. .
11
D. R. Thouvenot and C. M. Bourgeois, Ann. Inst. Pasteur, -9 120 617 (1971). M. Margosis, J. T. Tanner, and J. P. F. Lambert, J. Pharm. Sci., &, 1550 (1971). R. S. Eisenber and W. H. Oatway, Amer. Rev. Resp. Dis., 103
-9
f.
289 (1971
16 17o 18.
A. P. Barousse, C. DeBercovich, J. Firmat, and E. E. Malamud, Medecina (Buenas Aires), 26 (1971). V. Rodriguez, J. M. Bardwil, and G o P. Bodey, So. Med. J., 64, 396 (1971). B. T. Fields, Jr., J. H. Bates, and R. S . Abernathy, Appl. Microbiol., 22. 615 (1971). E. Newmark, A. C. Ellison, and H. E. Kaufman, Amer. J. Ophthalmol., 71, 718 (1971). I. Alteras, Brux. Med., 51, 501 (1971). U. Heynen, Z. Allgemeinmed., 47, 829 (1971). J. P. Beine, M. Lontie and J. Vandepitte, Brit. Med.
19
R. J. Fass and R. L. Perkins, Ann. Intern. Med., 74,
20.
Rb R. Davies and D. S. Reeves, Brit. Med. J.,
12
13
0
14
.
15
s,
J.,
1971, 2, 107 (1971).
535 (1971). 21. 22
.
-1,
557 (1971).
W. Marget and D. Adam, Acta Pediatr. Scand.,
1971
3,341
(1971) J. Bodenhoff, Acta Pathol. Microbiol. Scand. Section B.,
79, 345 (1971).
26.
W. Ritzerfeld and M. L. Venschott, Into Z. Klin. Pharmacol., lt, 204 (1971). S. Shadomy, Infect. Immun., 4, 143 (1971). J. A. Waitz, E. L, Moss, and M. J. Weinstein, Appl. Microbiol., 22, 891 (1971). S. Shadomy, Antimicrob. Agents Chemother. 1970, 169
27. 28.
M. A. H. Bayles, Arch. Dermatol., 476 (1971). W. L. Chiou and S. Riegelman, J. Pharm. Sci., 60, 1376
29
B. R. Allen, Lancet, 2, 840 (1971).
23.
24. 25 o
(1971)
-
30 0
31.
104,
(1971)
P. Naidoo, ibid, 2, 1590 (1971). H. B. Levine, J. M. Cobb, and R. H. Friedman, Sabouraudie,
8, 43 (1971).
32
33
34 35
0
P. Godts, P. Vermylen, and J. van Cutsem, Arzneim.Forsch., 21, 256 (1971). K. Ando, H. Oishi, S. Hirano, T. Okutomi, K. Suzuki, H. Okazaki, M. Sawada, and T. Sagawa, J. Antibiotics (Tokyo) 24, 347 (1971). R. Schlegel and H. Thrum, ibid, 24, 360 (1971). R. Schlegel and H. Thrum, ibid, 368 (1971).
z,
118 -
36
-
Sect, I l l
Chemotherapeutic Agents
'f . M. E.
K. D o r n b e r g e r , R. F h n e r , G. B r a d l e r ,
24,
a n d H.
Thrum,
172 (1971
37
ibid A. D .
38
M. Mizuno, Y. Shimojima, T. Sugawara, and I. Takeda,
-0,
Ed.
Butler,
Argoudelis,
Bergy,
and T.
R.
i b i d , 24,
Pyke,
543 (1971). i b i d . , 24, 896 (1971). S. H i g a s h i k a w a , K. Y a s u i ,
39 40.
i b i d , 3, 900 (197110 A. T a k a t s u k i , K. A r i m a ,
H. T e r a d a , a n d S. Kuyama,
a n d G.
Tamura,
&,
ibid.,
215
(1971)
0
41.
K. Uchida, T. I c h i k a w a , Y. Shimauchi, T. I s h i k u r a , a n d A.
42.
-, 24
M. MacLean,
ibid.,
747 (1971).
W. J. G o t t s t e i n , A . H. Eachus, P. F. Misco, L. C. Cheney,
43 44
Ozaki, i b i d . , 24, 259 (1971). S c o t t , W. van Walbeck, a n d W.
P. M.
.
45
. 47 48 . 46
a
M.
a n d K.
Misiek,
E.
Price,,
J. Med. Chem.,
(1971)
.
I. L a l e z a r i ,
H e G o l g o l a b , and M. Emami,
Fields,
H. Newman,
a n d R.
770
2,1123 i b i d . , 14,
ibid.,
(1971) T. L.
&,
B. A n g i e r ,
767 (1971) L. F i e l d , W.
5. Hanley,
I. McVeigh,
a n d 2.
14 202 (1971).
-¶
14, 252
D. M. Wiles a n d T. Suprunchuk, i b i d . , M. K i n o s h i t a , M. Wada, S. A b u r a g i , and J. A n t i b i o t i c s ,
Evans,
(Tokyo),
S.
ibid.,
(1971).
Umezawa,
24, 724 (1971).
R. W. R i c k a r d s , R. M. S m i z a n d B. T. G o l d i n g ,
3, 603 (1970).
ibid.,
R e C . Pandey, V. F. German, Y. Nishikawa, and K. L. R i n e h a r t , Jr., J. Amer. Chem. SOC., 2, 3738 (1971). K. L. R i n e h a r t , Jr., W. P. T u c k e r , a n d R. C . Pandey, ibid., 3747 (1971). H e A. Whaley, i b i d . , 91, 3767 (1971). R . W. R i c k a r d s , J. A n t i b i o t . , (Tokyo) 715 (1971). C . Hansch and E . J. L i e n , J. Med. Chem., 653 (1971). K. Nose a n d A. Endo, J. B a c t e r i o l . , 105, 176 (1971). D. T. Won J-S. Horng, and R. S. Gordee, i b i d , ,
a,
52
.
53. 54 55 56.
24, 14,
,
106,
168 (19717. 57. 58
I. R. S h i m i , J. A n t i b i o t . , (Tokyo), 24, 593 (1971). R. S . Gordee, T. F. B u t l e r , a n d N . N a r a s i m h a c h a r i , ibid
-09
24,
561 (1971).
D. A. Cooney, R e D. Davis, E. R . Homan, N. R a k i e t e n , U.
.
60. 61
62. 63.
V a n a t t a , B r i t . J. P . N i e l s e n , A c t a P h y s i o l , Scand., B, S c h a e p i, a n d G.
140 (1971 . _. -
R.
Pharmacol.,
&,
-
106 (1971).
M. O t c e n a s e k a n d J. Dvorak, Z e n t r a l b l . B a k t e r i o l . ,
217,
96 (1971)G. Medoff, M. Comfort, and G o S. Kobayashi, P r o c . Exp. B i o l . Med., 571 (1971). M. A. A t h a r a n d H. I. Winner, J. Med. M i c r o b i o l . ,
138,
(1971)
SOC.
2,
505
Chapter 12. Antiviral Agents Timothy H. Cronin, Pfizer, Inc., Groton, Connecticut Introduction - Interest was high in several areas of antiviral research during the past year. A s research continues it becomes clear that interferon is a complex story and most likely just one facet of a much larger immunological picture. No new non-polymeric interferon inducing drugs were discovered. A single human study with tilorone was reported. The role of RNA directed DNA-polymerase with regard to oncogenic viruses has been discussed' and a search for inhibitors of this enzyme as potential antiviral agents has focused on the ansamacrolides. Isoprinosine is claimed to have a range of antiviral activity in experimental laboratory infections and uncontrolled human trials claiming efficacy have been reported from Argentina. A notable advance is the discovery of a drug for the prevention of Marek's disease in poultry. Several reviews2-6 discussed the state-of-the-art during 1971. Interferon - Human interferon was shown to have a 1 mited but measurable activity against a number of strains of aden0virus.j The absence of interferon8 in serial serum specimens collected prior to and during the incubation and acute phase of transfusion associated hepatitis may in part be related to the chronicity of the disease. Human leukocytal interferon has been utilized in at least two controlled clinical trials. In the first trial9 it was administered to patients with confirmed influenza and found to rapidly and dramatically reduce the systemic symptoms (headache, dizziness, malaise) a to a lesser degree the respiratory tract symptoms. The second study" utilized interferon prophylactically and was conducted with children in Moscow during the "flu" season. There was a 45-60% reduction in the incidence of influenza and respiratory infections. Production of interferonll in volunteers infected with either partly attenuated influenza A2/Leningrad/65 or B/England/62 is greatest in those who develop most antibody. There was no correlation between amount of interferon produced and disease severity. The importance of antibody in an untreated infection has recently been demonstrated.12 Normal mice given a sublethal dose of vaccinia virus produce interferon and antibody. Mice immunosuppressed by cyclophosphamide treatment or whole body X-irradiation do not produce antibody and exhibit 100% mortality after vaccinia challenge even though interferon is still formed. Administration of antibody causes a marked reduction in mortality. On the other hand immunosuppressed mice are protected13 against lethal vaccinia infection when treated early enough with the interferon inducers poly I:C or Newcastle disease virus (NDV) Other "factors" which resemble or are identical with interferon have also been identified. A serum protective factor (SPF) has been isolated14 from mice infected with Langat virus. It was shown that SPF is not an immunoglobulin, but it is found in the globulin fraction, and it also differs from interferon in that it does not protect mice under 3 weeks of
120 -
Sect. I l l
-
Chemotherapeutic Agents
Butler, Ed.
age or neonatally thymectomized mice up to 6 weeks of age against Langat virus infection. The species specificity of SPF was not examined nor was its effect against other viruses tested. Poly IC was found t o cause the formation of a colony inhibitor which appeared to be identical to interferon.15 The interaction of sensitized mouse peritoneal or splenic leukocytes with L-cells was found to release inteferon,16 An experiment conducted with mouse-monkey hybrid cells17 indicated that there were different genetic sites for the synthesis of interferon and the protein responsible for the antiviral state. This data is consistent with recent in vitro experiments18 conducted with actinomycin D. In these experiments cells were incubated with interferon for different time intervals, the interferon removed, and the cells incubated with actinomycin for 3 hours and then challenged with vesicular stomatitis virus (VSV) and plaques counted. There was no antiviral state produced when actinomycin was added prior to interferon, but the antiviral state was achieved and potentiated some 30-fold when actinomycin was added at 4-5 hours and became maximal (100-fold) when actinomycin was added at 5 112-6 hours. These data are consistent with the following scheme: Interferon
hrs*>
Antiviral Protep
4-6 hrs.
y 4-6 hrs >
Control Protein
\1
Antiviral State Similar experiments have also been carried out using poly 1C.l’ In further recent experiments2° a tissue antagonist of interferon was isolated which may be the control protein, because when it was added at 4-6 hours under the same experimental conditions described above, it decreased by 40 fold the antiviral state induced by interferon. Its activity is blocked by actinomycin D. The protection against MM virus afforded by NDV, statalon, endotoxin, pyran copolymer, poly IC or interferon is also antagonized by estrone.21 Interferon Inducers
1) Polynucleotides - Low titres of interferon were seen in 14 out of 20 human subjects given intravenous poly IC in doses up to 4 mg/kg. The chief clinical feature was a febrile response and there were no abnormalities reported in any of the clinical parameters studied. Subjects given a second injection of poly IC gave an interferon response, whereas repeated daily in ections caused a refractory state.22 Experiments with mice indicatei3 that the refractory state can be overcome to some degree by following a strict dosage regimen of either 25 mcg. or 200 mcg. of poly IC every 12 hours for 6 days. This practice was shown to give sustained levels (hundreds of units) of interferon. With rabbits,24 it was shown
Chap. 12
Antiviral Agents
Cronin
121 -
that there was no correlation between interferon response and febrile response to poly IC. In addition, prior administration of indomethacin markedly reduced the elevation of body temperature but was without effect on the interferon stimulation by poly IC. In animal protection studies has been poly IC at 1 mg/kg either intravenously or intramu~cularly~~ demonstrated to protect rabbits against up to 625 LD50 of rabies street virus, and to protect mice against Semliki Forest virus (SFV) infection26 when treatment (100 mg intraperitoneally) was begun as late as 5 days after infection when high titers of virus were already in the brain. It did not prevent infection in calves challenged with infectious bovine rhinotracheitis (IBR) but it did ameliorate the clinical systems of respiratory illness, when adminis ered at doses of 1 mg/kg intravenously and provided complete protection2! from the pneumonic lung lesions of IBR. An attempted cure of a single infant with herpes type 1 encephalitis using a dosage of 1 mg/kg of poly IC for 11 days, was discussed.28 Further toxicological studies with poly IC have shown it to have no adverse effect on HFL-1B cells.29 -In vivo experiments indicate a depression of zinc and iron concentrations in the serum of rats and rabbits but not monkeys;30 in acute and subchronic (42 days) studies using 2 mg/kg/day, poly IC was well tolerated by rodents but not by dogs;3I in calves it caused32 CNS depression and respiratory symptoms at doses of 0.1-1.2 mg/kg intravenously although at these doses very low titers of interferon were detected in the serum. Effects of poly IC on viral onco enesis have been widely studied and a review on the subject has a~peared.~' A recent study34 using a double-stranded RNA of fungal origin dramatically indicates the types of responses that are seen in such experiments. Innoculation of mice with Friend virus results in a progressive increase in spleen size, followed by eventual rupture and death. Administration of double-stranded RNA prior to or in the early stages of infection increases the severity of the disease, whereas treatment with the RNA beginning 5 days after infection causes a marked reduction in spleen size and a more normal histological appearance of the spleen. The treated mice remained in remission for the 6 week duration of the experiment. The beginning of treatment at day 5 corresponds to the time of rapid proliferation of cells which cause the spleens to increase in size. There have been some interesting probes into the structural requirements for activity with double-stranded polynucleotides. Greater in vitro antiviral activity than is found with poly IC can be obtained by the sequential addition of the single-stranded homopolymer constituents;35 e.g. addition of poly I followed at 10 min or even 1 day by poly C causes enhanced antiviral activity as does the addition of poly C followed at 1 min or 10 min by poly I. In vivo the homopolymers must be injected intravenously within 1 minute of each other to achieve interferon levels even comparable with poly IC. This may well be a reflection upon the metabolic stability of single double-stranded RNA. Incubation of poly IC or even the alternating ribonucleotide copolymer poly r (A-U) at 37" in
122 -
Sect. I l l
-
Chemotherapeutic Agents
Butler, Ed.
Eagles minimal essential medium causes an enhancement of interferon ~ poly IC in which the inducing activity.36 A systematic ~ t u d y 3of molecular weight of only one of the homopolymers was varied at a time leaving the other component of the duplex intact showed that antiviral activity and toxicity (mouse LD50) decreased in parallel as the molecular weight of the variable molecular weight component was decreased. A convenient method for molecular weight determination of polynucleotides is also described.37 A later study with poly C (Ip5)I confirms these results.38 Complexes of poly IC and DEAE-dextran are known to enhance the potency of the former. It was concluded39 from a study of this effect using various concentrations of DEAE-dextran that optimal activity was achieved when the complex aggregates, and that this facilitates uptake by cells and protects against endonucleases. These same authors showed40 that poly I-poly (1-vinylcytosine) is equivalent to poly IC in inducing interferon on human skin fibroblasts and postulated that its reduced chargelmass ratio and tendency to aggregate causes enhanced cellular uptake leading to activity. Additional double-stranded RNAs were discovered to be interferon inducers. The activity of a DNA-RNA hybrid synthesized from singlestranded DNA of fl phage was demonstrated by complement f ation techniques to be entirely due to contaminanting double-stranded RNA." Other ctive double-stranded RNAs were isolated from normal mammalian cells.42,43 Finally, it is claimed that a double-stranded RNA equivalent in potency to poly IC, could be produced on large scale using a restrictive E. & strain and a mutant f2 phage.44 S tat01on~~ administered intranasally protected mice against influenza, and was shown to produce interferon in the trachea and lungs. It was non-antigenic, and its protective effect lasted for at least 1 week.
-
was found to 2) Other Polymers Chlorite oxidized oxyamylose protect mice against foot and mouth disease virus but did not protect swine against the natural infection. In a hog cholera infection COAM provided no increase in survival time but did delay the onset of disease symptoms. Circulating interferon was not detected in swine treated with COAM. Although COAM given prophylactically to ce afforded some protection against influenza A/PR8, it was concluded'' that it acts by triggering host response & interferon. and not y Phosphomannans isolated from several species of yeast48 are a new class of relatively non-toxic (acute LD50) interferon inducers. They cause formation of lower amounts of interferon in the rabbit than poly IC, but have similar induction kinetks. The materials retained their activity after digestion with beef pancreatic ribonuclease, thus ruling out the presence of RNA. 3 ) Tilorone - The bulk of the biological studies reported in preliminary form last year have now been confirmed by others.49 Additional analogs possessing activity similar to tilorone were also described.50 The first clinical experiments were described5I this year. This study examined the
Chap. 12
Antiviral Agents
Cronin
123 -
interferon response after administration of tilorone to the eyes of 10 subjects (1 drop of 200 mg/ml solution), and 1.0 g orally to 3 subjects; no interferon was detected by either route, and it was observed that the drug was deposited in the corneal epithelium. This deposit required up to 2 months after drug administration for complete disappearance. With the exception of some gastrointestinal irritation, no other adverse effects were noted. Tilorone did not induce circulating interferon in the chick, nor did it afford protection against Avian influenza.52 In this test statolon was effective but poly IC was not. Natural Products Rifampicin when applied as a 10% ointment or 15% cream to the vaccination sites of human subjects prevented a positive reaction in about 50% of the cases.53 With the use of the cream formulation a decrease in immune response was noted in all subjects as measured by seroconversion. There was no antiviral activity by the oral route. In animal experiments, oral rifampicin had no effect against herpes simplex, Mengo virus, intranasal nfluenza A/PR 8 or against intracerebral vaccinia infections of mice. 5i However, a significant dose-related reduction of tail lesions in vaccinia infected mice was demonstrated; the optimum regimen was 250 mg/kg of rifampicin beginning 24 hours prior to infection and continuing for 4 days.
-In vitro studies55 of anti-vaccinia activity have been carried out with a series of rifamycin derivatives and with their corresponding aminopiperazine side chains. Several of the side chains per se were claimed to be more active than the rifamycin. These effects could not be demonstrated by other workers.56 It was shown by plaque assays and by morphological changes in cells, that the side-chain of rifampicin had no effect on the course of virus infection. Several mechanisms of antiviral action have been proposed57 ,58 for rifamycin derivatives but the greatest interest centers around the inhibition of RNA-directed DNA polymerase. Several rifamycin derivatives but not rifampicin itself exhibit greater than 50% inhibition5’ of the EWA-directed DNA polymerase of Moloney sarcoma virus (MSV) at concentrations of 50-100 mcg/ml. Rifampicin inhibits60 focus formation by Rous sarcoma virus in chick embryo fibroblasts, but it was postulated that this effect was due primarily to the inhibition of cell proliferation that was also seen. A similar situation was described6I for the l-amino-2,6-dimethyl-benzylpiperazine derivative of rifamycin which, in addition to totally inhibiting focus formation and virus replication of MSV, was also found to reduce cell proliferation by 60%. With a more highly purified sample of drug, however, there was inhibition of viral replication and cell transformation, but there was no decrease in cell proliferation. The streptovaricins, which are also ansamacrolides, appear to elicit effects similar to the rifamycins. Inhibition of focus formation by MSV was demonstrated62 with streptovaricins at doses 4 times lower than the cytotoxic dose. It is speculated that the inhibition of cell transforma-
124
Sect. I l l
-
Chemotherapeutic Agents
Butler, Ed.
tion is due to inhibition of the viral DNA polymerase. Streptovaricin when administered at a dose of 1.5 g/kg/day in feed to leukemia virus infected mice, caused a 50% reduction in spleen weight.63 Virus replication in the spleen was unaffected. Since there was no reduction of spleen weight in mice with a non-viral transplantable tumor (L1210) strain, it was reasoned that streptovaricin did not inhibit malignant cell proliferation and therefore presumably inhibited a virus specific event in cell transformation such as the reverse transcriptase. Some miscellaneous natural products which have exhibited limited in~ ~vitro vs. NDV; fusidin65 in vitro,vs. antiviral activity are f i l i ~ i n--influenza A/PR 8; melanacidins66 (from the 3,6-epidithiadiketopiperazine vivo vs. herpes virus; tunicamycin67 in vitro ~6 NDV; antibiotics group) from starf*?n vitro vs influenza; L - a s p a r a z n a in vitro and in viva (rabbit eye) ~6 vaccinia and myxoma; colchicine, demecolcine, vinblastine and vincristine70 vivo (rabbit eye) ~6 herpes simplex. A clinical trial with vitamin C 7 m 40 subjects challenged with a cold virus has been carried out but the results have not been published in the scientific literature. Nucleosides - It appears that there is increasing use of cytosine arabinoside in varicella infections in leukemic children. A dramatic improvement in a disseminated varicella infection in a leukemic patient was achieved72 with cytosine arabinoside administered daily by the intravenous route at doses of 100 mg/meter2. Most recently, it was reported73 that best results are obtained by continuous intravenous infusion at doses of 10-40 mg./ meter2. It was noted that if the patient survives for 48-72 hours there is a good response to the drug. High doses of cytosine arabinoside (100 mg/kg intraperitoneally) were demonstrated74 in a toxicology study to cause malformation of embryos in pregnant rats. Reviews on the use of idoxuridine in herpes simplex75 and herpes h ~ m i n i svirus ~ ~ infections have been published.
-
Isoprinosine (NPT-10381) It is proposed’17 that the anti-influenza activity of isoprinosine (the p-acetamidobenzoate salt of the 1:3 complex of inosine and dimethylaminoisopropanol) is due to an alteration of ribosomes such that they are more selective for host mRNA and less selective for viral mRNA. Isoprinosine administered to mice 24 hours after infection with influenza virus provided protection against mortality78 and with sublethal virus innocula it decreased the respiratory morbidity. In experiments79 with herpes, vaccinia, polio and echovirus there was no reduction in cytopathic effect but there was a reduction in virus yield. -In vivo experiments79 indicated a decrease in mortality from herpes corneal infection in hamsters and a reduction in tail lesions in vaccinia infected mice. No protection was afforded against encephalomyocarditis in the mouse. A controlled study80 of the effect of isoprinosine (1 g q.i.d.) in subjects with viral hepatitis indicated that hepatitis-associated antigen (HAA) positive patients do not respond to the drug, but HAA negative patients improved considerably (liver function parameters) relative to
Chap. 12
A n t i v i r a l Agents
Cronin
125
the placebo group. Isoprinosine (4-6 glday) was shown81 to be of no value in the treatment of amyotropic lateral sclerosis. A large uncontrolled study82 of isoprinosine (40 mglkglday in children; 50 mg/kg/day in adults) in influenza, rhinovirus, mumps and measles was claimed to ameliorate the systemic symptoms (fever, headache, malaise) and to reduce the time and intensity of the specific disease symptoms.
-
when administered continuously in feed at a level of 0.0002% (1) was effective83 in preH 2 N ~ S 0 2 ~ ~ C O N venting H 2 the mortality and tumor development in birds infected with Marek's 1 disease.
Marek's Disease
p-Ureido-p'-aminodiphenylsulfone
-
Amines Double-blind trials were conducted with cyclooctylamine hydrochloride administered intranasally for 2 days prior to and for 7 days following nasopharyngeal challenge with 64,000 TC ID50 of influenza, A2IHK. The drug was effective in reducing the severity of the disease as measured by reduced febrile responses, lower virus recovery and reduced serum antibody titer. Structure-activity relationships within the amantadine series have been discussed.84 Miscellaneous Synthetics - Florenal (undisclosed structure) was shown to have in vitro and in vivo activity against herpes virus.85 An uncontrolled clinical trial in a large number of patients claimed85 dramatic results in the treatment of herpetic keratitis, adenovirus conjunctivitis and epidemic keratoconjunctivitis. 5-Fluoro-2-(a-hydroxybenzyl)-l-propylbenzimidazole was reported86 to be 10 times more potent than the unfluorinated parent against polio and coxsackie virus in human cell monolayers. Derivatives of the related benzoxazole and benzothiazole series are inactive.a7 N-Methyl and N-e thy1 isatin 6-thiosemicarbazone were shown88 to directly inactivate the Rous sarcoma virus in vitro. Methisazone was inactive against chickenpox and infectious mononucleosis in a controlled clinical trial.89 5-Cyanothiophene-2-aldehyde thiosemicarbazone is reported90 to be more active than methisazone. The L-enantiomer of cytosine arabinoside was inactiveg1 in vitro vs herpes virus. The 02, 02' anhydroderivative of c tosine arabinoside did have anti-herpes activity in vitro and in vivo .81 1-(3,5-Dihydroxy-4-nitrobenzy1)-morpholine was reportedg2 to be active in the mouse against encephalomyocarditis. References
1. D. W. Allen and P. Cole, N. Eng. J. Med., 286, 70 (1972). 2. S. Z. Hirschman, Am. J. Med., 51, 699 (1971). 3 . D. L. Swallow, Progress in Medicinal Chemistry, 8, 119 (1971). . 0 , 210 (1971). 4. D. C. Brown, Invest. Ophthalmology, l
126 5. 6. 7. 8. 9. 10.
11.
12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33.
Sect. I I I
-
Chemotherapeutic Agents
Butler, Ed.
C. Stuart-Harris, Brit. Med. J., I, 387 (1971). K. H. Schmidt-Ruppin, Chemotherapy, 16,130 (1971). J. G. Gallagher and N. Khoobyarian, Proc. SOC. Exptl. Biol. Med., 136 920 (1971). D. A. Hill, J. H. Walsh and R. H. Purcell, Proc. SOC. Exptl. Biol. Med., 136 853 (1971). L. A. Kursinova, E. A. Bukharina, G. I. Makarova and L. I. Neklyudova, Vopr. Virusol, 194 (1971). G. P. Busuek, I. N. Gailonskaya, T. M. Lozinskaya, V. P. Banina, N. I. Zhurnikova and M. A. Tsiprina, Vopr. Virusol, 226 (1971). A. A. Smorodintsev, A. S . Beare, M. L. Byone, B. Head and D. A. J. Tyrrell, Archiv Ges. Virus Forsch., 33, 9 (1971). Federation of American Societies for Experimental Biology, Chicago, Illinois (April 12-17) Abstracts, M. Worthington and S. Baron, p 241 (1971). M. Worthington and S . Baron, Proc. SOC. Exptl. Biol. Med., 136 349 (1971). I. S . Thind and W. H. Price, J. Immunol., 106 1559 (1971). T. A. McNeill and W. A. Fleming, Immunology, 2 761 (1971). L. Borecky, N. Fuchsberger, J. Zemla and V. Lackovic, Europ. J. Immunol., 1, 213 (1971). R. Cassingzna, C. Chany, M. Vignal, H. Suarez, S. Estrade and P. Lazar, Proc. Natl. Acad. Sci., 68 580 (1971). C. Chany, F. Fournier and S . Rousset, Nature New Biology, 230, 113 (1971). Y. H. Ke and M. Ho, Proc. SOC. Exptl. Biol. Med., 136 365 (1971). F. Fournier, C. Chany and M. Sarragne, Nature New Biology, 235, 47 (1972). D. J. Giron, P. T. Allen, F. F. Pindak and J. P. Schmidt, Infect. and Immunity, 3, 318 (1971). A. K. Field, C. W. Young, I. H. Krakoff, A. A. Tytell, G. P. Lampson, M. M. Nemes and M. R. Hilleman, Proc. SOC. Exptl. Biol. Med., 136, 1180 (1971). C. E. Buckler, H. G. DuBuy, M. L. Johnson and S. Baron, Proc. SOC. Exptl. Biol. Med., 136,394 (1971). E. Piperno, A. K. Field and A. A. Tytell (ref. 12) p 242. P. Fenje and B. Postic, J. Infect. D i s . , 123,426 (1971). M. Worthington and S . Baron, Proc. SOC. Exptl. Biol. Med., 136 323 (1971). K. W. Theil, S . B. Moharty and F. M. Hetrick, Proc. SOC. Exptl. Biol. Med., 137 1176 (1971). J. A. Bellanti, L. W. Catalano, Jr., and R. W. Chambers, J. Pediatrics, 78 136 (1971). C. L. Baugh, A. A. Tytell and M. R. Hilleman, Proc. Soc. Exptl. Biol. Med., 137 1194 (1971). R. S. Pekarek, Proc. SOC. Exptl. Biol. Med., 136 584 (1971). B. M. Phillips, R. E. Hartnagel, P. J. Kraus, R. P. Tamayo, E. H. Fonseca and R. L. Kowalski, Toxicology and Applied Pharmacology, 18 220 (1971). B. D. Rosenquist, Am. J. Vet. Res., 32, 35 (1971). C. W. Young, Med. Clin. of North America, 55, 721 (1971).
Chap. 12
Antiviral Agents
Cronin
127
34. D. J. F. Pilch and D. N. Planterose, J . Gen. Virol., 10 155 (1971). 35. E. De Clercq and P. De Somer, Science, 173 260 (1971)T 36. E. De Clercq, R. D. Wells, R. C. Grant and T. C. Merigan, J . Mol. Biol. , 56 83 (1971). 37. J . F. Niblack and M. B. McCreary, Nature New Biology, 233, 52 (1971). 38. P. M. Pitha and W. A. Carter, Nature New Biology, 234 105 (1971). 39. P. M. Pitha and W. A. Carter, Virology, 45 777 (1971). 40. J. Pitha and P. M. Pitha, Science, 172 1146 (1971). 41. C. Colby, B. D. Stollar and M. I. Simon, Nature New Biology, 229 172 (1971). 42. E. De Maeyer, J. De Maeyer-Guignard and L. Montagnier, Nature New Biology, 229 109 (1971). 43. R. Stern and R. M. Friedman, Biochemistry, 10 3635 (1971). 44. J . Doskocil, N. Fuchsberger, J. Vetrak, V. Lackovic and L. Borecky, Acta virol. , 15 523 (1971). 45. W. J. Kleinschmidt and F. Streightoff, Infect. and Immunity, 4 738 (1971). 46. J. Leunen, J. Desmyter and P. De Somer, Applied Microbiology, 21 203 (1971). 47. A. Billiau, J . J . Muyembe and P. De Somer, Applied Microbiology, 21 580 (1971). 48. S. Suzuki, M. Suzuki and M. Imaya, Japan J . Microbiol., IS, 485 (1971). 49. E. De Clercq and T. C. Merigan, J . Infect. Dis., 123 190 (1971). 50. Eleventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlantic City, N.J. (Oct. 19-22) Abstracts, R. F. Krueger, G. D. Mayer, K. P. Camyre and S. Yoshimura, p. 26 (1971). 51. H. E. Kaufman, Y. M. Centifanto, E. D. Ellison and D. C. Brown, Proc. SOC. Exptl. Biol. Med., 137 357 (1971). 52. J. Portnoy and T. C. Merigan, J. Infect. Dis., 124 545 (1971). 53. A. Moshkowitz, N. Goldblum and E. Heller, Nature, 229 422 (1971). 54. H. MUckter, H. Saus, G. Poszich and J. Nijssen, Arzneim-Forsch., 21 1571 (1971). 55. G. Lancini, R. Cricchio and L. Thiry, J. Antibiotics, 24, 64 (1971). 56. E. A. C. Follet and T. H. Pennington, Nature, 230, 117 (1971). 57. B. Mass, E. N. Rosenblum and P. M. Grimley, Virology, 45 123 (1971). 58. B. G. T. Pogo, Virology, 44 576 (1971). 59. C. Gurgo, R. K. Ray, L. Thiry and M. Green, Nature New Biology, 229 111 (1971). 60. H. L. Robinson and W. S. Robinson, J . Natl. Cancer Inst., 46 785 (1971). 61. M. Calvin, V. R. Jass, A. J . Hackett and R. B. Owens, Proc. Natl. Acad. Sci., 68 1441 (1971). 62. W. A. Carter, W. W. Brockman and E. C. Borden, Nature New Biology, 232 212 (1971). 63. E. C. Borden, W. W. Brockman and W. A. Carter, Nature New Biology, 232 214 (1971). 64. R. J . Ash, Virology, 43 536 (1971). 65. T. Ya Goncharskaya and S. M. Navashin, Antibiotiki, 16 57 (1971). 66. A. D. Argaudelis and F. Reusser, J. Antibiotics, 24 383 (1971). 67. A. Takatsuki and G. Tamura, J . Antibiotics, 24 232 (1971). 68. Y. Shimizu, Experientia, 27, 1188 (1971).
128 -
69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82.
83.
84. 85. 86. 87. 88. 89. 90 91. 92.
Sect. I l l
-
Chemotherapeutic Agents
Butler, Ed.
R. Maral and G. H. Werner, Nature New Biology, 232 187 (1971). T. Tokumaru and A. Avitabite, Proc. SOC. Exptl. Biol. Med., 137 29 (1971). Chemical Week, February 10, 1971, p. 50. D. Prager, M. Bruder and A. Sawitsky, J. Pediatrics, 78 321 (1971). Medical World News, January 7, 1972, p 51 E. J. Ritter, W. J. Scott and J. G. Wilson, Teratology, 4, 7 (1971). H. Ashton, E. Frenk and C. J.: Stevenson Brit. J. Dermat., 84 496 (1971). A. Luger, Z. Haut-Geschl. Kr., 46 399 (1971). P. Gordon, E. R. Brown and B. Rorsen (ref 12.) p. 242. E. R. Brown and P. Gordon (ref. 12) p. 242. T. W. Chang and L. Weinstein, (ref. 50) p 29. E. A. Dainko (ref. 50) p. 30. A. K. Percy, L. E. Davis, D. M. Johnston and D. B. Drachman, N. Eng. J. Med., 285 689 (1971). J. Ink, F. J. Andres, G. M. Antonini, V. Scarpiello, J. C. Stefano, N. Coronel, M. G. Genoves, R. Spataro, C. Natelli, 0. Buey, R. L . Ink, I. Goijman, N. Pernas, R. J. Andres, 0. R. Sumary, I. Casol and 0. Cudemo, Prensa Medica Argentina, 57 2050 (1971). 162nd American Chemical Society Meeting, Washington, D.C. (Sept. 12-17), Abstracts, T. Y. Chen, D. B. R. Johnston, N. P. Jensen, W. V. Ruyle, J. J. Friedman, M. W. Fordice, J. F. McPherson, K. H. Boswell, T. A. Maag, R. W. Burg, R. M. Pellegrino, M. E. Jewell, C. A. Morris, H. L. Easterbrooks and B. J. Skelly, P MEDI-44 (1971). P. E. Aldrich, E. C. Hermann, W. E. Meier, M. Paulshock, W. W. Prichard, J. A. Snyder and J. C. Watts, J. Med. Chem., 14, 535 (1971). Y. F. Maichuk, Investigative Ophthalmology, 10, 408 (1971). D. G. O'Sullivan, C. M. Ludlow and A. K. Wallis, Experientia, 27, 1025 (1971). F. Gualtiere, G. Brody, A. H. Fieldsteel and W. A. Skinner, J. Med. Chem., 14 546 (1971). W. Levinson, B. Woodson and J. Jackson, Nature New Biology, 232, 116 (1971). A. K. Sinha, Brit. J. Clinical Practice, 25, 177 (1971). Phannascope, Investigational Drugs, Dec. 1971; from Seventh Int. Cong. Chemother. Prague, Czechosl. Aug. 71, abst. A-5/13. D. T. Gish, G. L. Neil and W. J. Wechter, J. Med. Chem., 14,882 (1971). Unlisted Drugs, 24, 3 (1972).
Chapter 13.
A n t i n e o p l a s t i c Agents
C . C. Cheng, Midwest Research I n s t i t u t e , Kansas C i t y , M i s s o u r i 64110
I n t r o d u c t i o n - An account of a conference on t h e N a t i o n a l Cancer I n s t i t u t e chemotherapy program has been p u b l i s h e d . Topics i n c l u d e d s c r e e n i n g , sel e c t i o n of a g e n t s f o r s c r e e n i n g , c e l l k i n e t i c s and chemotherapy o f c a n c e r , t r e a t m e n t schedule dependency o f experimental a n t i l e u k e m i c (L1210) d r u g s , l a b o r a t o r y of t o x i c o l o g y , drug development programs o f t h e N a t i o n a l Cancer I n s t i t u t e , c l i n i c a l t r i a l s and combination chemotherapy, and s u p p o r t i v e c a r e i n cancer therapy. I n a d d i t i o n t o t h e s u b j e c t s which a r e p r e s e n t e d i n t h i s r e v i e w , o t h e r s t u d i e s beginning t o have an impact on t h e approaches t o cancer chemotherapy i n c l u d e molecular o r b i t a l c a l c u l a t i o n s and mathematical c o r r e l a t i o n s of l i p o p h i l i c parameters and p a r t i t i o n c o e f f i c i e n t measurements of a g e n t s of b i o l o g i c a l importance. Human p i t u i t a r y growth hormone, p r o s t a g l a n d i n s , c y c l i c AMP, RNA-dependent DNA polymerase--their f u n c t i o n , r e l a t i o n s h i p , immunological a s p e c t s , and i n f l u e n c e on o t h e r hormones, Poly A:U, and tumor growth--also show promise. n
A l k y l a t i n g Agents - 5-Aziridinyl-2,4-dinitroben~amide~ ( I ) has e x c e p t i o n a l a c t i v i t y a g a i n s t t h e Walker carcinoma. I t s a n t i t u m o r a c t i v i t y i s r e v e r s e d by 4-amino-5 -imidazolecarboxamide. Compound 1 i s s i m i l a r t o melphalan ( L - s a r c o l y s i n ) i n i t s e f f e c t s on DNA and RNA s y n t h e s i s . An azo compound 2 , formed i n vivo from two molecules o f 1, h a s been proposed a s a p o s s i b l e a c t i v e form.
-
Suppression of c e l l membrane t r a n s p o r t p l a y s a r o l e i n t h e r e s i s t a n c e t o n i t r o g e n mustard (HN2) by t h e Yoshida sarcoma c e l l s 3 . Metabolism of cyclophosphamide (?a, cytoxan) by r a t h e p a t i c microsomes has been r e p o r t ed4. The a c t i v e m e t a b o l i t e & i s formed by a t h r e e - s t e p enzymatic r e a c t i o n .
0 II,NH2 N-P, C 1 CH2 CH2’ 6 O-CH2 -CH2 -C02H C1-CH2 -CH2,
-3a. b.
X = CH2 X = CO
- -
Sect. I l l
-
Chemotherapeutic Agents
Butler, Ed.
4-Ketocyclophosphamide (2b) is an inactive metabolite.5 Significant synergistic action of potassium iodide on the therapeutic effect of 2 was not confirmed.6 Busulfan appears to be the treatment of choice for chronic mye locytic leukemia. 9
-
5-Azacvtidine 5-Azacytidine inhibits the incorporation of tritiated thymidine or deoxyadenosine into DNA to a greater extent than it does tritiated uridine into RNA. The inhibition can be nullified by cytidine, or by uridine, but not by deoxycytidine or deoxyuridine. 5-Azacytidine inhibits the S phase (DNA synthesis) of the cell cycle.’ The activity of uridine kinase in mouse leukemia cells resistant to 5-azauridine is reduced to ca. 50% of that in the sensitive cells.lO,ll This enzyme is responsible for the initial phosphorylation step of uridine, cytidine, and 5-azacytidine
.’
Cytosine Arabinoside (1-B-D-arabinofuranosylcytosine, ara-C, cytarabine) Enzymatic phosphorylation studies confirm that ara-C and its phosphorylated derivatives are deoxycytidine antagonists rather than cytidine antagonists.I2 Inhibition of DNA polymerase activity is considered more significantl.3 to antineoplastic properties than either blocking the uptake of thymidinel4 or the inhibition of the conversion of cytidine diphosphate to deoxycytidine diphosphate. Ara-C rapidly kills S phase cells. It affects the passage rate of cells from S to G2 phase more than from G1 to s15.
-
Ara-C is effective against acute lymphocytic and myeloblastic leukemia,l6 and also in the palliation of advanced epidermoid carcinoma of the head and neck but duration of therapeutic benefit is brief.17 Unlike 5-FU and MTX, ara-C does not cause mucositis. Recovery of cellular colony-forming unit is much faster after ara-C treatment than with BCNU.la A sensitive test for detecting ara-C in plasma has been developed.19 The 5’-adamantoate of ara-C has been studied as a depot form of ara-C.20 Many 5’-esters of ara-C possess immunosuppressive and antileukemic activities .zl The 3-N-oxide derivative retains antileukemic action against leukemia L-1210 ,22 but 1-B-L-arabinofuranosylcytosine, the enantiomer of ara-C, has no antineoplastic a ~ t i o n . ~ ~ , ~ ~
-
5-Fluorouracil and Related Pyrimidines 5-Fluorouracil (5-FU) might be more effective in patients with liver metastases when given orally, due to high drug concentrations in the portal system, Oral dosage with 5-FU is safe and effective in metastatic colorectal carcinoma.25 5-FU enhances the antitumor effect of irradiation in bronchogenic carcinoma.26 It supports hepatic tyrosine aminotransferase (TAT) induction by altering in vivo turnover of glucocorticoid-induced TAT .27 Catabolism of 5-FU is delayed by the presence of 5-cyano~racil.~~ 5-FU
Chap.
13
A n t i n e o p l a s t i c Agents
Cheng
131 -
i n combination with an a n t i c o a g u l a n t (warfarin) i n c r e a s e s t h e antitumor e f f e c t .29 2 '-Deoxy-5-(trifluoromethyl)uridine (F3TDR) induces remissions i n a c u t e leukemias. Doses of F3TDR causing leukopenia i n p a t i e n t s a r e n o t accompanied by g a s t r o i n t e s t i n a l t o x i c i t y . 3 0 Prolonged bone marrow depress i o n has hampered the good i n h i b i t o r y a c t i v i t y of F3TDR i n p a t i e n t s with b r e a s t and colon cancer .31 5-Bromo-2 I-deoxyuridine i s incorporated i n t o c e l l u l a r DNA, b u t i n h i b i t s t h e t r a n s c r i p t i o n of only c e r t a i n genes i n t o Z-RNA. 32
-
-
5-Formamide 1-B - r i b 0 furanosy 1t h i o imidazo le-46-Mercap topurine carboxamide 2 ' , 3 ' , 5 ' - t r i f o r m a t e , i s comparable with 6-mercaptopurine (6-MP) f o r the treatment of leukemias.33 It i s c r o s s - r e s i s t a n t with 6-MP. Conv e r s i o n of 6-MP ribonucleoside t o 6-MeMP r i b o n u c l e o t i d e has been shown i n L-1210 leukemia c e l l s , adenocarcinoma 755 c e l l s , H. Ep. No. 2 c e l l s and o t h e r systems. 6-MeMP r i b o n u c l e o t i d e i s r e s p o n s i b l e f o r t h e i n h i b i t i o n of purine s y n t h e s i s produced by 6-MP.34 Metabolism of 6-MeMP i n E h r l i c h asc i t e s c e l l s has been studied.35 Breakdown of the a c t i v e n u c l e o t i d e form of the 6-thiopurines by a l k a l i n e phosphohydrolase i s probably r e s p o n s i b l e f o r the r e s i s t a n c e of n u c l e o p l a s t i c c e l l s t o these agents. 36
-
F o l i c Acid Antagonists In c e r t a i n c e l l s f o l i c acid antagonists, such a s methotrexate (M'M) , homofolic a c i d o r tetrahydrohomofolic a c i d , i n h i b i t the i n c o r p o r a t i o n of t h e C-8 carbon i n t o 4-aminoimidazole-5-carboxamide r i b o t i d e . I n h i b i t i o n of DNA s y n t h e s i s by MTX and r e l a t e d antago n i s t s is not s e l e c t i v e , but i s balanced by concurrent i n h i b i t i o n of RNA and/or p r o t e i n s y n t h e s i s .37-39 A t h e r a p e u t i c advantage with reduced t o x i c i t y i s achieved by t h e a d m i n i s t r a t i o n of high doses of MTX, followed by "rescue" with f o l i n i c a c i d a s an a n t i d o t e . 37,40,41 Dosage schedules and t o x i c o l o g i c a l s t u d i e s of methasquin, a p o t e n t i n h i b i t o r of d i h y d r o f o l a t e MTX, t h i s quinazoline compound is reductase , were r e p 0 r t e d . 3 ~943 ~ ~ Unlike ~ poorly absorbed from t h e g a s t r o i n t e s t i n a l t r a c t . The N-10 n i t r o g e n atom of f o l i c a c i d i s b i o l o g i c a l l y ~ i g n i f i c a n ts i~n~c e N-10-deazafolic a c i d has no antineop l a s t i c a c t i v i t y .45 A study o f i n d u c t i o n of c y t o t o x i c i t y by MTX has shown t h a t MTXt r e a t e d lymphocytes added t o a l l o g e n e i c primary c u l t u r e s of embryo c e l l s produced a c y t o t o x i c e f f e c t ; no e f f e c t w a s observed when they were added t o syngeneic c e l l s of p r i m a r y embryo c u l t u r e . Normal syngeneic lymphoc y t e s when t r e a t e d with MTX, suppressed tumor c e l l growth i n mice.46 MTX i n h i b i t s the immune response t o i n s u l i n . The suppression i s r e versed by f o l i n i c a ~ i d . 4 ~Vitamin B12 promotes DNA-thymidine s y n t h e s i s i n C3H mouse c e l l s by r a i s i n g t h e l e v e l of f o l a t e coenzymes.48
132
Sect. I I I
-
Chemotherapeutic A g e n t s
B u t l e r , Ed.
-
[ N , N ' - ( 4 , 4 ' - D i a c e t y l ) d i p h e n y l l u r e a Bisguanylhydrazone (DDUG) DDUG (5) i n h i b i t s a number o f leukemias and some mammary tumors i n mice. R e s i s t a n c e t o DDUG i s a s s o c i a t e d w i t h a reduced uptake of t h e compound, b u t t h e i n t r a c e l l u l a r d i s t r i b u t i o n and drug b i n d i n g was unchanged. S t r a i n s r e s i s t a n t t o DDUG a r e c r o s s - r e s i s t a n t t o 2-chloro-4' ,4"-bis (2imidazolin-2yl)terephthalanilide, but remain s e n s i t i v e t o methylglyoxal b i s (guanylhydrazone) and v i n c r i s t i n e . The s i t e s o f i n h i b i t o r y a c t i o n of a l l four agents a r e different.49
-
The c y t o t o x i c i t y of hydroxyurea was compared i n n o r Hydroxyurea mal and i n r a p i d l y p r o l i f e r a t i n g epidermis ;5O deoxyribonucleoside i n c o r p o r a t i o n was i n v e s t i g a t e d i n a l k y l a t e d , non-dividing human lymphocytes .51 The a b s o r p t i o n , d i s t r i b u t i o n , and e x c r e t i o n of hydroxyurea i n p a t i e n t s was reported.52 The c y t o t o x i c i t y o f hydroxyurea i s due t o i n h i b i t i o n of r i b o n u c l e o t i d e r e d u c t a s e i n DNA s y n t h e s i s . Hydroxyurea i n h i b i t s s k i n c a r c i n o g e n e s i s ;53 a c t i v i t y a g a i n s t nonr e s e c t a b l e cancer of t h e lung i s comparable w i t h t h a t of cyclophosphamide.54 It i s a n e f f e c t i v e agent i n epidermoid carcinoma of t h e head.55 However, c l i n i c a l t r i a l s a g a i n s t malignant melanoma56 and a c u t e myelocyt i c leukemia57 a r e d i s c o u r a g i n g .
-
1,3-Bis (2-chloroethyl) - 1 - n i t r o s o u r e a (BCNU) , 1- (2Nitrosoureas c h l o r o e t h y l ) -3-cyclohexyl-1-nitrosourea (CCNU) a r e extremely l i p i d s o l u b l e and r e a d i l y c r o s s t h e blood-brain b a r r i e r . 5 8 CCNU i s more e f f i c a c i o u s than BCNU a g a i n s t implanted gliomas and leukemia L-1210. Clinically, BCNU and CCNU a r e e f f e c t i v e i n p a t i e n t s w i t h bronchogenic carcinoma, mal i g n a n t lymphoma and a c u t e leukemia i n children.59 T h e i r most important use i s f o r t h e t r e a t m e n t o f p a t i e n t s with malignant b r a i n tumors.59-62 Because of t h e i r l i p i d s o l u b i l i t y and r e l a t i v e nonionic c h a r a c t e r , n i t r o s o u r e a s a r e d i s t r i b u t e d widely i n plasma, c e r e b r a l s p i n a l f l u i d , b r a i n , muscle and o t h e r t i s s u e s . They a r e r e a d i l y metabolized; o n l y a small amount of p a r e n t m a t e r i a l can be i s o l a t e d from t i s s u e s t o g e t h e r w i t h l a r g e amounts of metabolite^.^^,^^ The a n t i n e o p l a s t i c a c t i v i t y of CCNU may be due t o m o d i f i c a t i o n o f c e l l u l a r p r o t e i n s and t o a l k y l a t i o n o f n u c l e i c a c i d s . 6 3 N i t r o s o u r e a s a c t on marrow s t e m c e l l s , cause a double f a l l i n the WBC count, and induce a more prolonged r e d u c t i o n i n colonyforming u n i t s t h a n does c y t o s i n e a r a b i n o s i d e . 18 N i t r o s o u r e a s o f t e n cause delayed bone marrow t o x i c i t y , t r a n s i e n t h e m a t o c r i t d e p r e s s i o n and hematop o i e t i c s u p p r e s s i o n , which may be r e l a t e d t o t h e drug-induced a l t e r a t i o n s i n t h e c e l l cycle.64 This e f f e c t may be r e l i e v e d by a change i n dosage regimen .62 S t r u c t u r a l m o d i f i c a t i o n s of N-nitrosoureas a r e r e p o r t e d .65
Chap. 13
Ant i neopl a s t i c Agents
Cheng
I33
-
"Pseudourea" 2,2 '-(9,lO-Anthrylenedimethylene)bis-(2-thiop~eudourea) dihydrochloride (6), has shown activity against mouse leukemia L-1210. It complexes with DNA and inhibits both DNA synthesis and DNA-dependent RNA polymerase activity.66 Initial clinical studies revealed undesired phototoxicity in most patients with metastatic cancer.67 NH II
-6
CH2-S-C-NH2 II NH
-
5-(3,3-Disubstituted 1-triazeno)imidazole-4-carboxamide(7 DIC) DIC is used for treating disseminated malignant melanoma;68,fi it is reported to have activity against carcinoma of the lung70,71 and primary brain tumors.71 However, it is of no use in malignant melanoma in Uganda.72 Bone marrow depression, vomiting, diarrhea, oral ulceration, hepatocellular damage, CNS effects, fever, and a delayed flu-like syndrome are reported side effecgs. DIC is transformed to 9 via 5-diazoimidazole-4-carboxamide (8) .73 DIC undergoes s tepwise demethylation to 5-aminoimidazole-4-carboxamide (AIC) .74975 The monomethylated intermediate (w75or diazomethane76 may be the active metabolites of DIC The imidazole-4-carboxamide 11 (BIC) is transformed into an ionic product 12 77 in vivo,which may explain the differences in antileukemic action and resistance development of DIC and BIC.75 Cytotoxicity study78 and preliminary clinical trials76 of BIC are reported. The action of 5-diazoimidazole-4-carboxamide (8) was studied in rabbit platelets ; the sulfhydryl group and pyrophosphate structures may be involved in the mechanism of release of 5-hydroxytryptamine by &,79 Two isomeric compounds of DIC were synthesized. 5-(3,3-Dimethyl-lstable toward light and heat; it has good activity against leukemia L-1210 and less toxicity than 1.80 triazeno)pyrazole-4-carboxamide. (13)is
The isomeric 5carboxamide 14 lacks antileukemic activity.80 H
-7
R = N=N-N(CH3)2 R = (N2)+ 10 R = N=N-NH(CH3)
-8
11 R
= N=N-N(CH~CH~C~Z)
1
N- N-CHzCH2-Cl
134
Sect, I l l
-
Chemotherapeutic Agents
Butler, Ed.
-
Steroids Large doses of estrogen inhibit prolactin stimulation of mammary tumor growth as demonstrated by the effect of estradiol benzoate to DMBA-induced mammary adenocarcinomas in female rats Estrogen may be involved in transport of RNA from nucleus to cytoplasm.82 Specific binding of estradiol within the nucleus is confined to hormone -dependent tumors. 83 6a-Methylpregn-4-ene-3,llY2O-trione produces favorable responses against malignant melanoma, carcinoma of the breast and prostate with only mild toxicity when given orally .84 Hydroxyprogesterone caproate gave excellent responses in adenocarcinoma of the uterine corpus .85 Preliminary clinical studies with phenesterin in patients with advanced breast cancer were disappointing.86 A spectrophotometric analysis for diethylstilbestrol diphosphate has been deve loped.87 Andros terone defi ciency is associated with poor prognosis of lung cancer.88
-
l-(g-Chlorophenyl) -1-@-chlorophenyl) -2,2-dichloroethane (0,p I DDD) o ,p '-DDD produces favorable clinical responses of adrenocortical carcinoma in man is effective in an adrenal preparation in vitro but not in the adrenal slice. ~,E'-DDD does not affect base-line steroid production when ACTH-induced steroidogenesis is completely blocked, which indicates that ~,E'-DDD interferes with the mechanism by which ACTH stimulates steroidogenesis.89
-
-
Actinomycin D Kinetic studies with actinomycin D (act-D) in transplanted leukemic mice showed that a single dose provided cytotoxic concentrations for up to 24 hours." The characteristics of act-D resistance in L5178Y cells show that alterations in membrane composition and conformation in the drug-resistant subline accounts for the observed changes in the permeability of this drug.91 Act-D enhances the toxicity of morphine by increasing brain ~ermeability.~~ Exposure of leukemia P388 to act-D causes respiratory depression, a decrease in malic and lactic dehydrogenase and an increase in glucose6-phosphate dehydrogenase. These effects are similar to those caused by nitrogen mustard.93 Act-D stimulates isoperoxidase activity at low concentration and represses it at higher ~oncentration.~4 It inhibits the activity of DNA polymerase .95
Chap. 13
Antineoplastic Agents
Cheng
135
Vitamin A acid causes mucous metaplasia in the skin tumor keratoa ~ a n t h o m a . ~Mucus ~ was not observed after topical application of act-D to the skin tumor prior to the usage of Vitamin A acid.97 Adriamycin and Daunorubicin - The structure and absolute stereochemistry of daunorubicin (& daunomycin, rubidomycin) were determined.98 0
OH
15a. b. C.
R = CO-CH3 R = CHOH-CH3 R = CO-CH20H
Clinical trials of in children with acute lymphoblastic leukemia were compared and reviewed.99 This antibiotic has some value in children with advanced disseminated neuroblastoma,loo but may ultimately find its use in combination chemotherapy.lol, lo2 Daunorubicin is rapidly metabolized in rats to daunorubicinol and the aglycones of 15a and m . 1 0 3 Compound 15b was isolated from human urine and enzymatic reactions.104 and adriamycin complex strongly to DNA, inhibit Daunorubicin (*) mitotic activity, DNA s y n t h e ~ i s ~ 0 5and ~ ~ proliferation ~6 of HeLa cells. Daunorubicinol is only slightly active in inhibiting DNA synthesis and cellular proliferation.106 When the amino sugar of these compounds is masked or exchanged €or a-D-glucosamine, the resulting derivatives lack biological activity. The ability of these compounds to bind DNA is associated with the structure of the amino sugar.lo5 This observation supports the antileukemic triangulation pharmacophore hypothesis .44
(z), (u)
The pharmacokinetics, pharmacology, chemotherapeutic effects, toxicity, chromosome aberations and mutagenic potency of adriamycin were reported.105-109 Adriamycin is useful for acute lymphoblastic and chronic myelogenous leukemias, transitional cell carcinoma, liposarcoma, squamous cell carcinoma, and adenocarcinoma of the breast. It is less toxic than daunorubicin. Resistance to daunorubicin is due to changes in the cellular membrane.110 Both antibiotics possess immunosuppressive properties.111
-
Complete structures of the bleomycins have not been Bleomycins elucidated. Bleomycin A2 is active against the ascites type of Ehrlich carcinoma and sarcoma 180 in mice, and is clinically useful in the treatment of human epidermoid cancer, squamous cell carcinoma of the head and neck, lymphosarcoma, Hodgkin's disease, mycosis funoides, Kaposi's sarcoma, carcinoma of the thyroid, and brain tum0rs.~~2-114It exhibits very
I36
Sect. I I I
-
Butler, Ed.
Chemotherapeutic Agents
low renal toxicity and rarely causes leukopenia, thrombocytopenia or hematopoiesis in patients. Bleomycin A2 frequently causes pulmonary toxicity. It inhibits DNA synthesis in E. Ehrlich carcinoma and HeLa cells, inhibits ATP-dependent DNA ligase activity, causes DNA strand scission -in vivo and in vitro, and decreases the melting temperature of DNA in the It prevents presence of hydrogen peroxide or sulfhydryl compounds.115 3 cells from entering visible mitosis. 117 The activity of DNA polymerase from rat ascites hepatoma AH-130 cells is reduced by bleomycin but -in vitro addition of this antibiotic to the DNA polymerase assay system does not produce noticeable inhibition. An increase in the number of chromosomal aberrations was observed in cancer patients following administration of the antibiotic.l19
a,
The sulfur-containing chromophore (E),which is the "core" of all bleomycins , was revealed through x-ray analysis and confirmed by synthesis.l2O Partial structure of bleomycins A2, Ap', A5, 4 , B1 and B2 are represented by 17. In bleomycin A2 , X is 3-aminopropyldimethylsulfonium halide; in other bleomycins X is a straight chain polyamine.
17 -
16 -
Bleomycin A2 (M.W. ca 1400) contains two sugars (1-glucose and 3-0carbamoyl-D-mannose) and the peptide and amino acids 18-20.121 (L) p 2 YH2 H2N -CH2-CH-C02H I H02C-CH2-kH C02H N,?
T-cH-To
y,..
NH2 18
19 -
N\
N '
OH
CH3-FH
NH2
~H-OH
20
-
NH I
CH3
CH3-CH-C02H
Mitomycin C Human sarcoma cells exposed to mitomycin C stimulated DNA synthesis in autochthonous lymphocytes. Preexposure of the tumor cells to autochthonous serum abrogated lymphocyte stimulation.122 The use of mitomycin C in combination with cycle-phase specific drugs that may block cell repair.or with agents having a different mode of action has been suggested,123 but preliminary combinations with phenylalanine mustard, and vincristine in the treatment of osteogenic sarcoma was without much effect.124
Chap. 13
Antineoplastic Agents
Cheng
137 -
-
Camptothecin An alkaloid from the tree Camptotheca acuminata, camptothecin (21) exhibits antineoplastic activity against the mouse leukemias, the plasma cell tumor YPC-1, Walker 256 rat carcinosarcoma and has cytotoxic activity against several cell lines.125-127 Total synthesis128,129 and preliminary structure-activity relationship studies130 are reported. Camptothecin is not crossresistant to leukemias made refractory to the antifols, BCNU, cytosine arabinoside, 6-mercaptopurine, L-asparaginase, or vin0 cristine.127 The primary effect of this 21 alkaloid is on DNA synthesis. It also causes a G2 "lesion" which prevents subsequent mitosis. The major effect of 21 is to affect cells in S phase and the capacity of these cells to go through Go phase.127 Inhibition of DNA synthesis in L-1210 cells by camptothecin is initially reversible, but becomes irreversible when exposure to the drug is prolonged. 131 Camptothecin resistant L-1210 subline is not characterized by a drug permeability barrier nor by altered levels of cell surface glycoprotein, which differ from characteristics of actinomycin D-resistance cell lines.131
pJJyq
Camptothecin inhibits ribosomal RNA synthesis without affecting the RNA synthesis inhibition transfer RNA or protein synthesis;132 is rapidly reversible upon removal of the drug. 133 Initial claims of clinical activity of camptothecin in gastrointestinal cancer134,135 have not yet been confirmed.
& -
Among other antineoplastic agents of plant origin, the narcissus alkaloid pseudo lycorine (22) is active against Rauscher leukemia.136 Taxol , Ho from Taxus brevifolia, is active against a number of experimental neoplastic systems; its structure CH~O (23)was reported. 137 The sesquiterpene lactones138 l.39 and bufadien~lidesl~~ are cytotoxic. 0
I
C6H5 -Co
I
COCH3
I
OCH~
24 -
22 -
138 -
Sect. I l l
-
Chemotherapeutic A g e n t s
B u t l e r , Ed.
The f a c t o r r e s p o n s i b l e f o r c y t o t o x i c i t y of t h e s e s q u i t e r p e n e l a c t o n e s i s t h e O=k-k=CH* moiety.l38 T o t a l s y n t h e s i s of t h e t u m o r - i n h i b i t o r y aporphine a l k a l o i d s , t h a l i c a r p i n e (24) and h e r n a n d a l i n e was accomplished. 141 Emetine - A s an i n h i b i t o r of p r o t e i n s y n t h e s i s a t t h e t r a n s c r i p t i o n l e v e l , emetine i s a l s o a c t i v e a g a i n s t leukemias L-1210 and P-388, B16 melanomas, E h r l i c h a s c i t e s carcinoma and Yoshida sarcoma. Pharmacologic s t u d i e s showed t h a t i t e f f e c t s a sympathetic blockade, a n t a g o n i z e s h y a l u r o n i d a s e , i n h i b i t s o x y d a t i v e N-demethylation of aminopyrine and N-ethylmorphine a s w e l l a s t h e S-demethylation of 6-MP r i b o s i d e i n v i t r o . 14*9 143
P r e l i m i n a r y c l i n i c a l t r i a l s i n d i c a t e d t h a t emetine reduced lung tumor s i z e and p u r u l e n t bloody v a g i n a l d i s c h a r g e ; s e v e r e muscle weakness i s t h e most important d o s e - l i m i t i n g t o x i c e f f e c t . Emetine i s n o t myelos u p p r e s s i v e and may be u s e f u l i n p a t i e n t s w i t h poor marrow r e s e r v e . l 4 4 C a r d i o t o x i c e f f e c t s o f t h i s a l k a l o i d and i t s 2-dehydro analog were noted i n r a b b i t h e a r t . The observed c a r d i o p a t h y compares w i t h t h o s e n o t accompanied by v a s c u l a r symptoms b u t a s s o c i a t e d w i t h n e c r o s e s due t o e l e c t r o l y t e and s t e r o i d d i s t u r b a n c e . 145 N-Substituted a-emetine d e r i v a t i v e s have a l s o been found t o i n h i b i t growth of E h r l i c h a s c i t e s c a r c inoma . I 4 6 Vitamin A Acid - Vitamin A a c i d i s c a p a b l e o f inducing r e g r e s s i o n s i n a benign as w e l l a s malignant e p i t h e l i a l tumor. It has a t h e r a p e u t i c e f f e c t on e s t a b l i s h e d s k i n papillomas and s k i n carcinomas induced by 7,12-dimethybenz[g]anthracene and c r o t o n o i l . 147 I n i t i a l c l i n i c a l t r i a l has e s t a b l i s h e d t h e e f f e c t o f t o p i c a l l y a p p l i e d v i t a m i n A a c i d on b a s a l c e l l carcinomas on t h e s k i n i n man.148
-
Two L-glutamine a n t a g o n i s t s (6-diazo-5-0x0-L-norL-Asparaginase l e u c i n e and a z a s e r i n e ) produce a d d i t i v e a n t i l e u k e m i c e f f e c t s w i t h La s p a r a g i n a s e i n mouse leukemia L5178y.149 Rapid development of L-aspara g i n a s e r e s i s t a n c e w a s observed. 149 L-Asparaginase from d i f f e r e n t s o u r c e s p o s s e s s e s v a r i e d tumor i n h i b i t o r y p r o p e r t i e s . The enzyme from S e r r a t i a marcescens i s more i n h i b i t i v e a g a i n s t 6C3HED lymphoma t h a n t h a t from E. c o l i . 1 5 0 L-Asparaginase h a s a weak a c t i v i t y i n a d u l t a c u t e myelocytic leukemia; i t produces about 50% r e m i s s i o n s i n a d u l t s w i t h a c u t e lymphoc y t i c leukemia151 and h a s some a c t i v i t y i n c h i l d r e n w i t h advanced l e u It w i l l have t o be combined w i t h o t h e r drugs i f i t i s t o kernia.152,153 s i g n i f i c a n t l y a f f e c t s u r v i v a l of leukemia p a t i e n t s . 1 5 4 A c r o l e i n i n t o b a c co smoke155 and hormonal a n t i b o d i e s 1 5 6 reduce t h e t h e r a p e u t i c a c t i v i t y of L- a,sparaginase
.
Chap. 13
Antineoplastic Agents
Cheng
139
L-Asparaginase is a potent immunosuppressive agent. 157-159 This effect was not decreased by heat treatment or simultaneous administration of L-asparagine.lG0 L-Asparaginase from E. coli has a tetrameric structure with identical units, each possessing a single catalytic site.161,162 Extensive cross-linkage and alterations of substrate specificity can occur when the enzyme is treated with tetranitromethane.163 The native enzyme has 10% b-helices and 45% @-structure; the rest are o f the unordered types. Lyophilization increases the content of B-structure.164 Production by tumor cells and the effect of asparagine analogs were studied.165 Its action on mitotic activity during induced hepatocarcinogenesis was reported. 166 t-RNA Methyltransferase - Abnormally high levels of methyltransferase enzymes methyltransferase activity were found in neoplastic tissues including virally induced, chemically induced, and spontaneous tumors.167-171 The t-RNAs of many tumors contain highly elevated amounts of N-methylated, C-methylated, and the 2'-0-methylated nucleosides .I68 t-RNA from solid human tumors with t-RNAs from normal tissues was compared chromatographically.172 t-RNAs are associated with the regulation of protein synthesis at the translation level and since alkylating carcinogens were found to alkylate t-RNA in vivo, the aberrancy of methyltransferase could be involved in the initiation of tumor induction and neoplasia. 168 Inhibitors of methyltransferase are postulated to be of potential value in cancer chemotherapy. 168 Ricin - A phytotoxic protein from Ricinus communis is inhibitory towards protein synthesis in experimental tumor cells. It has a moderate inhibitory effect on DNA synthesis without affecting RNA synthesis. Its mode of action is not known, but is not due to impairment of glucose metabolism nor amino acid uptake in tumor cells.173 Gallium Salts - With a special affinity for malignant tumors, gallium salts are used as diagnostic tools for detection of neoplastic bone metabolism and allied neoplastic diseases. 174,175 Gallium bromide, chloride, citrate, iodide, and nitrate as well as ammonium gallium chloride have antitumor activity against Walker carcinosarcoma 256 and P-1798 lymphosarcoma. Gallium 5-fluoroorotate is active against leukemia L-1210 in mice. Autoradiographic studies of gallium-67 salts in rodent tissue show more than 70% of the 67Ga activity was localized in the cytoplasm. High concentrations of 67Ga were observed in the epithelium of renal convoluted tubules. 176 Four Group 111-A elements (aluminum, gallium, indium, and thallium) had some antitumor activity but only Ga+3 and, to a lesser extent, In+3 inhibited tumor growth when the tumor was innoculated by a
140
Sect. I l l
-
Butler, Ed.
Chemotherapeutic Agents
route different from that of the salts. The decreasing order of toxicity was In(NO3)3 2 TlCl3 > Ga(N03)3 > A1(N03)3. Some gallium salts may be useful for treatment of solid tumors in man.177j178
-
exhibited Platinum Complexes cis-Diamminedichloroplatinum (g), potent antitumor activity against sarcoma 180, Ehrlich ascites carcinoma, leukemia L-1210, Dunning ascites leukemia, Walker 256 carcinoma, DMBAinduced mammary carcinoma, and virus-induced reticulum cell sarcoma in experimental animals.179 2 180
- - - -Nr3 :\ ' Pt4 2 ; C1-
These platinum complexes cause a consistent inhibition of DNA synthesis in vivo.181 At very low concentrations, 25 selectively inhibited the
#
/
\ '
C1.- ---NH3
25
incorporation of th~idine-CHg-~H, uridine-5-3H, L-leucine-lk and Lleucine-3H into mammalian cells.181,182 It may undergo sequential transformations with loss of chloride, and the resultant platinum species may act bifunctionally to crosslink adjacent nuclephilic centers of DNA through covalent binding. 183 The acute toxic and pathogenic effects of 25 in rats include pronounced effects on many of the rapidly proliferating normal tissues (i.e., in the intestines , the marrow, and the renal tubules). 184,185 Hematologic studies show a decrease in circulating reticulocytes and lymphocytes after administration of 25, and histologic studies showed striking changes in thymus and spleen.186 Deafness was noted in preclinic trials, An aryl congener of 25, cis-dichlorodipyridineplatinum, possessed actions similar to those of the inorganic species, albeit l e s s potent.187 References 1. 2.
3. 4.
5.
6. 7. 8.
C . G . Zubrod, e t a l . , " F i r s t J o i n t Working Conference, N a t i o n a l Cancer I n s t i t u t e Chemotherapy Program," Cancer Chemother R e p t s . , P a r t 3,2, 1 (1971). T. A. Connors and D. H . Melzack, I n t . J . C a n c e r , 1,86 ( 1 9 7 1 ) . M . I n a b a and Y. S a k u r a i , I n t . J . Cancer, l,430 (1971). N . E. S l a d e k , Cancer Res., 1, 901 (1971). H . - J . H o h o r s t , A. Ziemann, and N . Brock, A r z n e i m . - F o r s c h . , 25, 1254 (1971). A. Primack, Proc. SOC. E x p t l . B i o l . Med., 604 ( 1 9 7 1 ) . M. P. G o l l e r k e r i and G. B. Shah, Cancer, 3, 596 ( 1 9 7 1 ) . D. T. Kaung, H . P . C l o s e , R. M. W h i t t i n g t o n , and M. E. P a t n o , Cancer, 3, 608
x,
(1971).
c(".
L. H. Ll. E. J . O l i n , T. F r a s e r , and 3. K. Bhuyan, Cancer R e s . , 1, 2770 (1971). 10. J . Vesely; M . gvo:ik, A. i h s k , a n d F. Sorm, I n t . J . Cancer, S, 310 (1971). 11. J. Vesely', A . Cihak, and F. $ o m , Eur. J. Biochem., 2,551 ( 1 9 7 1 ) .
9.
12. Y . Kozai and Y . Sugino. Cancer R e s . , 2, 1376 (1971). 13. F. L. Graham and G. F. Whitmore, i b i d . , ;So, 2627, 2636 ( 1 9 7 0 ) . 14. F. D . B e r t a l a n f f y and M . H. L. Gibson, i b i d . , 1, 66 (1971). 861 ( 1 9 7 0 ) . 15. M. Karon and S. S h i r a k a w a , J . Nat. C:ncer I n s t . , 9, 16. D. G . T r a g g i s , A . D o h l w i t z , L. Das, N . J a f f e , W. C . Moloney, and T . C . H a l l , Cancer, 28, 815 (1971).
Chap. 17. 18. 19. 20. 21.
13
A n t i n e o p l a s t i c Agents
25.
31. 32 *
33. 34. 35. 36.
37* 38. 39. 40. 41. 42. 43. 44. 45.
46. 47. 48. 49. 50. 51 * 52
-
53 * 54.
55. 56. 57.
58* 59 * 6c. 61. 62.
63. 64.
I41 -
R . J . Papac and J . J . F i s c h e r , Cancer C h e o t h e r . R e p t s . , 2,193 (1971). H . D. P r e i s l e r and E. S. Henderson, J . Nat. Cancer I n s t . , 971 (1971). B. C. Baguley and E.-M. Falkenhaug, Cancer Chemother. R e p t s . . 2, 291 (1971). C. L. N e i l , H. H. B u s k i r k , T . E . Moxley, R. C. Manak, S. L. Kuentze1,and B. K . Bhuyan, Biochem. Pharmacol., 20, 3295 (1971). D. T. G i s h , R. C. K e l l y , G. W . Camiener, and W. J. Wechter, J. Med. Chem.
5,
14,
1159 22. R . P. 23. D. T . 24. R. L. 26.
Cheng
(1971). P a n z i c a , R. K. R o b i n s , and L. B. Townsend, J . Med. Chem., 259 (1971). G i s h , G . L. N e i l , a n d W . J . Wechter, J . Med. Chem., 3, 882 (1971). Tolman and R . K. Robins, J . Med. C h m . , 14,1112 (1971). S. R. L a h i r i , G . B o i l e a u , and T. C . H a l l , Cancer, 902 (1971). J . L. Cohen, M. J . K r a n t , B. I . S h n i d e r , P. I . M a t i a s , J . Horton, and D. B a x t e r , Cancer Chemother. R e p t s . , 3,253 (1971). R . D. Magus, S. W . King, and J. D. H a r r i s o n , Biochem. P h a r m a c o l . , 20.2239 (1971). G. A. G e n t r y , P . A . Morse, Jr., and M. T. D o r s e t t , Cancer R e s . , 1, 909 (1971). H . H i g a s h i and C. H e i d e l b e r g e r , Cancer Chemother. R e p t s . , 3, 29 (1971). L. H e l s o n , A . Yagada, M. McCarthy, M. L. Murphy, and I . H . K r a k o f f , Proc. A m e r . Assoc. Cancer Res., 11, 136 (1970). F. J . A n s f i e l d and G. R a i m i r e z , Cancer Chemother. R e p t s . , 2, 205 (1971). R. H . S t e l l w a g e n and G. M. Tomkins, Proc. Nat. Acad. S c i . USA, 68, 1147 (1971). A . Hoshi, F. Kanzawa, and K. K u r e t a n i , Cancer Chemother. R e p t s . , 3,229 (1971). L . L . B e n n e t t , Jr., and P. W . A l l a n , Cancer Res., 1, 152 (1971). D. H. W . Ho, Biochem. Pharmacol., E , 3538 (1971). M. K. W o l p e r t , S . P. Damle, J . E . Brown, E. S z u y c e r , K. C. Agrawal, and A . C. S a r t o r e l l i , Cancer R e s . , 2, 1620 (1971). “ F o l a t e A n t a g o n i s t s a s Chemotherapeutic A g e n t s . ” J. R. B e r t i n o , e d . , Ann. N.Y. Acrd. S c i . , 5-519 (1971). M. T . H a k a l a , Cancer R e s . , 1, 813 (1971). S. M a r g o l i s , F. S. P h i l i p s , and S. S. S t e r n b e r g , Cancer R e s . , 1, 2037 (1971). W . R . Vogler and J . J a c o b s , Cancer, 894 (1971). M. C. S t r a u s , N. Mantel, and A . G o l d i n , Cancer R e s . , 2, 1429 (1971). F. S. P h i l i p s , S. S. S t e r n b e r g , J . E. S o d e r g r e n , and P. V i d a l . Cancer Chemother. R e P t s . , 2, 35 (1971). D. J. H u t c h i s o n , M. Shimoyama, and F. A. Schmid, i b i d . , 2,123 (1971). K. Y. Zee-Cheng and C . C . Cheng, J . Pharm. S c i . , 2, 1630 (1970). R. F. S t r u c k , Y . F. S h e a l y , and J . A . Montgomery, J . Med. Chem., 3, 693 (1971). Z. G . Kadaghidze and G. J. Svet-Moldavsky, J . N a t . Cancer I n s t . , 921 (1971). D. R. Makulu and P. H. W r i g h t , J . Pharmacol. E x p t l . T h e r a p . , 66 (1971). F. Rotherham, F. M . P r i c e , T . T . O t a n i , and V. J . Evans, J . N a t . Cancer I n s t . , 277 11971). M. T . Hakala, Biochem. Pharmacol., 20, 81 (1971). H . Hennings and F. Devik, Cancer R e s . , 1, 277 (1971). M. W. Lieberman, S. S e l l , and E. F a r b e r , Cancer R e s . , 2,1307 (1971). F. R o s n e r , H. Rubin, and F. P a r i s e , Cancer Chemother. R e p t s . , 167 (1971). H. Hennings, J . Nat. Cancer I n s t . , 841 (1971). D. T. Kaung, S. S b a r , and M . E . P a t n o , Cancer Chemother. R e p t s . , 87 (1971). S. M. A r i e l , Cancer, 3,705 (1970). J . A. G o t t l i e b , E. F r e i , 111, and J . K . Luce, Cancer Chemother. R e p t s . , 2, 277 (1971). F. R o s n e r , 0. G l i d e w e l l , e t a l . , Cancer Chemother. R e p t s . , 52, 199 (1971). V. T. O l i v e r o , W. M. V i e t z k e , M. K. W i l l i a m s , e t a l . , Cancer R e s . , 0, 1330 (1970). H. H . Hansen, 0. S. S e l a w r y , F. M. Muggia, and M. D. Walker, Cancer R e s . , 2, 223 ( 1971 * W . R. S h a p i r o , J . Nat. Cancer I n s t . , 46, 359 (1971). H. H . Hansen and F . M. Muggia, Cancer Chemother. R e p t s . , 2, 99 (1971). M. D. Walker and M . L. Rosenblum, Cancer Chemother. R e p t s . , 3,10G (1971). C . J . Cheng, S. F u j i m u r a , D. G r u n b e r g e r , and I . B. W e i n s t e i n , Cancer Res. 22 (19721. D. A. Bray, V. T . DeVita, R. H . Adamson, and V. T . O l i v e r i o , Cancer Chemother.
a,
18,
186,
a,
5,
D,
a,
5,
s,
z,
z,
142 65.
66. 67. 68. 69. 70.
71. 72.
73. 74. 75.
76. 77. 78. 79. 80.
81.
Sect.
Ill
- Chemotherapeutic Agents
B u t l e r , Ed.
R e P t s . , Z, 215 (1971). T. P. Johnson, G. S. McCaleb, P. S. O p l i g e r , W . R. L a s t e r , and J A . Montgomery, J . Med. Chem. , 2, 600 (1971). P . P. Saunders and G. F. S a u n d e r s , Molecular Pharmacol., 335 1 9 7 1 ) . E. F r e i , 1 1 1 , J . K . Luce, and T . L. Loo, Cancer Chemother. R e p t s , 9 1 (1971). D. H. Cowan and D. E. B e r g s a g e l , Cancer Chemother. R e p t s . , 3,175 ( 1 9 7 1 ) . P . J . Burke, W. H. McCarthy, and G. W . M i l t o n , Cancer, 3, 744 (1971). J. B. Migerd, R . M. Amick, H. M. H i l a l , and M. E. Patno, Cancer Chemother. R e p t s .
6,
z883
a,
(1971).
G . S. Kingra,
R. Comis, K. B. Olson, and J . Horton, i b i d . , 52, 281 (1971).
C . L. Vogel, R.
Comis, J . L. Z i e g l e r and J . W . M. Kiryabwire, i b i d . ,
3, 143
(1971).
1, 135 (1971). E. Housholder and T. L. Loo, J . Pharmacol. E x p t l . T h e r a p . , 11p. 386 ( 1 9 7 1 ) .
D. K e s s e l , Cancer R e s . , G.
I. K l i n e , R. J . Woodman, M. Gang, and J . M. V e n d i t t i , Cancer Chemother. R e p t s . ,
2, 9 (1971).
18,
J. L. Skibba and G. T. Bryan, T o x i c o l . Appl. Pharmacol., 707 (1971). C. L. Vogel, V. T . DeVita, C. Denham, H. T . F o l e y , R . B. F i e l d , and P. P.
Carbone, Cancer Chemother. R e p t s . , 159 (1971). F. V a l e r i o t e and S. T o l e n , Cancer Chemother. R e p t s . , 5, 43 (1971). H. I w a t a , I. Yamamoto, and K. Murak1,Biochem. Pharmacol., 20, 297 (1971). C . W . Noel1 and C . C . Cheng, J . Med. Chem., 12, 545 ( 1 9 6 9 ) ; i b i d . , 3, 1 2 4 5 ( 1 9 7 1 ) . J. M e i t e s , E. C a s s e l l , and J. C l a r k , Proc. SOC. E x p t l . B i o l . Med., 1225
s,
m,
(1971). 82. 83. 84.
85. 86.
87. 88. 89. 90.
91. 52.
93. 94.
95. 96. 97. 98. 99. 100. 101. 102.
103.
L. W . Redman, M . R. G a r l a n d , R. Thomson, T . Ng, and J . F. R i c h a r d s , Cancer R e s . ,
31,
265 (1971). W . L. McGuire, and J. A. J u l i a n , Cancer R e s . , 31, 1440 (1971). G . Ramirez, A. J. Weiss, D. B. R o c h l i n , and H. F. B i s e l , Cancer Chemother. R e p t s . , 265 (1971). E. C. R e i f e n s t e i n , Cancer, 3, 485 (1971). F. J . A n s f i e l d , A . C. C a r t e r , I . S. Goldenberg, and A. S e g a l o f f , Cancer Chemot h e r . R e p t s . , zfi, 259 (1971). D. L. Simmons, R . J . Ranz, and R. C . C o r n e l l , Canad. J . Pharm. S c i . . 6, 2 8 ( 1 9 7 1 ) . L. G. S. Roo, N a t u r e , 220 ( 1 9 7 2 ) . M. M. Hart and J . A . S t r a w , Biochem. Pharmacol., 20, 1679, 1689 (1971). T . V i e t t i and F. V a l e r i o t e , J . Nat. Cancer I n s t . , 1177 (1971). D. K e s s e l and H. B. Bosmann, Cancer Res., 30, 2695 ( 1 9 7 0 ) . H. H . Loh, F.-H. Shen, and E. L. Way, J . Pharmacol. E x p t l . T h e r a p . , 326
z,
m,
5,
a,
(1971).
9,
D. H a z l e t t and C. A . Ackerman, J . Nat. Cancer R e s . , 1309 (1971). Novacky and J . Wheeler, Amer. J . Botany, 858 (1971). A . Waqar and L. A . Burgoyne, Biochem. Biophys. Res. C o m u n . , 2, 1024 (1971). P r u t k i n and B. B o g a r t , J . I n v e s t . D e r m a t o l . , _ 2 2 , 249 ( 1 9 7 0 ) . P r u t k i n , Cancer R e s . , 31, 1080 (1971). Arcamone, G . C a s s i n e l l i , G. F r a n c e s c h i , R . Mondelli, P. O r e z z i , and S. Penco, Gazz. C h e m . I t a l . , 100, 949 ( 1 9 7 0 ) . B. J o n e s , J . F. H o l l a n d , and o t h e r s , Cancer R e s . , 2, 84 ( 1 9 7 1 ) . L. D. Samuels, W . A . Newton, J r . and R. Heyn, Cancer, 3, 831 ( 1 9 7 1 ) . N . R . Bachur and M. Gee, J . Pharmacol. E x p t l . Therap.. 567 ( 1 9 7 1 ) . N. R. Bachur, ibid., =,573 (1971). J . J . Wang, D. S . Chervinsky, and J . Rosen, Proc. Amer. Assoc. Cancer R e s . , 12, L. A. M. L. L. F.
9,
z,
77 ( 1 9 7 1 ) . 104. A. DiMarco, F. Zunino, R. S i l v e s t r i n i , C . Gambarucci, and R . A . Gambetta, Biochem. Pharmacol., 0, 1323 (1971). 105. E. Arena, N. d ’ A l e s s a n d r o , L . Dusonchet, N . Gebbia, F. G e r b a s i , M. P a l a z z o a d r i a n o , A. R a i n e r i , L . Rausa, and E. Tubaro, Arzneium-Forsch., 21, 1258 (1971). 106. J . J . Wang, E. C o r t e s , L. F. S i n k s , and J . F. Holland, C a n c e r , 837 (1971). 107. E. Middleman, J . Luce, and E. F r e i , 111, Cancer, 844 ( 1 9 7 1 ) .
8,
a,
13
Chap.
A n t i n e o p l a s t i c Agents
143 -
Cheng
108.
N. W o l l n e r , C. Tan, F. Ghavimi, 0. Rosen, M . T e f f t , and M. L. Murphy, Proc. h e r . Assoc. Cancer R e s . , 2,75 (1971). 109. B. K. V i g , Cancer Res. 1, 32 (1971). 110. H. Riehm and J . L. B i e d l e r , Cancer R e s . , 2, 409 (1971). 111. A . M. Casazza, A. DiMarco, and G. DiCuonzo, Cancer R e s . , 1, 1971 ( 1 9 7 1 ) . 112. T. Ichikama, Asian Med. J . , 2,(8), 210 ( 1 9 7 0 ) . 113. S. S h a s t r i . R. E. S l a y t o n , J . W o l t e r , C . P. P a r l i a , and S. G . T a y l o r , 111, Cancer 1142 (1971). 114. I . Kimura, T . Onoshi, I. Kunimasa, and J . Takano, Cancer, 2, 58 ( 1 9 7 2 ) . 115. H. Yamaki, H. S u z u k i , K. Nagai, N . Tanaka, and H. Umezawa, J . A n t i b i o t . , 24,
28,
178 (1971).
116.
a,
120. 121.
M. Miyaki, T . Ono, and H. Umezawa, J . A n t i b i o t . , 587 (1971). M. Nagatsu, T. Okagaki, R. M. R i c h a r t , and A. Lambert, Cancer R e s . , 2, 992(1971) T. Kobayaski, J . A n t i b i o t . , 519 ( 1 9 7 1 ) . R. S. B o r n s t e i n , D. A . Hungerford, G. H a l l e r , P . F. Engstrom, and J . W . Y a r b r o , Cancer R e s . , 2, 2004 (1971). K . Y . Zee-Cheng and C. C . Cheng, J. H e t e r o c y c l . Chem., 1,1439 ( 1 9 7 0 ) . T. T a k i t a , T . Yoshioka, Y. Muraoka, K. Maeda, and H. Umezawa, J . A n t i b i o t . , 2,
122
F. Vanky, J. S t e r n s w a r d , G . K l e i n , and U. N i l s o n n e , J. Nat. Cancer I n s t .
117.
4,
118. 119.
795 !J-971).
9,
95 (1971). 123 124. 125.
126. 127.
W. W . Sutow, J . R. W i l b u r , T . J . V i e t t i , P. Vuthibhagdee, T . F u j i m o t o , and A. Watanabe, Cancer Chemother. R e p t s . , 2, 285 (1971). N. J a f f e , D. T r a g g i s , and C . E n r i q u e z , Cancer Chemother. R e p t s . , 189 (1971). R. E . Perdue, J r . , R. L. Smith, M. E. W a l l , J . L. H a r t w e l l , and B. J . A b b o t t , Agr. Res. S e r v i c e ( U . S . Dept. Agr.) Tech. B u l l . , 1415 (1970). J. A. G o t t l i e b , A. M. Guarino, J . B. C a l l , V. T . O l i v e r i o , and 3. B. B l o c k , Cancer Chemother. R e p t s . , 461 ( 1 9 7 0 ) . R. C. G a l l o . J . Whang-Peng, and R. H. Adamson, J . Nat. Cancer I n s t . , 789
s,
2,
(1971). 128. 129.
G. S t o r k and A .
131 132
133 * 134.
135.
136. 137. 138. 139140. 141. 142. 143. 144. 145.
S c h u l t z , J . Amer. Chem. S O C . , 2, 4074
(1971).
R. Volkman, S. D a n i s h e f s k y , 3. E g g l e r , and D. M. Solomon, J. Amer. Chem. S O C . , 2
130
G.
46,
8
5576 (1971).
3. L. H a r t w e l l and B. J . Abbott, Adv. Pharmacol. Chemother., 1,117 (1969). D. K e s s e l , Cancer R e s . , 2, 1883 ( 1 9 7 1 ) . S. B. Horwitz, C . - K . Chang, and A . P . Grollman, The P h a r m a c o l o g i s t , 12, 283 (#452) (1970 1. R . S. Wu, A. Kumar, and J . R. Warner, Proc. Nat. Acad. S c i . U . S . , 3009 (1971) J . A. G o t t l i e b , A. M. Guarino, V. T . O l i v e r i o , and J. B. B l o c k , P r o c . h e r . Cancer R e s . , 31 (#121) (1970). C. G. M o e r t e l , R. J . R e i t e m e i e r , A . J. S c h u t t and R . G. Hahn, P r o c . Amer. Cancer R e s . , 18 ( ~ ( 6 9 )(1971). E. Furusawa, S. Furusawa, S . Morimoto and W . C u t t i n g , Proc. SOc. E x p t . B i o l . Med., 1168 (1971). M . C. Wani, H . L. T a y l o r , M. E. W a l l , P. Coggan, and A . T. McPhail, J . Amer. 2325 (1971). Chem. S o c . , K.-H. Lee, E . 4 . Huang, C. P i a n t a d o s i , J. S. Pagano, and T. A . Geissman, Cancer Res. , 1649 (1971). S. M. Kupchan, M. A. E a k i n , and A. M. Thomas, J. Med. Chem. 1147 (1971). S. M. Kupchan, I . Ognyanov, and J. L. Moniot, Bioorg. Chem., 1, 13 (1971). S. M. Kupchan and A. J . L i e p a , Chem. Commun., 599 ( 1 9 7 1 ) . W . R. J o n d o r f , B. J. A b b o t t , N . H. Greenberg, and J . A. R. Mead, P h a r m a c o l o g i s t , 1 2 , 282 ( 1 9 7 0 ) . R . K. Johnson, P. Mazel, J . D. Donahue, and W . R. J o n d o r f , Biochem. Pharmacol. I 20, 955 ( 1 9 7 1 ) . P a n e t t i e r e and C. A. Coltman, Cancer, 3, 835 ( 1 9 7 1 ) . S. C. B a r t s o k a s , D. G. P a p a d i m i t r i o u , C. B l a s s o p o u l o s , J . H a t z i m i n a s , D. Kannas, and 2. K a t a p o t i , Arzneim. -Forsch. , 11, 1543 (1971).
68,
11, 12,
136,
s, s,
-
2,
144
S e c t,
L_
146. 147. 148. 149. 150. 151.
152. 153. 154.
155. 156.
157. 158. 159. 160. 161. 162. 163. 164. 165. 166. 167.
168. 169. 170. 171. 172. 173.
174. 175. 176. 177* 178. 179. 180. 181. 182. 183. 184. 185. 186. 187.
III
-
Chemotherapeutic Agents
B u t l e r , Ed.
Gradnik, L. D a l l ' A s t a , and A. P e d r a z z o l i , J. Med. Chem., 3, 255 (1971). B o l l a g , Cancer Chemotherapy R e p t s . , 3,53 (1971). B o l l a g and F. O t t , Cancer Chemotherapy R e p t s . , 2,59 (1971). A. Schmid and D. J. H u t c h i s o n , Cancer Chemother. R e p t s . , 3 , 115 (1971). J. W. Boyd and A . W . P h i l l i p s , J. Nat. Cancer I n s t . , 1271 (1971). T . Ohnuma, F. R o s n e r , R. N . Levy, J. C u t t n e r , J. H . Moon, R . T . S i l v e r , J . Blom, G. F a l k s o n , R. Burningham, 0. G l i d e w e l l , and J . F. H o l l a n d , Cancer Chemother. R e P t s . , 5, 269 (19,711. L . T a l l a l , C . Tan, H. O e t t g e n , e t a l . , Cancer, 3,306 (1970). W . W. Sutow, F. G a r c i a , K. A . S t e r l i n g , T . E . W i l l i a m s , D. M. Lane, and E . A . Gehan, Cancer, 28, 819 (1971). B. G . L e v e n t h a l and E. S . Henderson, Cancer, 28, 825 (1971). M. H. B i l l m o r i a , and M . A . N i s b e t , Proc. Soc. E x p t l . B i o l . Med., lj6,696(1971). S. Vadlamudi, M. P a d a r a t h s i n g h , E. Bonmassar, V. Waravdekar, and A . G o l d i n , C a n c e r , 3, 1321 (1971). S. D. Nelson, M. B. Lee, and J. M. B r i d g e s , T r a n s p l a n t a t i o n , 2 566 (1970). A. Kahn, and J . M. H i l l , J. Immunol., 679 (1970). M. Mlura, K . Kawashima, T . U e t a n i , M. Hirano. H. Kakizawa, R. Ohno, A. M o r i t a , N. N l s h i w a k i , and K. Yamada, Cancer R e s . , 2, 114 (1971). G. B r a m b i l l a , S. P a r o d i , M. Cavanna, C. E. C a r a c e n i , and L. B a l d i n i , Cancer Res., 2665 (1970). B. H. F r a n k , A. H. P e k a r , A . J . V e r o s , and P. P. K . Ho, J . B i o l . Chem., P & , 3716 (19701. R. C. J a c k s o n and R. E . Handschumacher, B i o c h e m i s t r y , 9, 3585 (1970). Y. P. Liu and R. E. Handschumacher, J . B i o l . Chem., 66 (1972). H. Rosenkranz, and W . S c h o l t a n , 2. P h y s i o l . Chem., 1081 (1971). T . C. Chou and R . E. Handschumacher, Blochem. Pharmacol., 21, 39 (1972). F. F. Becker and K. M. K l e i n , Cancer R e s . , 1, 169 (1971). S. F u j i o k a , R. C. Ting and R . C. C a l l o , Cancer R e s . , 2,451 (19'71). E. Borek, e t a l . , "Symposium: t - R N A and t - R N A m o d i f i c a t i o n i n d i f f e r e n t i a t i o n 596-721 (1971). and n e o p h a s i a , " Cancer R e s . , 2, B. S c h e i d , S. M . Wilson, and H. P. M o r r i s , Cancer R e s . , 2, 774 (1971). R . L. Hancock and J . Grunau, J. Nat. Cancer I n s t . , 971 (1971). T. P. Waalkes, R. H. Adamson, R. W. O'Gara, and R . C. G a l l o , Cancer R e s . , 31, 1069 (1971). E. E. Penhoet and J. J . H o l l a n d , J . N a t . Cancer I n s t . , 3, 1173 (1971). J.-Y. L i n , K. L i u , C . - C . Chen, and T.-C. Tung, Cancer R e s . , 1, 921 (1971). A. Ando and K . - I . H i s a d a , R a d i o i s o t o p e s , 9, 246 (1970). D. C. S w a r t z e n d r u b e r , B. L. Byrd, R. L. Hayes, B. N e l s o n , and R . L. T y n d a l l , J , Nat. Cancer I n s t . , 695 (1970). D. C. S w a r t z e n d r u b e r , B. N e l s o n , R. L. Hayes, J. Nat. Cancer I n s t . , 941 (1971)* M. M. Hart and R . H. Adamson, Proc. Nat. Acad. S c l . USA, 1623 (1971). M. M. H a r t , C. F. Smith, S. T. Yancey, and R . H. Adamson, J . Nat. Cancer I n s t . , Q>1121 (1971). B. Rosenberg, L. VanCamp, J . E. T r o s k o , and V. H. Mansour, N a t u r e , 222, 385 (1969). C . W. Welsch, J . Nat. Cancer I n s t . , Q, 1071 (1971). J . A. Howle and G. R. G a l e , Blochem. P h a r m a c o l . , 2757 (1970). H. C . Harder and B. Rosenberg, I n t . J . Cancer, 207 (1970). J. A. Howle, H. S. Thompson, A. E. S t o n e , and G. R . G a l e , Proc. Soc. E x p t l . B i o l . Med., 820 (1971). R. J . Kociba and S. D. Sleigh;, Cancer Chemother. R e p t s . , 2, 1 (1971). M. Bdk, J. Drobnik, and 2. Rezhy, Cancer R e s . , 2, 595 (1972). H. S. Thompson and G. R. G a l e , T o x i c o l . Appl. P h a r m a c o l . , 3, 602 (1971). G. R. G a l e , J. A. Howle, and E. M. Walker, J r . , Cancer R e s . , 2, 950 (1971). B. W. W. F.
46,
104,
z,
e,
z,
s,
44,
s,
68,
u,
6.
m,
Chapter 14.
A n t i p a r a s i t i c Agents
M. H o f f e r and A . I.Rachlin, Hoffmann-La Roche Inc., Nutley, N.J. 07110
I n t r o d u c t i o n - The r e c e n t 1 i t e r a t u r e contains many c i t a t i o n s t o p a r a s i t e r e l a t e d diseases and problems p e r t a i n i n g thereto. I n a r e c e n t paper' several areas r e q u i r i n g i n t e n s i f i e d research and the development o f new o r improved drugs were i d e n t i f i e d . I n t h e past year, a s i n g l e p e r i o d i c a l has c a r r i e d papers on amebicides,2 ant helm in tic^,^ m a l a r i a , 4 y 5 amebic and b a c t e r i a l dysentery,6 i n t e s t i n a l helminths and f i l a r i a s i s , 7 trypanosomia s i s and leishmaniasis,8 schistosomiasis ,9 and immunodiagnosis o f paras i t i c diseases. 0 Considerable i n f o r m a t i o n r e l a t i n g t o c u r r e n t treatment of these a f f l i c t i o n s may be found i n these papers as w e l l as i n a r e p o r t c a l l ed "Drugs f o r P a r a s i t i c I n f e c t i o n s " . The proceedings of two r e c e n t symposia have been published, i . e . , on methodology f o r t h e develop